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Abstract (English) 
The discovery of octahedral chiral-at-metal complexes that promote highly enantioselective 
non-photochemical or photochemical transformations, or both, is a challenging goal. This thesis details 
the discoveries and applications of two distinct classes of chiral-at-metal iridium(III) complexes for 
asymmetric catalysis, one is a metal-templated enamine/H-bonding catalyst and the other is a 
metal-based Lewis-acid catalyst. 
The octahedral enamine/H-bonding catalyst (-Ir4) promotes the enantioselective -amination of 
aldehydes with catalyst loadings down to 0.1 mol%. In this metal-templated design, the iridium serves 
as a structural center and affords the exclusive source of chirality, whereas the catalysis is mediated 
through the organic ligand sphere (chapter 3.1). 
The chiral-at-metal complex -IrO bearing two hemilabile acetonitrile ligands can be used as a 
chiral Lewis acid catalyst. It efficiently catalyzes the enantioselective Friedel-Crafts addition of 
indoles to ,-unsaturated 2-acyl imidazoles with high yields (75-99%) and high enantioselectivities 
(90-98% ee) at low catalyst loadings (0.25-2 mol%). Counterintuitively, this complex maintains its 
metal-centered configuration despite the rapid acetonitrile ligand exchange which is required for 
satisfactory catalytic activity. Since this initial discovery, this novel class of reactive chiral-at-metal 
complexes has been successfully applied to many other asymmetric catalytic reactions in the Meggers 
group (chapter 3.2). 
The Lewis-acid catalyst -IrO and its derivative -IrS can also be competent photoredox catalyst 
for challenging asymmetric photoredox catalysis. With a single catalyst -IrS (2 mol%), the 
visible-light-activated enantioselective alkylation of 2-acyl imidazoles with electron-deficient benzyl 
bromides and phenacyl bromides provided excellent enantioselectivities (90-99% ee) and excellent 
yields (84-100%). In this mono catalysis strategy, the chiral-at-metal complex serves as an in situ 
photosensitizer precursor for photoredox catalysis and at the same time provides very effective 
asymmetric induction for -functionalization of ketones (chapter 3.3). Subsequently, this new catalytic 
strategy has been expanded to realize highly enantioselective -trichloromethylation (chapter 3.4) and 
-perfluoroalkylation (chapter 3.5) through visible-light-activated photoredox catalysis. Previously, 
most of the successful approaches for asymmetric photoredox catalysis needed two catalysts, one for 
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the photoredox activation, and the other for stereoinduction. The single catalyst strategy fulfills an 
unmet need in the photoredox synthetic toolbox and provides new avenues for the efficient and 
economical synthesis of enantioenriched molecules. 
Alternatively, in some cases the synergistic catalysis strategy still has its advantages over the single 
catalyst system. By merging the chiral Lewis acid -RhS with an external photosensitizer, an efficient 
enantioselective addition of organotrifluoroborates to electron-deficient alkenes was readily realized 
under photoredox conditions. This practical method provides yields up to 97% with excellent 
enantioselectivities up to 99% ee and can be classified as a redox neutral, electron-transfer-catalyzed 
reaction. The previously developed dual function photoredox/chiral Lewis acid catalysts -IrO or 
-IrS are not applicable for this photoreaction and this has been pinpointed to slow ligand exchange 
kinetics in the iridium system (chapter 3.6). 
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Zusammenfassung (Deutsch) 
Die Entdeckung oktaedrischer "chiral-at-metal"-Komplexe, die hoch enantioselektive 
nicht-photochemische- und photochemische Umwandlungen katalysieren oder beide gleichzeitig, ist 
eine anspruchsvolle Herausforderung. Diese Dissertation beschreibt die Entdeckung und Anwendung 
zweier unterschiedlicher Klassen von Komplexen mit metallzentrierter Chiralität in der 
asymmetrischen Katalyse, und zwar einerseits ein Enamin/Wasserstoffbrückenbindungs-Katalysator 
und zum anderen ein Lewis-Säure-Katalysator. 
Der oktaedrische Enamin/Wasserstoffbrückenbindungs-Katalysator (Λ-Ir4) katalysiert die 
enantioselektive α-Aminierung von Aldehyden mit Katalysatorladungen bis hinab zu 0.1 mol%. Bei 
diesem Metall-basierten Katalysator fungiert das Iridium als strukturelles Zentrum und stellt 
gleichzeitig das einzige Chiralitätszentrum dar, wohingegen die eigentliche Katalyse durch die 
Ligandensphäre vermittelt wird (Kapitel 3.1). 
Der zwei hemilabile Acetonitril-Liganden enthaltende "chiral-at-metal"-Komplex Λ-IrO kann als 
Lewis-Säure-Katalysator genutzt werden. Dieser katalysiert effizient die enantioselektive 
Friedel-Crafts-Addition von Indolen an α,β-ungesättigte 2-Acylindole mit hohen Ausbeuten (75-99%) 
und hohen Enantioselektivitäten (90-98%) bei gleichzeitig niedrigen Katalysatorladungen (0.25-2 
mol%). Überraschenderweise behält dieser Komplex seine metallzentrierte Stereoinformation trotz des 
schnellen Austauschs der Acetonitril-Liganden, welcher für eine zufriedenstellende katalytische 
Aktivität erforderlich ist. Seit dieser Entdeckung ist diese neue Klasse von Komplexen mit 
metallzentrierter Chiralität erfolgreich für viele andere asymmetrische Reaktionen im Arbeitskreis 
Meggers eingesetzt worden (Kapitel 3.2). 
Der Lewis-Säure-Katalysator Λ-IrO und der davon abgeleitete Katalysator Λ-IrS können auch als 
leistungsfähige Photoredoxkatalysatoren in anspruchsvollen asymmetrischen Photoredoxreaktionen 
eingesetzt werden. Mit dem Katalysator Λ-IrS (2 mol%) ist die durch sichtbares Licht angetriebene 
Alkylierung von 2-Acylimidazolen mit elektronenarmen Benzyl- und Phenacylbromiden mit 
exzellenten Enantioselektivitäten (90-99%) und exzellenten Ausbeuten (84-100%) möglich. Bei dieser 
nur einen Katalysator umfassenden Strategie dient der "chiral-at-metal"-Katalysator als ein in-situ 
Photosensibilisator-Vorläufer für die Photoredoxkatalyse und vermittelt gleichzeitig eine sehr effektive 
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Stereoinduktion bei der α-Funktionalisierung von Ketonen (Kapitel 3.3). Anschließend wurde diese 
neue katalytische Strategie  ausgedehnt auf die hoch enantioselektive α-Trichloromethylierung 
(Kapitel 3.4) und α-Perfluoroalkylierung (Kapitel 3.5) durch Licht-aktivierte Photoredoxkatalyse. 
Zuvor wurden für die meisten erfolgreichen asymmetrischen Photoredoxkatalysen stets zwei 
Katalysatoren benötigt, einer für die Photoredox-Aktivierung und ein anderer für die Stereoinduktion. 
Der hier beschriebene Katalysator füllt daher eine Lücke im Werkzeugkasten der Photoredoxsynthese 
und ermöglicht neuartige und ökonomische Synthesen von enantioangereicherten Molekülen. 
Allerdings haben in einigen Fällen synergistische Katalysestrategien ihre Vorteile gegenüber der 
Verwendung eines einzelnen Katalysators. Durch Hinzufügen eines externen Photosensibilisators zur 
chiralen Lewis-Säure Λ-RhS konnte eine effiziente Addition von Organotrifluoroboraten an 
elektronenarme Alkene bereitwillig unter Photoredoxbedingungn erzielt werden. Diese praktische 
Methode liefert Ausbeuten bis zu 97% bei exzellenten Enantioselektivitäten von bis zu 99% ee und 
lässt sich klassifizieren als eine redoxneutrale, Elektronentransfer-katalysierte Reaktion. Die zuvor 
entwickelten bifunktionalen photoredox-/chirale Lewis-Säure-Katalysatoren Λ-IrO und Λ-IrS können 
nicht für diese Reaktion genutzt werden, was nachweislich auf die langsame Ligandenaustauschrate 
bei den Iridium-Komplexen zurückzuführen ist (Kapitel 3.6). 
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Chapter 1: Theoretical Part 
1.1 Introduction 
Asymmetric catalysis is seen as one of the most efficient strategies to satisfy the growing demand 
for enantiomerically pure compounds in the fine chemical and pharmaceutical industry1. Visible light 
has been recognized as an environmentally friendly and sustainable form of energy for triggering 
chemical transformations and catalytic chemical processes.2 The interaction between light and matter 
constitutes one of the most active areas of scientific research.3 In 2014, the Nobel prizes for physics 
and chemistry were awarded for the development of efficient light emitting devices and for the use of 
fluorescence in ultrahigh-resolution microscopy, respectively. For these reasons, visible-light-driven 
catalytic asymmetric chemistry is a subject of enormous current interest (Figure 1).2 
 
 
 
Figure 1 The interaction between light and matter constitutes one of the most active areas of scientific 
research (Image with respect to Nobel Prize winers was taken from the official web site of the Nobel 
Prize with permission). 
Over the past decade, organocatalysis and metal-based catalysis have emerged as two main branches 
of asymmetric catalysis.4 A wide range of asymmetric organocatalysts have been developed for 
controlling the stereochemistry of organic reactions (Figure 2a), such as amine catalysis,5 H-bonding 
catalysis,6 Brønsted acid catalysis,7 carbene catalysis,8 counterion catalysis,9 and phase transfer 
catalysis.10 Asymmetric metal-based catalysis (Figure 2b), in particular asymmetric hydrogenation,11 
has been applied to the synthesis of non-racemic compounds extensively. The asymmetric inductions 
of these catalysts are typically provided by one or more tetrahedral stereogenic centers, axial chirality 
and planar chirality. In contrast, there have been only few instances of chiral catalysts that transfer 
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their chirality exclusively from an octahedral stereocenter.12 
 
Figure 2 Typical chiral organocatalysts and metal-based catalysts for asymmetric catalysis. 
Photoredox catalysis provides the opportunity to generate highly reactive radical ion intermediates 
with often unusual or previously unconventional reactivities under mild reaction conditions.13 In 
such systems, photoactivated sensitizers initiate a single electron transfer from (or to) a closed-shell 
organic molecule to produce radical cations or radical anions whose reactivities are then exploited for 
interesting or unusual chemical transformations. However, the high reactive intermediates involved 
in photoreactions often have very short lifetimes and can be difficult to controlled with external chiral 
catalysts. Thus, the design of catalysts that promote highly enantioselective photochemical processes 
has proven to be a formidable challenge.14 
This chapter will summarize and discuss recent progress on: 1) non-photochemical asymmetric 
catalysis with octahedral chiral only-at-metal complexes, with an emphasis on the applications of 
chiral iridium(III) complexes developed by Meggers; 2) visible-light-induced enantioselective 
photoredox catalysis with dual catalysis strategy and mono catalysis strategy (single catalyst). 
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1.2 Asymmetric Catalysis with Octahedral Chiral-at-Metal Complexes 
Despite the enormous numbers of chiral catalysts that have been developed for the generation of 
enantiopure compounds, no universal catalyst or chiral ligand exists for solving all the problems in 
asymmetric transformations. For instance, achieving very high turnover numbers (1 mol% loadings) 
in organocatalysis remains a significant challenge with few general solutions. On the other hand, most 
metal-based asymmetric catalysts profoundly rely on chiral organic ligands. These chiral ligands are 
often more synthetically challenging to approach compared to the achiral analog, which might cause 
the multiple functional groups cannot be readily installed around the metal center. 
The chemistry of using chiral only-at-metal complexes for asymmetric catalysis had been largely 
ignored over the past decades indicated by the limited number of publications.12 To develop an 
efficient chiral-at-metal catalyst, the interdisciplinary research that combines organic, inorganic, 
organometallic, even biomimetic chemistry, is often required. This great barrier stands between 
different directions of chemistry, and only few research groups have successfully carried out research 
in this field. 
1.2.1 Representative Chiral Only-at-Metal Ru(II) and Co(III) Complexes for 
Asymmetric Catalysis 
In 2003, Fontecave and co-workers reported a chiral only-at-metal -ruthenium(II) complex which 
was a competent asymmetric catalyst (Figure 3).15 Albeit only 18% ee was provided by asymmetric 
oxidation of sulfide to sulfoxide. The authors proposed a Ru(VI)-oxo intermediate as the true oxidant. 
This example demonstrated, for the first time, that chiral-only-at-metal complexes can be used as true 
asymmetric catalysts.16 
 
Figure 3 Fontecave’s asymmetric oxidation with chiral-at-metal Ru(II) complex. 
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The Gladysz group recently introduced simple chiral-at-metal Werner complexes which can serve as 
hydrogen bond catalysts (Figure 4).17 The Michael addition of dimethyl malonate to cyclopentenone 
proceeded with only 78% yield and 33% ee. The solubility of enantiopure -Werner complex in 
CH2Cl2 was enhanced by the bulky BArF24 (tetrakis[(3,5-di-trifluoromethyl)phenyl]borate) 
counterion. Since the catalyst is substitutionally inert, the authors suggested that the asymmetric 
induction takes place through the N-H bonds as H-bonding donors around the metal center. 
 
Figure 4 Gladysz’s asymmetric Michael addition with chiral-at-metal Co(III) Werner complex. 
1.2.2 Chiral-at-Metal Ir(III) Complexes for Asymmetric Catalysis Developed in the 
Meggers Group 
For the past several years, the Meggers group has conducted interdisciplinary research ranging from 
biochemistry, inorganic chemistry to organic chemistry. Our group has mastered the design and 
synthesis of chiral-at-metal ruthenium and iridium complexes for enzyme inhibition and asymmetric 
catalysis.18  
 
Figure 5 Chiral-at-metal iridium(III) complex catalyzed asymmetric transfer hydrogenation. 
In 2013, the Meggers group reported an inert chiral-at-metal iridium(III) complex for highly 
efficient catalytic asymmetric transfer hydrogenation of ,-disubstituted nitroalkenes (Figure 5).19 
This metal-templated catalyst mediated chirality transfer relying on exclusive chirality at the metal 
center. The reactions did not involve any direct metal coordination but operated exclusively through 
hydrogen bond interactions with functional groups arranged in the ligand sphere of the iridium 
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complex. Although this iridium complex only relies on the formation of three hydrogen bonds, it 
surpasses the reactivities of most organocatalysts with respect to the combination of enantiomeric 
excess (93-99% ee) and catalyst loading (down to 0.1 mol%). Remarkably, this seminal work 
represented the first example of highly enantioselective catalytic reactions being performed with a 
chiral only-at-metal catalyst. 
The proposed mechanistic model for asymmetric transfer hydrogenation is outlined in Figure 6. 
Accordingly, the nitroalkene is activated by the double hydrogen bonding donor arranged in the 
amidopyrazole moiety. The steric clash is curious for stabilizing two formed hydrogen bonds between 
the nitro group and the amidopyrazole. This steric hindrance might facilitate the proper binding mode 
of the nitroalkene substrate and restricts dynamic motion. Meanwhile, one of the two OH groups, 
which are placed in the cyclometalated phenylbenzoxazole ligands, serves as a hydrogen bond 
acceptor to activate the hydride nucleophile through formation of a hydrogen bond between the NH 
group of Hantzsch ester and a lone pair of the OH group. The three hydrogen bonds formed at the 
proper position turn the nitroalkene into a stronger electrophile, and the Hantzsch ester into a better 
hydride donor. Thus, the transfer hydrogenation catalyzed by the bifunctional chiral-at-metal iridium 
complex smoothly proceeds to afford the chiral nitroalkanes with excellent enantioselectivities and 
yields. Interestingly, the absolute configuration of the central metal remains unchanged during the 
overall catalytic process, which can be attributed to the stabilizing bis-cyclometalated chelate effect. 
 
Figure 6 The proposed mechanistic model for asymmetric transfer hydrogenation with a 
chiral-at-metal iridium(III) complex. 
The unique nature of this metal-templated chiral-at-metal catalyst was later expanded to more 
challenging transformations, such as the asymmetric conjugate addition of indoles to ,-disubstituted 
nitroalkenes for the construction of all-carbon quaternary stereocenters with high yields and high 
enantioselectivities (Figure 7). The reactivity of this catalyst was dramatically improved by replacing 
the hydroxyl group with N,N-diethylcarboxamide, a stronger H-bonding acceptor, as well as switching 
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the 3,5-dimethylphenyl to a carbazolyl moiety. Interestingly, this catalyst can be recycled multiple 
times without significant loss of catalytic activity. 
 
Figure 7 Chiral-at-metal iridium(III) complex catalyzed asymmetric Friedel-Crafts alkylation. 
Besides these two applications, subsequent work demonstrated that such inert Ir(III) metal templates 
can be applied as asymmetric Brønsted base catalysts (Figure 8).20 The treatment of the acidic N-H 
bond in the aminopyrazolato ligand with base gave rise to a neutral chiral Brønsted base catalyst. 
Remarkably, the highly effective asymmetric sulfa-Michael addition and aza-Henry reactions can 
permit catalyst loadings down to 0.02 and 0.25 mol%, respectively. Mechanistically, due to the pKa of 
the protonated catalyst of about 16, which higher than that of the thiophenol substrate (pKa of about 
10), the thiol can be effectively activated through deprotonation. Subsequently, an ion pair between 
thiolate and cationic Ir(III) complex forms through double H-bonding. Meanwhile, the Michael 
acceptor is activated via a three-center hydrogen bond with one OH group. This dual activation allows 
the catalytic transformation to proceed with high-rate acceleration and high asymmetric induction. 
 
Figure 8 Asymmetic Brønsted base catalysis with chiral-at-metal Ir(III) complexes. 
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In above enantioselective applications, the octahedral chiral-at-metal iridium(III) complexes 
developed by Meggers have severed as the most efficient chiral-at-metal asymmetric catalysts, which 
rely on three defined hydrogen bonds between substituents on the periphery of the metal complexes 
and the substrates, and in which the iridium center serves as an unreactive bystander fulfilling a purely 
structural role. As achiral ligands are used, the ligand scope for chiral-at-metal complexes is massively 
increased. That means that multiple functional groups can be more readily introduced to the octahedral 
skeleton. It can be assumed that multifunctional chiral-at-metal complexes as metal templates could be 
exploited and applied in many different asymmetric catalysis applications as metal-templated 
“organocatalysts” in which interactions are only executed through the organic ligand sphere. 
However, metal coordination is arguably one of the most powerful approaches for activating 
substrates towards chemical transformations. Consequently, chiral metal complexes are employed 
extensively in industry and academia for the catalytic synthesis of non-racemic chiral compounds.1 A 
guiding principle for the design of such metal-coordination-based asymmetric catalysts is the 
generation of a chiral environment around the metal, which is typically introduced through the 
association with chiral mono- or multidentate organic ligands (Figure 9). 21  In theory, instead 
implementing chirality directly at the reactive metal center by exploiting the metal as a source of 
centrochirality would be highly attractive since the close proximity of the metal to the coordinating 
substrate promises a highly effective transfer of chirality during the asymmetric induction.22 However, 
a considerable obstacle for the realization of such reactive chiral-only-at-metal asymmetric catalysts 
constitutes the retention of the relative and absolute metal-centered configuration during the reaction 
since the coordination number at the metal varies during each catalytic cycle and thereby provides 
ample opportunities for the stereochemistry of the metal to scramble.1  
 
Figure 9 Traditional Lewis acid catalyst and the prospect of a chiral-only-at-metal complex. 
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1.3 Asymmetric Photoredox Catalysis Activated by Visible Light 
Although photoredox chemistry has experienced a renaissance over the last several years, the 
control of absolute stereochemistry in photoredox reactions is still in its infancy.23 Two established 
strategies for visible-light-induced asymmetric catalysis, namely dual catalysis (two catalysts) and 
mono catalysis (single catalyst), are briefly reviewed in the following sections. 
1.3.1 Dual Catalysis Strategies in Asymmetric Photoredox Catalysis 
In most of the reported examples, the photoinduced asymmetric catalysis is shared by two catalysts, 
a racemic or achiral photoredox sensitizer for triggering visible light induced redox chemistry in 
combination with an asymmetric catalyst (organocatalysts or metal-based complexes) to provide the 
required stereocontrol and the activation of one substrate.24 
1) Enamine catalysis 
 
Figure 10 MacMillan’s dual catalysis strategies for visible-light-induced asymmetric catalysis. 
MacMillan and coworkers reported the first visible light induced asymmetric photoredox catalysis 
in 2008. 25  The direct asymmetric alkylation of aldehydes was accomplished through merging 
photoredox catalysis with organocatalysis. As shown in Figure 10, in the presence of photosensitizer 
Ru(bpy)3Cl2 and a 15 W fluorescent light bulb (CFL), the coupling of aldehydes with electron 
deficient diethyl bromomalonate or phenacyl bromides provided the -alkylated aldehydes with good 
yields and enantioselectivies. Subsequently, switching the sensitizer to iridium complex 
Ir(ppy)2(dtbbpy)PF6 or fac-Ir(ppy)3, MacMillan’s group extended this strategy to asymmetric 
trifluoromethylations and benzylations still with outstanding asymmetric induction. 
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Mechanistically, the catalytic cycle is initiated by reduction of photoexcited PS* with a sacrificial 
amount of formed enamine (not shown in Figure 11) to produce the reductive PS, which transfers a 
single electron to alkyl halides, such as electron deficient diethyl bromomalonate, phenacyl bromides, 
perfluoroalkyl iodides or benzyl bromides, followed by release of a halide leaving group with the 
formation of an electrophilic radical. This radical rapidly reacts with the electron-rich double bond of 
the stereodefined enamine, which was formed by the condensation of chiral imidazolidinone catalyst 
with aldehyde substrate. The generated -aminoalkyl radical is very prone to oxidation and upon 
removal of an electron, the formed iminium ion hydrolyzes and releases the chiral amine catalyst for a 
new catalytic cycle. Quantum yields determined by Yoon and coworkers for a representative model 
reaction reveal that this intermediate -aminoalkyl radical can directly transfer an electron to another 
electrophile substrate, thereby rendering this reaction a chain process (not shown in Figure 11).26 
 
Figure 11 Proposed mechanism for merging photoredox catalysis with asymmetric organocatalysis. PS, 
photosensitizer; SET, single electron transfer; EWG, electron withdrawing group. The chain 
mechanism is not shown here for simplification. 
Stimulated by this pioneering work, Zeiter, König, and Pericàs later revealed that organic dyes and 
inorganic semiconductors are also suitable photosensitizers in this and related systems.27 Recently, 
Luo’s group extended this strategy to build all-carbon quaternary stereocenters with high efficacy and 
enantioselectivities by merging photoredox catalysis and primary amine catalysis (Figure 12).28 This 
open-shell photoradical approach enables -alkylations that are challenging under thermal conditions. 
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Figure 12 Luo’s asymmetric -photoalkylation of -ketocarbonyls by primary amine catalysis. 
2) Lewis acid catalysis 
In 2014, Yoon’s group described a strategy for asymmetric [2+2] photocycloadditions of 
,-unsaturated ketones to cyclobutanes by using a dual catalyst system consisting of photoredox 
catalyst Ru(bpy)3Cl2 and 10 mol% Lewis acid Eu(OTf)3 in combination with 20-30 mol% chiral ligand 
(Figure 13).29 A series of cyclobutanes were produced with 34-80% yields and 84-97% ee. Notably, 
switching the chiral Schiff base ligand to the corresponding reduced secondary amine led to a reverse 
diastereoselectivity from 1,2-trans to 1,2-cis cyclobutanes, that means both the relative and absolute 
stereochemistry of the [2+2]-photocycloaddition products can be obtained through the chiral ligand 
modification. 
 
Figure 13 Yoon’s asymmetric Lewis acid catalyzed [2+2]-cycloaddition of ,-unsaturated ketones 
via photoredox catalysis. 
Mechanistically (Figure 14), photoactivated [Ru*(bpy)3]2+ accepts an electron from iPr2NEt to 
produce the reduced complex [Ru(bpy)3]+ which serves as the reducing agent and transfers a single 
electron to a Lewis acid coordinated aryl enone. The hereby generated intermediate radical anion can 
subsequently participate in efficient [2+2]-cycloaddition reaction with another Michael acceptor. The 
formed cyclobutane containing ketyl radical loses an electron and thereby closes the electron catalysis 
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cycle. Apparently, all reactive intermediates remain coordinated to the chiral europium Lewis acid 
throughout the catalytic cycle so that high enantio- and diastereoselectivities can be reached. The 
authors point out that the high enantioselectivities profit from the fact that no background reaction 
occurs in the absence of the Lewis acid.  
 
Figure 14 Yoon’s proposed mechanism for asymmetric Lewis acid catalyzed [2+2]-cycloaddition via 
photoredox catalysis. 
Yoon and coworkers later reported a catalytic enantioselective addition of -aminoalkyl radicals to 
,-unsaturated carbonyl compounds using a similar dual catalysis strategy (Figure 15).30 The 
addition products were obtained with 33-96% yields and 85-96% ee under visible light irradiation. 
They used scandium(III) triflate together with a pybox ligand as a chiral Lewis acid to control the 
stereochemistry of photoinitiated -aminoalkyl radical Michael additions. The authors concluded that 
the rate acceleration afforded by the Lewis acid catalyst must be large enough to overcome a 
significant racemic background addition in the absence of Lewis acid catalyst. However, catalyst 
loadings of the employed chiral scandium complex are fairly high, and the system is limited to silanes 
with amines in -position. 
 
Figure 15 Yoon’s dual Lewis acid/photoredox catalysis system for the enantioselective 
aminoalkylation of ,-unsaturated carbonyl compounds. 
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One proposed mechanism is shown in Figure 16, the reaction is initiated by oxidative desilylation to 
generate nucleophilic α-aminoalkyl radicals, which in turn add to the coordinated alkene acceptor to 
yield a secondary radical intermediate. It can be expected that the scandium(III) Lewis acid activates 
the Michael acceptor by bidentate coordination, thereby increasing its reactivity towards the 
stereocontrolled addition of the nucleophilic α-aminoalkyl radical. A subsequent single electron 
reduction of the formed α-carbonyl radical followed by protonation provides the product and after 
decomplexation allows another catalytic cycle. Furthermore, it is likely that chain propagation need to 
be considered, since the α-silylamines not only can be oxidized by photoexcited ruthenium sensitizer, 
but also possible by the α-carbonyl radical intermediate. 
 
Figure 16 The proposed mechanism for Yoon’s enantioselective addition of photogenerated α-amino 
radicals to Michael acceptors. 
3) Brønsted acid catalysis 
In 2013, the Knowles group reported a catalytic protocol for enantioselective aza-pinacol 
cyclizations (Figure 17).31 Accordingly, these reactions proceed through a ketyl radical intermediate, 
which was produced via a concerted proton-coupled electron transfer (PCET) event jointly induced by 
a chiral phosphoric acid catalyst (10 mol%) and the photosensitizer Ir(ppy)2(dtbbpy)PF6 (2 mol%). 
The authors propose that H-bonding exists between the neutral ketyl radical and the conjugate base of 
the Brønsted acid. The subsequent C-C bond forming step proceeds under stereocontrol to produce syn 
1,2-amino alcohol derivatives with 77-95% ee. What makes the PCET concept so attractive is the fact 
that proton-coupling facilitate the single electron reduction of functional groups with very negative 
reductive potential, and provides an opportunity to achieve asymmetric induction by using chiral 
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Brønsted acids. 
 
Figure 17 Knowles’ asymmetric aza-pinacol cyclization by merged photoredox catalysis and chiral 
brønsted acid catalysis. 
4) Hydrogen bonding/counterion catalysis 
Stephenson and Jacobsen recently developed an approach for the oxidative, enantioselective C–H 
functionalization of tetrahydroisoquinoline derivatives through sequential two steps reactions (Figure 
18).32 As shown, in the first step, the photoinduced oxidation with co-oxidant CCl4 afforded the 
-chloramines; In a second step in absence of light, switching the solvent to less polar MTBE at 60 
C, and the addition of chiral thiourea ligand (20 mol%) resulted in the formation of counterion pair 
between H-bonded chloride anion and the iminium cation. The counterion catalytic addition of silyl 
enol ether to iminium cation provided the products with 14-72% yields and 42-99% ee. 
 
Figure 18 Asymmetric iminium nucleophilic addition via sequential catalysis through photoinduced 
oxidation followed by asymmetric counterion binding catalysis with a chiral thiourea. 
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5) N-Heterocyclic carbene catalysis 
The Rovis group reported a catalytic asymmetric -acylation of N-aryltetrahydroisoquinolines with 
aldehydes facilitated by the combination of chiral N-heterocyclic carbene catalysis and photoredox 
catalysis (Figure 19).33 Under the irradiation by 15 W blue LEDs, the -acylation products were 
produced with 51-94% yields and 61-92% ee. 
Mechanistically, the reaction is initiated by the condensation of an N-heterocyclic carbene catalyst 
with aldehyde providing a nucleophilic chiral Breslow intermediate, which was trapped by the 
photo-oxidatively generated iminium ion. That results in an enantioselective -acylation of 
N-aryltetrahydroisoquinolines. In the photoredox cycle, the stoichiometric m-dinitrobenzene (m-DNB) 
serves as an oxidative quencher of the photoexcited Ru(bpy)32 and provides the sensitizer 
intermediate Ru(bpy)33, which oxidizes the N-aryltetrahydroisoquinolines to the corresponding amine 
radical cations, followed by the hydrogen atom abstraction to afford the iminium ion. Notably, the 
trace oxygen existing in the reaction mixture likely acts as a terminal oxidant in the photoredox cycle. 
 
Figure 19 Rovis’ asymmetric -acylation of N-aryltetrahydroisoquinolines via N-heterocyclic 
carbene/photoredox combination. 
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6) Nickel catalysis 
In 2014, Molander34 and MacMillan35 reported an impressive merger of photoredox catalysis and 
nickel-catalyzed cross-coupling. In the case of the Molander system, alkoxyalkyl- and benzyl 
trifluoroborates were capable of cross-coupling with aryl bromides under mild photoredox conditions 
using Ni(COD)2/photosensitizer combination (Figure 20).36 Interestingly, Molander and Kozlowski 
later demonstrated that by employing a chiral bisoxazoline ligand, this protocol can be rendered 
enantioselective, albeit with only modest enantioselectivities (three examples, 57-65% ee). 37 
Mechanistically, the single electron oxidation of the trifluoroborate induces a fragmentation into BF3 
and an alkylradical, which is supposed to add to a chiral nickel(0) complex and leads to the formation 
of an alkylnickel(I) intermediate, which in turn undergoes an oxidative addition with the aryl bromide 
to forge a pentacoordinate chiral nickel(III) intermediate. The intermediate nickel(III) complex 
undergoes a rapid enantioselective reductive elimination under release of the cross-coupling product 
and a nickel(I) species which then takes up an electron to close the catalytic cycle. 
 
Figure 20 Molander’s asymmetric cross-coupling by photoredox/nickel dual catalysis. 
MacMillan and Fu later developed an asymmetric decarboxylative Csp3-Csp2 cross-coupling via the 
synergistic merger of photoredox and nickel catalysis (Figure 21).38 Compared to Molander’s system 
(Figure 20), the use of -amino acids as carbon-centered radical precursors, a semicorrin-like chiral 
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ligand as chirality source, provided the benzylic amines with higher enantioselectivities (82-93% ee) 
under mild photoredox conditions. It is worth noting that the highlighted chiral ligand is commercially 
available and air stable. This enantioconvergent approach provides ready access to synthesize 
enantioenriched benzylic amines with low-cost -amino acids as starting materials. 
 
Figure 21 MacMillan and Fu’s asymmetric decarboxylative cross-coupling via photoredox/nickel dual 
catalysis. 
In preliminary summary, strategies recently have been developed in which efficient catalytic 
photochemical processes that work under stereochemical control and provide chiral molecules in an 
asymmetric fashion can be carried out by two catalysts that work in tandem for a single chemical 
transformation.8 In such dual-catalyzed reactions, visible light redox sensitizers are combined with 
asymmetric co-catalysts, such as chiral secondary amines, chiral Lewis acids, chiral Brønsted acids, 
chiral thiourea, chiral N-heterocyclic carbenes, or chiral nickel complexes. 
The octahedral RuII and IrIII complexes have proven to be well-suited as photoredox catalysts for 
these dual catalytic applications. Notably, the octahedral complexes themselves, though chiral, have 
exclusively been used in racemic form. In above instances, the metal-centered chirality has not been 
investigated to influence enantioselectivity of visible-light-activated reactions.39 
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1.3.2 Single Catalyst Induced Asymmetric Photoredox Catalysis 
With respect to single catalyst, apart from applications of UV light in combination with hydrogen 
bonding or Lewis acid interaction has been used previously in pioneering work to trigger 
enantioselective catalysis, 40  there have been only few instances shown as below for 
visible-light-induced asymmetric photoreactions in one-catalyst systems. 
1) Hydrogen bonding catalysis 
Recently, Bach group reported a chiral thioxanthone H-bonding organocatalyst for enantioselective 
[2+2] photocycloaddition reactions induced by visible light (Figure 22).41 In the presence 10 mol% of 
this catalyst, the [2+2] photocycloadditions of 4-(pent-4-enyl)quinolones and their heteroatom 
analogues proceeded with good enantioselectivities (87-94% ee) and high yields (79-95%). Compared 
to the previously established UV-light xanthone sensitizers in Bach group,42 thioxanthones have a 
long wavelength absorption ( = 387 nm). Accordingly, the authors proposed an H-bonding complex 
as the mechanistic model for the asymmetric induction and sensitization. The thioxanthone not only 
can serve as light-harvesting antenna and transfer the energy of the absorbed photon to the quinolones, 
but also provides enantioface differentiation by the planar thioxanthone moiety so that attack at the 
quinolone double bond occurs with good selectivity. The authors mention that the catalyst could be 
recovered in high yield (8510%) after the photocatalytic experiments. However, it should be pointed 
out that the practical synthesis of chiral thioxanthone catalyst is limited to the separation of two 
enantiomers with semipreparative HPLC. This work acts as one of the few examples in which a single 
catalyst is capable to forge enantioenriched compounds via visible light activation. 
 
Figure 22 Bach’s photoinduced asymmetric [2+2] intramolecular cycloaddition via energy transfer. 
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2) Enamine catalysis 
In 2013, Melchiorre and coworkers reported that a chiral amine organocatalyst (20 mol%) can even 
execute the photocatalytic asymmetric -alkylation of aldehydes with electron deficient benzyl 
bromides and phenacyl bromides in the absence of any external photoredox sensitizer (Figure 23).43 
Extensive mechanistic work demonstrated that the reactions proceed through a colored transient 
electron donor-acceptor (EDA) complex III, which is capable to absorb visible light and triggers a 
single electron transfer from the enamine to the organobromine (chiral radical ion pair IV). The 
proposed colored EDA complex consists of an in situ formed colorless electron-rich enamine (donor) 
and a colorless electron-deficient organobromine (acceptor). Thus, EDA formation allows 
SET-triggered redox neutral transformations to be performed without any external photosensitizers. 
 
Figure 23 Melchiorre’s stereoselective catalytic -alkylation of aldehydes driven by photoactive 
electron donor-acceptor complex. 
Notably, the proposed EDA complex formation relied on nonpolar solvent, which is unfavorable for 
the enamine generation, so that high amine catalyst loading is required to hold the effective 
concentration of in situ formed enamine. Compared to the enamine/photosensitizer dual catalysis 
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strategy (Figure 10), the enantioselectivities are slightly lower which is likely caused by the product 
racemization under the elongated reaction time (40-103 h). Later, the Melchiorre group extended this 
strategy to enantioselective -alkylation of cyclic ketones using a quinidine-derived primary amine 
catalyst (Figure 24). 44  After the irradiation (3  23 W CFL) for a long time at 0 C, the 
enantioenriched cyclic ketones were provided with 62-95% ee and 38-94% yield. 
 
Figure 24 Melchiorre’s enantioselective -alkylation of cyclic ketones by means of 
photo-organocatalysis. 
In a related transformation without any external photosensitizer to generate radicals through 
reductive fragmentation and combination with enamine catalysis, MacMillan’s group reported a 
photoinduced asymmetric -amination of aldehydes with 30 mol% chiral secondary amine as catalyst 
(Figure 25). 45  Mechanistically, the reaction is likely initiated by reduction of photoexcited 
2,4-dinitrophenylsulfonyloxy-N-functionalized carbamates with a sacrificial amount of formed 
enamine to release of 2,4-dinitrophenylsulfonate anion and an (electron-deficient) N-centered radical. 
The N-centered radical subsequently undergoes a radical addition to the electron-rich double bond of 
the formed enamine intermediate. In analogy to the described mechanism in Figure 11, it is likely that 
the intermediate α-amino radical directly reduces another substrate 
dinitrophenylsulfonyloxy-N-functionalized carbamate, thereby triggering a chain process. Notably, the 
enamine intermediate and a possible EDA complex are also likely capable of absorbing sufficient 
visible light to induce single electron transfer.46 These two alternative mechanistic pathways were not 
discussed in this work. Furthermore, it should be noted that the generation of this new developed 
chiral secondary amine catalyst requires the separation of two enantiomers with preparative SFC 
which reduces the practical value of this catalyst. 
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Figure 25 MacMillan’s enantioselective -amination of aldehydes via a photoredox mechanism. 
To sum up, in single catalyst system, an enantioselective cycloaddition induced by visible light has 
been introduced, although not including photoinduced electron transfer but instead relying on 
photoinduced energy transfer. Furthermore, some special case of enamine photocatalysis has been 
disclosed in which transient electron donor-acceptor (EDA) complexes are capable of absorbing 
visible light and triggering a charge transfer. However, the photoactive EDA complex system reduces 
the reaction rate, requires nonpolar solvents and high catalyst loadings. Therefore, general solutions 
for interfacing visible light induced photoredox chemistry and asymmetric catalysis with single 
catalysts are highly desirable and will potentially provide new opportunities for reaction design by 
having a closer control over the entire reaction path including the crucial stereodiscrimination step. 
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1.4 Conclusions 
The Meggers group developed a novel class of octahedral chiral-at-metal asymmetric catalysts. 
These inert, rigid metal-templated catalysts transfer chirality relying on exclusive chirality at the metal 
center. A key feature of these synthetic applications is the low catalyst loadings are applicable for all 
described asymmetric reactions, thereby surpassing the performance of most asymmetric 
organocatalysts. Besides hydrogen-bonding catalysts, new inert metal-templated “organocatalysts” are 
highly desirable to be developed through installing other achiral functional ligands around the metal 
center, such as amines (enamine catalysis), nucleophiles (nucleophilic catalysis), acid functional 
groups (Brønsted acid catalysis) or imidazolium ions (NHC carbene catalysis).  
In the described instances of chiral-at-metal iridium(III) complexes promoted asymmetric reactions, 
the catalysis was only mediated through the ligand sphere and did not involve any direct metal 
coordination. In other words, these inert octahedral iridium(III) complexes have limited the nature of 
metal center serving as Lewis acid. Since there are not substitutionally labile ligands installed around 
the metal center, substrates cannot be directly activated by the metal center upon ligand exchange. 
In above examples of asymmetric photoredox catalysis, the octahedral RuII and IrIII complexes have 
been used as photoredox catalysts for photoinduced electron transfer. These racemic octahedral 
transition-metal complexes have promoted the dual catalytic applications in which the photosensitizer 
is combined with a second, stereocontrolling catalyst. The few successes in single catalyst induced 
asymmetric photoreactions profoundly relied on amine catalysts and were restricted to high catalyst 
loadings (20-30 mol%). These significant efforts have proven the design of catalysts that promote 
highly enantioselective photoreactions is still a challenging goal. 
Considering that the prototypical RuII and IrIII photoredox catalysts are chiral octahedral complexes, 
but typically used only as racemates, it is rational to assume that Meggers’ chiral-at-metal iridium(III) 
complexes can also be competent visible-light photoredox catalysts. The development of 
chiral-at-metal iridium(III) complexes would provide new opportunities to realize highly efficient 
asymmetric photoredox catalysis with single chiral-at-metal complexes. 
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Chapter 2: Aim of the Work 
The overall aim of this work is to develop new type of chiral-at-metal octahedral asymmetric catalysts 
and investigate their thermal and photochemical reactivities. The aim of this work contains the 
following three parts. 
2.1 Development and non-photochemical application of metal-templated 
chiral-at-metal enamine/H-bonding dual catalyst 
Recently, our group has reported octahedral chiral-at-metal iridium(III) complexes as low-loading 
asymmetric hydrogen bonding catalysts.1 We wish to expand the metal-templated chiral-at-metal 
technology from H-bonding catalysis to other modes of oganocatalysis. The dual activation by 
multifunctional catalysts has emerged as a powerful concept for the design of high performance 
asymmetric metal-based catalysts and asymmetric organocatalysts.2 A typical bifunctional catalyst 
interacts with both the nucleophile and electrophile (dual activation) through at least overall two 
functional groups (bi- or multifunctional catalysis). However, although appealing as a concept, the 
design of high performance multifunctional catalysts remains challenging since it relies on a distinct 
positioning of carefully chosen functional groups within the chiral catalyst template in order to gain a 
maximum advantage from functional group cooperativity. Hence, one can assume that most 
multifunctional, dual activation catalysts do not reach the theoretically possible rate acceleration and 
asymmetric induction. 
We hypothesize that inert octahedral metal complexes are general, powerful templates for the 
efficient design of multifunctional catalysts since octahedral stereocenters allow the straightforward 
construction of molecular entities with high shape and stereochemical complexity. Herein, we try to 
develop a chiral-at-metal octahedral iridium(III) complex which can serve as a scaffold for the 
straightforward rational design of asymmetric enamine/H-bonding dual activation catalyst. 
Chapter 2. Aim of the Work 
26 
 
 
2.2 Development and non-photochemical application of chiral-at-metal 
Lewis acid catalyst 
Metal-based asymmetric synthesis profoundly relies on organic ligands with point or axial chirality, 
or both.3 The Meggers group has demonstrated that chiral-only-at-metal iridium(III) complexes are 
capable to mediate the asymmetric induction effectively with exclusive metal-centered chirality. 
However, in these examples, catalysis was exclusively mediated through the ligand sphere without any 
direct interaction between the metal center and a substrate. On the other hand, direct metal 
coordination poses a highly attractive mode of activation. One goal was therefore to expand 
chiral-at-metal catalysis from merely metal-templated catalysis to catalysis involving reactive metal 
complexes. 
We here wish to develop a substitutionally labile (reactive) yet configurational stable chiral-at-metal 
iridium(III) Lewis acid catalyst. In the design, the chiral metal center serves the dual function of 
activating a substrate by metal coordination and at the same time provides the required asymmetric 
induction. The chirality of the Lewis acid entirely relies on achiral ligands in the coordination sphere. 
A considerable challenge with respect to these highly desirable features is the potential racemization of 
the metal complexes. Therefore, the synthesis and stability of such chiral-at-metal Lewis acids will be 
carefully investigated. Finally, a suitable model reaction will be performed in presence of the newly 
developed catalyst to verify the viability of this approach. 
 
2.3 Development of catalytic enantioselective photoredox catalysis with 
chiral-at-metal complexes 
The widespread use of octahedral Ir(III) and Ru(II) complexes as photosensitizers can be directly 
attributed to their ability of visible light absorption going along with an electronic excitation. Such 
complexes are typically used in racemic form and do not influence the enantioselectivities of the 
photoreactions.4 We here intend to realize the visible-light-activated asymmetric catalysis with newly 
developed chiral-at-metal complexes. In such a theme, the chiral complex serves both as a 
photosensitizer to induce redox chemistry in the presence of light and at the same time as an 
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asymmetric catalyst. An array of well established asymmetric photoreactions based on dual catalysis 
strategies will be chosen as model reactions to confirm the viability, such as the alkylation of ketones 
with various electron-deficient electrophiles, namely the visible-light-driven benzylation, 
trichloromethylation, perfluoroalkylation; and the Michael addition of stabilized alkyl radicals to 
electron-deficient alkenes. 
Several considerable challenges need to be addressed for this strategy. First, the stability of 
chiral-at-metal complexes under visible light irradiation needs to be investigated, in particular, the 
possible racemization of the catalyst needs to be excluded. Second, the structural optimization of the 
catalyst will impact both enantioselectivity and photophysical properties at the same time. Third, the 
complicated mechanisms of redox chemistry require detailed mechanistic studies to provide insights 
for reaction optimization. Furthermore, non-photochemical (closed-shell) alternative reactions need to 
be considered and model reactions should be selected where redox catalysis is highly advantageous or 
even required. 
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Part I: Non-Photochemical Asymmetric Catalysis with a 
Metal-Templated “Organocatalyst” 
 
3.1 Metal-Templated Asymmetric Enamine/H-Bonding Dual Catalysis 
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3.1 Metal-Templated Asymmetric Enamine/H-Bonding Dual Catalysis 
3.1.1 Catalyst Design and Synthesis 
Recently, the Meggers group has established that octahedral chiral-at-metal iridium(III) complexes 
are exceptionally effective asymmetric catalysts for hydrogen bonding catalysis.1-2 Herein, a class of 
chiral-at-metal octahedral iridium(III) complex was rationally designed to serve as a scaffold for 
asymmetric enamine/H-bonding dual catalysis (Figure. 26). Traditional enamine/H-bonding 
organocatalysts have been widely developed for enantioselective -functionalizations of aldehydes, 
in which the H-bond donor directs the Re face approach of electrophile (A=B) and at the same time 
serving as sterically directing group facilitates the formations of (E)-anti enamine. 3  In this 
metal-templated setup, an achiral ligand containing a secondary amine is installed around the chiral 
metal center, which is anticipated to result in the formation of a configurationally inert 
bis-cyclometalated octahedral complex. There are several factors that seem of particular importance 
in developing such a metal-templated bifunctional catalyst. First, the coordinated amine ligand must 
be capable of forming enamine with aldehydes. Second, only one configuration of enamine is 
favorable to be produced through the steric control of ligand sphere. Third, one of H-bonding donors 
(XH) needs to be an appropriate distance from the secondary amine moiety to allow for a proper 
positioning of the approaching electrophile in relation to the enamine intermediate. Finally, the 
H-bonding directing group must be capable of efficient activation of different electrophiles. 
 
Figure 26 Organic versus metal-templated (this study) bifunctional asymmetric enamine catalysts for 
enantioselective -functionalizations of aldehydes. 
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To confirm the viability of this metal-templated strategy, five bis-cyclometalated octahedral 
iridium(III) complexes -Ir1-5 have been devised for the reaction development (Figure 27).4 In these 
designs, a coordinated 2-pyridyl-5,6-dihydro-4H-pyrrolo[3,4-d][1,3]oxazole ligand contains a 
secondary amine for performing enamine catalysis (nucleophile activation). In order to use the ready 
methods for the synthesis of cyclometalating ligands,5 a simple hydroxyl (-Ir1) or hydroxymethyl 
substituent (-Ir2-4) at the 5-position of the benzoxazole ligands is selected to serve as a potential 
hydrogen bonding donor for the activation and positioning of an electrophile (electrophile activation). 
By comparison of -Ir1 (hydroxyl as H-bond donor) and -Ir2 (hydroxymethyl as H-bond donor), 
the effects of the positioning of H-bonding donors can be evaluated. -Ir5 would verify whether the 
hydrogen bonding activation exists in the catalytic cycle. While the sterically directing group R at the 
5-position of metalated phenyl group is envisioned to direct the enamine conformation. Whether this 
steric hindrance is required or not, which can be figured out by comparison of -Ir2 and -Ir3. If it is 
essential for the satisfactory asymmetric induction, the catalysts -Ir3 and -Ir4 would provide 
significant insights for intuitional optimization. 
 
Figure 27 Metal-templated chiral-at-metal enamine/H-bonding catalysts. 
With the design of metal-templated enamine/H-bonding catalyst completed, the synthesis of 
-Ir1-5 is initiated. The secondary amine ligand 1 was synthesized according to a reported method 
(Scheme 1).6 Cbz-protected amino alcohol 2 was coupled with picolinic acid to afford amide-alcohol 
3 in 93% yield. Oxidation with Dess-Martin oxidant provided the ketone 4, which was unstable on 
silica gel column. After simple workup by washing with NaOH aqueous solution, the crude product 4 
was cyclized using phosphorus pentachloride to afford oxazolopyrrolidine 5. Deprotection of the Cbz 
group to yield the secondary amine ligand 1 was achieved using the strong Lewis acid trimethylsilyl 
iodide. Notably, the typical palladium catalytic hydrogenation for the removal of Cbz is not applicable 
for this system, since palladium catalyst poisoning can be caused by N,N-bidentate coordination. 
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Scheme 1 Synthesis of secondary amine ligand (1). 
With the secondary amine ligand 1 in hand, the synthesis of chiral-at-metal dual activation 
iridium(III) catalysts was investigated. The Meggers group previously developed a synthetic strategy1 
for the generation of enantiomerically pure iridium(III) complexes which relies on the use of 
(S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline 6 as a chiral auxiliary. As described in Scheme 2, 
racemic iridium(III) precursor complexes rac-8a-e were converted to diastereomeric iridium 
complexes, then resolved into single diastereomers by flash silica gel column chromatography, and 
followed by an acid-induced substitution of the auxiliary under complete retention of configuration to 
afford the enantiomerically pure iridium complexes.7 
 
Scheme 2 Outline of the synthesis of the enantiomerically pure catalysts -Ir1-5 and -Ir4. 
NaBArF24 = sodium tetrakis[(3,5-di-trifluoromethyl)phenyl]borate. 
Cyclometalated iridium(III) μ-chloro-bridged dimers rac-8a-e and its derivatives were synthesized 
according to published procedure,8 which involves refluxing IrCl3•nH2O with 2.0–2.5 equivs of 
cyclometalating ligand in a 3:1 mixture of 2-methoxyethanol and water. Accordingly, the 
corresponding substituted benzoxazole ligand was added to iridium chloride in a mixture of 
methoxyethanol/water (3:1). The reaction mixture was heated at reflux (120 °C) for 24 h. The resulting 
Chapter 3. Results and Discussion 
32 
 
precipitate was collected by centrifugation, washed with diethyl ether and dried to yield the iridium 
dimer complexes rac-8a-e as a yellow powder (60-89% crude yield), which were used without further 
purification. The subsequent reaction of chiral thiazoline auxiliary (S)-6 with dimer complexes 
afforded iridium(III) complexes -(S)-9a-e (32-38% yield) and -(S)-9d (37% yield) as a mixture of 
diastereomers, which can be resolved and isolated by silica gel chromatography on 500 mg scale. 
The separated diastereomers -(S)-9a-e or -(S)-9d reacted with secondary amine 1 in the presence 
of the weak acid NH4PF6 to afford the enantiopure iridium catalysts -Ir1-5 (46-71% yield) or -Ir4 
(80% yield) after counterion exchange. The bulky BArF24 anion was used to improve the solubility of 
the iridium catalysts in nonpolar solvents which are favorable for hydrogen bonding catalysis. The 
counterion exchange experiments were performed in Et2O in the presence of 1.0 equivalent NaBArF24 
(sodium tetrakis[(3,5-di-trifluoromethyl)phenyl]borate) providing the BArF24 salt in quantitative yield. 
Whereas the similar procedures in other solvents (DCM, toluene, CH3CN) afforded a mixture 
complexes of BArF24/PF6 salts. The absolute configurations of the obtained -configured iridium(III) 
complexes were verified by CD spectroscopy in analogy to reported complexes.1 The enantiomeric 
purities of -Ir4 and -Ir4 have been verified by chiral HPLC analysis (> 99% ee). 
> 
3.1.2 Reaction Development 
The reaction development was initiated by screening the reactions which have been well established 
for -functionalizations of aldehydes with the typical enamine/H-bonding organocatalysts (Figure 
28).3 Disappointingly, in the presence of 4 mol% newly developed -Ir1, reacting the aldehyde 1a 
with different electrophiles, the desired conjugate addition product (-Nitrostyene 11a as electrophile), 
hydroxyamination product (nitrosobenzene 11b as electrophile) and the Mannich reaction product 
(N-PMP imine 11c as electrophile) were not afforded by the corresponding reactions. For the 
hydroxyamination reaction, the electrophile nitrosobenzene 11b was consumed rapidly (1.5 h) and 
some unidentified compounds were formed. Switching the temperature to 0 °C or 20 °C, did not 
provide any improved results. Encouragingly, when the azodicarboxylate was chosen as the 
electrophile, the configurationally stable amination product 
N-(benzyloxycarbonylamino)oxazolidinone (S)-12a was obtained after in situ reduction with NaBH4 
and NaOH-induced cyclization in 91% yield and with encouraging 22% ee. Notably, to avoid partial 
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racemisation of the initially formed sensitive -hydrazino aldehydes, enantioselectivies were 
determined after aldehyde reduction and subsequent base induced cyclization. Therefore, the direct 
catalytic -amination of aldehydes was chosen as a model reaction with azodicarboxylates as the 
electrophile.9  
 
Figure 28 Attempts toward the -functionalizations of aldehydes with the newly developed 
metal-templated catalyst -Ir1. 
The further optimizations toward the -amination of aldehydes are detailed in Table 1. Accordingly, 
when aldehyde 10a reacted with dibenzyl azodicarboxylate 11d in toluene at 0 °C in the presence of 4 
mol% of -Ir1, (S)-12a was produced with an improved enantioselectivity of 31% ee (Table 1, entry 
1). A repositioning of the hydrogen-bond donor by replacing the phenolic OH by a hydroxymethyl 
group slightly improved the ee value to 39% (-Ir2; Table 1, entry 2). Considering that the low 
enantiodifferentiation might be the result of a missing discrimination between the two possible 
enamine conformations upon reaction of the secondary amine of -Ir2 with aldehyde 12a, so that the 
introduction of steric hindrance at the 5-position of the metalated phenyl group would provide the 
necessary bias towards a single enamine conformation. Indeed, -Ir3, containing a 2,6-Me2Ph 
substituent at the 5-position of the metalated phenyl group provided oxazolidinone (S)-12a with a 
significantly improved ee value of 65% (Table 1, entry 3). Increasing this steric hindrance with the 
more bulky 2,4,6-iPr3Ph substituent (-Ir4) further improved the enantioselectivity to 97% ee at a 
yield of 96% with 4 mol% of -Ir4 (Table, entry 4). Even with a reduced catalyst loading of 1 mol% 
-Ir4, the oxazolidinone (S)-12a was obtained with 91% ee at room temperature (Table 1, entry 5). 
Finally, upon optimization of the reaction conditions by increasing the concentrations of aldehyde 10a 
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(1.5 M) and azodicarboxylate 11d (1.0 M), the reaction time was significantly decreased while 
improving the enantiodifferentiation to 97% ee with 1 mol% -Ir4 (entry 6). Gladly, under these 
conditions, the catalyst loading could be decreased further down to 0.2 mol% (entry 7) and even 0.1 
mol% (entry 8) while retaining satisfactory enantionselectivities of 94% and 91% ee, respectively. 
Table 1 Development of a chiral-at-metal iridium(III) catalyst for the enantioselective -amination of 
aldehydes with azodicarboxylatesa 
 
Entry Cat Loading Cond t(h) yield (%)b ee (%)c 
1 -Ir1 4 mol% 11d (0.1 M), 0 °C 1.5 87 31 
2 -Ir2 4 mol% 11d (0.1 M), 0 °C 2.5 93 39 
3 -Ir3 4 mol% 11d (0.1 M), 0 °C 2.5 93 65 
4 -Ir4 4 mol% 11d (0.1 M), 0 °C 2.5 96 97 
5 -Ir4 1 mol% 11d (0.1 M), RT 36 92 91 
6 -Ir4 1 mol% 11d (1.0 M), RT 12 96 97 
7 -Ir4 0.2 mol% 11d (1.0 M), RT 30 91 94 
8 -Ir4 0.1 mol% 11d (1.0 M), RT 36 89 91 
9 -Ir5 4 mol% 11d (0.1 M), 0 °C 6 88 0 
10 -Ir4 1 mol% 11d (1.0 M), RT, DMF 8 78 28 
11 -Ir4 1 mol% 11d (1.0 M), RT, MeOH 15 13 9 
a Reaction conditions: To a mixture of 11d (0.20 mmol) and iridium catalyst -Ir1-5 (0.1-4 mol%) in 
anhydrous toluene (2.0 mL for entries 1-5 and 9, 0.2 mL for entries 6-8), DMF (0.2 mL) or MeOH (0.2 
mL) at 0 °C was added the aldehyde 10a (0.30 mmol). After being stirred at 0 °C or room temperature 
for 1.5-36 h under reduced light, MeOH (2.0 mL) was added, followed by the careful addition of 
NaBH4 (0.26 mmol) at 0 °C. The products were isolated after basic workup and chromatography. 
b 
Isolated yields. c Enantiomeric excess determined by chiral HPLC analysis. 
Under the assumption that the minor enantiomer is formed from the uncatalyzed background 
reaction, for 0.1 mol% catalyst loading one can calculate an impressive turnover number of almost 103 
with a rate acceleration of 1.0  104. Table 2 reveals the substrate scope of -Ir4, providing the 
corresponding -hydroxyhydrazines (after in situ reduction of the aldehyde) or oxazolidinones (after 
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NaOH-induced cyclization of the -hydroxyhydrazines) with satisfactory yields (73-96%) and high 
enantioselectivities (89-97% ee). Thus, rational design with just a few rounds of optimization afforded 
the highly active chiral-only-at-metal iridium catalyst -Ir4 for the enantioselective -amination of 
aldehydes. 
It’s worth noting that the catalyst can be recycled several times without any significant loss of 
enantioselectivity as determined for the conversion 10a+11d(S)-12a catalyzed by -Ir4 (1 mol%): 
Cycle 1 (1.0 mmol scale) = 76% yield, 97% ee, 81% catalyst recovery; cycle 2 (0.81 mmol scale) = 
71% yield, 95% ee, 78% catalyst recovery; cycle 3 (0.63 mmol scale) = 67% yield, 96% ee, 76% 
catalyst recovery. 
Table 2 Substrate scope of the enantioselective -amination of aldehydes with iridium catalyst -Ir4a 
 
Entry R1 R2 Product t(h) yield (%)b ee (%)c 
1 tBu (10a) Bn (11d) (S)-12a 12 96 97 
2 nBu (10b) Bn (11d) (S)-12b 15 81 94 
3 iPr (10c) Bn (11d) (S)-12c 14 89 95 
4 nPr(10d) Bn (11d) (S)-12d 15 78 96 
5 Et (10e) Bn (11d) (S)-12e 15 73 93 
6 Allyl (10f) Bn (11d) (S)-12f 14 87 92 
7 nHex (10g) Bn (11d) (S)-12g 15 75 95 
8 C6H11 (10h) Bn (11d) (S)-12h 15 77 95 
9 BnOCH2(10i)  Bn (11d) (S)-12i 15 75 91 
10 Bn (10j) Bn (11d) (S)-12j 15 91 89 
11 Bn (10j) tBu (11e) (S)-13kd 15 91 96 
12 Bn (10j) Et (11f) (S)-13ld 15 88 95 
a Reaction conditions: To a mixture of azodicarboxylate 11d-f (0.2 mmol) and -Ir4 (1.0 mol%) in 
anhydrous toluene (0.2 mL, 1.0 M) at 0 °C was added the aldehyde 10a-j (0.30 mmol, 1.5 M). After 
being stirred at RT for 12-15 h, MeOH (0.2 mL) was added followed by the careful addition of NaBH4 
(10 mg, 0.26 mmol) at 0 °C. The products were isolated after basic workup and chromatography. b 
Isolated yields. c Enantiomeric excess determined by chiral HPLC analysis. d No suitable chiral HPLC 
conditions to resolve the two enantiomers were found for the corresponding cyclization products. 
Chapter 3. Results and Discussion 
36 
 
 
3.1.3 Proposed Mechanism 
The mode of action of iridium complex -Ir4 can be rationalized by a bifunctional, dual activation 
catalysis which converts the aldehyde into a nucleophilic enamine, while at the same time activating 
the azodicarboxylate electrophile through hydrogen bonding with one OH-group (Figure 29). The 
asymmetric induction is then achieved by sterically enforcing the (E)-syn enamine conformation 
through sterically preventing the unfavored (E)-anti conformation induced by a bulky 2,4,6-iPr3Ph 
substituent, in combination with a preference for the Si face approach of the electrophile favored by a 
hydrogen bond between a hydroxymethyl group of the benzoxazole moiety and a nitrogen or carbonyl 
oxygen atom of the azodicarboxylate. The importance of this hydrogen bond for catalysis rate and 
enantioselectivity is demonstrated by the result with iridium complex -Ir5, devoid of the hydroxyl 
methyl substituent on the benzoxazole moiety, resulting in the completely racemic formation of 
oxazolidinone 12a (Table 1, entry 9). The importance of this key hydrogen bond for catalysis also 
explains why the aprotic, nonpolar solvent toluene provides superior results to polar (28% ee in DMF, 
entry 10 in Table 1) or protic (9% ee and low yield in MeOH, entry 11 in Table 1) solvents in which 
competing hydrogen bonds disfavor the proposed hydrogen bonded binary complex shown in Figure 
29. A structure of the iridium complex cation of the catalyst -Ir4 (obtained by a former graduate 
student Dr. Chen Fu in Meggers group), derived from a crystal structure of racemic /-Ir4, is shown 
in Figure 30 and illustrates the local environment around the secondary amine with the steric 
interference of one closeby isopropyl group and a neighboring hydroxyl group for hydrogen bond 
interactions, thereby supporting the proposed rationale for the observed efficient asymmetric 
induction. 
 
Figure 29 Proposed enamine/H-bonding mechanism of the -amination of aldehydes (blue) with 
azodicarboxylates (green) catalyzed by iridium complex -Ir4. 
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Figure 30 Structure of -Ir4 (ORTEP drawing with 30% probability thermal ellipsoids). The iridium 
complex was crystallized as an iodide salt in its racemic form. The iodide counterions and the 
-isomer are omitted from the unit cell for clarity. 
 
 
3.1.4 Conclusions 
In conclusion, the first example of an asymmetric enamine catalyst build from an octahedral 
chiral-at-metal complex was presented. 10  With respect to catalyst loading in asymmetric 
organocatalysis,11 iridium complex -Ir4 constitutes one of the most efficient catalysts for the 
enantioselective -amination of aldehydes to date. The high performance and straightforward design 
of the developed enamine/H-bonding dual activation catalyst through just a few cycles of ligand 
optimization indicates the power for a metal-templated design of “organocatalysts”, in which the 
octahedral stereocenter orchestrates the tailored arrangement of functional groups in the 
three-dimensional space, whereas the limited flexibility of the metal scaffold provides entropic 
benefits and promotes the rational catalyst design. 
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3.2 Enantioselective Friedel-Crafts Conjugate Addition with a 
Chiral-at-Metal Lewis Acid Catalyst 
3.2.1 Catalyst Design 
The recently developed metal-templated chiral-at-metal complexes in Meggers group, which 
provide asymmetric induction only through the coordinated ligand sphere (Figure 31).1 These inert 
chiral-at-metal iridium (III) complexes have limited its potential as Lewis acid catalysts. Herein, a 
class of chiral-at-metal iridium(III) complex bearing two labile ligands (acetonitrile) was designed to 
serve as a chiral Lewis acid catalyst. These labile ligands would provide access to iridium center for 
efficient ligand exchange. The direct interactions between substrate and metal center should be 
accessible. In this theme, it is envisioned that the reactive metal center can be highly configurational 
inertness and retains the metal-centered absolute configuration during the asymmetric induction. The 
bis-cyclometalated ligand plays as a very important role in this design. Since it needs to stabilize the 
metal-centered configuration during each catalytic cycle and at the same time it needs to be capable of 
directing one substrate approach to influence the enantioselectivity. Thus, the development of 
chiral-at-metal Lewis acid catalyst should be initiated by designing the bis-cyclometalated ligand. 
 
Figure 31 Catalyst design for the substitutionally labile yet configurationally stable chiral-at-metal 
iridium complex. 
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3.2.2 Initial Experiments 
Considering the H-bonding activation has been well studied in our group, the initial design plan for 
Lewis acid catalyst was based on Lewis acid/H-bonding dual activation strategy. As shown in Figure 
32, the complex -Ir6 was designed to serve as the first generation chiral Lewis acid catalyst. The 
Friedel-Crafts addition of indole to ,-unsaturated 2-acyl pyrazoles was chosen as the model reaction 
to examine the viability. With respect to the proposed mechanistic model, the 2-acyl pyrazole was 
supposed to undergo fast ligand exchange with labile acetonitrile ligands to afford a transitional 
iridium intermediate complex. Meanwhile, the indole was activated and positioned by a formed 
hydrogen bond between NH group of indole and the lone pair of triazole moiety. The indole attacks 
the activated double bond of acceptor from Re face, which would provide the enantioenriched 
compounds. 
 
Figure 32 Initial design plan for directing asymmetric catalysis with metal-centered chirality. 
Encouragingly, the viability of metal coordination strategy was rapidly confirmed with rac-Ir6 as 
the Lewis acid catalyst. The reaction of 14c (R = H) with indole (1.5 equiv) in the presence of 10 
mol% rac-Ir6 afforded the Friedel-Crafts addition product 15c in 92% yield (Figure 33). It’s 
confirmed that the C-C bond formation did not occur in absence of rac-Ir6. When more steric 
substrate 15a or 15b was applied to this protocol, only a negligible amount of addition product was 
observed, respectively. This transformation did not proceed efficiently either in the presence of higher 
catalyst loading (20 mol%) or at higher temperature (40 C). The depressed conversion can be 
rationalized that the metal center of Ir6 severed as a Lewis acid is not electron deficient enough due to 
Chater 3. Results and Discussion 
42 
 
the extended -system of triazole moiety. So next increasing the reactivity of Lewis acid metal center 
might improve the reaction efficiency. 
 
Figure 33 Rac-Ir6 catalyzed Friedel-Crafts additions of indole to ,-unsaturated 2-acyl pyrazoles. 
Comparing to that no detectable addition product 15a was formed with catalyst rac-Ir6, a dramatic 
improvement was observed when a more electron deficient Lewis acid catalyst rac-Ir7 was employed 
(Scheme 3). The 99% yield of 15a was achieved from the reaction of 14a with indole in the presence 
of 10 mol% rac-Ir7, which demonstrated that the nature of the metal center is crucial for substrate 
activation. Whereas the hydrogen bond activation of indole is not required for the Friedel-Crafts 
Michael addition. Considering the expected asymmetric induction, the nucleophile not only can 
approach from Re face of the coordinated acceptor, but also can attack the coordinated acceptor from 
Si face, both of the sides are not sterically shielded differently. Therefore, the chiral Ir7 was not be 
synthesized for the further investigation. 
 
Scheme 3 Evaluation of Friedel-Crafts addition with rac-Ir7. 
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3.2.3 Development of Catalyst -IrO and -IrO 
Base on the above evaluations, -IrO and -IrO were designed for investigating the scope of 
asymmetric catalysis with reactive but configurationally stable chiral-only-at-metal complexes (Figure 
34). The C2-symmetrical complex IrO contains two cyclometalating 
5-tert-butyl-2-phenylbenzoxazoles and two labile acetonitrile ligands. The tBu group arranged in one 
of cyclometalating ligand blocks one face of the coordinated electrophile, leaving the other face open 
for approach of nucleophile. Despite all ligands being achiral, metal-centered chirality leads to a - 
(left-handed propeller) and -enantiomer (right-handed propeller). In this design, the metal center 
serves the dual function of activating a substrate by metal coordination and at the same time comprises 
the configurationally stable sole element of chirality, thus entirely relying on achiral ligands in the 
coordination sphere. 
 
Figure 34 Enantiomers of a substitutionally labile yet configurationally stable chiral-at-metal 
iridium(III) complex. 
The synthesis of the complexes -IrO and -IrO is straightforward and draws from methodology 
recently developed in Meggers laboratory. 2 , 3  Accordingly, the reaction of IrCl33H2O with 
benzoxazole 16 affords the cyclometalated racemic iridium(III) dimer rac-17 in a diastereoselective 
fashion (Scheme 4). The subsequent reaction of rac-17 with the chiral auxiliary ligand 
(S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline 6 provides the two diastereomeric complexes 
-(S)-18 and -(S)-18 which can be resolved by standard silica gel chromatography, followed by the 
conversion to virtually enantiopure -IrO and -IrO (each 99% ee), respectively, through the 
stereospecific substitution of the chiral auxiliary ligand (upon protonation by NH4PF6) by two 
acetonitrile ligands. 
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Scheme 4 Synthesis of the enantiomerically pure complexes -IrO and -IrO. 
The auxiliary removal of -(S)-18 has been examined under different conditions (Table 3). 
According to the reported procedure of related process in Meggers group,2 adding 5 equivalents of 
trifluoroacetic acid to the reaction mixture in acetonitrile, the chiral auxiliary was removed completely 
in 5 minutes as monitored by TLC (entry 1). When the crude material was subjected to the silica gel 
column utilizing CH3CN / KNO3 (sat.aq) / H2O (200:3:1) as mobile phase, after the counterion exchange 
only moderate yield of 41% was obtained. It is worth to point out that counterion anion exchange was 
processed due to the compatible solubility of PF6 ion complex in most of organic solvent. The crude 
acetonitrile complex was found partial decomposed on the reversed phase silica gel column. When 
hydrochloric acid was used, the same problem caused the lower formation of -IrO in entry 2. When 
the reaction was performed in the presence of weak acid NH4PF6 at 50 C, -IrO can be directly 
isolated in quant yield as a PF6 complex. Combined solvent system in the presence of CH3CN is 
curious for stabilization of Lewis acid catalysts on the silica gel column. 
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Table 3 The optimization toward the synthesis of enantiopure catalyst -IrO. 
 
Reaction conditions: Diastereomeric complexe -(S)-18 (0.05 mmol), proton source (5 eq or 20 eq) in 
CH3CN (1.0 mL) were stirred at the indicated time under nitrogen. FC = flash chromatography 
It’s worth noting that the protocol using NH4PF6 as proton source (entry 3) sometimes could not be 
reproduced well due to the unstable commercial quality of NH4PF6. After purification by silica gel 
chromatography, the related products were often obtained as a mixture of iridium complexes. The 
1H-NMR revealed that this mixture did not contain any chiral auxiliary ligand moiety, which seems 
reasonable considering that these complexes were consistent of non-acetonitrile, mono-acetonitrile and 
diacetonitrile complexes. When the impure complexes were subjected to follow-up chemistry in the 
presence of bipyridine (Scheme 5), the desired complex Ir8 was isolated in 95% yield, which also 
supported this assumption. So an alternative protocol was developed for the synthesis of -IrO (table 
1, entry 4). In this case, the counterion exchange is firstly carried out before silica gel chromatography. 
The reverse mobile phase used in Entry 1-2 is not required for this protocol. Instead, using the 
combined solvent CH2Cl2/CH3CN as the mobile phase for the chromatography, the pure -IrO can be 
obtained in 87% yield. Despite the yield is slightly worse, this protocol is practical and very easy to be 
reproducted. 
entry conditions yield 
1 TFA (5 eq), rt, 5 min, FC purified by CH3CN/KNO3(sat.aq)/H2O (200:3:1) 
finally precipitated by excess NH4PF6 (20 eq) 
41% 
2 HCl (5 eq), rt, 5 min, FC purified by CH3CN/KNO3(sat.aq)/H2O (200:3:1) 
finally precipitated by excess NH4PF6 (20 eq) 
35% 
3 NH4PF6 (20 eq), 50 C, 4 h, FC purified by CH3CN/DCM (10:1) 100% 
4 TFA (5 eq), rt, 5 min, counterion exchange with excess NH4PF6 (20 eq) 
finally FC purified by CH3CN/DCM (10:1) 
87% 
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Scheme 5 The transformation of impure complexes derived from the auxiliary complex -(S)-5. 
A crystal structure of -IrO confirms the assigned absolute metal-centered configurations (Figure 
35, obtained by a former graduate student Dr. Chen Fu in Meggers group). HPLC traces using a chiral 
stationary phase are shown in Figure 36 and reveal the high enantiopurity of the synthesized 
complexes -IrO and -IrO. Interestingly, these substitutionally labile chiral-only-at-metal 
complexes are configurationally stable as -IrO did not show any significant sign of configurational 
lability or decomposition upon standing in CH2Cl2 on the benchtop for 8 days, as verified by 1H-NMR 
and chiral HPLC analysis (see Experimental Part). 
 
Figure 35 Crystal structure of -IrO. The hexafluorophosphate counteranion is omitted for clarity. ORTEP 
drawing with 50% probability thermal ellipsoids. 
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Figure 36 Chiral HPLC traces demonstrating the enantiopurity of synthesized -IrO and -IrO. 
HPLC conditions: Daicel Chiralcel IB, 250 × 4.6 mm, flow rate = 0.5 ml/min, 0.1% aq. TFA with 
MeCN as eluent (20-43% in 60 min). 
3.2.4 Reaction Optimization and Substrate Scope 
 
Figure 37 Substrate design results in improved reaction efficiency. 
With the enantiopure -IrO in hand, the asymmetric catalytic reactions were performed with 
substrates bearing the different auxiliaries (Figure 37). Considering the isomerisation of double bond 
of alkene 14a will decrease the enantioselectivity, the substrate 14a was replaced by 16a bearing the 
3,5-dimethyl substitution in the pyrazole moiety to prevent isomerisation. The ,-unsaturated 2-acyl 
pyrazole 16a provided the product 17a in 41% yield and with encourage 88% ee. Using the 
,-unsaturated 2-acyl imidazole 18a, the yield and enantioselectivity could be improved to 99% and 
97% ee, respectively. 
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Based on the above observation, the further optimization was focused on the Friedel-Crafts 
conjugate addition of indole to ,-unsaturated 2-acyl imidazole 18a (Table 4).4 Revealingly, the 
reaction of 18a with indole (1.5 eq) in the presence of 1 mol% -IrO afforded the Friedel-Crafts 
alkylation product (S)-19a with high enantioselectivity (95% ee) albeit with only a slow conversion of 
just 35% after 20 h at room temperature in MeCN (Table 4, entry 1). A solvent screening revealed that 
MeOH, CH2Cl2 and THF, among others, provide higher catalysis rates (entries 2-4). Optimization of 
the reaction conditions with THF as the solvent by increasing the concentration of 18a and the 
equivalents of indole (2.5 eq) led to full conversion at room temperature within 20 h and a high ee of 
96% (entry 5). Interestingly, the reaction is insensitive to air (entry 6) and water (entry 7), and the 
enantioselectivity can be further improved by reducing the temperature, reaching 97% ee at 0 °C 
(entry 8). 
Table 4 Enantioselective Friedel-Crafts addition of indole to ,-unsaturated 2-acyl imidazole 18a 
catalyzed by -IrOa 
 
entry solvent conditions conv (%)b ee (%)c 
1 MeCN 1.5 eq indole (0.75 M), rt, 20 h 35 95 
2 MeOH 1.5 eq indole (0.75 M), rt, 20 h 70 95 
3 CH2Cl2 1.5 eq indole (0.75 M), rt, 20 h 90 94 
4 THF 1.5 eq indole (0.75 M), rt, 20 h 85 96 
5 THF 2.5 eq indole (2.5 M), rt, 20 h 100 96 
6 THF as entry 5 plus air 100 96 
7 THF as entry 5 plus air and 1% H2O 88 96 
8 THF 2.5 eq indole (2.5 M), 0 °C, 36 h 100 97 
a Reaction conditions: Imidazole 18a (0.30 mmol), indole (0.45 mmol or 0.75 mmol), and -IrO (1.0 
mol%) in the indicated solvent (0.60 mL or 0.30 mL) were stirred at the indicated temperature under 
argon or air. b Conversion determined by 1H-NMR. c Determined by chiral HPLC analysis. 
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Next, the substrate scope of catalyst -IrO was investigated. Table 5 shows that a selection of 
thirteen substituted indoles provide the desired Friedel-Crafts alkylation products (S)-19a-m with high 
enantioselectivities (90-98% ee) in yields of 75-99% in the presence of 1-2 mol% of -IrO. Electron 
acceptor substituted less reactive indoles require a somewhat increased catalyst loading (2.0 mol%) 
(entries 4 and 5), while the more reactive 2-methyl indole needs a lower reaction temperature to 
achieve a high ee value (entry 12). 
Table 5 Enantioselective Friedel-Crafts addition of substituted indoles to ,-unsaturated 2-acyl 
imidazole 18a catalyzed by -IrOa 
 
entry indoles -IrO 
(mol%) 
T 
(°C) 
t 
(h) 
yield 
(%)b 
ee 
(%)c R1 R2 R3 R4 
1 H H H H 1.0 rt 20 97 96 
2 H Me H H 1.0 rt 18 98 94 
3 H MeO H H 1.0 rt 22 99 94 
4 H Br H H 2.0 rt 48 75 92 
5 H Cl H H 2.0 rt 48 77 94 
6 MeO H H H 1.0 rt 18 91 95 
7 H H H Me 1.0 rt 22 99 96 
8 H H H Bn 1.0 rt 22 82 95 
9 H Me H Bn 1.0 rt 18 92 94 
10 H MeO H Bn 1.0 rt 18 91 94 
11 MeO H H Bn 1.0 rt 22 90 95 
12 H H Me Me 2.0 0 36 93 98 
13 H H Ph Me 2.0 rt 40 97 90 
a Data reported as entry, reaction conditions: Indoles 20a-m (0.75 mmol), imidazole 18a (0.30 mmol) 
and -IrO (1.0 or 2.0 mol%) in THF (0.30 mL) were stirred at the indicated temperature under argon. 
b Isolated yields. c Determined by chiral HPLC analysis. 
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The substrate scope with respect to different ,-unsaturated 2-acylimidazoles 18b-g is shown in 
Table 6 and demonstrates that upon adjustment of the catalyst loading (1-2 mol% -1 or -1), reaction 
temperature (0 °C or room temperature), and concentration (1.0 or 2.0 M 18b-g), very good to 
excellent enantioselectivities (91-98% ee) and yields (78-99%) are achieved for each system (entries 
1-6). The ,-unsaturated 2-acylimidazole 18g, bearing an N-isopropyl substituent at the imidazole 
instead of a methyl group, even allows to reduce the catalyst loading to 0.25 mol% without affecting 
the enantioselectivity (97% ee) (entries 6-8). This reflects a respectable turnover number of 364, while 
not affecting the stereochemical integrity of the metal-centered chirality during all the catalytic cycles. 
Table 6 Enantioselective Friedel-Crafts addition of indole to ,-unsaturated 2-acyl imidazoles 18b-g 
catalyzed by -IrO or -IrOa 
 
entry imidazolesb 
cat (mol%) T (°C) t (h) yield (%)c ee (%)d 
R5 R6 
1 Et Me -IrO (2.0) 0 48 89 (21a) 96 
2 nBu Me -IrO (2.0) rt 20 97 (21b) 91 
3e iPr Me -IrO (2.0) rt 48 78 (21c) 93 
4 Ph Me -IrO (1.0) rt 16 98 (21d) 93 
5 CO2Et Me -IrO (1.0) rt 24 97 (21e) 98 
6 Me iPr -IrO (1.0) rt 24 99 (21f) 97 
7 Me iPr -IrO (0.5) rt 44 97 (21f) 97 
8 Me iPr -IrO (0.25) rt 60 91 (21f) 97 
a Data reported as entry, reaction conditions: Imidazoles 18b-g (0.30 mmol), indole (0.75 mmol) and 
-IrO or -IrO (0.25-2.0 mol%) in THF (0.30 mL) were stirred at the indicated temperature under 
argon. b 18b-g consecutively listed from entry 1 to 6. c Isolated yields with the individual products 
indicated in brackets. d Determined by chiral HPLC analysis. R-configuration: entries 1, 2, and 4-8. 
S-configuration: entry 3. e Increased concentration of 18d (2.0 M) in order to speed up the reaction. 
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3.2.5 Proposed Mechanistic Model 
The C2-symmetrical iridium complex IrO was designed to serve as a chiral Lewis acid by activating 
,-unsaturated 2-acyl imidazoles through bidentate N,O-coordination. A proposed model for the 
asymmetric induction in the course of the indole addition that is consistent with the experimental 
results is shown in Figure 38 and demonstrates that one face of the alkene is sterically shielded 
effectively by one of the tert-butyl group, and the other face is leaving open for the approach of 
nucleophile. An intermediate crystal structure with N-iPr 2-acyl imidazole (provided by a former 
graduate student Dr. Xiaodong Shen in Meggers group), is shown in Figure 39 and reveals the local 
environment around chiral metal center, thereby supporting the proposed mechanistic mode for 
observed efficient asymmetric induction. 
 
Figure 38 Proposed model for the asymmetric induction in the transition state in which one face of the 
alkene is shielded by the C2-symmetrical catalyst. 
 
Figure 39 An intermediate crystal structure of ,-unsaturated 2-acyl imidazole complexes with IrO. 
The hexafluorophosphate counteranion is omitted for clarity. ORTEP drawing with 50% probability 
thermal ellipsoids. 
Chater 3. Results and Discussion 
52 
 
It is worth noting that the high lability of the coordinated MeCN ligands of catalyst IrO is a 
consequence of the strong trans-effect of the Ir-C bonds. 1H-NMR spectra recorded in CD2Cl2 at room 
temperature after the addition of acyl imidazole 18a to catalyst -IrO support the fast bidentate 
coordination of 18a to the catalyst upon release of the two labile acetonitrile ligands (see Experiment 
Part). Thus, the mechanistic mode of action of catalyst IrO relies on the coordinative lability of the 
MeCN ligands in combination with a high configurational stability of the remaining octahedral 
coordination sphere in order to retain the metal-centered chirality at all times. 
 
3.2.6 Conclusions 
In conclusion, a novel class of asymmetric transition metal catalysts was developed, in which the 
metal fulfills a dual function by coordinatively activating a substrate and at the same time serving as 
the sole source of chirality. Whereas typical metal-coordination-based asymmetric catalysts rely on 
chiral ligands for their asymmetric induction, the here introduced bis-cyclometalated iridium(III) 
complex IrO is distinguished by its simplicity as it just contains two achiral cyclometalating 
phenylbenzoxazoles and two labile acetonitriles. The high configurational stability of the octahedral 
iridium chiral center is unexpected considering that labile ligands generally reduce the activation 
barrier for isomerization. Beyond its conceptual appeal, bis-cyclometalated octahedral iridium(III) 
complex IrO might be of high practical value as it provides an excellent substrate scope for the highly 
enantioselective Friedel-Crafts addition of indoles to ,-unsaturated 2-acyl imidazoles at low catalyst 
loadings (0.25-2 mol%), while at the same time catalyst IrO displays a high solvent tolerance, does 
not rely on cryogenic temperatures, and can even be used under open flask conditions.5 This high 
performance indicates the value of a direct chirality transfer from the chiral metal to the coordinated 
substrate. 
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This novel class of reactive chiral-at-metal complexes has proven to be of high value for a large 
variety of asymmetric transformation. Since the initial discovery of this chiral-at-metal iridium(III) 
Lewis catalyst, efforts in this process have proven to be promising. -IrO has been successfully 
extended to a series of asymmetric transformations (Figure 40). The further optimization and 
mechanistic insights of listed reactions were investigated by Xiaodong Shen, a graduate student in 
Meggers group.6 Progresses towards these value transformations were detailed in his PhD thesis. 
 
Figure 40 A series of asymmetric reactions were found to be catalyzed by -IrO. 
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3.3  Visible-Light-Activated Enantioselective Alkylation with a Chiral 
Iridium Complex 
3.3.1 Reaction Design 
The inherent nature of -IrO as a chiral Lewis acid catalyst has been proven by the enantioselective 
Friedel-Crafts addition of indoles to ,-unsaturated 2-acyl imidazoles in chapter 3.2,1  which 
simulated us to extend the study from non-photochemical applications to asymmetric photoredox 
catalysis with chiral-at-metal iridium complex.2 
 
Figure 41 Initial design plan for asymmetric photoredox catalysis with chiral-at-metal -IrO. 
The Yoon group recently reported enantioselective conjugate addition of -amino radicals through 
cooperative catalysis with two catalysts (Figure 41).3 This study was initiated by investigating the 
similar addition of -silylamine 22 to ,-unsaturated 2-acyl imidazole 18a with single catalyst -IrO 
under photoredox conditions. As shown in Figure 41, the addition of photo-oxidatively generated 
-aminoradicals to the coordinating Michael acceptor might produce non-racemic compound. Two 
possible scenarios were envisioned. First, -IrO or the coordinated intermediate complex can sever as 
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a photosensitizer to mediate the photoredox chemistry. Second, the -IrO can strongly accelerate the 
involved key radical addition step to overcome the racemic background reaction with uncoordinated 
substrates. 
The viability of this initial plan was rapidly confirmed with the newly developed catalyst -IrO 
(Figure 42). In the presence of 20 mol% -IrO, the conjugate addition product 23 was provided in 
43% yield and with 37% ee. The control experiment verified the visible light is essential for the 
product formation. Disappointingly, with catalytic amount of -IrO (10-30 mol%), the further 
optimization based on the concentration, solvent, temperature, -amino radical precursors and the 
ratios of reaction partners did not provide any promising results. That means the prevailing racemic 
background reaction could not be overcome efficiently in this single catalyst system. Notably, when 
running the reaction with stoichiometric -IrO (100 mol%), the good enantioselectivity (85% ee) can 
be realized, albeit with depressed yield of 16%. 
 
Figure 42 Initial experiments to the photoinduced reaction of ,-unsaturated 2-acyl imidazole 7 with 
-silylamine 22 catalyzed by -IrO. 
The above observation suggests that the chiral iridium complex IrO can serves as an photoredox 
catalyst and at the same provide asymmetric induction, while the hindrance caused by uncatalyzed 
background reactions needs to be addressed with new strategy. The enamine catalysis has been widely 
applied in asymmetric photoredox catalysis for the -alkylation of aldehydes or ketones, in which the 
electron rich enamine intermediates enable to couple with various electron-deficient electrophilic 
radicals under stereocontrol (Figure 43).4 Our group recently realized the asymmetric -amination of 
2-acyl imidazoles with -IrO through enolate activation mode (non-photochemical application).5 
Thus, extending the study of asymmetric photoredox catalysis from enamine catalysis to enolate 
chemistry is highly reasonable. It promises new access to asymmetric photoredox catalysis with single 
catalyst. The alkylation of 2-acyl imidazoles with electron-deficient radicals was chosen as the model 
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reaction. In this system, the formation of enolate species only relies on the coordination activation; the 
reaction can avoid uncatalyzed background reaction and provide the enantioenriched compounds. 
 
Figure 43 New strategy for photoredox catalysis based on the enolate activation mode. 
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3.3.2 Reaction Optimization 
The reaction of 2-acyl imidazole 24a with the electron deficient benzyl bromide 25a was selected as 
the starting point (Table 7). Encouragingly, in the presence of a 14 W energy saving household lamp, 
-IrO at a loading of 5 mol% was able to catalyze the reaction between 24a and 25a, providing the 
-alkylation product 26a in a good yield of 85% and with high enantioselectivity of 95% ee after 20 
hours photolysis at room temperature (entry 1 of Table 7). Optimization of the reaction conditions by 
empirically adjusting the solvent, increasing the concentration to speed up the reaction, slightly raising 
the temperature to promote ligand exchange at the iridium center, and adding the weak base Na2HPO4 
to facilitate enolate chemistry, provided the product 26a in an excellent yield of 97% with 95% ee 
already after exposure to visible light for just 3 h in the presence of a reduced catalyst loading of just 2 
mol% -IrO (entry 4).  
The derivative catalyst -IrS (firstly synthesized by the Xiaodong Shen, a graduate student in 
Meggers group) was used for the further optimization.6 The catalyst -IrS (2 mol%) even provided 
the -alkylation product in quantitative yield with a superior enantioselectivity of 99% ee and a further 
reduced reaction time of 1.5 h (entry 5). Remarkably, the loading of the catalyst -IrS can be further 
decreased to merely 0.5 mol% without affecting much the yield (97%) and enantioselectivity (98% ee) 
(entry 6). The reaction was inhibited completely in the presence of air, which is consistent of a radical 
mechanism. Importantly, neither the catalyst -IrS alone in the dark (entry 8) nor visible light in the 
absence of the catalyst (entry 9) trigger this reaction to a significant degree under these conditions, 
thus unequivocally demonstrating that it is the combination out of iridium(III) catalyst and visible light 
that is necessary to catalyze the enantioselective C-C bond formation. 
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Table 7 Initial evaluation and optimization of the photoinduced enantioselective alkylation of acyl 
imidazole 24a with benzyl bromide 25a catalyzed by -IrO or -IrS. 
 
Entry Catalyst ha Reaction conditionsb t (h) yield (%)c ee (%)d 
1 -IrO 
(5 mol%) 
visible light 24a (0.3 M, 3 eq), MeOH, r.t. 20 85 95 
2 -IrO 
(2 mol%) 
visible light Na2HPO4, 24a (0.6 M, 1.5 eq), 
MeOH/THF (4:1), r.t. 
5 70 89 
3 -IrO 
(2 mol%) 
visible light Na2HPO4, 24a (1.2 M, 3 eq), 
MeOH/THF (4:1), r.t. 
5 97 92 
4 -IrO 
(2 mol%) 
visible light Na2HPO4, 24a (1.2 M, 3 eq), 
MeOH/THF (4:1), 40 °C 
3 97 95 
5 -IrS 
(2 mol%) 
visible light same as entry 4 1.5 100 99 
6 -IrS 
(0.5 mol%) 
visible light same as entry 4 4.5 97 98 
7 -IrS 
(2 mol%) 
visible light same as entry 4,  
but without degassing 
12 0 n.a. 
8 -IrS 
(2 mol%) 
dark same as entry 4 1.5 <5 n.d. 
9 none visible light same as entry 4 16 0 n.a. 
a Light source: 14 W white light energy saving lamp. b All reactions performed under exclusion of air. 
See Experimental Part for more details. c Isolated yields. d Enantiomeric excess determined by HPLC 
analysis on chiral stationary phase. n.d. = not determined, n.a. = not applicable, r.t. = room 
temperature. 
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Using 24a and 24k as representative substrates, different bases were also evaluated in these 
alkylation reactions (Table 8). The screening of bases revealed that Na2HPO4 was the best choice of 
base for these reactions and it can significantly accelerate the reaction rate. Although for the acidic 
substrate 24k, the base is not essential for the achieving high conversions and excellent 
enantioselectivities (entry 8), even the base can slightly decrease the enantioselectivity (entry 7). 
While the base Na2HPO4 was still preferred due to the significant rate acceleration. Moreover, the 
affect of the enantioselectivivity caused by the base can be further overcome by raising the reaction 
temperature to 40 C to promote the ligand exchange rate (entry 7). 
Table 8 Screening of different bases in the photoinduced alkylation reaction. 
 
Entry R1 Base t (h) yield (%)a ee (%)b 
1 Ph NaHCO3 3.5 99 86 
2 Ph Na2CO3 5 65 12 
3 Ph NaOAc 3 73 21 
4 Ph DTBPc 6 85 87 
5 Ph 2,6-lutidine 3 99 91 
6 Ph NaH2PO4 15 85 76 
7 Ph Na2HPO4 2 99 93/97
d 
8 Ph none 15 90 97 
9 Me Na2HPO4 15 87 91 
10 Me none 15 19 91 
aIsolated yields. b Enantiomeric excess determined by HPLC analysis on chiral stationary phase. c 
DTBP = 2,6-Di-tert-butylpyridine. d The reaction was run at 40 C. 
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3.3.3 Substrate Scope 
Examples of the photoinduced enantioselective -alkylation of 2-acyl imidazoles with benzyl 
bromides catalyzed by -IrS are summarized in Figure 44 (next page). A variety of electron acceptor 
substituted benzyl bromides provide the -alkylation products in up to quantitative yields (97-100%) 
and with up to almost perfect enantioselectivities (94-99% ee), while requiring only short reaction 
times of 1.5 to 6 hours (26a-d). On the other hand, the 2-phenacyl-N-methylimidazole substrates 
tolerate steric (products 26e and 26f), electron donating (product 26g) and electron accepting (product 
26h) substituents in the phenyl moiety, while the benzene moiety can be replaced by the bicyclic 
aromatic naphthalene (product 26i) or heteroaromatic thiophene (product 26j). Furthermore, the 
photoredox catalyzed reaction also tolerates less acidic 2-acyl-N-methylimidazoles devoid of any 
aromatic substituent at the methylene group as demonstrated for the products 26k and 26l. For these 
substrates, the addition of a weak base is essential for achieving high conversions and excellent 
enantioselectivities. A different class of electrophiles were also suitable for this chemistry, namely 
phenacyl bromides, and found that they readily provide the expected C-C bond formation products 
with very good yields of 86-91% and high enantioselectivities of 90-91% ee (products 26m-p). In 
order to reach satisfactory enantioselectivities, the N-methyl substituent at the imidazole moiety was 
replaced against the more bulky isopropyl group (26m vs 26m’, 26n vs 26n’). Overall, it can be 
concluded that -IrS highly effectively catalyzes the -alkylation of acyl imidazoles with acceptor 
substituted benzyl bromides and phenacyl bromides in the presence of visible light with high to 
quantitative yields and impressive enantioselectivities, while only using a catalyst loading of 2 mol%. 
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Figure 44 Substrate scope of the photoinduced enantioselective alkylation of 2-acyl imidazoles with 
acceptor substituted benzyl bromides and phenacyl bromides. Reported yields represent isolated yields 
after chromatographic purification. Enantiomeric excess was determined by HPLC on a chiral 
stationary phase. aFor comparison, in the absence of base a yield of 18% with 91% ee was obtained 
after photolysis for 24 h. bIrradiated instead with a blue LED light source (3 Watt) in order to improve 
the yield. 
Interestingly, this chemistry is also amenable to -alkylation of phenacyl bromides without acceptor 
substituted group (Figure 45), providing general access to the asymmetric synthesis of 
1,4-dicarboxylate compounds. The corresponding products were obtained with good 
enantioselectivities and high yields. Likewise, the adjustment of N-substituent group at the imidazole 
moiety is required for the satisfactory enantioselectivities (26s vs 26s’). 
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Figure 45 Examples of the photoinduced enantioselective alkylation of 2-acyl imidazoles without 
acceptor substituted phenacyl bromides. 
Before the -IrS was applied to this system, a range of different electrophiles had been investigated 
under the optimal conditions with -IrO. In order to give a clear comparison of the catalytic 
efficiency of -IrO and -IrS, the related results were summarized in Figure 46. Apparently, the 
-IrS always provides -alkylation products with better enantioselectivies. The improved 
enantioselectivity can be attributed to an increased steric hindrance in -IrS compared to -IrS 
created by the long C-S bonds of the benzothiazole moieties which position the two tert-butyl groups 
somewhat closer to the exchange-labile acetonitrile ligands (Figure 47, next page). Therefore, the 
better steric induction and faster catalytic turnover rate can be achieved by -IrS. 
 
Figure 46 Comparison of the catalytic efficiency of -IrO and -IrS. 
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dC35-C40 = 4.83 Å
dC16-C43 = 4.88 Å
-Ir1: carbons in cream
-Ir2: carbons in grey
b)
c)
a)
dC16-C43 = 5.18 Å, dC35-C40 = 5.20 Å
 
Figure 47 Comparison of the structures of IrO and IrS. a,b) Distances between the quaternary carbon 
atoms of the tert-butyl groups and the nitrile carbons of the neighboring MeCN ligands in -IrO and 
-IrS. c) Superimposed structures of the cationic complexes of -IrO and -IrS. -IrO was 
obtained by mirror imaging the previous crystal structure of -IrO.  
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3.3.4 Plausible Mechanism 
A plausible mechanism in which photoredox catalysis intertwines with asymmetric catalysis is 
shown in Figure 48. Herein, the catalysis is initiated by the coordination of 2-acyl imidazoles (24) to 
the iridium catalyst in a bidentate fashion (intermediate I), followed by the formation of a nucleophilic 
enolate iridium(III) complex (intermediate II) upon deprotonation. The subsequent chirality generating 
key step constitutes the exergonic addition of a photo-reductively generated electrophilic radical to the 
electron rich metal-coordinated enolate double bond, thereby affording an iridium-coordinated ketyl 
radical (intermediate III). Oxidation of this ketyl intermediate to a ketone by single electron transfer 
provides the iridium-coordinated product (complex IV), which is released upon exchange against 
unreacted starting material, followed by a new catalytic cycle. The single electron transfer either 
regenerates the iridium(III) photosensitizer or leads to the reduction of another arganobromide 
substrate, thereby initiating a chain reaction. Proposed key intermediate which uniquely connects the 
asymmetric catalysis with the photoredox cycle is the iridium(III) enolate complex II, which not only 
provides the crucial asymmetric induction in the catalysis cycle and but at the same time serves as the 
in situ generated active chiral photosensitizer.7 A series of investigations have been executed to verify 
the proposed mechanism in the following section. 
 
Figure 48 Plausible mechanism for a combined photoredox and asymmetric catalysis. SET = single 
electron transfer, EWG = electron withdrawing group, PS = photosensitizer in form of enolate 
complex II. 
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3.3.5 Mechanistic Investigations 
1) Crystal structure analysis 
To start with, as confirmed by X-ray crystallography (Figure 49), 2-acyl-N-methylimidazoles 
efficiently coordinate to the iridium catalyst -IrS in a bidentate fashion upon release of the two 
monodentate acetonitrile ligands, thereby providing the proposed intermediate complex I. Subsequent 
deprotonation generated intermediate enolate iridium(III) enolate complex II, which was 
independently isolated and unambiguously characterized by X-ray crystallography (the crystals of 
intermediate I and II were obtained by the group member, Dr. Lilu Zhang). This structure also 
illustrates that one face of the prochiral enolate -bond is blocked by a tert-butyl group, thereby 
rationalizing the observed high asymmetric induction in the course of the proposed diastereoselective 
addition of the electron-deficient radical to the electron rich double bond (Figure 50). 8  The 
determined absolute configurations of the -alkylation products are consistent with this mechanistic 
picture. This reaction step relates to recent reports of the photosensitized generation of 
electron-deficient radicals and their stereoselective addition to electron-rich  systems of chiral 
enamines.9 
 
Figure 49 X-Ray crystal structures of the proposed Ir(III) intermediate complex I (the left one) and II 
(the right one). These compounds were crystallized as a racemic mixture, and only the -enantiomer is 
shown here, as an ORTEP drawing with 30% probability ellipsoids. 
 
Figure 50 Proposed model for the asymmetric induction of photoredox alkylation reactions. 
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2) Verification of catalytic activity of enolate complex II 
The independently synthesized racemic iridium(III) enolate complex II catalyzes the photoredox 
reaction with an identical efficiency compared to IrS, thereby confirming that complex II is 
catalytically competent and supporting the notion that complex II has a dual function as a chiral 
nucleophile in the catalytic cycle and the in situ photosensitizer in the photoredox cycle (Scheme 6). 
 
Scheme 6 Evaluation of the catalytic activity of enolate complex II. 
3) Trapping experiment with TEMPO 
When 2.5 equivalents of 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) were added to the reaction 
after irradiation for 22 hours, only trace of the benzylation product 26a was observed. The 
corresponding alkoxyamine adducts of the 2-acyl imidazole 24a and of the alkyl fragment of 
electrophile 25a were formed in 92% yield and 87% yield, respectively (Scheme 7). The ratio of 
compound 27 and 28 is nearby 1:1. It was confirmed that this transformation did not occur either 
under dark conditions or in the absence of the catalyst IrS. 
The compound 27 can be rationalized as the coupling product between benzyl radical and free 
TEMPO radical. There are two possible pathways to produce the product 28. First, it can be generated 
from the addition of TEMPO radical with electron-rich double bond of iridium(III) enolate complex II 
followed by the single electron oxidation of the corresponding ketyl radical. Second, an alternative 
formation of 28 was provided by the nucleophilic addition of enolate species to an oxidatively 
generated N-oxoammonium cation. These results support the radical mechanism involved in the 
photoinduced alkylation of 2-acyl imidazoles. 
 
Scheme 7 Trapping experiment with excess TEMPO. 
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Low concentration of TEMPO (5 mol% with respect to 25a) was also applied for the trapping 
experiment (Scheme 8). As a result, TEMPO was consumed within 15 min and products 27 and 28 
were observed by 1H-NMR analysis of the crude reaction mixture. In this case, TEMPO only retarded 
the commencement of the alkylation process, which then proceeded normally after the TEMPO was 
consumed completely. 
 
Scheme 8 Trapping experiment with catalytic amount of TEMPO. 
4) Trapping experiment with electron rich alkene 
Adding 2.5 equivalents of the 1,1-diphenylethylene into the reaction mixture caused a significant 
inhibition of the formation of 26a. Instead, the adduct product 29 was obtained in yield of 57% 
(Scheme 9). Apparently, reductively generated benzyl radicals are trapped effectively by the 
1,1-diphenylethylene, which seems reasonable considering that the steady-state concentration of the 
enolate intermediate complex II cannot exceed the catalyst loading (2 mol%) and is therefore much 
lower compared to 1,1-diphenylethylene. Compound 29 was supposed to be produced through 
nucleophilic addition of methanol to photo-oxidatively generated diaryl methine carbocation. Whereas 
the diaryl methine carbocation can be formed from the addition of reductively generated benzyl radical 
with electron-rich double bond of iridium(III) enolate complex II followed by the single electron 
oxidation of the corresponding diaryl methine radical. 
 
Scheme 9 Trapping experiment with electron rich alkene. 
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5) Light-dark interval experiment 
The direct correction between photolysis and product formation is demonstrated by a light-dark 
interval reaction shown in Figure 51. The light-dark interval experiments were performed according 
the general catalysis procedure (entry 5 in Table 7) with 0.3 mmol benzyl bromide 25a. The 
conversion was determined by 1H NMR analysis of an aliquot from the reaction mixture. An aliquot 
was taken out of the reaction system via syringe for every 15 min until complete conversion was 
achieved. The whole process was performed under argon with Schlenk line. The NMR spectra shown 
below demonstrate that no significant byproducts are formed in this photoredox reaction (Figure 52). 
These results suggested that the light is essential for the present reaction. Although no obvious yield 
increase of 26a was observed in the absence of light, which do not definitively exclude the radical 
chain mechanism due to the short lifetimes of chain propagation process.10 The asymmetric catalysis 
and photoredox cycle operate in concert at least to some extent, a contribution of the chain 
propagation mechanism as a function of the nature of the substrates is feasible, and might even explain 
the differences in photolysis times for the individual reactions. 
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Figure 51 Light-dark interval experiment for the reaction 24a  25a  26a. 
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Figure 52 1H NMR (300 MHz, in CDCl3) spectra of 25a, 26a (both as reference) and the crude 
product from the light-dark interval experiment. Conversion was inferred by area integration ratio 
(signals A and B). 
6) Luminescence quenching experiments 
In order to verify the potential photosensitizers involving in the photoredox cycle, enolate complex 
II and IrS were selected to perform the fluorescence quenching experiments with electrophile 25a. 
Accordingly, Stern-Volmer plots (Figure 53) illustrate that the luminescence emission of the enolate 
complex II is quenched by benzyl bromide 25a much more efficiently compared to IrS which can be 
attributed to a fast electron transfer from the 3MLCT/3LC excited state of enolate iridium complex II 
to the electron deficient benzyl bromide. This result proves that the enolate complex II serves as the in 
situ assembled photosensitizer is greatly favored and the Ir(III)/Ir(IV) cycle is operative. It is 
noteworthy that the possibility of photocatalyst acting via energy transfer cannot be excluded by 
fluorescence quenching experiments. While energy transfer to activate the benzyl substrate or other 
aromatic system and facilitate the bond homolysis cannot be ruled out. However, no observation of 
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significant byproducts derived from free radicals, such as dimerization derivatives or hydrogen 
abstraction, which suggest that energy transfer process is highly unlikely in this catalytic system. 
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Figure 53 Luminescence quenching experiments. Io and I are respectively luminescence intensities in 
the absence and presence of the indicated concentrations of the electron deficient benzyl bromide 25a. 
 
7) Cyclic voltammetry measurements  
The cyclic voltammetry in collaboration with the Prof. Hilt group (Faculty of Chemistry, University 
of Marburg), reveals that the enolate complex II has a significantly decreased oxidation potential by 
around 1 V compared to the cationic complex IrS and thus comprises a much stronger reducing agent 
in the ground state and even more so in its photoexcited state (Figure 54). The estimated excited state 
reduction potential E1/2(II*/II+) of 1.74 V vs. Ag/AgCl for the enolate complex II is comparable to 
fac-[Ir(ppy)3] (ppy = 2-phenylpyridine),11 an iridium sensitizer that has been used previously for the 
reductive cleavage of electron deficient benzyl bromides.9 These data support the intermediate 
iridium(III) enolate complex II constitutes the active in situ assembled photosensitizer in the 
photoredox cycle. Since iridium(III) complex II apparently represents the only neutral iridium(III) 
complex within the entire reaction mixture, these data is also consistent with observed trends 
regarding redox and photophysical properties of iridium(III) complexes, namely that neutral 
bis-cyclometalated iridium(III) photosensitizers are significantly stronger photoreducing agents than 
their cationic counterparts.12 
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Figure 54 Cyclic voltammetry. Cyclic voltammograms and differential pulse voltammograms of the 
catalyst IrS (0.25 mM) and the enolate iridium complex II (0.25 mM) in CH2Cl2 containing 0.1 M 
nBu4NBF4. 
 
8) UV-visible spectroscopy analysis 
As shown in Figure 55, compared to IrS and established iridium(III) photosensitizers12, the enolate 
complex II displays a bathochromically shifted long wavelength absorbance maximum with an 
additional shoulder at around 500 nm, thus permitting an excitation across half of the visible spectrum 
ranging from violet to green light. The visible light absorbance of enolate complex II is not affected 
by the presence of organic bromide substrates, thus ruling out that an electron-donor-acceptor complex 
out of enolate complex II and bromide substrate is responsible for the light absorption (Figure 56)13. 
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Figure 55 Absorption and emission properties of the catalyst IrS and the intermediate iridium enolate 
complex II. The complexes were measured as solutions in solvent MeOH/THF 4:1 (0.1 mM). 
 
Figure 56 Investigation of the influence of bromide substrates on the optical absorption spectra of 
enolate complex II. Recorded in MeOH/THF 4:1 with enolate complex II at a concentration of 0.1 
mM and an excess of substrate (0.2 M). 
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9) An alternative putative mechanism 
Finally, one distinct variation of the outlined mechanism needs to be considered (Figure 57). A 
radical-radical coupling mechanism between the benzyl radical and the oxidized iridium sensitizer is 
reasonable. However, a major contribution of this recombination process is unlikely since both 
reactive intermediates will not be generated in close proximity, considering that the fragmentation of 
the formed radical anion does not occur instantaneously. In this respect, it has been established that the 
life time of such radical anions significantly increases in protic solvents and with a decreasing energy 
of the * orbitals.14 This notion is supported by the trapping experiment in which low concentrations 
of the radical trap TEMPO were still able to capture the intermediate benzyl radical (Scheme 8), thus 
rendering an efficient radical-radical coupling of the benzyl radical with the oxidized iridium sensitizer 
unlikely and instead favoring an addition of the intermediate electron-deficient benzyl radical with the 
electron-rich -bond of the enolate iridium(III) complex II which is present in solution at a much 
higher steady state concentration. 
 
Figure 57 Mechanistical variations based on radical-radical recombination for the combined 
photoredox and asymmetric catalysis. 
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3.3.6 Conclusions 
In conclusion, a unique case of visible-light-induced asymmetric redox catalysis by a single, 
structurally simple catalyst has been developed. The two catalytic cycles are connected through an 
intermediate iridium(III) enolate complex, formed from the initial catalyst and the 2-acyl imidazole 
substrate, which is not only the key nucleophilic intermediate in the asymmetric catalysis cycle but 
also constitutes the in situ generated active visible light photosensitizer. Despite the structural 
simplicity of the metal-based catalyst IrS, the metal center serves multiple functions at the same time: 
as a precursor for the photosensitizer, as a chiral Lewis acid for substrate activation, and as the 
exclusive chiral center for providing a highly effective asymmetric induction in the course of the C-C 
bond forming reaction.15 The here introduced reaction scheme may serve as a blueprint for the design 
of other catalytic asymmetric photoredox reactions, and will most likely provide new avenues for the 
efficient and green synthesis of non-racemic chiral molecules. 
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3.4 Visible-Light-Activated Enantioselective Trichloromethylation 
with a Chiral Iridium Complex 
3.4.1 Reaction Design 
A simple chiral-at-metal iridium complex (-IrS, Figure 58) as an effective asymmetric photoredox 
catalyst has been developed for the visible-light-induced enantioselective α-alkylation of 2-acyl 
imidazoles with electron deficient benzyl bromides and phenacyl bromides (Chapter 3.3).1 Despite its 
novelty, one can criticize that α-alkylations of carbonyl compounds with primary organobromides may 
be well executed under SN2 conditions without the absolute need for involving redox chemistry.2 
Going beyond the previous proof-of-principle demonstration, it is therefore highly desirable to seek an 
application in which redox catalysis is highly advantageous or even required. Electron-deficient 
bromotrichloromethane is intrinsically amenable electrophile precursor for the redox required 
chemistry. Addition of electron-deficient trichloromethyl radicals to catalytic enolate should access the 
direct enantioselective trichloromethylation through the single electron transfer process (SET). 
 
 
Figure 58 The redox required chemistry induced by visible-light-activated photoredox catalysis with 
chiral iridium complexes. 
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3.4.2 Reaction Optimization and Substrate Scope 
This study was initiated by investigating the enantioselective α-trichloromethylation of 2-acyl 
imidazoles. Encouragingly, when 2-acyl imidazole 30a was reacted with BrCCl3 in the presence of 
iridium catalyst -IrS and the base Na2HPO4 under visible light irradiation, the trichloromethylated 
product 31a was obtained in 69% yield and with 94% ee (Table 9, entry 1). Using the weaker base 
NaHCO3 provided 31a even in 77% yield and with outstanding 99.7% ee (entry 2). In the absence of 
any base, the yield and enantiomeric excess deteriorated (entry 3). More importantly, in the presence 
of air no trichloromethylation was observed, but instead a different product was obtained, namely the 
α-brominated 2-acyl imidazole 32 (entry 4). Compound 32 was also the only observed product in the 
dark (entry 5), while conversely under visible light irradiation no traces of 32 were generated as 
confirmed by NMR experiments (entry 2, see the NMR experiments in mechanistic study section). 
Obviously, in this system, light induces a complete switch in the product formation and the reaction 
mechanism: Whereas the α-trichloromethylation (31a) can be rationalized with photoredox chemistry, 
the α-bromination (32) in the absence of light must rely on closed-shell SN2 enolate chemistry with 
BrCCl3 serving as an electrophilic brominating reagent.3 Apparently, the reductive activation of 
BrCCl3 is required for the observed α-trichloromethylation. In this respect it is worth noting that the 
closely related iridium complex -IrO provides inferior results (entry 6), in line with recent 
observation in Meggers group that this catalyst is more suitable for catalyzing oxidative chemistry.4 
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Table 9 Initial experiments for the catalytic enantioselective α-trichloromethylation activated by 
visible lighta 
 
entry catalyst hb additive 31a (%)c 32 (%)c ee (%)d 
1 -IrS yes Na2HPO4  69e 0  94 
2 -IrS yes NaHCO3  77 0  99.7 
3 -IrS yes none  18 0  87 
4 -IrS yes NaHCO3, air  0 37  0 
5 -IrS no NaHCO3  0 51  0 
6 -IrO yes NaHCO3  13 0  93 
a Reaction conditions: 30a with 6 equiv BrCCl3 with catalyst (2 mol%) in MeOH/THF 4:1 at room 
temperature, optional with 1.1 equiv NaHCO3. b Light sources 20 W compact fluorescence lamp 
(CFL). c Isolated yields. d Enantioselectivities of 31a determined by HPLC on chiral stationary phase. e 
HCl elimination product was isolated in a yield of 11%. 
Having identified the optimal conditions in hand, the scope of the visible light activated 
enantioselective trichloromethylation was evaluated. Figure 59 shows the -IrS-catalyzed 
α-trichloromethylation of twelve 2-acyl imidazoles, with the products (62-96% yield) featuring 
different substituents at the stereogenic carbon, such as phenyl groups with electron donating or 
electron accepting groups (31a-f), a naphthyl (31g) and thiophenyl (31h) moiety, an ether (31i), and 
aliphatic groups (31j-l). One of the most remarkable features for this catalytic mode is the excellent 
enantioselectivities, which is proved by that ten of these products are formed with an enantiomeric 
excess of 99% or higher. For product 31c, absolute no traces of the minor enantiomer can be detected 
(≥99.9% ee), demonstrating the high degree of stereocontrol that can be reached in this catalytic 
reaction. 
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Figure 59 Substrate scope with 2-acyl imidazoles. a Higher catalyst loading to increase yield and 
enantioselectivity. 
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Unfortunately, there are still some 2-acyl imidazoles were found to be ineffective for 
-trichloromethylation (Figure 60). When substituted with steric groups at the stereogenic carbon, 
only traces of desired products were observed, the starting materials were remained (31m-p). 
Compared to ether moiety (Figure 59, 31i), the functional group of thiol ether is not similarly tolerant 
for this protocol (31q-r). The substrate decomposition was observed for the formation of 31q and 31r, 
which probably attribute to the oxidation of sulfide unit under the photoredox conditions. The 
photoexcited iridium complex is not able to compete with sulfide to be oxidized by the 
bromotrichloromathane, which can reasonable considering that the steady-state concentration of 
photoexcited iridium complex (2 mol% catalyst loading) is much lower than the amount of reaction 
free substrate. 
 
Figure 60 Some limitations of the substrate scope with respect to 2-acyl imidazoles. 
Next, the imidazole moiety was thinking to be replaced with another coordinating group and 
2-acylpyridines were selected due to the prevalence of pyridines and piperidines in bioactive 
compounds (Figure 61).5 Revealingly, a switch in cosolvent from THF to acetonitrile and at a higher 
catalyst loading of 4 mol% to compensate for overall slower reaction rates, 2-acyl pyridines 33 were 
converted to their α-trichloromethylated products 34 in satisfactory to high yields (65-91%) and with 
high enantioselectivities (90-99.6% ee). The 2-acylpyridines substrates readily tolerate aromatic (34a, 
34i) and aliphatic (34b-h) substituents at the stereogenic carbon. The electron donating (34c, 34h), 
withdrawing (34e-g), aromatic (34d) groups are suitable in the pyridine moiety. The pyridine unit can 
also be replaced by the isoquinoline (34i). 
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Figure 61 Substrate scope with 2-acyl pyridines. 
Similarly, some 2-acylpyridines also have proven to be unreactive or less efficient in this chemistry 
(Figure 62). The trichloromethylation is inhibited completely by the substitution at the 6-position of 
pyridine ring (34j, 34k), which can be rationalized that the steric hindrance prevent the efficient 
bidentate coordination of pyridine moiety to iridium center. An attempt of building the quaternary 
carbon center was unsuccessful (34l). When the methyl group at the stereogenic carbon was replaced 
by the more steric ethyl or propyl group (34m, 34n), no detectable product formed and the starting 
material was recovered completely. Although the electron withdrawing group facilitates the 
deprotonation to provide improving yield, still does not reach the satisfied efficiency (34o). The effect 
of the substitution at 5-position was also investigated. Surprisingly, substitution with electron rich or 
poor group both resulted in depressed results (34p, 34q). Thinking perhaps the electron rich group 
reduces the acidity of methylene group which make the deprotonation unfavorable (34q), and the 
electron poor group can cause slight racemization of formed product (34p). Overall, these results 
suggest that only the substitutions at the 4-position of pyridine unit are applicable to achieve 
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satisfactory yields and enantioselectivies for this photoreaction, the reactivity was highly limited to the 
steric substitutions. 
 
Figure 62 Some limitations of the substrate scope with respect to 2-acylpyridines. 
Finally, in order to access the synthetic application for organic synthesis. A variety of auxiliary with 
bidentate coordination sites have been investigated (Figure 63). Replacing the pyridine moiety with 
thiazole group, under the same conditions as the reactions in Figure 61, the 2-acyl thiazole substrate 
provided the trichloromethylation product with 71% yield and 94% ee (35a). The moderate conversion 
and enantioselectivity was afforded by the 2-acyl pyrazine substrate (35b). Disappointingly, except 
these two coordinating groups, no more auxiliary was found to be amenable for this transformation. 
The -amide ester (35d), pyrazole (35c) and Shibasaki auxiliary6 (35h) have been proven to be 
unreactive for the photocatalytic trichloromethylation. The acidic -ketoester substrate yield the only 
product 35e which can be rationalized as the HCl elimination product of the initial CCl3 product. Thus, 
the less acidic substrate (related to 35f) and tertiary substituted -ketoester (related to 35g) were used 
to address the HCl elimination, but no traces of 35f and 35g were detected under different conditions. 
 
Figure 63 Efforts to extend the coordinating auxiliary scope. 
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3.4.3 Efforts to Transformations of 2-Acyl Imidazole Products 
In order to expand the utility of the catalytic methodology, the cleavage of imidazole group was 
investigated (Scheme 10). One aromatic (31a) and one alkyl substituted (31l) products were selected 
to test the cleavage transformation. Unfortunately, only the HCl elimination derivatives were produced 
for these two CCl3 compounds. Although literatures reported 2-acyl imidazoles can be converted to a 
wide variety of useful organic synthetic blocks,7 such as the ketone, alcohol, ester and amide, these 
methods are not applicable to the trichloromethylation products due to the sensitivity of the CCl3 
group towards HCl elimination under basic conditions. It is also noteworthy that the unsuccessful 
transformation of imidazoles to other synthetic compounds does not affect the value of this 
asymmetric catalytic chemistry, since imidazoles themselves are privileged structural motifs in 
bioactive molecules.5 
 
Scheme 10 Efforts towards removal of imidazole auxiliary. 
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3.4.4 Plausible Mechanism 
A plausible mechanism is shown in Figure 64, which can be classified as an 
electron-transfer-catalyzed nucleophilic substitution via SRN1.8 Accordingly, the catalytic cycle is 
initiated by bidentate coordinating of the 2-acyl imidazole or 2-acylpyridine substrate to the iridium 
catalyst (intermediate I), followed by base-promoted deprotonation to an electron-rich iridium enolate 
(intermediate II). The subsequent addition of a reductively generated electrophilic trichloromethyl 
radical to the nucleophilic double bond provides an iridium-coordinated ketyl radical (intermediate 
III), which is oxidized to an iridium-coordinated product (intermediate IV) by single electron transfer, 
followed by product release. The single electron transfer can also leads to the reduction of another 
bromotrichloromethane, thereby initiating a chain reaction. A series of investigations in the following 
section have been executed to verify the iridium enolate complex II not only provides the crucial 
asymmetric induction in the catalysis cycle and but at the same time serves as the in situ generated 
active photosensitizer. 
 
Figure 64 Putative mechanism for the visible light activated asymmetric catalysis. SET = single 
electron transfer, PS = photosensitizer in form of enolate intermediate II. 
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3.4.5 Mechanistic Investigations 
1) Control experiments 
1.1) Control experiments in the dark: formation of the brominated product 
These control experiments were performed according the general catalysis procedure (see 
Experimental Part) with 0.2 mmol 2-acyl imidazole 30a. No trichloromethylated product 31a was 
observed in the dark. In contrast, no detectable brominated product 32 was formed in the overall 
photoredox process, which was demonstrated by the NMR spectra as shown below (Figure 65). The 
conversion of the photochemical process was determined by 1H-NMR analysis of aliquots from the 
reaction mixture taken out of the reaction system via syringe at different times. The light obviously 
severs as a complete switch in the formation of trichloromethylated and brominated products. 
 
Scheme 11 Control experiments for the comparison of the dark reaction and photoreaction. 
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Figure 65 1H NMR (300 MHz, in CD2Cl2) spectra of 30a, 31a, 32 (as references) and the crude 
product from the photolysis. Conversion was inferred by integration ratio (signals H1 and H3). 
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1.2) Control experiments without degassing: effect of aerobic conditions 
Aa a result shown below, not degassing caused an complete inhibition of the formation of 31a, 
which support the radical mechanism for photoinduced trichloromethylation. And instead the 
brominated product 32 was obtained as a racemic compound, which was consistent with the 
experimental observation in the dark. The inefficient enantioselectivity of 32 was probably caused by 
the racemization under basic and protic conditions. Compared to CCl3, the smaller Br group has a 
stronger electron withdrawing effect which was verified by the proton NMR shits of H2 (6.90 ppm) 
and H3 (6.58 ppm). Thus the brominated product 32 was highly sensitive for enolization in the basic 
reaction system (Scheme 12). 
 
Scheme 12 The effect of aerobic conditions for the photocatalytic trichloromethylation. 
1.3) Control experiments toward the base: effect of different Brønsted bases 
As shown in Figure 66, the depressed yield was obtained in the absence of base, which was 
consistent of the enolate activation mode. NaHCO3 serves as the optical base provide the 31a with 
77% yield and 99.7% ee, without traces of the HCl elimination product 36. The stronger bases either 
provide the product 31a with partial racemization (Na2HPO4), or yield the only elimination product 36 
(Na3PO4). Thus, the base is crucial role for intertwining with product formation and avoiding 
racemization or HCl elimination. 
 
Figure 66 The effect of base for the photocatalytic trichloromethylation. 
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2) Discussion of competition between bromination and trichloromethylation 
As shown in Table 9, the bromination product is the only observed product in the dark, whereas 
upon photolysis with visible light only the trichloromethylation product is observed. The following 
control experiments were performed to gain insight into the reason for not observing any brominated 
product in the presence of light. 
2.1) Comparison of initial rates for the dark reaction and photoreaction: 
 
Scheme 13 The comparison of rates for the formation of 32 and 31a. 
The comparison experiments were performed according the general catalysis procedure with 0.2 
mmol 2-acylimidazole 30a. The conversion was determined by 1H-NMR analysis of aliquots from the 
reaction mixture. Accordingly, the overall rate of the photoreaction is slightly faster compared to the 
bromination reaction in the dark. 
2.2) Considering a possible transformation of the bromination product: 
 
Scheme 14 Evaluating the possible transformation of bromination product 32. 
The reactions were performed with 0.2 mmol 2-acylimidazole 30a. In a first experiment, the 
reaction mixture was run in the dark until the brominated product 32 was formed with 71% conversion 
as monitored by 1H NMR. Then, the reaction was run for a further 10 hours under 20 W CFL. As a 
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result, the trichloromethylation was not observed in significant amounts by 1H-NMR (<10%) and 
product 32 was partially decomposed under irradiation. In a second experiment, the isolated 
bromination compound 32 was irradiated under the standard reaction conditions. As a result, no 
trichloromethylation product or starting compound could be detected. 
2.3) Proposed mechanism for the competition between bromination and trichloromethylation: 
Based on the above control experiments, the following plausible mechanism is proposed which can 
explain why the bromination reaction is not able to compete with the trichloromethylation in the 
presence of light (Figure 67). Accordingly, both catalytic cycles run through the intermediate iridium 
enolate complex II. The bromination product is formed through the reaction of II with the electrophile 
BrCCl3, whereas the trichloromethylation product is form through the reaction of II with a reductively 
formed trichloromethyl radical. Since the radical addition must be a very fast process that is almost 
diffusion controlled, the bromination reaction with the weak electrophile BrCCl3 will not be able to 
compete so that all enolate intermediate II only reacts with the trichloromethyl radical. Note that 
although the enolate reaction steps of the two catalytic cycles differ strongly, this is not the case for the 
overall reaction cycle which is in large parts dominated by slow ligand exchange processes. 
 
Figure 67 Plausible mechanism for explaining the suppressed bromination and exclusive formation of 
the trichloromethylated product in the presence of visible light. 
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3) Luminescence quenching experiments 
The stern-Volmer plot shown in Figure 68 strongly suggest that it is the neutral intermediate iridium 
enolate complex (II) which serves as the active photosensitizer, as its photoexcited state is quenched 
by BrCCl3 significantly faster compared to the cationic complexes I and rac-IrS. The oxidative 
quenching of the photoexcited state of enolate complex II indicates the single electron transfer through 
Ir(III)/Ir(IV) cycle, which is consistent with the experimental observation of photocatalytic 
-alkylation in Chapter 3.3 section. While the luminescence quenching experiments cannot exclude 
the energy transfer to BrCCl3 and facilitate the bond homolysis. It is need to point out that N-Methyl 
instead of N-phenyl imidazole derivatives were used for I and II due to higher stability of the enolate 
complex and stronger emission intensities. 
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Figure 68 Luminescence quenching experiments. I0 and I = luminescence intensities in the absence 
and presence of the indicated concentrations of BrCCl3, respectively.  
4) Trapping experiments with electron rich alkenes 
Adding two equivalents of the 1-phenyl-1-(trimethylsilyloxy)ethene (39) into the reaction mixture 
caused a complete inhibition of the formation of 31b  and the 2-acyl imidazole 30b can be recovered 
completely (Scheme 15). Instead, the compound 40 was isolated in a yield of 53%. Apparently, 
reductively generated trichloromethyl radicals are trapped effectively by the enolether 39, which 
seems reasonable considering that the steady-state concentration of the enolate intermediate complex 
II cannot exceed the amount of added iridium catalyst (2 mol% catalyst loading) and is therefore much 
lower compared to 39. The product 40 can be rationalized as being the HCl elimination product of the 
initial CCl3 product which is not stable under the basic conditions. 
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Scheme 15 Trapping experiments with electron rich silyl enolether 39. 
5) Trapping experiment with TEMPO 
When two equivalents of TEMPO were added to the reaction after irradiation for 23 h, the 
trichloromethylation product 31b could not be detected. The corresponding alkoxyamine adduct (41) 
of the 2-acyl imidazole 30b was formed in 40% yield. It was confirmed that the generation of the 
oxyaminated product did not occur under dark conditions. The single-electron-oxidized complex II 
can be trapped efficiently, which is consistent of the radical mechanism and supports the enolate 
complex II as a key intermediate in the catalytic cycle. 
 
Scheme 16 Trapping experiment with TEMPO. 
6) Quantum yield measurement 
The quantum yield was measured by standard ferrioxalate actinometry. A 6 W blue LED lamp (420 
nm) was used as the light source. The measured method was designed according to procedures 
reported by Yoon and coworkers with slight modifications.9 The described catalytic cycle (Figure 64) 
intertwines with a photoredox cycle that generates a trichloromethyl radical upon SET from the 
photoactivated photosensitizer to BrCCl3 and subsequent release of bromide. A determined quantum 
yield of 5 indicates that the trichloromethyl radical is also formed by direct electron transfer from the 
strongly reducing ketyl radical intermediate III to BrCCl3, thereby leading to a chain reaction. 
 
Scheme 17 The model reaction for the quantum yield measurement. 
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7) Coordination strength comparison of 2-acyl imidazoles and 2-acylpyridines 
In order to evaluate the differences in coordinative strength between 2-acylimidazole 30a and the 
2-acylpyridine 33a, a competition experiment was devised and analyzed by 1H-NMR (Figure 69). The 
result demonstrates that the binding constant of the pyridine substrate exceeds the binding constant of 
the imidazole substrate by around one order of magnitude. In the case of the stronger coordinating 
2-acyl pyridines, the replacement of coordinated product with new substrate (IVI, Figure 64) is 
probably mediated by an initial coordination of one or two acetonitriles, thus explaining the 
requirement for acetonitrile as a cosolvent. 
Reaction 1 (serves as a reference): 30a (0.2 mmol) plus Rac-IrS (0.01 mmol, 5 mol%) 
Reaction 2 (serves as a reference): 33a (0.2 mmol) plus Rac-IrS (0.01 mmol, 5 mol%) 
Reaction 3 (competition reaction): 30a (0.1 mmol), 33a (0.1 mmol) plus Rac-IrS (0.01 mmol, 10 
mol%) 
 
● Signals of tBu in complex I-a. ■ Signals of tBu in complex I-b. ♥ Signals of released CH3CN. 
 
Figure 69 1H NMR (300 MHz, in CD2Cl2) spectra of reactions 1-3. Conversion was inferred by area 
integration ratio (signals ‘●’ and ‘■’ ). 
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3.4.6 Conclusions 
In conclusion, the first example of an enantioselective, catalytic trichloromethylation has been 
developed and two types of ketone, namely 2-acyl imidazoles and 2-acylpyridines have been applied 
to this catalytic system with outstanding efficiencies.10 Excellent enantioselectivities are observed 
with multiple reactions reaching 99% ee and even higher. A range of mechanistic investigations 
confirmed the chiral iridium complex IrS which serves a dual function, as a catalytically active chiral 
Lewis acid and simultaneously as a precursor for an in situ assembled visible-light-triggered 
photoredox catalyst. The photocatalyst enolate complex II has been proven as a common intermediate 
of both the light and dark reaction cycle, and the observed light-induced switch in product formation 
can be explained with an out competition of the electrophilic bromination by the fast radical addition 
step. Unfortunately, attempts at extending the coordination auxiliary from imidazole and pyridine to 
other functional groups have largely been unsuccessful. Nevertheless, efforts to the cleavage of the 
imidazole auxiliary in the formed products were not operative, due to the sensitivity of the CCl3 group 
towards HCl elimination under basic conditions. Thus, the further research should be considered 
developing new chelating group which can be removed under mild reaction conditions, or developing 
new chiral-at-metal complexes which can directly activate the ketone without any prefunctionalizing. 
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3.5 Visible-Light-Activated Enantioselective Perfluoroalkylation with 
a Chiral Iridium Complex 
3.5.1 Reaction Design Plan 
Recently, Meggers’s group reported several examples of cooperative photoredox and asymmetric 
catalysis using a single chiral iridium1 or rhodium2 complex, which serves both as a photosensitizer 
precursor to induce and catalyze redox chemistry and at the same time as an asymmetric catalyst 
(Figure 70). For instance, a visible-light-activated enantioselective α-alkylation of 2-acyl imidazoles 
with electron deficient benzyl bromides and phenacyl bromides (chapter 3.3),1a as well as an 
enantioselective, catalytic trichloromethylation of 2-acyl imidazoles and 2-acylpyridines (chapter 
3.4).1b Herein the dual function chiral Lewis acid / photoredox catalyst concept is further advanced to 
develop a photoactivated enantioselective perfluoroalkylation of 2-acyl imidazoles.3 The photoredox 
chemistry through intermediate perfluoroalkyl radicals occurs at ambient temperature and requires 
visible light.  
 
Figure 70 Research plan for the visible-light-driven enantioselective perfluoroalkylation with single 
iridium photoredox catalyst. 
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3.5.2 Discovery and Optimization of Visible-Light-Activated Perfluoroalkylation 
1) The initial attempts at trifluoromethylation for the viability validation 
The study was started by investigating the -trifluoromethylation of 2-acyl imidazole 24a with the 
previously developed protocols, which have been successfully applied in the visible-light-induced 
-alklylation (chapter 3.3) and -trichloromethylation (chapter 3.4). Several typical CF3 group sources, 
namely the Togni’s reagent 42a-b, Umemoto’s reagent 42c, trifluoroiodomethane 42d and 
trifluoromethanesulfonyl chloride 42e, have been selected for the proposal validation (Figure 71). 
Disappointingly, when 2-acyl imidazole 24a reacted with with different CF3 electrophiles in the 
presence of Lewis acid RhS and Na2HPO4 (1.1 equiv) under irradiation with 6 w blue LEDs, no 
detectable trifluoromethylation product 43 was produced. The decomposition of CF3 reagents (42a-c) 
could be observed and some unidentified side products were formed. 
 
Figure 71 Initial attempts for trifluoromethylation with different CF3 electrophiles. 
Notably, although CF3SO2Cl as the CF3 radical source did not provide any desired product 43 in the 
presence of -RhS, instead it produced the -chlorination compound 44 in 97% yield and with 21% 
ee (Figure 72, entry 1). The control experiments revealed the light and inert atmosphere were not 
essential for this transformation, that suggested the -chlorination was a closed-shell SN2 reaction 
between the formed enolate intermediate and the electrophile CF3SO2Cl. The low enantioselectivity 
was highly probably caused by the racemization of product under the basic or acidic condition, which 
was confirmed by the comparison the ee value of crude product (40% ee) and the pure compound 
(22% ee) after silica gel purification. The strong withdrawing chloro-substituent increases the acidity 
of -carbonyl CH group and thereby facilitates the enolization. Increasing the steric hindrance of the 
N-substituted group improved the enantioselectivies step by step. Finally, the N-anthryl imidazole can 
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provide the chlorination product in 98% yield and with 97% ee (entry 6). The N-anthryl product did 
not loss any enantioselectivity after the purification by silica gel column. Whereas, attempts at 
removing the N-anthryl imidazole chelating group have largely been unsuccessful, which have 
suppressed the extension study for the -chlorination chemistry. 
 
Figure 72 The undesired chlorination of 2-acyl imidazoles in the absence of light. (Results are shown 
as entries.) 
2) The lessons from chlorination of 2-acyl imidazoles. 
The exclusive SN2 chlorination product was produced by the -IrS, which indicated the enolate 
chemistry involved in the reaction process and CF3 radical formation was suppressed. The -IrS 
cannot serves as a suitable photosensitizer precursor for these initial experiments. Therefore modifying 
the photophysical properties of the dual-function catalyst should solve the problem of CF3 radical 
generation. Inspired by recent work of MacMillan and coworkers on the asymmetric 
-trifluoromethylations of aldehyde via photoredox organocatalysis (Figure 73).3a In this dual catalysis 
strategy, the chiral amine catalyst was applied for enamine formation and stereochemistry induction, 
the photoredox cycle was relied on an independent sensitizer Ir(ppy)2(dtbbpy)PF6. This photosensitizer 
has proven to be efficient for CF3 radical generation from perfluoroalkyl iodides. Thereby, dual 
catalysts system was considered to get rid of the optimization of the photosensitizer. 
 
Figure 73 MacMillan’s catalyst combination strategy for -trifluoromethylation of aldehydes. 
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3) Two catalysts induced the enantioselective trifluoromethylation of 2-acyl imidazoles. 
Next, the reaction with two catalysts was design to examine the trifluoromethylation of 2-acyl 
imidazoles (Table 10). According to MacMillan’s reaction conditions, the previous developed -RhO4 
was used as the Lewis acid to facilitate the enolate formation, which is similar to the enamine 
generation created by chiral amine catalyst in MacMillan’s system. Compared to the -IrO or -IrS, 
the derivative -RhO can tolerate more coordinating polar solvent (DMF, DMSO, NMP, NMA, 
CH3CN) for efficient ligand exchange;2 the weaker absorbance of -RhO at the visible light region 
reduce the effect of competing light absorbance with photosensitizer.5 
Table 10 Initial experiments to identify an optimal catalyst/sensitizer combinationa 
 
entry sensitizer/catalyst conditions yieldc eed 
1 
[Ir] (2 mol%) 
-RhO (2 mol%) 
30a (1 eq, 0.4 M), 2,6-lutidine (1.1 eq), RT, 21 h 56% 79% 
2 
[Ir] (0.5 mol%) 
-RhO (2 mol%) 
30a (1 eq, 0.4 M), 2,6-lutidine (1.1 eq), RT, 21 h 50% 90% 
3 
[Ir] (0.5 mol%) 
-RhO (2 mol%) 
46a (1 eq, 0.4 M), 2,6-lutidine (1.1 eq), RT, 21 h 55% 92% 
4 
[Ir] (0.5 mol%) 
-RhO (2 mol%) 
46a (1 eq, 1.0 M), 2,6-lutidine (1.1 eq), RT, 21 h 75% 93% 
5 
[Ir] (0.5 mol%) 
-RhO (2 mol%) 
46a (1 eq, 1.0 M), NaHCO3 (1.1 eq), RT, 21 h 76% 93% 
6 
[Ir] (0.5 mol%) 
-RhO (2 mol%) 
Same as ‘entry 4’ but in dark 0 n.a. 
7 
[Ir] (0 mol%) 
-RhO (2 mol%) 
Same as ‘entry 4’ 0 n.a. 
8 
[Ir] (0.5 mol%) 
-RhO (4 mol%) 
46a (1 eq, 1.0 M), 2,6-lutidine (1.1 eq), RT, 14 h 65% 88% 
9 
[Ir] (0.5 mol%) 
-RhO (1 mol%) 
46a (1 eq, 1.0 M), 2,6-lutidine (1.1 eq), RT, 21 h 49% 93% 
a Conditions: 30a, 46a and CF3I (about 10 eq) with catalyst -RhO (1-4 mol%), and photosensitizer 
(none or 0.5-2 mol%) in DMF at r.t. for 14-21 h under irradiation with visible light. Light source: 20 
W compact fluorescence lamp. c Isolated yields. d Enantioselectivities of 45a and 47a determined by 
HPLC on chiral stationary phase. n.a. = not applicable. 
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Encouragingly, 2-acyl imidazole 30a readily react with CF3I in the presence of rhodium catalyst 
-RhO and sensitizer Ir(ppy)2(dtbbpy)PF6 under visible light irradiation, trifluoromethylated product 
45a is obtained in 56% yield and with 79% ee (table 1, entry 1). Reducing the photosensitizer loading 
improved the enantioselectivity to 90% ee (entry 2). Replacing the N-Ph with a 2-MePh substituent 
and increasing the reaction concentration provided the product 47a with improved 93% ee and in 
improved 75% yield, respectively (entry 4). The 2-MePh substituent in the imidazole moiety can 
suppressed the racemization efficiently. The compound 47a did not loss any ee value after purification 
with silica gel column. When replacing 2,6-lutidine with a weak inorganic base NaHCO3, a similar 
efficiency could be obtained (entry 5). The control experiments confirmed the visible light and the 
photosensitizer are required for the product formation (entry 6, 7). Furthermore, the higher or lower 
Lewis acid catalyst loadings cannot provide any improved efficiency (entry 8, 9). 
Meanwhile, this dual catalysis protocol has been examined with different CF3 radical precursors in 
Figure 71 under the developed conditions (Table 10, entry 4). No traces of trifluoromethylated product 
47a were observed under visible light irradiation. An interesting observation need to be pointed out, 
with a different reaction condition, the Umemoto’s reagent 42c can provide the product 47a through a 
closed-shell SN2 reaction with a single catalyst -RhO (Scheme 18). After the optimization of reaction 
conditions, the compound 47a can be obtained in 55% yield and with 93% ee. Apparently, this 
protocol in the absence of light and external photosensitizer is a good alternative method for 
asymmetric trifluoromethylation. Considering there is no other derivative reagents for the 
corresponding perfluoroalkylation, the photocatalytic technology is still more promising for accessing 
the perfluoroalkylation with perfluoroalkyl iodides. 
 
Scheme 18 Asymmetric trifluoromethylation with Umemoto’s reagent in the absence of light. 
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4) Single catalyst induced the enantioselective perfluoromethylation of 2-acyl imidazoles. 
After accessing the asymmetric trifluoromethylation through visible-light-induced dual catalysis, 
the perfluoroalkylation with single dual function catalyst -IrS was exploited again (Figure 74). 
Using the established conditions for dual catalysis, the imidazole 46a readily reacted with 
perfluorobutyl iodide (6 equivs) to provide the product 48a in 74% yield and with 97% yield. 
Encouragingly, the compound 48a can also be produced by the previous developed dual-function 
Lewis acid/photoredox catalyst -IrS in 29% yield and with excellent enantioselectivity of 98% ee. 
Whereas a comparison experiment with CF3I as the electrophile, no traces of trifluoromethylation 
compound were produced by the -IrS. This observation can be reasoned that CF3I cannot be reduced 
by photoexcited -IrS due to its more negative reduction potential comparing to C4F9I. Thereby the 
optimization of the catalyst structure to adjust the photophysical properties should improve the 
reaction efficiency. 
 
Figure 74 Attempts at extending the two catalysts into single catalyst system for perfluoroalkylation. 
The viability of modification of catalyst structure was investigated in Table 11. One new dual 
function chiral Lewis acid/photoredox catalyst -IrS(tBu) was designed for the enantioselective 
perfluoroalkylation of 2-acyl imidazoles using the previously established conditions.1a-b When 2-acyl 
imidazole 30a reacted with C4F5I (6 equiv.) in the presence of NaHCO3 (1.5 equiv.) and 4 mol% -IrS, 
the desired α-perfluoroalkylation product 48a’ was provided in a disappointing yield of 24% and with 
unsatisfactory enantioselectivity of 92% ee (entry 1). Increasing the steric congestion of the 2-acyl 
imidazole by replacing the N-Ph substituent (30a) with N-(2-MePh) (46a) improved the 
Chater 3. Results and Discussion 
103 
 
enantioselectivity but the yield remained low (29%) (entry 2, also see in Figure 74). 
Surprisingly, replacing -IrS with the related catalyst -IrS(tBu), this reaction afforded the 
perfluoroalkylation product 48a both with a satisfactory yield (78%) and excellent enantioselectivity 
(99%, entry 3). The catalyst loading of -IrS(tBu) could even be reduced to 2 mol% without affecting 
the performance (entry 4). Control experiments conducted either in the absence of the catalyst or in the 
dark confirmed that this reaction requires the combined presence of the iridium catalyst and light, 
otherwise no traces of product were observed (entries 5 and 6). Furthermore, the presence of air 
completely suppresses the perfluoroalkylation (entry 7), thus supporting the conclusion that this 
process constitutes a photoredox process that proceeds via intermediate perfluoroalkyl radicals. 
Table 11 Optimization of the visible-light-driven enantioselective perfluoroalkylation with single 
chiral iridium complex.a 
 
entry Ar catalyst (mol%)b lightc yield (%)d ee (%)e 
1 Ph -IrS (4.0) yes 24 92 
2 2-MeC6H4 -IrS (4.0) yes 29 98 
3 2-MeC6H4 -IrS(tBu) (4.0) yes 78 99 
4 2-MeC6H4 -IrS(tBu) (2.0) yes 79 99 
5 2-MeC6H4 -IrS(tBu) (2.0) no 0 n.d. 
6 2-MeC6H4 none yes 0 n.d. 
7f 2-MeC6H4 -IrS(tBu) (2.0) yes 0 n.d. 
aReaction conditions: 30a or 46a with C4F9I (6 eq), NaHCO3 (1.5 eq) and catalyst (0-4 mol%) in 
MeOH/THF (4:1) at room temperature for 34-46 h. b Catalyst loading (mol%) in brackets. c Light 
source: 21 W compact fluorescent lamp (CFL). d Isolated yields. e Determined by chiral HPLC. n.d. = 
not determined. f Under air atmosphere. 
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Figure 75 shows the crystal structure of the catalyst Δ-IrS(tBu) (obtained by Xiaoqiang Huang, a 
graduate student in Meggers group). This complex bears two cyclometalating 2-phenylbenzothiazole 
ligands in addition to two exchange-labile acetonitrile groups; the chirality originates exclusively from 
metal centrochirality and thereby creates a C2-symmetrical propeller-type coordination sphere.6 
Compared to IrS, IrS(tBu) contains two additional tBu-groups serving as the electron donating groups 
at the phenyl moieties. This modification raises the HOMO and renders IrS(tBu) a better electron 
donor in the ground and excited state,7  which is apparently beneficial for perfluoroalkylation 
described herein. Furthermore, the aliphatic substituent can increase the solubility of catalyst and the 
corresponding intermediate complexes; the increasing steric repulsion facilitates the ligand exchange 
that result in faster reaction rate. All these cases can improve the catalytic efficiency of IrS(tBu) for 
the photocatalytic perfluoroalkylation. 
 
Figure 75 Crystal structure of Δ-IrS(tBu). ORTEP drawing with 30% probability thermal ellipsoids. 
The counter ion is omitted. 
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3.5.3 Substrate Scope of Perfluoroalkylation 
Along with Xiaoqiang Huang, a graduate student in Meggers group, the substrate scope of this 
reaction was investigated. The scope with respect to the 2-acyl imidazole substrate is shown in Figure 
76. Satisfactory yields (59-90%) and excellent enantioselectivities (96-99% ee) were achieved for 
introducing a C6F13 substituent into the -position of the 2-acyl imidazoles, providing the products 
49a-h bearing aromatic (49a-d) or aliphatic (49e-g) substituents in -position of the carbonyl group. 
Even 49h, bearing an aryl ether, was tolerated. The key feature of this catalytic transformation is the 
outstanding enantioselectivities, as demonstrated by three of these products were obtained with 99% 
ee. 
 
Figure 76 Substrate scope with respect to 2-acyl imidazoles. 
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The scope of the reaction with respect to the perfluoroalkyl groups was also investigated, 
synthesizing the perfluoroalkylated products 47a-f. As shown in Figure 77, CF3, C3F7, C4F9, C6F13 and 
C10F21 substituents can be introduced in a highly enantioselective fashion (47a-f). Furthermore, 
perfluorobenzylation (47f) is achieved in 93% yield, providing virtually only a single enantiomer 
(>99.5% ee), demonstrating the high asymmetric induction that can be achieved by this new developed 
-Ir(tBu) in this asymmetric photoredox catalysis. 
 
Figure 77 Substrate scope with respect to perfluoroalkyl iodides and perfluorobenzyl iodide. 
3.5.4 Proposed Mechanism 
The proposed mechanism for the perfluoroalkylation involves the intermediate iridium(III) enolate 
complex II that is highlighted in Figure 78, which is expected to act as the chiral reaction partner for 
the electron-deficient perfluoroalkyl radicals and, simultaneously, serves as the active photosensitizer 
(II + hII* II+ + e-). Accordingly, coordination of the 2-acyl imidazole substrate 46 into -Ir(tBu) 
under release of the two acetonitrile ligands generates the substrate-coordinated intermediate I, which 
upon deprotonation subsequently converts into the key intermediate, namely the enolate complex II. 
The electron-rich -system of the enolate double bond enables a rapid reaction with the 
electron-deficient perfluoroalkyl radicals, which themselves are generated by a SET-reduction of the 
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corresponding perfluoroalkyl halides. 8  The highly stereoselective radical addition generates an 
intermediate iridium-coordinated ketyl III, which is strongly reducing and converts to 
iridium-coordinated product IV upon oxidation. Release of the product and coordination to a new 
substrate then leads to a new catalytic cycle. The electron that is released upon oxidation of the ketyl 
intermediate (IIIIV + e-) either flows into the photoredox cycle by regenerating the oxidized enolate 
photoredox sensitizer (II+ + e-II) or it directly reduces a perfluoroalkyl halide substrate and thereby 
leads to a chain process. This process can be classified as a redox-neutral, electron-transfer-catalyzed 
(electron-catalyzed) reaction.9 
 
Figure 78 Plausible mechanism for the photoactivated asymmetric perfluoroalkylation of 2-acyl 
imidazoles. The proposed mechanism involves the highlighted intermediate iridium(III) enolate 
complex II, which most likely serves as the active photosensitizer and the chiral reaction partner for 
the electron deficient radicals.  
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3.5.5 Conclusions 
In summary, visible-light-activated highly enantioselective perfluoroalkylation of 2-acyl imidazoles 
with perfluoroalkyl iodides and perfluorobenzyl iodide have been reported.10 The process uses a dual 
function chiral Lewis acid / photoredox catalyst at loadings of 2-4 mol% and constitutes a 
redox-neutral, electron-catalyzed reaction that proceeds via intermediate perfluoroalkyl radicals. This 
work demonstrates the generality of the dual function chiral Lewis acid / photoredox catalyst concept. 
From the perspective of the catalyst, it is intriguing that the metal center is capable of serving multiple 
functions at the same time: it constitutes the exclusive center of chirality (only achiral ligands), the 
catalytically active Lewis acid center, and additionally functions as the key component of the 
photosensitizer that is formed in situ. The facile optimization of catalyst structure has proven to be 
promising for adjusting the photophysical properties. This chemistry was started with dual catalysts 
and ended at single catalyst, this research manner provide insights for looking for new reactions. The 
undesired chlorination of 2-acyl imidazoles via closed-shell SN2 reaction, indeed show the excellent 
levels of enantioselectivies; unfortunately, these products bearing the imidazole chelating group cannot 
be converted to any synthetic useful compounds. The -RhO catalyzed trifluoromethylation of 2-acyl 
imidazole with Umemoto’s reagent, has been demonstrated as a closed-shell SN2 reaction, which 
provides an alternative method for CF3 introduction. 
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Chapter 3: Results and Discussion 
 
 
Part IV: Asymmetric Photoredox Catalysis with a 
Chiral-at-Metal Rhodium Complex 
 
 
 
3.6 Visible-Light-Activated Enantioselective Conjugate Addition 
3.6.1 Reaction Design 
The newly developed chiral-at-metal iridium complexes (IrO, IrS, IrS(tBu)) catalyzed the 
enantioselective -functionalization of carbonyl compounds through visible-light-activated 
photeredox catalysis. This method allows direct access to -benzylation/phenacylation (chapter 3.3),1 
-trichloromethylation (chapter 3.4) 2  and perfluoroalkylation (sections 3.5). 3  However, the 
satisfactory enantioselectivities are still previously inaccessible for producing -functionalized ketones 
in chiral-at-metal catalyst system (see Figure 42 in chapter 3.3). 
Despite the conjugate addition of nucleophilic alkyl radicals to electron deficient acceptors is an 
established and much applied method for the formation of -functionalized ketones, efficient catalytic 
enantioselective versions are still limited and this can be pinpointed to the high background 
(uncatalyzed) reactivity of the involved alkyl radicals.4 Sibi and co-workers reported one of the most 
impressive examples of chiral Lewis acid catalysis in conjugate radical additions, namely using a 
magnesium bisoxazoline complex at 5 mol% loading for catalyzing the enantioselective conjugate 
isopropyl radical addition to an oxazolidinone cinnamate (Figure 79).5 However, the reaction needs 
equimolar amounts of a toxic stannane and is executed at 78 °C to achieve such low catalyst loading. 
The Yoon group recently reported a catalytic enantioselective addition of α-aminoalkyl radicals to 
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α,β-unsaturated carbonyl compounds under photoredox conditions (also see Figure 15-16 in Chapter 
1.3).6 However, catalyst loadings of the employed chiral scandium complex are fairly high and the 
system is restricted to silanes with amines in α-position. Thus new strategies involved a practical 
reaction setting will be developed in this chapter to provide new approach for enantioselective radical 
conjugate addition. 
 
Figure 79 Research plan for catalytic enantioselective radical addition to acceptor substituted alkenes 
with chiral-at-metal complex. 
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3.6.2 Reaction Optimization and Substrate Scope 
Inspired by recent work of Molander and coworkers on using organotrifluoroborates as precursors 
for radicals under oxidative photoredox conditions,7 this study was started by investigating the 
reaction of the α,β-unsaturated acyl imidazole 18a with potassium benzyltrifluoroborate 54a under 
photoredox conditions (Table 12). 
Table 12 Initial experiments to identify an optimal catalyst/sensitizer combinationa 
 
entry catalyst sensitizer hb product yield (%)c ee (%)d 
1 -IrO none yes 55a 0 n.a.  
2 -IrS none yes 55a 0 n.a. 
3 -IrS 56 yes 55a <5 n.d. 
4 -RhO 56 yes 55a 43 79 
5 -RhS 56 yes 55a 67 88 
6 -RhS 56 yes 55b 66 93 
7 -RhS 56 yes 55c 73 94 
8 -RhS 57 yes 55c 73 96 
9 -RhS 56 no 55c 0 n.a. 
10 -RhS none yes 55c 0 n.a. 
11 none 56 yes 55c 29 0 
a Conditions: 18a, 18g, 53c and 54a (1.5 eq) with catalyst (none or 4 mol%), and photosensitizer (none 
or 2 mol%) in acetone/H2O (1:1) at r.t. for 4-6 h under irradiation with visible light. b Light source: 24 
W blue LEDs. c Isolated yields. d Enantioselectivities of 55a-c determined by HPLC on chiral 
stationary phase. n.a. = not applicable, n.d. = not determined. 
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Disappointingly, in the presence of the previously developed dual function photoredox /chiral Lewis 
acid catalysts -IrO or -IrS under visible light irradiation,1-3, 8 no desired C-C bond formation 
product 55a was detectable (entries 1-2). The presence of an additional photosensitizer did not 
improve the result (entry 3). Encouragingly, when the chiral Lewis acid -RhO9 in combination with 
the photosensitizer 56 was applied to this system, the reaction proceeded in 43% yield and with 79% 
ee.10 The newly developed Lewis acid -RhS,11 which provides an increased steric hindrance due to 
long C-S bonds, afforded the product 55a with an improved yield of 67% and 88% ee (entry 5). An 
optimization of the imidazole auxiliary by replacing the N-methyl (53a) with an isopropyl (53b) or a 
phenyl (53c) substituent, improved the enantioselectivity to 93% ee (55b) and 94% ee (55c), 
respectively (entries 6 and 7). Using the substrate 53c in combination with the less expensive organic 
sensitizer 5712 provided the C-C formation product even with 96% ee (entry 8). Meanwhile, control 
experiments verified that the photosensitizer and visible light are essential for product formation 
(entries 9 and 10). However, in absence of the chiral Lewis acid -RhS, the radical addition product 
55c was still generated in 29% yield, albeit as a racemic mixture (entry 11).13 This observation 
demonstrates that -RhS must strongly accelerate the radical addition in order to overcome the 
prevailing racemic background reaction. 
Next, the scope of the visible-light-induced enantioselective addition of trifluoroborate 54a to 
electron-deficient alkenes 53c-k was evaluated, providing the C-C bond formation products 55c-k 
with 40-90% yields and 83-96% ee. Figure 80 summarizes the effect of various alkene substituents. 
The reaction is tolerant of aliphatic substituents (55c-f), an ether (55g), and aromatic moieties with 
electron-rich or electron-deficient groups (55h-k). It is noteworthy that depending on the particular 
alkene, different N-imidazole substituents provide the best results as can be seen by the comparison of 
55d with 55d (Me favored) and 55e with 55e (iPr favored), which allows for an individual 
optimization of yields and enantioselectivities. 
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Figure 80 Substrate scope with respect to different 2-acyl imidazoles. 
The scope of this reaction with respect to organotrifluoroborates is outlined in Figure 81. A wide 
range of trifluoroborates (54b-p), ranging from benzyltrifluoroborates with electron withdrawing and 
electron donating substituents, various alkoxylmethyltrifluoroborates, secondary alkyltrifluoroborates, 
and tertiary alkyltrifluoroborates, can be used in this reaction providing the products 55l-z in yields of 
61-97% and with 77-99% ee. The addition of the 4-methoxybenzyl radical to 53h gave 55l in 97% 
yield and with perfect 99% ee. As shown, the products derived from benzyl radical addition are well 
tolerated of electron-donating group (55l-m), electron-withdrawing group (55p), an ortho substituent 
(55n) and a naphthyl (55o) group. Likewise, a range of alkoxymethyl radicals can be applied to this 
protocol (55q-v). The potassium alkoxymethylborates bearing a steric tertbutyl, an ether group, TMS 
moiety reacted with 53h to provide 55q (98% ee), 55r (95% ee) and 55v (94% ee), respectively. 
Furthermore, the secondary (refer to 55w-y) and tertiary (refer to 55z) alkyltrifluoroborates, regardless 
of acyclic or cyclic structures, produced the products in high yields (76-93%) and with excellent 
enantioselectivities (97-98% ee). 
Chater 3. Results and Discussion 
115 
 
 
Figure 81 Substrate scope regarding organotrifluoroborates. 
Next, to improve the practical utility of this reaction, seeking a synthetically more versatile class of 
alkene substrates is highly desirable. And α,-unsaturated N-acyl-3,5-dimethylpyrazoles (58a-e) were 
found that they readily react with benzyltrifluoroborates (54a-e) under developed reaction conditions 
to provide the C-C bond formation products 59a-g in yields of 54-75% and with 83-97% ee (Figure 
82). 
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Figure 82 Substrate scope with respect to 2-acyl pyrazoles. 
It is worth noting that some reactions have been proven to be unreactive or less efficient for this 
catalytic system (Figure 83). As shown, the unstabilized primary radical addition only provides adduct 
in 37% yield (entry 1) and the unreactive alkene acceptor can be recovered, which can be rationalized 
that the high oxidation potentials of primary trifluoroborate (E > +1.5 V) inhibits the alkyl radicals 
formation. 14  Silicates as C-centered unstabilized primary radical precursors were reported by 
Fensterbank very recently.15 The remarkerable feature of silicates is the low oxidation potentials (E ~ 
+0.75 V for primary alkylsilicates). Thus alkylsilicates most likely can sever as an alternative 
precursor to overcome the low reactivity of primary C-centered radical formation. The -ester 
substituted alkenes only afforded the radical addition products in moderate enantioselectivities (entry 
2). The -furan substituted alkenes were found to be decomposed under the developed conditions and 
resulted in the depressed yields (entry 3). For the -aromatic substituted 2-acyl pyrazoles, unsatisfied 
enantioselectivities were obtained due to the strong racemic background reaction (entry 4, see also 59g 
in Figure 82). The alkoxylmethyltrifluoroborates (entry 5) and secondary / tertiary 
alkyltrifluoroborates (entry 6) have been proven to be unsuitable for the 2-acyl pyrazole acceptors, 
only provide unidentified side products. 
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Figure 83 Some limitations for the developed asymmetric photocatalytic Michael addition. (Results 
are shown as entries.) 
The carboxylic acids have been reported serving as the alkyl radical sources for racemic 
photocatalytic conjugate addition.13 Thus, some carboxylic acids were selected to examine the 
rhodium catalyzed asymmetric transformation (Figure 84). As shown, these carboxylic acids readily 
react with the electron-deficient alkene 18a under the described condition to provide the addition 
products in 33-51% yields and without any ee (entries 2-4). In contrast, potassium tert-butyl 
trifluoroborate afford adduct in 53% yield and with 91% ee (entry 1). For the decarboxylative addition, 
the base is essential for the deprotonation of carboxylic acid to facilitate the single electron oxidation. 
Whereas the formed conjugate base can coordinate with the rhodium center to result in a neutral 
complex. The neutral rhodium complex is more stable than the cation complex, and it probably 
prevent the catalytic turnover leading to a racemic reaction. So trifluoroborates serving as the alkyl 
precursors are crucial for the asymmetric achievements.  
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Figure 84 The effect of radical sources for the asymmetric photocatalytic Michael addition. (Results 
are shown as entries.) 
3.6.3 Synthetic Transformations 
Finally, the conversion of two typical products, one imidazole and one pyrazole, to useful synthetic 
building blocks is illustrated in Scheme 19. Cleavage of the pyrazole auxiliary in 59e under reductive 
conditions afforded the alcohol 59e quantitatively and with unchanged ee.16 On the other hand, the 
removal of the imidazole moiety of 55w smoothly proceeded to provide ethyl ester 55w in 90% yield 
and without loss any ee.17 
 
Scheme 19 Transformation of selected products.  
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3.6.4 Plausible Mechanism 
The proposed mechanism is shown in Figure 85. The reaction is initiated by the now 
well-established photosensitized oxidative conversion of organotrifluoroborates to carbon-centered 
radicals,7,14 which in turn add to N,O-rhodium-coordinated 2-acyl imidazole or N-acyl pyrazole 
substrate (intermediate I, see experimental section for a crystal structure with an N-acyl pyrazole 
substrate), thereby generating the secondary radical intermediate II. Remarkly, Intermediate II is 
subsequently reduced by SET to a rhodium enolate (intermediate III), which upon protonation by 
water provides rhodium-bound product (intermediate IV). The formed product is released upon 
exchange against unreacted starting material, followed by a new catalytic cycle. It is worth noting that 
the organotrifluoroborates were not only oxidized by the photoexcited sensitizer, but most likely 
oxidized by the intermediated II, thereby leading to a chain process. Except the control experiments in 
Table 12 reveal visible light and photosensitizer are essential for any product formation, there are still 
a number of investigations in the mechanism study section which have been executed to verify the 
proposed mechanism. 
 
Figure 85 Proposed simplified mechanism without indicating possible chain transfer. SET = single 
electron transfer, PS = photosensitizer. 
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3.6.5 Mechanistic Investigations 
1) Competition experiments 
According to the described mechanism, it is unusual that with catalyst loadings of just 4 mol%, 
enantioselectivities of up to 99% ee can be obtained, and all this even at room temperature. Apparently, 
the radical addition to the double bond of free substrate (background reaction) cannot compete with 
the radical addition to rhodium-coordinated substrate (Lewis acid catalyzed reaction). This is 
counterintuitive considering the high reactivity of alkyl radicals towards acceptor-substituted alkenes 
combined with the fact that at the beginning of the reaction free substrate is in large excess (25-fold) 
over rhodium-coordinated substrate. The rhodium-based Lewis acid must therefore provide a strong 
acceleration of the radical addition. This is indeed the case as determined by competition experiments 
shown in Figure 86: rhodium coordination increases the radical addition rate by at least a factor of 3 x 
104. This acceleration is obviously the reason for the ability to perform the developed enantioselective 
radical reaction with low loadings of the chiral Lewis acid. 
 
Figure 86 Evaluating the acceleration of the radical addition step by rhodium coordination. 
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2) Trapping experiment with TEMPO 
When two equivalents of TEMPO were added to the reaction after irradiation for 15 h, the radical 
conjugate addition product 55l could not be detected (Scheme 20). The formation of oxyaminated 
product 61 was formed in 85% yield. It was confirmed that this C-O bond formation did not occur 
either in the dark or in the absence of the photosensitizer [Acr-Mes]ClO4. Meanwhile, the Michael 
acceptor 53h could be recovered in 80% yield and with unchanged E/Z value. The C-O coupling 
product 62 was not observed which does not support the possible involvement of radical-radical 
coupling pathway. 
 
Scheme 20 Radical trapping experiment with TEMPO. 
It’s worth noting that one alternative pathway for 61 generation cannot be excluded, in which the 
formation of 61 involving the nucleophilic addition of trifluoroborates to an oxidatively generated 
N-oxoammonium cation. However, as reported by related investigation (Scheme 21), when the 
-substituted (E)-allyltrifluoroborates were examined, the -oxyaminated products were obtained as a 
mixture of E/Z isomers.14(a) Thus the TEMPO trapping experiments confirm the intermediate 
generation of alkyl radicals from organotrifluoroborates. 
 
Scheme 21 Photocatalytic coupling of TEMPO and allylic alkyl radical reported by Akita. 
Chater 3. Results and Discussion 
122 
 
3) Control experiments 
3.1) Control experiments without degassing 
 
Figure 87 The control experiments in the presence of oxygen. 
The described experiments were performed according the general procedure in Figure 80 and Figure 
81. The conversion of the photochemical process was determined by 1H-NMR analysis with 
1,3,5-trimethoxybenzene as internal standard. Aa a result shown above, not degassing caused an 
obvious inhibition of the formation of 55h and 55p. The reaction of trifluoroborate (54b) with alkene 
53h is not affected, which seems reasonable considering that the benzyl radical bearing electron 
donating group serving as a more stabilized radical is not reactive enough to be trapped by oxygen. In 
contrast, the formation of 55p using electron deficient substituted trifluoroborate (54f) as radical 
source was inhibited almost completely. Instead a significantly formed aldehyde was observed in the 
1H-NMR spectra of crude product (Figure 88), which also demonstrate the benzyl radicals can be 
trapped by oxygen resulting in the inhibition of conjugate addition. 
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Figure 88 1H NMR (300 MHz, in CDCl3) spectra of 53h, 55p (as references) and the crude product 
from the photolysis. Yield and conversion was inferred by integration ratio. 
3.2) Control experiments in deuterated solvent 
Two typical substrates, one imidazole, one pyrazole, were selected for the deuterium labeling 
experiments which were performed under the standard conditions in the indicated solvent system 
(Figure 89). The ratios of H/D were calculated by 1H-NMR analysis (Figure 90). Accordingly, the 
combined solvent of CD3COCD3/H2O provide the radical adduct with H/D ratio of 99/1, and this ratio 
does not change in the solvent of CH3COCH3/D2O in the presence of Lewis acid catalyst RhS. In 
contrast, H/D ratio of 1/1 was observed in the mixed solvent of CH3COCH3/D2O. The product 
deuteration upon performing the reaction in acetone/D2O supports the proposed SET/protonation 
sequence (Figure 85) as opposed to an alternative H-abstraction from acetone. 
 
Figure 89 Control experiments in a mixed deuterated solvent system. 
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Figure 90 1H NMR (300 MHz, in CDCl3) spectra of illustrated compound (a) and (b). Ratio was 
inferred by area integration (signals ‘●’ and ‘■’). 
4) UV/Vis-absorption spectra 
The absorption spectra of the different components of the reaction were measured in solution of 
acetone/H2O (4:1) (Figure 91). The spectra indicate that not only the sensitizers 
Ir[dF(CF3)ppy]2(bpy)PF6 (max = 375 nm) and [Acr-Mes]ClO4 (max = 420 nm) absorb in the visible 
region but also the Lewis acid catalyst RhS (max = 400 nm) and even more so RhS coordinated to the 
2-acyl imidazole 53c (5 equivalents) (max = 390 nm). These absorption spectra suggest a possible 
interaction between photocatalyst and Lewis acid need to be considered. Such as the static quenching 
(an inner filter effect) of photocatalyst by RhS most likely can be observed. 
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Figure 91 UV/Vis-absorption spectra of the used photoredox catalysts, the Lewis acid catalyst RhS 
and a combination out of RhS and the 2-acyl imidazole substrate 53c. Measured as solutions in 
acetone/H2O 4:1 (0.05 mM). a.u. = absorbance units. 
5) Luminescence quenching experiments 
The luminescence quenching experiments with the photoredox catalyst were investigated both in the 
presence and absence of RhS and olefin. The solutions of Ir[dF(CF3)ppy]2(bpy)PF6 were excited at 
max = 375 nm and the emission was measured at 475 nm (emission maximum). The sensitizer 
Ir[dF(CF3)ppy]2(bpy)PF6 was used for the quenching experiments due to stronger luminescence 
intensities. 
Quenching experiments with Ir[dF(CF3)ppy]2(bpy)PF6 in the absence of RhS and olefin: 
The photoexcited iridium sensitizer (Eox  1.3 V)7(a) is quenched by the benzyl and α-oxy 
trifluoroborates (54c and 54h) in a concentration-dependent fashion (Figure 92). As expected it cannot 
be quenched by alkyl trifluoroborate 54m due to its significantly higher oxidation potential (Eox  1.5 
V)14(f). For such alkyl trifluoroborates the alternative sensitizer [Acr-Mes]ClO4 (Eox  2.1 V)14(f) 
serves as a stronger and more suitable oxidant and indeed provided efficient transformations (see 
substrate scope in Figures 80 and 81). 
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Figure 92 Stern-Volmer plots. I0 and I are respective luminescence intensities in the absence and 
presence of the indicated concentrations of the corresponding quencher. 
Quenching experiments with Ir[dF(CF3)ppy]2(bpy)PF6 in the presence of RhS and olefin: 
When the experiments were performed in the presence of RhS and the Michael acceptor 53c, a 
decreased luminescence of Ir[dF(CF3)ppy]2(bpy)PF6 was observed, which is demonstrated by the 
emission intensity of the mixture solution of Ir[dF(CF3)ppy]2(bpy)PF6, RhS and alkene 53c (Figure 
93). The ratios of the components were chosen to be analogous to the actual reaction conditions: 
([Ir]:[Rh]:53c = 1:2:20). Despite the lower luminescence intensity of the iridium sensitizer, which is 
apparently due to a static and dynamic quenching caused by RhS, the expected 
concentration-dependent quenching of the photoexcited state of Ir[dF(CF3)ppy]2(bpy)PF6 by the 
benzyl trifluoroborate 54c can still be observed (Figure 94). 
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Figure 93 Emission spectra of the photoactive species. The photoactive species were measured as 
solutions in solvent acetone/H2O 4:1 (0.05 mM). a.u. = arbitrary unit. 
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Figure 94 Stern-Volmer plots in the presence and absence of RhS. I0 = luminescence intensity in the 
absence of 4-MePhCH2BF3K. I = luminescence intensity in the presence of the indicated 
concentrations of 4-MePhCH2BF3K. 
In summary, these luminescence quenching experiments support the proposed mechanism (Figure 
85) in which an initial electron transfer occurs between the excited photoredox sensitizer (acceptor) 
and the trifluoroborate (donor), while the electron deficient alkene substrates are not involved in this 
process. The Lewis acid RhS reduces the efficiency of this process most likely due to a combination 
of direct light absorption and quenching of the excited state of the photoredox sensitizer. 
6) Quantum yield measurement 
The quantum yield was measured by standard ferrioxalate actinometry. A 150 W xenon lamp (50% 
of light intensity, 420  5 nm bandpass filter) was used as the light source. The potassium ferrioxalate 
solution measures the decomposition of ferric ions to ferrous ions, which are coordinated to 
1,10-phenanthroline and monitored by absorbance at 510 nm. The moles of generated 
iron-phenanthroline complex is related to moles of incident photons, thus the photon flux was 
calculated as 9.51  10-10 einstein/s (Scheme 22). 
 
Scheme 22 The model reaction for the quantum yield measurement. 
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6.1) Overall quantum yield: 
The model reaction was stirred for specified time intervals (2, 3, 4 h) under the irradiation of 420 
nm light. The moles of product formed was measured by GC analysis (FID detector, column: HP-5) 
using tetradecane as internal standard. Thereby two independent measurements were executed to 
provide the overall quantum yield () of the photoreaction as 0.31 and 0.32 respectively. It is 
important to note that these values present overall quantum yields and do not take into account that 
there are more than one photoactive species in this system (see Figure 91). 
 
6.2) Evaluating the quantum yield with respect to the photoredox sensitizer [Acr-Mes]ClO4: 
Considering that photons are not only absorbed by the photosensitizer but also by rhodium 
complexes in solution, the fraction of light that is absorbed directly by [Acr-Mes]ClO4 was evaluated. 
Since the absorbance of [Acr-Mes]ClO4 in acetone/H2O (4:1) at a concentration of 2 mM, which is a 
typical concentration for a reaction, showed saturation at 420 nm (Figure 95), the wavelength at which 
we determined the quantum yield, all investigated samples were 40-fold diluted from the concentration 
used in a typical reaction (Figure 96). 
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Figure 95 Absorbance of [Acr-Mes]ClO4 (2 mM in acetone/H2O 4:1). 
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The absorbances of the diluted solutions conclude that the photoredox sensitizer absorbs only a 
fraction of the overall light due to a competing light absorbance from present rhodium complexes. 
Thus, the quantum yield with respect to the photoredox sensitizer [Acr-Mes]ClO4 is >0.32 and its 
exact value is inconclusive. 
For the diluted solutions, the following absorption at 420 nm was obtained: 
For diluted reaction mixture: 
A(420 nm) = 1.226, [Rh] = 0.1 mM, [Acr-Mes]ClO4 = 0.05 mM. 
For diluted reaction solution devoid of [Acr-Mes]ClO4: 
A(420 nm) = 0.908, [Rh] = 0.1 mM 
For the diluted [Acr-Mes]ClO4 alone: 
A(420 nm) = 0.281, [Acr-Mes]ClO4 = 0.05 mM. 
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Figure 96 Absorption spectra of the photoactive reaction species. (in acetone/H2O 4:1, [Rh] = 0.1 mM, 
[Acr-Mes]ClO4 = 0.05 mM for the corresponding solution). 
6.3) Mechanistic conclusions for quantum yield measurement: 
Considering the competing light absorbance of the rhodium complexes, partial quenching of the 
photoexcited photoredox sensitizer by rhodium complexes (inner filter effect), and further taking into 
account unproductive processes such as back electron transfer after the initial photoinduced electron 
transfer from the organotrifluoroborate to the excited photoredox sensitizer, the contribution of chain 
processes can be expected. 
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3.6.6 Conclusions 
In conclusion, a very efficient and practical catalytic enantioselective conjugate addition has been 
reported and a broad range of organotrifluoroborates readily react with various acceptor-substituted 
alkenes under mild photoredox conditions.18 Key feature is a rhodium-based Lewis acid which not 
only provides an excellent stereocontrol but also accelerates the involved key radical addition step by 
at least four to five orders of magnitude, thereby laying the foundation for the low catalyst loadings for 
this radical reaction. This method for radical generation is much nicer than that used by Sibi,19 and 
more general than that used by Yoon.20 The imidazole and pyrazole auxiliary groups are easily 
cleaved with unchanged ee, which has proved the practical utility for this chemistry. The proposed 
mechanism was supported by an array of mechanistic investigations. Efforts to apply this chemistry to 
C-centered unstabilized primary radical have met with modest success (37% yield, 96% ee for the 
selected example). Considering the silicates with low oxidation potentials as alternative radical 
precursors, the proposal in this process should be promising. 
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Chapter 4: Summary and Outlook 
4.1 Summary 
Two types of chiral-at-metal octahedral complexes have been developed as exceptionally effective 
asymmetric catalysts, namely the metal-templated enamine/H-bonding dual catalyst -Ir4 and the 
active Lewis-acid catalyst -IrO and -IrS(tBu). These novel catalysts or their derivatives have been 
successfully utilized in a number of enantioselective non-photochemical reactions and 
visible-light-activated transformations (Figure 97). Remarkably, a single chiral Lewis-acid complex 
has proven to be capable to serve as photoredox catalyst and at the same time provide very effective 
asymmetric induction for -functionalization of carbonyl compounds. These novel asymmetric 
photoredox catalysts, in which the iridium metal center simultaneously act as the exclusive source of 
chirality, the catalytically active Lewis acid center, and the photoredox center, offer new opportunities 
for the economical synthesis of enantioenriched molecules. 
 
Figure 97 An overview for this thesis: chiral-at-metal catalyst discoveries and their applications in the 
asymmetric non-photochemical and photoredox catalysis. 
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1) Metal-templated enantioselective enamine/H-bonding dual activation catalysis 
 
Figure 98 Enantioselective -amination of aldehydes with metal-templated iridium complex. 
An asymmetric enamine catalyst (-Ir4) built from an octahedral chiral-at-metal complex was 
developed.1 This complex catalyzed enantioselective -amination of aldehydes with only 1 mol% 
catalyst loadings, even down to 0.1 mol% (Figure 98). With respect to catalyst loading in asymmetric 
organocatalysis, iridium complex -Ir4 constitutes one of the most efficient catalysts for the 
enantioselective -amination of aldehydes to date. Mechanistically, the enamine was produced as 
(E)-syn form by preventing the unfavorable (E)-anti conformation with a bulky 2,4,6-iPr3Ph group. 
The si face approach of azodicarboxylate was induced by an H-bonding between of the OH group and 
a nitrogen or carbonyl oxygen atom of the azodicarboxylate. The catalyst -Ir4 was synthesized 
through chiral auxiliary strategy developed in Meggers group. 2  Two generated diastereomeric 
complexes -(S)-9 and -(S)-9 (each 37%) which can be resolved by standard silica gel 
chromatography. The virtually enantiopure -Ir4 and -Ir4 (each >99% ee) were obtained after 
stereospecific substitution of the chiral auxiliary with secondary amine ligand (1). 
 
Figure 99 Synthesis of the enantiomerically pure enamine/H-bonding catalysts -Ir4 and -Ir4. 
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2) Asymmetric catalysis with substitutionally labile yet stereochemically stable chiral-at-metal 
iridium(III) complex: discovery and the non-photochemical application of -IrO/-IrO 
 
Figure 100 Enantiomers of a substitutionally labile yet configurationally stable chiral-at-metal 
iridium(III) Lewis acid -IrO and -IrO. 
A metal-coordination-based asymmetric catalyst utilizing metal centrochirality as the sole element 
of chirality was newly developed (Figure 100).3 The Lewis acid complexes -IrO and -IrO were 
synthesized straightforwardly according to chiral auxiliary strategy developed in Meggers group 
(Figure 101).2 Accordingly, two generated diastereomeric complexes -(S)-18 and -(S)-18 which can 
be resolved by standard silica gel chromatography. The virtually enantiopure -IrO and -IrO 
(verified by HPLC, each 99% ee) were yielded after stereospecific substitution of the chiral auxiliary 
ligand (upon protonation by NH4PF6) by two acetonitrile ligands. Notably, -IrO and -IrO have 
proven to be bench stable and tolerant to a large range of solvents. 
 
Figure 101 Synthesis of enantiomerically pure Lewis acid complexes -IrO and -IrO. 
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The introduced substitutionally labile, chiral-at-metal octahedral iridium(III) complex exclusively 
bears achiral ligands and effectively catalyzes the enantioselective Friedel-Crafts addition of indoles to 
,-unsaturated 2-acylimidazoles (19 examples) with high yields (75%-99%) and high 
enantioselectivities (90-98% ee) at low catalyst loadings (0.25-2 mol%) (Figure 102). 
Counterintuitively, despite its substitutional lability, which is mechanistically required for coordination 
to the 2-acylimidazole substrate, the metal-centered chirality is maintained throughout the catalysis. 
This novel class of reactive chiral-only-at-metal complexes has proven to be of high value for a large 
variety of asymmetric transformations in Meggers group. 
 
Figure 102 Enantioselective Friedel-Crafts addition of indoles to a,-unsaturated 2-acyl imidazoles 
catalyzed by -IrO or -IrO. 
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3) Visible-light-activated asymmetric photoredox catalysis with a chiral iridium(III) complex 
Since the chiral-at-metal iridium complex -IrO has proven to be competent Lewis acid catalyst for 
non-photochemical Friedel-Crafts additions, shortly it was also found to be photoactive, and this 
property can be exploited to perform highly stereoselective photredox catalysis (Figure 103).4 As 
demonstrated in chapter 3.3, the chiral iridium complex -IrO or its derivative -IrS can serves as a 
sensitizer precursor for photoredox catalysis and at the same time provide very effective asymmetric 
induction. The stereocontrol of photochemical reactions have historically proved challenge to handle 
(see theoretical part). Most of the successful approaches have needed two catalysts, one mediating the 
photoredox activation, the other providing stereoinduction. This discovery of a single chiral-at-metal 
Lewis acid that fulfils both functions is a crucial conceptual step forward. 
 
Figure 103 Chiral iridium complexes for asymmetric photoredox catalysis. (S, substrate; I, 
intermediate; P*, enantioenriched product.) 
As a model reaction, the enantioselective alkylation of 2-acyl imidazoles provided the almost 
perfect enantioselectivities (up to 99% ee) and yields (up to 100% yield) for a lot of cases (Figure 104). 
Mechanistically, the catalysis is initiated by the coordination of 2-acyl imidazoles to the iridium 
catalyst in a bidentate fashion (intermediate I), followed by deprotonation resulting in the formation of 
a nucleophilic enolate iridium(III) complex (intermediate II). Subsequently, the addition of a 
photo-reductively generated electrophilic radical to the electron rich metal-coordinated enolate double 
bond, thereby affords an iridium-coordinated ketyl radical (intermediate III) with a stereogenic carbon 
center. Oxidation of this ketyl intermediate to a ketone by single electron transfer provides the 
iridium-coordinated product (complex IV), which is released upon exchange against unreacted starting 
material, followed by a new catalytic cycle. The single electron transfer either regenerates the 
iridium(III) photosensitizer or leads to the reduction of another organobromide substrate, thereby 
initiating a chain process. Proposed key iridium(III) enolate complex II, which not only provides the 
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crucial asymmetric induction in the catalytic cycle and but at the same time serves as the in situ 
generated active chiral photosensitizer. This process can be classified as redox-neutral, 
electron-catalyzed reaction. 
 
Figure 104 Visible-light-induced enantioselective alkylation of 2-acyl imidazoles with acceptor 
substituted benzyl bromides and phenacyl bromides. 
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4) Enantioselective, catalytic trichloromethylation through visible-light-activated photoredox 
catalysis with a chiral iridium complex 
The first example of an enantioselective, catalytic trichloromethylation of 2-acyl imidazoles and 
2-acylpyridines has been developed.5 Excellent enantioselectivities are often observed with multiple 
reactions reaching 99% ee and even higher (Figure 105). As an extensive research of single catalyst 
induced photochemical -functionalization of ketones with electron-deficient alkyl halide, the 
mechanism is in analogy to the described catalytic cycles in Figure 104. The chiral-at-metal -IrS can 
serve a dual function, as a catalytically active chiral Lewis acid and simultaneously as a precursor for 
an in situ assembled visible-light-triggered photoredox catalyst. However, attempts at extending the 
achiral templates from imidazole and pyridine to other easily removable moieties have largely been 
unsuccessful; efforts to the cleavage of the imidazole auxiliary of products met with failure, due to the 
sensitivity of the CCl3 group towards HCl elimination under basic conditions. 
 
Figure 105 Photocatalytic, asymmetric trichloromethylation of 2-acyl imidazoles and 2-acylpyridines. 
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5) Visible-light-activated enantioselective perfluoroalkylation with a chiral iridium photoredox 
catalyst 
A visible-light-activated enantioselective radical perfluoroalkylation of 2-acyl imidazoles with 
perfluoroalkyl iodides and perfluorobenzyl iodide at the α-position of the carbonyl group is 
developed.6 Enantioselectivities with up to >99.5% ee are achieved (Figure 106). The process uses a 
dual function chiral Lewis acid / photoredox catalyst loadings of 2-4 mol% and constitutes a 
redox-neutral, electron-catalyzed reaction which proceeds through intermediate perfluoroalkyl radicals. 
This work demonstrates the generality of the dual function chiral Lewis acid / photoredox catalyst 
concept. The facile optimization of catalyst structure has proven to be promising for adjusting the 
photophysical properties. This chemsitry was started with two catalysts and ended at single catalyst, 
this research strategy provide insights for looking for new asymmetric photochemical reactions. 
 
Figure 106 Catalytic, enantioselective perfluoroalkylation through visible-light-activated photoredox 
catalysis with a chiral iridium complex. 
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6) Catalytic, enantioselective addition of alkyl radicals to alkenes via visible-light-activated 
photoredox catalysis with a chiral rhodium complex 
A very efficient and practical catalytic enantioselective conjugate addition has been developed,7 
and a broad range of organotrifluoroborates (alkyl, benzyl and alpha-oxy moieties) readily react with 
various acceptor-substituted alkenes in the presence of only 4 mol% rhodium catalyst (Figure 107). 
Key feature is this rhodium-based Lewis acid which not only provides an excellent stereocontrol but 
also accelerates the involved key radical addition step by at least four to five orders of magnitude, 
thereby laying the foundation for the low catalyst loadings for this radical reaction. This method for 
radical generation is much nicer and more general than that used by Sibi and Yoon (see also Figure 
79).8 The imidazole and pyrazole auxiliary groups are easily cleaved with unchanged ee, which has 
proved the practical utility for this chemistry. 
 
Figure 107 Visible-light-activated enantioselective conjugate addition of alkyl radicals to alkenes. 
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4.2 Outlook 
Considering some unmet need and expected potentials in this thesis, the future investigations can be 
builded on the following aspects: 
1) Simplify the asymmetric synthesis of chiral-at-metal catalysts: Although grams scale synthesis 
of the chiral Lewis acid -IrO and -IrS are allowed by the previously established protocol in 
Meggers group. This strategy relied on the preformed chiral auxiliary and did not get rid of standard 
silica gel chromatography. The relatively high-cost of synthesis has limited its potential commercial 
valuable. Thus, the choice of simple, readily available, and easily removable chiral auxiliary is highly 
desirable for this system, such as the low-cost natural amino acids. Attempts to get various 
amino-acid-based diastereomers and investigate their differences in solubility would provide a chance 
to isolate them only relying on recrystallization. The well established directing groups, which have 
been widely applied in transition-metal catalyzed C-H functionalization, are also rational chiral 
templates candidates. 
 
2) Measure the redox potentials of chiral-at-metal complexes: With respect to the photoredox 
catalysis, despite the previous investigations revealed the -IrO is more suitable for oxidative 
chemistry, and -IrS is more favorable for reductive chemistry. The general rules of photophysical 
properties for these iridium complexes are still elusive. The optimization of catalyst structure has 
proven to be promising in chapter 3.5. Compared to IrS, the derivative IrS(tBu) contains two 
additional t-Bu behaved as a more stronger reductant. Thus, measuring the redox potentials for all 
classes of chiral-at-metal complexes in our group, including the intermediate complexes, would 
provides straightforward insights for catalyst structure optimization. The location of HOMO and 
LUMO for these complexes will be likely figured out, and then we can adjust the redox potential of 
catalysts through introducing electron rich or deficient groups at the fixed position of achiral ligand. 
The previous unmet synthetic applications are highly possible to be realized. 
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3) Consider the photochemical reactions with enamine/H-bonding catalyst: Attributing to the 
non-facile synthesis and the sensitive -amino methylene group of enamine catalyst -Ir4, its 
photoproperties have not been systematically investigated. As a starting point, the sample 
bis-cyclometalated ligand without H-bonding donors can be selected to synthesize the enamine 
catalyst. As the model reaction, we can consider the alkylation of aldehydes with electron deficient 
benzyl bromides and phenacyl bromides. If the direct alkylation of aldehydes can be realized through 
visible-light-induced photoredox catalysis with -Ir4 or its derivatives, we would fulfill the synthetic 
toolbox in Meggers group, and get rid of the necessity of prefunctionalizing the substrates and the 
subsequent removal of the chelating group. 
 
4) Realize the direct activation of ketones: Considering the substrates for chiral-at-metal Lewis 
acid catalysis is often limited to the imidazole or pyridine achiral templates, the development of new 
strategy for chiral-at-metal complexes that allow direct activation of ketones and aldehydes is highly 
attractive. Except using the well established chiral Ir-based or Rh-based Lewis acid catalysts or their 
derivatives to look for amenable ketone substrates via high throughput screening; exploiting Ru-based 
chiral-at-metal Lewis acid or metal-templated Brønsted acid catalysts would provide new chances for 
this unmet activation. 
 
5) Exploit new photoreactions for unmet synthetic applications: Some long-standing challenge 
transformations for photoredox catalysis are needed to be addressed, Such as the asymmetric 
conjugate addition of unstabilized primary carbon radicals to alkenes, the enantioselective radical 
conjugate addition toward the construction of chiral all-carbon quaternary center; enantioselective - 
and -alkylation of carbonyl compounds based on the enolate/enamine technologies; asymmetric 
photocatalytic C-H activation based on HAT; photocatalytic multiple metal catalysis; asymmetric 
photoredox catalysis mediated by the electron shuttles (cocatalysts). 
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Chapter 5: Experimental Part 
5.1 Materials and Methods 
All reactions were carried out under an atmosphere of nitrogen or argon with magnetic stirring. The 
catalysis reactions were performed in a Schlenk tube. 
Solvents and Reagents 
Solvents were distilled under nitrogen from calcium hydride (CH3CN, CHCl3, CH2Cl2 and DMF), 
magnesium turnings/iodine (MeOH) or sodium/benzophenone (Et2O, THF). HPLC grade solvents, 
such as chlorobenzene, 1,2-dichloroethane, ethanol, acetone and toluene were used directly without 
further drying. All reagents were purchased from Acros, Aldrich, Alfa, TCI, ChemPur, Strem and 
Fluorochem and used without further purification. 
 
Chromatographic Methods 
The course of the reactions and the column chromatographic elutions were traced by thin layer 
chromatography [Macherey-Nagel (ALUGRAM®Xtra Sil G/UV254) or Merck (aluminum silica gel 
60 F254)] with fluorescent indicator UV254 or color developing agent (cerium sulfate / ammonium 
molybdate solution). For column chromatography silica gel, Merck (particle size 0.040-0.063 mm) 
was used. The elution was performed at room temperature using a compressed air overpressure. The 
corresponding mobile phase was specified in the followed procedure. If substance showed poor 
solubility in eluent solvent, the crude product was firstly absorbed by proper amount of silica gel, and 
then the adsorbed gel was subjected to the silica gel chromatographic column. 
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
1H-NMR, proton decoupled 13C-NMR, and proton coupled 19F-NMR spectra were measured on the 
below spectrometers at ambient temperature. 
Bruker Advance 300 MHz (1H-NMR: 300 MHz, 13C-NMR: 75 MHz, 19F NMR: 282 MHz) 
Bruker DRX 400 MHz (1H-NMR: 400 MHz, 13C-NMR: 100 MHz) 
Bruker AM 500 MHz (1H-NMR: 500 MHz, 13C-NMR: 125 MHz) 
Chemical shifts are given in ppm on the  scale, and were determined after calibration to the residual 
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signals of the solvents, which were used as an internal standard. NMR standards used are as follows: 
1H-NMR spectroscopy:  = 7.26 ppm (CDCl3),  = 5.32 ppm (CD2Cl2),  = 1.94 ppm (CD3CN),  = 
2.05 ppm (CD3COCD3),  = 2.50 ppm (CD3SOCD3),  = 3.31 ppm (CD3OD); 13C-NMR spectroscopy: 
 = 77.0 ppm (CDCl3),  = 53.8 ppm (CD2Cl2),  = 118.26, 1.32 ppm (CD3CN),  = 206.26, 29.84 
ppm (CD3COCD3),  = 39.52 ppm (CD3SOCD3),  = 49.0 ppm (CD3OD). 19F NMR spectroscopy:  = 
0 ppm (CFCl3). The characteristic signals were specified from the low field to high field with the 
chemical shifts (δ in ppm). 1H-NMR spectra peak multiplicities indicated as singlet (s), doublet (d), 
doublet of doublet (dd), doublet of doublet of doublet (ddd), triplet (t), doublet of triplet (dt), quartet 
(q), multiplet (m).The coupling constant J indicated in hertz (Hz). And 1H-NMR spectra and 19F-NMR 
peak also show the number of protons. 
 
High-Performance Liquid Chromatography (HPLC) 
Chiral HPLC was performed with an Agilent 1200 Series or Agilent 1260 Series HPLC System. All 
the HPLC conditions were detailed in the individual procedures. 
 
Infrared Spectroscopy (IR) 
IR measurements were recorded on a Bruker Alpha-P FT-IR spectrometer. The absorption bands were 
indicated a wave numbers v (cm1). All substances were measured as films or solids. 
 
Circular Dichroism Spectroscopy (CD) 
CD spectra were recorded on a JASCO J-810 CD spectropolarimeter. The parameters we used as 
follows: from 600 nm to 200 nm; data pitch (0.5 nm); band width (1 nm); response (1 second); 
sensitivity (standard); scanning speed (50 nm/min); accumulation (5 times). The concentration of the 
compounds for the measurements was 0.2 mM. The formula for converting θ to ε is shown as below. 
 
)()/(32980
deg][
cmLLmolc
m



 
C = concentration of the sample; L = thickness of the measurement vessel 
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Crystal Structure Analysis 
Crystal X-ray measurements and the crystal structure analysis were carried out by Dr. Klaus Harms 
(Chemistry Department, Philipps University of Marburg) on the devices IPDS-II (Mo-Kα-irradiation, 
bis 2θ = 77°, Oxford Cryosystem) or IPDS-IIT (Mo-Kα-irradiation, bis 2θ = 135° , Oxford 
Cryosystem). The solution and refinement of the structures were carried with the corresponding 
programs. Details of crystal structures can be found in the Appendix. 
 
UV/Vis Analysis Spectroscopy 
UV/Vis measurements were taken on a Spectra Max M5 microplate reader in a 10.0 mm quartz 
cuvette. 
 
Optical Rotation Polarimeter 
Optical rotations were measured on a Krüss P8000-T or Perkin-Elmer 241 polarimeter with []D22 
values reported in degrees with concentrations reported in g/100 mL.  
Chapter 6. Experimental Part 
148 
 
 
5.2 Enantioselective -Amination of Aldehydes with a Chiral-at-Metal 
Iridium(III) Complex 
5.2.1 Synthesis of the Iridium Catalysts -Ir1-5 and -Ir4 
1) Synthesis of benzoxazole ligands 
 
Figure 108 Synthesisof the benzoxazole ligands. Benzoxazole 7b-2, 7b1 and 7a2 were synthesized 
according to published procedures. 
General procedure for synthesis of methyl 2-phenylbenzo[d]oxazole-5-carboxylates 
(condensation/oxidation procedure):3 A solution of 2-aminophenol (5.0 mmol) and benzaldehyde or 
substituted benzaldehyde (5.0 mmol) in m-xylene (25 mL) was stirred at 120 °C for 0.5 h. Then 
4-methoxy-TEMPO (5 mol% in 0.5 mL m-xylene) was added to the mixture which was stirred at 
120 °C for additional 5 h under an oxygen atmosphere. The reaction mixture was cooled and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(eluent: EtOAc/ hexane = 1:20). 
General procedure for synthesis of 5-hydroxymethyl-2-phenylbenzo[d]oxazoles (reduction 
procedure):1 To a solution of methyl 2-phenylbenzo[d]oxazole-5-carboxylate (4.0 mmol) in THF (20 
mL) at 0 °C was added a solution of DIBAL-H (1.0 M in hexane, 10.0 mL, 10.0 mmol) dropwise. 
After being stirred at 0 °C for 5 min, the reaction was quenched with a saturated aqueous solution of 
sodium tartrate and stirred vigorously for 1 h at room temperature. The reaction mixture was extracted 
with EtOAc (4 × 20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, 
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and concentrated under reduced pressure. The residue was purified by flash chromatography on silica 
gel (eluent: MeOH/CH2Cl2 = 1:50). 
2',6'-Dimethylbiphenyl-3-carbaldehyde (7b-1) 
 
3-Bromobenzaldehyde (2.775 g, 15 mmol) and (2,6-dimethylphenyl)boronic acid (3.150 g, 21 mmol) 
were dissolved in a mixture of 1 M aqueous sodium carbonate solution (30 mL), toluene (30 mL), and 
EtOH (15 mL). After degassing with argon for 30 min, Pd(PPh3)4 (0.0867 g, 0.75 mmol) was added. 
The reaction mixture was stirred under argon atmosphere at 80 °C for 20 h. The reaction mixture was 
cooled to room temperature and water was added to the reaction mixture. The mixture was diluted 
with EtOAc and the insoluble material was filtered through celite. The combined organic layers were 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (eluent: EtOAc/hexane = 1:20) to give compound 7b-1 
(2.961 g, yield: 94%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 10.09 (s, 1H), 7.977.88 (m, 
1H), 7.767.70 (m, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.527.43 (m, 1H), 7.317.08 (m, 3H), 2.06 (s, 6H). 
All spectroscopic data were in agreement with the literature.4 
 
Methyl 2-(2',6'-dimethylbiphenyl-3-yl)benzo[d]oxazole-5-carboxylate (7c-2) 
 
According to the general condensation/oxidation procedure, 7c-2 (1.767 g, yield: 99%) was obtained 
as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.48 (dd, J = 1.2, 0.5 Hz, 1H), 8.28 (dt, J = 7.8, 1.4 Hz, 1H), 8.198.08 
(m, 2H), 7.687.54 (m, 2H), 7.40 (dt, J = 7.6, 1.4 Hz, 1H), 7.277.12 (m, 3H), 3.98 (s, 3H), 2.10 (s, 
6H). 13C NMR (75 MHz, CDCl3) δ 166.6, 164.3, 153.6, 142.2, 142.1, 140.5, 135.8, 132.8, 129.2, 128.4, 
127.5, 127.4, 127.1, 126.9, 126.2, 122.0, 110.3, 52.2, 20.8. IR (film) max: 3064, 2952, 2917, 1716, 
1618, 1545, 1461, 1431, 1284, 1213, 1188, 1082, 978, 918, 901, 834, 811, 772, 742, 704 cm1. HRMS 
(ESI, m/z) calcd for C23H20NO3 [M+H]+: 358.1438, found: 358.1438. 
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(2-(2',6'-Dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methanol (7c) 
 
According to the general reduction procedure, 7c (1.223 g, yield: 93%) was obtained as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.24 (dt, J = 7.8, 1.4 Hz, 1H), 8.07 (t, J = 1.5 Hz, 1H), 7.74 (d, J = 0.6 
Hz, 1H), 7.60 (t, J = 7.7 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.397.31 (m, 2H), 7.247.08 (m, 3H), 
4.80 (s, 2H), 2.53 (br s, 1H), 2.08 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 163.5, 150.2, 142.1, 142.0, 
140.6, 137.9, 135.9, 132.4, 129.2, 128.3, 127.42, 127.39, 127.3, 126.0, 124.4, 118.4, 110.4, 77.4, 77.0, 
76.6, 65.2, 20.8. IR (film) max: 3422, 3063, 3024, 2931, 2862, 1543, 1456, 1438, 1375, 1324, 1263, 
1189, 1051, 979, 905, 801, 761, 726, 702 cm1. HRMS (ESI, m/z) calcd for C22H20NO2 [M+H]+: 
330.1489, found: 330.1490. 
 
2',4',6'-Triisopropylbiphenyl-3-carbaldehyde (7c-1) 
 
Synthesized according to a reported method with some modifications. 5  Accordingly, 
2,4,6-triisopropylphenylboronic acid (1.488 g, 6.0 mmol), 3-bromobenzaldehyde (0.0736 g, 4.0 mmol), 
anhydrous K3PO4 (2.544 g, 12.0 mmol) and dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl) phosphine 
(Sphos, 0.0164 g, 0.4 mmol) were mixed in toluene (40.0 mL). After degassing with argon for 30 min, 
Pd(OAc)2 (0.0450 g, 0.2 mmol) was added. The reaction mixture was stirred under argon atmosphere 
at 110 °C for 24 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, and the 
insoluble material was filtered through Celite. The combined organic layers were concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (eluent: 
EtOAc/hexane = 1:30) to give compound 7c-1 (1.158 g, yield: 94%) as a white solid. 1H NMR (300 
MHz, CDCl3) δ 10.05 (s, 1H), 7.89 (dt, J = 7.6, 1.3 Hz, 1H), 7.71 (s, 1H), 7.58 (t, J = 7.6 Hz, 1H), 
7.48 (dt, J = 7.5, 1.3 Hz, 1H), 7.08 (s, 2H), 2.96 (hept, J = 6.9 Hz, 1H), 2.52 (hept, J = 6.9 Hz, 2H), 
1.33 (s, 3H), 1.31 (s, 3H), 1.10 (s, 3H), 1.09 (s, 3H), 1.08 (s, 3H), 1.07 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 192.4, 148.6, 146.4, 142.0, 136.3, 135.9, 135.5, 131.3, 128.7, 127.7, 120.7, 34.3, 30.4, 24.09, 
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24.05, 24.0. IR (film) max: 2959, 2926, 2868, 1690, 1604, 1572, 1459, 1372, 1282, 1250, 1164, 878, 
802, 729, 705, 652 cm1. HRMS (ESI, m/z) calcd for C22H28ONa [M+Na]+: 331.2032, found: 
331.2033. 
 
Methyl 2-(2',4',6'-triisopropylbiphenyl-3-yl)benzo[d]oxazole-5-carboxylate (7d-2) 
 
According to the general condensation/oxidation procedure, 7d-2 (2.048 g, yield: 90%) was obtained 
as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.568.42 (m, 1H), 8.378.22 (m, 1H), 8.14 (t, J = 1.5 Hz, 1H), 8.11 
(dd, J = 8.6, 1.7 Hz, 1H), 7.647.55 (m, 2H), 7.497.38 (m, 1H), 7.11 (s, 2H), 3.97 (s, 3H), 2.98 (hept, 
J = 6.9 Hz, 1H), 2.64 (hept, J = 6.8 Hz, 2H), 1.34 (d, J = 6.9 Hz, 6H), 1.14 (d, J = 6.5 Hz, 6H), 1.11 (d, 
J = 6.5 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 166.7, 164.4, 153.7, 148.5, 146.4, 142.3, 141.9, 135.8, 
133.4, 129.1, 128.7, 127.0, 126.5, 126.1, 122.0, 120.7, 110.3, 77.4, 77.0, 76.6, 52.2, 34.3, 30.4, 24.2, 
24.13, 24.07. IR (film) max: 2958, 2869, 1722, 1624, 1557, 1460, 1437, 1358, 1294, 1209, 1125, 1085, 
1054, 841, 810, 756, 702 cm1. HRMS (ESI, m/z) calcd for C30H34NO3 [M+H]+: 456.2533, found: 
456.2529. 
 
(2-(2',4',6'-Triisopropylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methanol (7d) 
 
According to the general reduction procedure, 7d (1.674 g, yield: 98%) was obtained as a white solid.  
1H NMR (300 MHz, CDCl3) δ 8.26 (dt, J = 7.8, 1.4 Hz, 1H), 8.11 (t, J = 1.5 Hz, 1H), 7.75 (d, J = 0.9 
Hz, 1H), 7.57 (t, J = 7.7 Hz, 1H), 7.49 (d, J = 8.3 Hz, 1H), 7.40 (dt, J = 7.6, 1.3 Hz, 1H), 7.34 (dd, J = 
8.4, 1.6 Hz, 1H), 7.11 (s, 2H), 4.80 (s, 2H), 2.98 (hept, J = 6.9 Hz, 1H), 2.64 (hept, J = 6.8 Hz, 2H), 
2.52 (br s, 1H), 1.34 (d, J = 6.9 Hz, 6H), 1.14 (d, J = 6.6 Hz, 6H), 1.11 (d, J = 6.6 Hz, 6H). 13C NMR 
(75 MHz, CDCl3) δ 163.6, 150.2, 148.4, 146.4, 142.2, 141.8, 137.9, 135.9, 133.1, 128.9, 128.6, 126.8, 
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125.9, 124.4, 120.6, 118.4, 110.4, 65.2, 34.3, 30.4, 24.2, 24.13, 24.08. IR (film) max: 3277, 2958, 2929, 
2869, 1609, 1554, 1460, 1433, 1257, 1190, 1051, 1022, 877, 810, 781, 704 cm1. HRMS (ESI, m/z) 
calcd for C29H34NO2 [M+H]+: 428.2584, found: 428.2583. 
 
2) Synthesis of the secondary amine ligand 
Benzyl 3-hydroxy-4-(picolinamido)pyrrolidine-1-carboxylate (3) 
 
To a solution of picolinic acid (4.0 g, 32.8 mmol) in THF (120 mL) at 0 C was added successively 
Et3N (9.1 mL, 65.6 mmol) and ethyl chloroformate (3.1 mL, 32.8 mmol). After being stirred at 0 C 
for 1 h, a solution of 26 (7.1 g, 30.0 mmol) in THF (30 mL) was added. After being stirred at room 
temperature for overnight, the reaction was quenched with a saturated aqueous solution of NH4Cl and 
extracted with CH2Cl2 (4 × 50 mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica gel (eluent: MeOH/CH2Cl2 = 1:50) to give compound 3 (9.5 g, yield: 93%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.50 (d, J = 4.5 Hz, 1H), 8.21 (t, J = 6.0 Hz, 1H), 8.11 (d, J = 7.8 Hz, 
1H), 7.81 (td, J = 7.7, 1.7 Hz, 1H), 7.45–7.27 (m, 5H), 5.15 (s, 2H), 4.80 (br, 1H), 4.60–4.45 (m, 1H), 
4.40 (s, 1H), 4.11–3.91 (m, 1H), 3.76 (td, J = 11.4, 5.2 Hz, 1H), 3.53 (ddd, J = 15.3, 11.8, 3.2 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 165.1, 164.9, 154.9, 148.8, 148.1, 137.5, 136.5, 128.4, 127.9, 127.82, 
127.79, 126.6, 122.2, 74.5, 73.6, 67.0, 56.4, 56.0, 51.7, 51.4, 49.1. IR (film) max: 3346, 3056, 2952, 
2884, 1672, 1516, 1426, 1349, 1192, 1108, 738, 695, 595 cm1. HRMS (ESI, m/z) calcd for 
C18H20N3O4 [M+H]+: 342.1448, found: 342.1446. 
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Benzyl 2-(pyridin-2-yl)-4H-pyrrolo[3,4-d]oxazole-5(6H)-carboxylate (5) 
 
To a solution of 3 (2.0 g, 5.9 mmol) in CH2Cl2 (59 mL) at 0 C was added Dess-Martin reagent (6.1 g, 
14.4 mmol). After being stirred at room temperature for overnight, the reaction mixture was diluted 
with CH2Cl2 and washed with NaOH (0.5 M, 3  10 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product of 4 was 
used for next step without further purification. The crude 4 (5.9 mmol estimated on the theoretical 
yield) was dissolved in CHCl3 (59 mL). PCl5 (3.7 g, 17.7 mmol) was added at 50 C and stirring was 
continued for an additional 3 h. The reaction was quenched with a saturated aqueous solution of 
Na2CO3 and extracted with CH2Cl2 (4 × 20 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was passed through 
a short column of silica gel (eluent: MeOH/CH2Cl2 = 1:50) to afford the crude product as a black solid. 
The crude product was washed with MeOH (3  3 mL) and centrifuged to afford the 5 (663 mg, 35% 
in two steps) as a white solid. 1H NMR (300 MHz, CDCl3) δ 8.70–8.54 (m, 1H), 8.09–7.92 (m, 1H), 
7.72 (tt, J = 7.9, 1.5 Hz, 1H), 7.40–7.22 (m, 6H), 5.13 (d, J = 0.8 Hz, 2H), 4.63–4.50 (m, 2H), 
4.50–4.36 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 164.5, 154.7, 154.6, 149.9, 149.8, 149.4, 149.3, 
145.7, 140.3, 140.2, 137.0, 136.9, 136.24, 136.21, 128.4, 128.1, 128.07, 128.02, 127.9, 124.7, 121.7, 
121.6, 67.22, 67.20, 45.5, 45.4, 44.9, 44.7. IR (film) max: 3053, 2938, 2882, 1696, 1413, 1362, 1295, 
1095, 942, 797, 745, 695, 614 cm1. HRMS (ESI, m/z) calcd for C18H16N3O3 [M+H]+: 322.1186, found: 
188.0814. 
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2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[3,4-d]oxazole (1) 
 
To a solution of 5 (96.3 mg, 0.3 mmol) in CH3CN/CH2Cl2 (3 mL/1mL) at 0 C was added TMSI (0.12 
mL, 0.9 mmol). After being stirred at room temperature for 1 h, the reaction was quenched with dry 
MeOH (0.5 mL). The solvent was removed under reduced pressure. The residue was purified by flash 
chromatography on silica gel (eluent: MeOH/CH2Cl2 = 1:10) to give compound 1 (53.0 mg, yield: 
95%) as a white solid. 1H NMR (300 MHz, MeOD) δ 8.68 (d, J = 4.6 Hz, 1H), 8.11 (d, J = 7.9 Hz, 
1H), 8.03 (td, J = 7.8, 1.6 Hz, 1H), 7.70–7.47 (m, 1H), 4.33–4.20 (m, 2H), 4.19–4.02 (m, 2H). 13C 
NMR (75 MHz, MeOD) δ 167.0, 154.7, 151.0, 146.3, 145.0, 139.4, 126.8, 123.0, 44.4, 43.8. IR (film) 
max: 3036, 2934, 2882, 1423, 1363, 1296, 1209, 1153, 1095, 956, 738, 696 cm1. HRMS (ESI, m/z) 
calcd for C10H10N3O [M+H]+: 188.0818, found: 188.0816. 
 
3) Synthesis of iridium complexes 
Our developed synthetic strategy7 for the generation of enantiomerically pure iridium(III) complexes 
relies on the use of (S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline8  as a chiral auxiliary. As 
described in detail below, racemic iridium(III) precursor complexes were converted to diastereomeric 
phenolato complexes, then resolved into single diastereomers by flash silica gel column 
chromatography, and followed by an acid-induced substitution of the auxiliary under complete 
retention of configuration to afford the enantiomerically pure iridium complexes. 
 
3.1) Synthesis of iridium precursor complexes 
Cyclometalated iridium(III) μ-chloro-bridged dimers of the general formula [(C^N)2Ir(μ-Cl)Ir(C^N)2]  
(C^N = (2-phenylbenzo[d]oxazol-5-yl)methanol and its derivatives were synthesized according to a 
method reported by Nonoyama, 9  which involves refluxing IrCl3•nH2O with 2.0–2.5 equiv of 
cyclometalating ligand in a 3:1 mixture of 2-methoxyethanol and water. Accordingly, 
(2-phenylbenzo[d]oxazol-5-yl)methanol or its derivatives (2.0 mmol) were added to iridium chloride 
(1.0 mmol) in a mixture of methoxyethanol/water (3:1, 44 mL). The reaction mixture was heated at 
reflux (120 °C) with constant stirring for 24 h. The resulting precipitate was collected by 
centrifugation, washed with diethyl ether and dried to yield the product as a yellow powder (60-89%), 
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which was used without further purification. 
 
Scheme 23 Synthesis of cyclometalated Ir(III) μ-chloro-bridged dimers 8a-e. 
 
Preparation of iridium auxiliary complexes 
 
Scheme 24 Preparation of iridium precursor complexes Λ-(S)-9a-e. The complexes Λ-(S)-9b and 
Λ-(S)-9e were synthesized according to published procedures.1 
 
Preparation of iridium auxiliary complex Λ-(S)-9a. A mixture of iridium(III) dimer complex 8a 
(259.0 mg, 0.20 mmol), (S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline (S)-6 (110.5 mg, 0.50 
mmol), and triethylamine (0.28 mL, 2.0 mmol) in ethanol (20 mL) was purged with argon for 5 min 
and then heated at reflux overnight. The reaction mixture was cooled to room temperature and 
concentrated to dryness. The residue was subjected to a flash silica gel chromatography (eluent: 
EtOAc/CH2Cl2 = 1:10) to separate the two diastereomers. Only the first eluting diastereomer (yellow 
solid, 127.0 mg, 38%) was characterized and used for the synthesis of enantiopure iridium catalyst, 
which was assigned as Λ-configuration by CD spectroscopy in analogy to reported complexes.1 
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1H NMR (500 MHz, DMSO) δ 9.86 (s, 1H), 9.78 (s, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.69 (d, J = 9.0 Hz, 
1H), 7.66 (d, J = 6.9 Hz, 1H), 7.56 (d, J = 6.7 Hz, 1H), 7.33 (dd, J = 8.2, 1.7 Hz, 1H), 7.10 (d, J = 2.5 
Hz, 1H), 7.07 (ddd, J = 8.6, 6.8, 1.7 Hz, 1H), 6.97 (dd, J = 3.4, 2.6 Hz, 1H), 6.96 (dd, J = 3.4, 2.6 Hz, 
1H), 6.90 (t, J = 7.4 Hz, 2H), 6.79 (dtd, J = 8.7, 7.5, 1.3 Hz, 2H), 6.71 (d, J = 2.3 Hz, 1H), 6.52 (d, J = 
7.6 Hz, 2H), 6.296.21 (m, 1H), 6.18 (d, J = 7.6 Hz, 1H), 4.57 (d, J = 9.8 Hz, 1H), 3.47 (dd, J = 11.8, 
10.1 Hz, 1H), 3.17 (d, J = 5.2 Hz, 1H), 0.830.70 (m, 1H), 0.21 (d, J = 2.4 Hz, 3H), 0.19 (d, J = 2.4 
Hz, 3H). 13C NMR (125 MHz, DMSO) δ 177.7, 177.1, 167.4, 166.9, 156.2, 155.9, 150.6, 148.9, 143.4, 
143.0, 138.9, 138.7, 134.3, 133.02, 132.98, 131.6, 131.3, 131.0, 130.6, 130.2, 125.5, 125.0, 123.6, 
121.5, 120.6, 117.7, 113.8, 113.7, 112.8, 112.3, 112.0, 102.8, 101.0, 84.1, 31.0, 26.8, 18.6, 13.9. IR 
(film) max: 2958, 2925, 2867, 1592, 1561, 1530, 1440, 1388, 1355, 1299, 1160, 1028, 1003, 944, 816, 
741 cm1. HRMS (ESI, m/z) calcd for C38H30IrN3O5SNa [MNa]+: 856.1428, found: 856.1422. CD 
(MeOH): λ, nm (Δε, M-1cm-1) 356 (+40), 289 (28), 221 (47). 
 
Preparation of iridium auxiliary complex Λ-(S)-9c A mixture of iridium(III) dimer complex 8c 
(265.0 mg, 0.15 mmol), (S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline (S)-6 (83.0 mg, 0.38 mmol), 
and triethylamine (0.21 mL, 1.5 mmol) in ethanol (15 mL) was purged with argon for 5 min and then 
heated at reflux overnight. The reaction mixture was cooled to room temperature and concentrated to 
dryness. The residue was subjected to a flash silica gel chromatography (eluent: EtOAc/CH2Cl2 = 1:10) 
to separate the two diastereomers. Only the first eluting diastereomer (orange solid, 120.0 mg, 37%) 
was characterized and used for the synthesis of enantiopure iridium catalyst, which was assigned as 
Λ-configuration by CD spectroscopy in analogy to reported complexes.1 
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1H NMR (300 MHz, CDCl3) δ 7.68 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.527.39 (m, 5H), 7.256.98 (m, 
8H), 6.90 (d, J = 8.2 Hz, 1H), 6.686.56 (m, 2H), 6.53 (dd, J = 7.8, 1.7 Hz, 1H), 6.41 (d, J = 7.8 Hz, 
1H), 6.35 (t, J = 7.1 Hz, 1H), 4.96 (d, J = 9.7 Hz, 1H), 4.684.40 (m, 4H), 3.573.43 (m, 1H), 3.37 (t, 
J = 5.6 Hz, 1H), 2.79 (d, J = 11.3 Hz, 1H), 2.53 (t, J = 6.1 Hz, 1H), 2.09 (s, 3H), 1.99 (s, 3H), 1.75 (s, 
3H), 1.72 (s, 3H), 0.26 (d, J = 6.4 Hz, 3H), 0.24 (d, J = 6.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
178.5, 178.3, 167.67, 166.73, 149.4, 149.2, 147.9, 147.2, 141.5, 141.4, 139.8, 139.7, 138.8, 138.3, 
136.6, 136.4, 136.2, 135.8, 134.1, 133.6, 133.3, 133.2, 133.1, 132.6, 132.5, 131.6, 130.9, 130.2, 127.2, 
127.1, 127.03, 126.98, 126.8, 126.7, 126.0, 125.9, 124.1, 124.0, 123.5, 118.7, 116.0, 113.6, 113.4, 
111.3, 111.0, 86.0, 64.7, 64.4, 31.0, 27.4, 21.0, 20.9, 20.2, 20.1, 18.7, 14.0. IR (film) max: 2958, 2924, 
2869, 1598, 1560, 1524, 1463, 1436, 1364, 1253, 1191, 1148, 1031, 1014, 941, 836, 766, 742 cm1. 
HRMS (ESI, m/z) calcd for C56H51IrN3O5S [MH]+: 1070.3176, found: 1070.3189. CD (MeOH): λ, nm 
(Δε, M-1cm-1) 366 (+26), 328 (+30), 306 (28), 298 (28), 230 (26). 
 
Preparation of iridium auxiliary complex Λ-(S)-9d and -(S)-9d: A mixture of iridium(III) dimer 
complex 8d (324.0 mg, 0.15 mmol), (S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline (S)-6 (83.0 mg, 
0.38 mmol), silver triflate (77.1 mg, 0.30 mmol), and triethylamine (0.21 mL, 1.5 mmol) in ethanol 
(15 mL) was purged with argon for 5 min and then heated at reflux overnight. The reaction mixture 
was cooled to room temperature and concentrated to dryness. The residue was subjected to a flash 
silica gel chromatography (eluent: EtOAc/CH2Cl2 = 1:30) to separate the two diastereomers. Two 
eluting diastereomers was characterized and can be used for the synthesis of enantiopure iridium 
catalyst. The first eluting diastereomer (orange solid, 140.0 mg, 37%) was assigned as Λ-configuration 
by CD spectroscopy in analogy to reported complexes.1 The second eluting diastereomer (orange solid, 
140.0 mg, 37%) was assigned accordingly as -configuration. 
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1H NMR (300 MHz, CDCl3) δ 7.53 (s, 1H), 7.427.28 (m, 4H), 7.287.17 (m, 3H), 7.05 (dd, J = 8.6, 
1.4 Hz, 1H), 6.97 (ddd, J = 8.6, 6.8, 1.7 Hz, 1H), 6.856.73 (m, 4H), 6.63 (d, J = 8.5 Hz, 1H), 
6.496.35 (m, 3H), 6.21 (d, J = 7.8 Hz, 1H), 6.176.05 (m, 1H), 4.74 (d, J = 10.3 Hz, 1H), 4.61 (s, 
2H), 4.40 (s, 2H), 3.39 (t, J = 10.8 Hz, 1H), 2.862.61 (m, 3H), 2.612.40 (m, 2H), 2.292.14 (m, 2H), 
2.06 (s, 1H), 1.68 (br s, 2H), 1.08 (d, J = 3.7 Hz, 6H), 1.06 (d, J = 3.7 Hz, 6H), 0.88 (d, J = 5.3 Hz, 
3H), 0.86 (d, J = 5.4 Hz, 3H), 0.80 (dd, J = 6.9, 1.5 Hz, 6H), 0.75 (d, J = 6.9 Hz, 6H), 0.71 (dd, J = 6.8, 
1.8 Hz, 6H), 0.13 (d, J = 6.9 Hz, 3H), 0.01 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 178.6, 
167.9, 167.4, 149.6, 149.4, 147.7, 147.6, 147.1, 147.0, 146.8, 146.7, 139.6, 139.3, 139.1, 138.6, 136.8, 
134.0, 133.5, 133.4, 133.2, 133.1, 132.7, 131.4, 130.6, 129.7, 126.9, 126.6, 124.3, 124.1, 123.0, 120.6, 
120.5, 120.4, 120.3, 118.7, 116.1, 113.4, 113.2, 111.5, 111.2, 85.8, 65.0, 64.9, 34.2, 31.2, 30.2, 30.1, 
30.0, 27.4, 24.7, 24.4, 24.3, 24.13, 24.05, 24.0, 23.9, 18.6, 14.1. IR (film) max: 2958, 2926, 2867, 1599, 
1562, 1531, 1464, 1436, 1363, 1334, 1256, 1191, 1155, 1059, 1031, 1012, 942, 788, 748 cm1.  
HRMS (ESI, m/z) calcd for C70H79IrN3O5S [MH]+: 1266.5368, found: 1266.5361. CD (MeOH): λ, 
nm (Δε, M-1cm-1) 368 (+33), 329 (+41), 306 (35), 295 (35), 231 (26). 
 
 
1H NMR (300 MHz, CDCl3) δ 7.94 (s, 1H), 7.62–7.58 (m, 2H), 7.56–7.39 (m, 4H), 7.31 (dd, J = 7.9, 
1.7 Hz, 1H), 7.27 (d, J = 8.3 Hz, 1H), 7.12–6.96 (m, 4H), 6.88 (ddd, J = 8.6, 7.1, 1.7 Hz, 1H), 6.73 (d, 
J = 7.8 Hz, 1H), 6.65 (dd, J = 7.8, 1.8 Hz, 1H), 6.62–6.52 (m, 2H), 6.48 (d, J = 7.8 Hz, 1H), 6.34–6.21 
(m, 1H), 4.75–4.44 (m, 4H), 3.76 (d, J = 9.5 Hz, 1H), 3.07 (d, J = 11.4 Hz, 1H), 3.01–2.69 (m, 6H), 
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2.59–2.33 (m, 2H), 2.29–2.10 (m, 1H), 2.02 (t, J = 5.6 Hz, 1H), 1.32 (d, J = 3.3 Hz, 6H), 1.30 (d, J = 
3.3 Hz, 6H), 1.17 (d, J = 6.7 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.08 (d, J = 6.9 Hz, 3H), 1.06–0.97 (m, 
12H), 0.94 (d, J = 4.3 Hz, 3H), 0.92 (d, J = 4.3 Hz, 3H), 0.34 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 179.1, 168.8, 168.5, 149.7, 149.1, 147.9, 147.7, 147.5, 147.2, 147.0, 146.8, 146.5, 146.3, 
140.1, 139.4, 138.5, 138.4, 136.7, 135.2, 133.6, 133.4, 133.1, 132.7, 132.6, 132.0, 129.6, 129.5, 129.3, 
127.2, 126.5, 124.6, 124.0, 123.7, 121.8, 120.6, 120.5, 120.4, 120.3, 116.0, 115.2, 113.3, 111.3, 111.0, 
80.9, 64.9, 64.6, 34.19, 34.17, 31.6, 30.8, 30.1, 30.02, 29.95, 29.86, 24.7, 24.5, 24.4, 24.2, 24.03, 
23.96, 23.9, 20.2, 16.4. IR (film) max: 2958, 2868, 1599, 1564, 1530, 1437, 1365, 1319, 1252, 1199, 
1147, 1028, 942, 877, 816, 749 cm1. HRMS (ESI, m/z) calcd for C70H79IrN3O5S [MH]+: 1266.5369, 
found: 1266.5336. CD (MeOH): λ, nm (Δε, M-1cm-1) 328 (28), 304 (24), 288 (32).  
 
3.2) Synthesis of enantiopure iridium catalysts 
The enantiopure iridium catalysts were prepared according to a reported method with some 
modifications,1 which relies on the acid-induced substitution of the coordinated phenolato ligand 
against 2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[3,4-d]oxazole under retention of configuration and is 
analogous to previously reported auxiliary-mediated ruthenium(II) chemistry by Meggers et al.10 The 
absolute configurations of the obtained -configured iridium(III) complexes were verified by CD 
spectroscopy in analogy to reported complexes.1 The enantiomeric purities were verified by chiral 
HPLC analysis. 
 
Scheme 25 Synthesis of enantiopure iridium catalysts -Ir1-5 and -Ir4. 
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General procedure: A suspension of the iridium auxiliary complexes Λ-(S)-9a-e or -(S)-9d (1.0 eq), 
ligand 1 (2.0 eq), and NH4PF6 (5.0 eq) in acetonitrile (10 mM) was stirred at room temperature for 1 h 
under argon in the dark. Then, the reaction mixture was concentrated to dryness and dissolved in 
MeOH/CH2Cl2 (3:1, 10 mM). After being stirred at room temperature for 3 h, the reaction mixture was 
concentrated to dryness and subjected to a flash silica gel chromatography (eluent: MeOH/CH2Cl2 = 
1:30) to give the pure yellow solid as a hexafluorophosphate salt. The product was directly suspended 
in CH2Cl2. Sodium tetrakis[(3,5-di-trifluoromethyl)phenyl]borate (NaBArF24) (0.95 eq) was added in 
one portion and the mixture was stirred at room temperature for 10 min. After removal of the CH2Cl2 
in vacuo, the residue was taken up in Et2O (about 2.0 mL) twice and centrifuged. The combined 
organic layers were dried and concentrated in vacuo to give the pure product as the borate salt. 
 
 
Following the general procedure, -(S)-7a (83.3 mg, 0.10 mmol) was converted to -Ir1 (109.7 mg, 
yield: 66%) as an orange solid. 1H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 5.2 Hz, 1H), 7.85 (t, J = 7.8 
Hz, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.76 (d, J = 7.9 Hz, 1H), 7.71 (s, 8H), 7.567.46 (m, 1H), 7.41 (s, 
4H), 7.29 (d, J = 8.9 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.106.99 (m, 2H), 6.94 (t, J = 7.5 Hz, 1H), 
6.82 (dd, J = 9.0, 2.2 Hz, 1H), 6.67 (dd, J = 9.0, 2.3 Hz, 1H), 6.64 (d, J = 7.6 Hz, 1H), 6.54 (d, J = 7.6 
Hz, 1H), 5.78 (d, J = 2.1 Hz, 1H), 5.08 (d, J = 2.3 Hz, 1H), 4.01 (d, J = 13.9 Hz, 1H), 3.92 (d, J = 14.7 
Hz, 1H), 3.54 (d, J = 14.2 Hz, 1H), 3.25 (d, J = 13.8 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 178.01, 
177.96, 169.9, 162.6, 162.0, 161.3, 160.7, 157.7, 155.4, 154.4, 152.9, 146.1, 144.6, 144.4, 144.0, 
143.3, 141.5, 139.7, 138.0, 134.8, 133.5, 133.3, 132.9, 129.8, 129.5, 129.1, 129.0, 128.9, 128.7, 128.3, 
126.8, 126.4, 126.2, 123.8, 123.7, 123.4, 122.6, 119.0, 117.5, 114.4, 113.8, 113.2, 112.7, 100.2, 99.6, 
43.0, 41.8. IR (film) max: 1595, 1451, 1352, 1273, 1115, 888, 831, 738, 708, 672 cm1. HRMS (ESI, 
m/z) calcd for C36H25IrN5O5 [MBArF24]+: 800.1481, found: 800.1489. CD (MeOH): λ, nm (Δε, 
M-1cm-1) 337 (+40), 218 (45). 
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Following the general procedure, Λ-(S)-7b (43.3 mg, 0.050 mmol) was converted to -Ir2 (60.0 mg, 
yield: 71%) as an orange solid. 1H NMR (500 MHz, CD2Cl2) δ 8.28 (dt, J = 5.4, 1.2 Hz, 1H), 
8.158.09 (m, 2H), 7.87 (ddd, J = 7.7, 1.3, 0.4 Hz, 1H), 7.81 (dd, J = 7.7, 0.9 Hz, 1H), 7.72 (t, J = 2.3 
Hz, 8H), 7.677.60 (m, 3H), 7.54 (s, 4H), 7.33 (dd, J = 8.5, 1.7 Hz, 1H), 7.28 (dd, J = 8.6, 1.6 Hz, 1H), 
7.19 (td, J = 7.5, 1.0 Hz, 1H), 7.12 (td, J = 7.5, 1.0 Hz, 1H), 7.06 (td, J = 7.5, 1.4 Hz, 1H), 6.97 (td, J = 
7.5, 1.4 Hz, 1H), 6.70 (d, J = 7.5 Hz, 1H), 6.58-6.50 (m, 2H), 5.83 (d, J = 0.8 Hz, 1H), 4.77 (d, J = 
14.0 Hz, 1H), 4.71 (d, J = 14.0 Hz, 1H), 4.56 (d, J = 13.4 Hz, 1H), 4.52 (d, J = 13.4 Hz, 1H), 4.30 
(ddd, J = 15.1, 3.9, 2.1 Hz, 1H), 4.18 (ddd, J = 15.0, 3.7, 2.7 Hz, 1H), 3.74 (s, 3H), 3.62 (ddd, J = 14.1, 
3.9, 2.0 Hz, 1H), 3.22 (ddd, J = 14.1, 3.6, 2.6 Hz, 1H). 13C NMR (126 MHz, CD2Cl2) δ 178.3, 177.9, 
162.8, 162.4, 162.0, 161.6, 154.0, 149.9, 149.8, 147.0, 144.7, 142.2, 141.0, 140.6, 140.5, 138.1, 137.7, 
135.2, 134.0, 133.73, 133.72, 133.3, 129.7, 129.44, 129.42, 129.39, 129.37, 129.19, 129.17, 129.14, 
129.12, 128.94, 128.92, 128.89, 128.87, 128.3, 127.4, 127.0, 126.1, 124.8, 124.4, 124.2, 123.9, 121.8, 
118.0, 117.94, 117.91, 117.88, 117.85, 112.9, 112.6, 112.2, 111.5, 64.2, 64.1, 44.2, 42.9. IR (film) max: 
1600, 1520, 1446, 1391, 1354, 1274, 1116, 939, 888, 835, 741, 710 673 cm1. HRMS (ESI, m/z) calcd 
for C38H29IrN5O5 [MBArF24]+: 828.1797, found: 828.1789. CD (MeOH): λ, nm (Δε, M-1cm-1) 354 
(+26), 330 (+32), 261 (9), 226 (27). 
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Following the general procedure, Λ-(S)-7c (64.0 mg, 0.060 mmol) was converted to -Ir3 (79.8 mg, 
yield: 70%) as an orange solid. 1H NMR (300 MHz, CDCl3) δ 8.20 (d, J = 5.3 Hz, 1H), 7.837.68 (m, 
2H), 7.57 (d, J = 1.4 Hz, 9H), 7.52 (d, J = 1.7 Hz, 1H), 7.44 (d, J = 8.5 Hz, 2H), 7.417.35 (m, 1H), 
7.32 (s, 4H), 7.166.93 (m, 8H), 6.77 (dd, J = 7.8, 1.8 Hz, 1H), 6.68 (dd, J = 7.8, 1.8 Hz, 1H), 6.64 (d, 
J = 7.8 Hz, 1H), 6.55-6.38 (m, 2H), 5.72 (s, 1H), 4.62 (d, J = 14.1 Hz, 1H), 4.54 (d, J = 14.1 Hz, 1H), 
4.43 (d, J = 13.5 Hz, 1H), 4.36 (d, J = 13.5 Hz, 1H), 4.07 (d, J = 15.0 Hz, 1H), 3.88 (d, J = 15.1 Hz, 
1H), 3.59 (d, J = 14.0 Hz, 1H), 3.18 (d, J = 14.6 Hz, 1H), 2.49 (br s, 2H), 2.00 (s, 3H), 1.93 (s, 3H), 
1.81 (s, 6H), 1.56 (br s, 1H). 13C NMR (75 MHz, CDCl3) δ 177.8, 177.5, 169.5, 162.7, 162.0, 161.3, 
160.7, 160.5, 153.0, 149.3, 149.2, 145.9, 144.6, 140.6, 140.3, 140.2, 140.0, 139.7, 137.6, 137.4, 136.6, 
136.5, 136.2, 135.8, 135.5, 134.7, 134.0, 133.4, 129.9, 129.3, 129.2, 128.6, 127.6, 127.5, 126.9, 126.3, 
124.3, 123.8, 123.3, 122.7, 119.0, 117.4, 112.3, 111.5, 110.9, 63.7, 63.4, 43.6, 42.5, 20.9, 20.8, 20.6. 
IR (film) max: 1608, 1446, 1354, 1272, 1116, 1042, 943, 889, 837, 711, 673, 643 cm1. HRMS (ESI, 
m/z) calcd for C54H45IrN5O5 [MBArF24]+: 1036.3048, found: 1036.3053. CD (MeOH): λ, nm (Δε, 
M-1cm-1) 360 (+31), 332 (+33), 274 (15), 241 (18). 
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Following the general procedure, Λ-(S)-9d (140.0 mg, 0.11 mmol) was converted to -Ir4 (154.4 mg, 
yield: 67%) and -(S)-9d (140.0 mg, 0.11 mmol) to -Ir4 (185.5 mg, yield: 80%). Both complexes are 
orange solids. NMR spectra of -Ir4 and -Ir4 are identical: 1H NMR (500 MHz, CDCl3) δ 8.39 (d, J 
= 5.3 Hz, 1H), 7.92 (d, J = 7.8 Hz, 1H), 7.87 (td, J = 7.8, 1.4 Hz, 1H), 7.74 (d, J = 1.8 Hz, 1H), 7.70 (s, 
9H), 7.61-7.49 (m, 3H), 7.44 (s, 4H), 7.25 (d, J = 8.7 Hz, 1H), 7.19 (d, J = 8.7 Hz, 1H), 7.12 (d, J = 
1.6 Hz, 1H), 7.097.05 (m, 3H), 6.95 (dd, J = 7.8, 1.8 Hz, 1H), 6.87 (dd, J = 7.8, 1.8 Hz, 1H), 6.76 (d, 
J = 7.8 Hz, 1H), 6.57 (d, J = 7.8 Hz, 1H), 6.54 (s, 1H), 5.85 (s, 1H), 4.73 (d, J = 14.1 Hz, 1H), 4.67 (d, 
J = 14.1 Hz, 1H), 4.58 (d, J = 13.5 Hz, 1H), 4.50 (d, J = 13.5 Hz, 1H), 4.26 (d, J = 15.2 Hz, 1H), 4.05 
(d, J = 15.3 Hz, 1H), 3.76 (d, J = 14.8 Hz, 1H), 3.33 (d, J = 14.0 Hz, 1H), 2.97 (hept, J = 6.8 Hz, 1H), 
2.96 (hept, J = 6.8 Hz, 1H), 2.78 (hept, J = 6.9 Hz, 1H), 2.65 (hept, J = 6.9 Hz, 1H), 2.51 (hept, J = 6.9 
Hz, 1H), 2.46 (hept, J = 6.8 Hz, 1H), 1.33 (d, J = 6.8 Hz, 6H), 1.31 (d, J = 6.2 Hz, 6H), 1.19 (d, J = 6.8 
Hz, 3H), 1.17 (d, J = 6.9 Hz, 3H), 1.14 (d, J = 6.9 Hz, 3H), 1.07 (dd, J = 6.9, 1.9 Hz, 6H), 1.03 (d, J = 
6.9 Hz, 3H), 0.98 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 177.9, 
177.5, 169.9, 162.3, 161.9, 161.5, 161.1, 159.5, 153.2, 149.3, 149.2, 148.6, 148.5, 146.7, 146.6, 146.3, 
146.0, 145.2, 144.4, 144.2, 140.4, 140.1, 139.7, 139.5, 137.7, 137.4, 136.3, 135.61, 135.56, 135.5, 
134.7, 132.9, 132.7, 129.3, 129.1, 128.9, 128.8, 128.7, 128.6, 128.0, 127.7, 127.6, 125.5, 124.3, 123.8, 
123.5, 123.4, 121.2, 120.9, 120.8, 120.7, 120.5, 117.48,  117.45, 117. 42, 112.4, 112.3, 111.5, 110.6, 
63.7, 63.5, 43.7, 42.6, 34.3, 30.60, 30.56, 30.33, 30.26, 24.24, 24.15, 24.10, 24.02, 23.99, 23.96. 
-Ir4: IR (film) max: 2963, 1606, 1527, 1445, 1354, 1272, 1118, 1040, 886, 836, 711, 673, 640 cm1. 
HRMS (ESI, m/z) calcd for C68H73IrN5O5 [MBArF24]+: 1232.5242, found: 1232.5234. CD (MeOH): λ, 
nm (Δε, M-1cm-1) 361 (+36), 334 (+37), 269 (22), 238 (23). 
-Ir4: IR (film) max: 2961, 2912, 2872, 1606, 1525, 1445, 1353, 1274, 1119, 886, 835, 711, 673 cm1. 
HRMS (ESI, m/z) calcd for C68H73IrN5O5 [MBArF24]+: 1232.5242, found: 1232.5239. CD (MeOH): λ, 
nm (Δε, M-1cm-1) 361 (37), 335 (37), 272 (21), 241 (16). 
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Following the general procedure, Λ-(S)-9e (40.1 mg, 0.050 mmol) was converted to -Ir5 (38.0 mg, 
yield: 46%) as an orange solid. 1H NMR (500 MHz, CD2Cl2) δ 8.20 (dt, J = 5.4, 1.2 Hz, 1H), 
8.118.06 (m, 2H), 7.88 (ddd, J = 7.7, 1.4, 0.5 Hz, 1H), 7.83 (ddd, J = 7.7, 1.4, 0.5 Hz, 1H), 7.747.71 
(m, 9H), 7.717.69 (m, 1H), 7.597.56 (m, 1H), 7.55 (s, 4H), 7.46 (ddd, J = 8.5, 7.6, 1.2 Hz, 1H), 7.42 
(ddd, J = 8.5, 7.6, 1.1 Hz, 1H), 7.357.30 (m, 1H), 7.18 (td, J = 7.5, 1.0 Hz, 1H), 7.167.11 (m, 2H), 
7.04 (td, J = 7.5, 1.4 Hz, 1H), 6.98 (td, J = 7.5, 1.4 Hz, 1H), 6.706.64 (m, 1H), 6.626.57 (m, 1H), 
6.49 (ddd, J = 8.1, 1.1, 0.6 Hz, 1H), 5.81 (ddd, J = 8.1, 1.0, 0.6 Hz, 1H), 4.25 (ddd, J = 15.2, 4.3, 2.5 
Hz, 1H), 4.04 (ddd, J = 15.2, 4.4, 2.6 Hz, 1H), 3.50 (ddd, J = 14.2, 4.4, 2.5 Hz, 1H), 3.02 (ddd, J = 
14.2, 4.3, 2.6 Hz, 1H), 1.95 (s, 1H). 13C NMR (125 MHz, CD2Cl2) δ 178.0, 177.8, 169.9, 162.8, 162.4, 
162.0, 161.6, 161.0, 153.5, 150.71, 150.68, 147.4, 146.0, 145.0, 142.6, 140.4, 137.7, 137.5, 135.2, 
134.0, 133.8, 133.7, 133.3, 129.7, 129.5, 129.48, 129.46, 129.43, 129.41, 129.39, 129.3, 129.21, 
129.18, 129.16, 129.1, 128.9, 128.3, 127.4, 127.3, 127.05, 126.95, 126.7, 126.6, 126.1, 124.1, 124.01, 
123.92, 123.7, 121.8, 117.93, 117.90, 117.87, 114.6, 114.5, 113.05, 113.00, 44.2, 42.5. IR (film) max: 
1673, 1601, 1521, 1453, 1353, 1273, 1116, 937, 889, 743, 711, 673 cm1. HRMS (ESI, m/z) calcd for 
C36H25IrN5O3 [MBArF24]+: 768.1583, found: 768.1591. CD (MeOH): λ, nm (Δε, M-1cm-1) 354 (+25), 
328 (+30), 263 (10), 227 (25). 
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5.2.2 Iridium-Catalyzed Reactions 
 
Scheme 26 Iridium-catalyzed asymmetric -amination of aldehydes. 
General procedure for catalytic reactions of Table 1:  
To a solution of dibenzyl azodicarboxylate 11d (0.2 mmol) and -Ir1-5 (0.1-4 mol%) in anhydrous 
toluene (2.0 mL, 0.1 M for entries 1-5, 9 or 200.0 μL, 1.0 M for entries 6-8) at 0 C was added the 
3,3-dimethylbutyraldehyde 10a (0.30 mmol). After being stirred at 0 C (entries 1-4, 5) or RT (entries 
5-8) for 1.5 to 36 h under argon atmosphere, MeOH (2.0 mL for entries 1-5, 9 or 200.0 μL for entries 
6-8) was added followed by careful addition of NaBH4 (10.0 mg, 0.26 mmol) at 0 C. After 15 min, 
NaOH (0.5 M, 0.52 mL) was added and after an additional 2 h the mixtures were diluted with water. 
The aqueous phase was extracted with EtOAc (4 × 2 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (eluent: EtOAc/hexane = 1:4) to give compound 12a.  
 
General procedure for catalytic reactions of Table 2: 
Azodicarboxylates 11d-f (0.2 mmol) and -Ir4 (1 mol%) were mixed in a brown glass vial with 
anhydrous toluene (200.0 μL, 1.0 M), and the corresponding aldehyde 10a-j (0.30 mmol) was added at 
0 C. While being stirred at room temperature under argon atmosphere for 12-15 h, the amination 
products precipitated. MeOH (200.0 μL) was added followed by a careful addition of NaBH4 (10.0 mg, 
0.26 mmol) at 0 C. After 15 min, NaOH (0.5 M, 0.52 mL) was added and after an additional 2 h the 
mixtures were diluted with water (exception for entries 11-12: this NaOH step was skipped). The 
aqueous phase was extracted with EtOAc (4 × 2 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by 
flash chromatography on silica gel (eluent: EtOAc:hexane = 1:41:1) to give compounds 13k-l and 
12a-j.  
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Catalysis with the PF6 salt of -Ir4 (in analogy to entry 1 of Table 2): 
To a solution of -Ir4/PF6 (2.8 mg, 0.002 mmol) in anhydrous toluene (200.0 μL) was added sodium 
tetrakis[(3,5-di-trifluoromethyl)phenyl]borate (NaBArF24) (1.8 mg, 0.002 mmol) in one portion and 
the mixture was stirred at room temperature for 15 min. Then, dibenzyl azodicarboxylate 11d (60.0 mg, 
0.20 mmol) and 3,3-dimethylbutyraldehyde 10a (37.6 μL, 0.30 mmol) were added successively at 0 
C. After being stirred at room temperature for 15 h under argon atmosphere, MeOH (200.0 μL) was 
added followed by a careful addition of NaBH4 (10.0 mg, 0.26 mmol) at 0 C. After 15 min, NaOH 
(0.5 M, 0.52 mL) was added and after an additional 2 h the mixtures were diluted with water. The 
aqueous phase was extracted with EtOAc (4 × 2 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by 
flash chromatography on silica gel (eluent: EtOAc/hexane = 1:4) to give compound 12a (50.0 mg, 
yield: 85%, ee: 96%) as a white solid. 
 
Recycling experiments of catalyst -Ir4 (catalysis in analogy to entry 1 of Table 2).  
Cycle 1: Dibenzyl azodicarboxylate 11d (298.3 mg, 1.0 mmol) and -Ir4 (20.9 mg, 0.01 mmol) were 
mixed in a centrifuge tube with anhydrous toluene (1.0 mL), followed by the addition of 
3,3-dimethylbutyraldehyde 10a (188.0 μL, 1.5 mmol) at 0 C. After being stirred at room temperature 
for 15 h under argon atmosphere, n-hexane (300.0 μL) was added followed by centrifugation at 4 C. 
The mother liquor was transferred out and concentrated under reduced pressure. The residue (TLC 
showed it contained the catalyst along with a minor amount of amination product) was purified by 
flash chromatography on silica gel (eluent: MeOH/CH2Cl2 = 1:10) to give the pure catalyst -Ir4 
(17.0 mg, recovery yield: 81%). MeOH (1.0 mL) was added to the solid in the centrifuge tube 
followed by careful addition of NaBH4 (49.4 mg, 1.3 mmol) at 0 C. After 15 min, NaOH (0.5 M, 2.6 
mL) was added and after an additional 2 h the mixtures were diluted with water. The aqueous phase 
was extracted with EtOAc (4 × 3 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The crude compound 12a was purified by 
flash chromatography on silica gel (eluent: EtOAc/hexane = 1:4) to give compound 12a (222.3 mg, 
yield: 76%, ee: 97%) as a white solid. The recycled catalyst -Ir4 was used for another catalysis 
reaction (cycle 2).  
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Cycle 2: Dibenzyl azodicarboxylate 11d (242.1 mg, 0.81 mmol) and the recycled catalyst -Ir4 (17.0 
mg, 0.0081 mmol) were mixed in a centrifuge tube with anhydrous toluene (811.0 μL), followed by 
the addition of 3,3-dimethylbutyraldehyde 10a (152.0 μL, 1.22 mmol) at 0 C. After being stirred at 
room temperature for 15 h under argon atmosphere, n-hexane (250.0 μL) was added followed by 
centrifugation at 4 C. The mother liquor was transferred out and concentrated under reduced pressure. 
The residue (TLC showed it contained the catalyst along with a minor amount of amination product) 
was purified by flash chromatography on silica gel (eluent: MeOH/CH2Cl2 = 1:10) to give the pure 
catalyst -Ir4 (13.2 mg, recovery yield: 78%). MeOH (811.0 μL) was added to the solid in the 
centrifuge tube followed by a careful addition of NaBH4 (40.0 mg, 1.05 mmol) at 0 C. After 15 min, 
NaOH (0.5 M, 2.1 mL) was added and after an additional 2 h the mixtures were diluted with water. 
The aqueous phase extracted with EtOAc (4 × 3 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude compound 12a was 
purified by flash chromatography on silica gel (eluent: EtOAc/hexane = 1:4) to give compound 12a 
(168.0 mg, yield: 71%, ee: 95%) as a white solid. The twice recycled catalyst -Ir4 was used for 
another catalysis reaction (cycle 3). 
 
Cycle 3: Dibenzyl azodicarboxylate 11d (188.0 mg, 0.63 mmol) and the twice recycled catalyst -Ir4 
(13.2 mg, 0.0063 mmol) were mixed in a centrifuge tube with anhydrous toluene (630.0 μL), followed 
by the addition of 3,3-dimethylbutyraldehyde 10a (118.0 μL, 0.95 mmol) at 0 C. After being stirred at 
room temperature for 15 h under argon atmosphere, n-hexane (200.0 μL) was added followed by 
centrifugation at 4 C. The mother liquor was transferred out and concentrated under reduced pressure. 
The residue (TLC showed that it contained the catalyst along with a minor amount of amination 
product) was purified by flash chromatography on silica gel (eluent: MeOH/CH2Cl2 = 1:10) to give the 
pure catalyst -Ir4 (MeOH/CH2Cl2 = 1:10) (10.0 mg, recovery yield: 76%). MeOH (630.0 μL) was 
added to the solid in the centrifuge tube followed by a careful addition of NaBH4 (31.0 mg, 0.82 mmol) 
at 0 C. After 15 min, NaOH (0.5 M, 1.7 mL) was added and after an additional 2 h the mixtures were 
diluted with water. The aqueous phase extracted with EtOAc (4 × 3 mL). The combined organic layers 
were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude 
compound 12a was purified by flash chromatography on silica gel (eluent: EtOAc/hexane = 1:4) to 
give compound 12a (123.0 mg, yield: 67%, ee: 96%) as a white solid. 
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(S)-Benzyl 4-tert-butyl-2-oxooxazolidin-3-ylcarbamate (12a) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and 3,3-dimethylbutyraldehyde 10a (37.6 
μL, 0.30 mmol) for 12 h according to the general procedure to give 12a (56.0 mg, yield: 96%) as a 
white solid. Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IB column, 
ee = 97% (HPLC: IB, 254 nm, 40 °C, hexane/ isopropanol = 90/ 10, flow rate 0.5 mL/ min, tr(major) = 
25.0 min, tr(minor)= 28.7 min); []D20 10.0 (c 0.2, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.33 (s, 5H), 5.15 (q, J = 12.2 Hz, 1H), 4.39 (t, J = 8.8 Hz, 1H), 
4.253.98 (m, 1H), 3.83 (s, 1H), 0.93 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 158.9, 155.0, 135.4, 128.5, 
128.4, 128.0, 67.9, 64.5, 64.2, 33.3, 25.4. IR (film) max: 3320, 2959, 1762, 1721, 1505, 1410, 1371, 
1224, 1118, 1039, 995, 744, 692 cm1. HRMS (ESI, m/z) calcd for C15H20N2O4Na [M+Na]+: 315.1315, 
found: 315.1313. 
 
(S)-Benzyl 4-butyl-2-oxooxazolidin-3-ylcarbamate (12b) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and hexanal 10b (31.8 μL, 0.30 mmol) for 
15 h according to the general procedure to give 12b (47.0 mg, yield: 81%) as a colorless oil. 
Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IC column, ee = 94% 
(HPLC: IC, 254 nm, 40 °C, hexane/ isopropanol = 70/ 30, flow rate 0.8 mL/ min, tr(minor) = 23.0 min, 
tr(major)= 36.5 min); []D20 27.1 (c 1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.646.83 (m, 6H), 5.184.91 (m, 2H), 4.36 (s, 1H), 4.083.55 (m, 2H), 
1.811.57 (m, 1H), 1.531.31 (m, 1H), 1.301.00 (m, 4H), 0.81 (t, J = 7.1 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 157.5, 155.3, 135.3, 128.5, 128.3, 128.0, 67.9, 67.6, 56.7, 31.2, 26.4, 22.5, 13.8. IR 
(film) max: 3278, 2956, 2931, 2866, 1775, 1729 1503, 1458, 1420, 1227, 1118, 1049, 747, 697 cm1. 
HRMS (ESI, m/z) calcd for C15H20N2O4Na [M+Na]+: 315.1315, found: 315.1313. 
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(S)-Benzyl 4-isopropyl-2-oxooxazolidin-3-ylcarbamate (12c) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and 3-methylbutanal 10c (32.2 μL, 0.30 
mmol) for 14 h according to the general procedure to give 12c (49.3 mg, yield: 89%) as a colorless oil. 
Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IA column, ee = 95% 
(HPLC: IA, 254 nm, 40 °C, solvent A = 0.1% TFA, solvent B = MeCN, with a linear gradient of 30% 
to 50% B in 40 min, flow rate 0.5 mL/ min, tr(major) = 27.9 min, tr(minor)= 29.8 min); []D20 14.2 (c 
1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.34 (s, 5H), 7.14 (s, 1H), 5.16 (s, 2H), 4.36 (s, 1H), 4.123.66 (m, 2H), 
2.071.90 (m, 1H), 0.90 (t, J = 7.1 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 157.9, 155.2, 135.3, 128.6, 
128.4, 128.1, 68.0, 64.0, 60.8, 28.5, 17.7, 15.8. IR (film) max: 3272, 2963, 1771, 1723, 1505, 1460, 
1421, 1395, 1217, 1118, 1046, 744, 698 cm1. HRMS (ESI, m/z) calcd for C14H18N2O4Na [M+Na]+: 
301.1159, found: 301.1157. 
 
(S)-Benzyl 2-oxo-4-propyloxazolidin-3-ylcarbamate (12d) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and pentanal 10d (31.8 μL, 0.30 mmol) for 
15 h according to the general procedure to give 12d (43.2 mg, yield: 78%) as a colorless oil. 
Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IA column, ee = 96% 
(HPLC: IA, 254 nm, 40 °C, solvent A = 0.1% TFA, solvent B = MeCN, with a linear gradient of 30% 
to 45% B in 40 min, flow rate 0.5 mL/ min, tr(major) = 31.7 min, tr(minor)= 33.8 min); []D20 23.4 (c 
1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.35 (s, 5H), 7.21 (s, 1H), 5.15 (s, 2H), 4.43 (s, 1H), 4.063.80 (m, 2H), 
1.861.61 (m, 1H), 1.561.37 (m, 1H), 1.361.18 (m, 2H), 0.91 (t, J = 7.2 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 157.5, 155.3, 135.3, 128.5, 128.3, 128.1, 67.9, 67.6, 56.6, 33.6, 17.8, 13.9. IR (film) 
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max: 3300, 2965, 2934, 2875, 1778, 1701, 1512, 1258, 1228, 1202, 1113, 1052, 1010, 744, 694, 621, 
579 cm1. HRMS (ESI, m/z) calcd for C14H18N2O4Na [M+Na]+: 301.1159, found: 301.1157. 
 
(S)-Benzyl 4-ethyl-2-oxooxazolidin-3-ylcarbamate (12e) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and butyraldehyde 10e (27.0 μL, 0.30 
mmol) for 15 h according to the general procedure to give 12e (39.2 mg, yield: 73%) as a colorless oil. 
Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IA column, ee = 93% 
(HPLC: IA, 254 nm, 40 °C, solvent A = 0.1% TFA, solvent B = MeCN, with a linear gradient of 30% 
to 45% B in 40 min, flow rate 0.5 mL/ min, tr(major) = 23.8 min, tr(minor)= 25.3 min); []D20 19.2 (c 
1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.34 (s, 5H), 7.18 (s, 1H), 5.15 (s, 2H), 4.44 (s, 1H), 4.193.66 (m, 2H), 
1.911.66 (m, 1H), 1.651.39 (m, 1H), 0.88 (t, J = 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 157.5, 
155.3, 135.3, 128.5, 128.4, 128.1, 68.0, 67.1, 57.6, 24.3, 8.3. IR (film) max: 3279, 2964, 1768, 1724, 
1508, 1218, 1118, 1046, 745, 695 cm1; HRMS (ESI, m/z) calcd for C13H16N2O4Na [M+Na]+: 287.1002, 
found: 287.1003. 
 
(S)-Benzyl 4-allyl-2-oxooxazolidin-3-ylcarbamate (12f) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and pent-4-enal 10f (29.6 μL, 0.30 mmol) 
for 15 h according to the general procedure to give 12f (48.0 mg, yield: 87%) as a colorless oil. 
Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IA column, ee = 92% 
(HPLC: IA, 254 nm, 40 °C, solvent A = 0.1% TFA, solvent B = MeCN, with a linear gradient of 30% 
to 45% B in 40 min, flow rate 0.5 mL/ min, tr(major) = 28.0 min, tr(minor)= 29.7 min); []D20 36.5 (c 
1.0, CHCl3). 1H NMR (300 MHz, CDCl3) δ 7.27 (s, 5H), 7.07 (s, 1H), 5.60 (td, J = 17.0, 7.0 Hz, 1H), 
5.09 (s, 3H), 5.05 (s, 1H), 4.34 (t, J = 7.5 Hz, 1H), 4.02 (s, 2H), 3.92 (t, J = 8.1 Hz, 1H), 2.542.34 (m, 
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1H), 2.23 (dt, J = 14.5, 7.3 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 157.3, 155.3, 135.3, 131.2, 128.6, 
128.4, 128.1, 119.4, 68.0, 66.8, 55.8, 35.7. IR (film) max: 3271, 2912, 1772, 1726, 1502, 1425, 1226, 
1119, 1050, 924, 749, 698 cm1. HRMS (ESI, m/z) calcd for C14H16N2O4Na [M+Na]+: 299.1002, found: 
299.1000. 
 
(S)-Benzyl 4-hexyl-2-oxooxazolidin-3-ylcarbamate (12g) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and octanal 10g (31.8 μL, 0.30 mmol) for 
15 h according to the general procedure to give 12g (48.0 mg, yield: 75%) as a colorless oil. 
Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IA column, ee = 95% 
(HPLC: IA, 254 nm, 40 °C, solvent A = 0.1% TFA, solvent B = MeCN, with a linear gradient of 30% 
to 60% B in 40 min, flow rate 0.5 mL/ min, tr(major) = 33.2 min, tr(minor)= 35.1 min); []D20 24.8 (c 
1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.26 (s, 6H), 5.07 (d, J = 2.0 Hz, 2H), 4.35 (s, 1H), 4.103.55 (m, 2H), 
1.821.54 (m, 1H), 1.40 (s, 1H), 1.18 (s, 8H), 0.80 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
157.5, 155.3, 135.3, 128.5, 128.3, 128.0, 67.9, 67.6, 56.7, 31.6, 31.5, 29.0, 24.3, 22.4, 13.9. IR (film) 
max: 3274, 2925, 2857, 1774, 1728, 1502, 1458, 1420, 1220, 1118, 1048, 748, 698 cm1. HRMS (ESI, 
m/z) calcd for C17H24N2O4Na [M+Na]+: 343.1628, found: 343.1628. 
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(S)-Benzyl 4-cyclohexyl-2-oxooxazolidin-3-ylcarbamate (12h) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and 2-cyclohexylacetaldehyde 10h (37.8 
mg, 0.30 mmol) for 15 h according to the general procedure to give 12h (49.0 mg, yield: 77%) as a 
colorless oil. Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IC column, 
ee = 95% (HPLC: IC, 254 nm, 40 °C, hexane/ isopropanol = 70/ 30, flow rate 0.8 mL/ min, tr(minor) = 
23.9 min, tr(major)= 52.3 min); []D20 24.1 (c 1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.34 (s, 1H), 7.26 (s, 5H), 5.314.65 (m, 2H), 4.27 (s, 1H), 3.98 (t, J = 
8.2 Hz, 1H), 3.85 (s, 1H), 1.881.32 (m, 6H), 1.320.61 (m, 5H). 13C NMR (75 MHz, CDCl3) δ 158.1, 
155.2, 135.3, 128.5, 128.3, 128.0, 67.8, 64.6, 60.3, 38.5, 28.3, 26.3, 26.1, 25.8, 25.5. IR (film) max: 
3265, 2925, 2854, 1771, 1722, 1504, 1449, 1419, 1213, 1121, 1047, 741, 696 cm1. HRMS (ESI, m/z) 
calcd for C17H22N2O4Na [M+Na]+: 341.1472, found: 341.1470. 
(S)-Benzyl 4-(benzyloxymethyl)-2-oxooxazolidin-3-ylcarbamate (12i) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and 3-(benzyloxy)propanal11 10i (49.2 mg, 
0.30 mmol) for 15 h according to the general procedure to give 12i (51.2 mg, yield: 75%) as a 
colorless oil. Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IC column, 
ee = 91% (HPLC: IC, 254 nm, 40 °C, hexane/ isopropanol = 80/ 20, flow rate 0.5 mL/ min, tr(minor)= 
27.4 min, tr(major) = 30.6 min); []D20 13.2 (c 1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.507.20 (m, 10H), 7.10 (s, 1H), 5.284.96 (m, 2H), 4.52 (s, 2H), 4.44 
(t, J = 7.8 Hz, 1H), 4.304.00 (m, 2H), 3.59 (qd, J = 10.2, 3.7 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 
157.1, 155.3, 137.3, 135.2, 128.5, 128.3, 128.1, 128.0, 127.7, 73.3, 67.9, 67.7, 64.8, 55.8. IR (film) 
max: 3273, 3031, 2867, 1774, 1728, 1499, 1453, 1213, 1105, 1038, 742, 697 cm1. HRMS (ESI, m/z) 
calcd for C19H20N2O5Na [M+Na]+: 379.1264, found: 379.1262. 
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(S)-Benzyl 4-benzyl-2-oxooxazolidin-3-ylcarbamate (12j) 
 
From dibenzyl azodicarboxylate 11d (60.0 mg, 0.20 mmol) and 3-phenylpropanal 10j (29.6 μL, 0.30 
mmol) for 22 h (5 C for 14 h, then up to RT for additional 8 h) according to the general procedure to 
give 12j (59.2 mg, yield: 91%) as a colorless oil. Enantiomeric excess established by HPLC analysis 
using a Daicel Chiralpak IC column, ee = 89% (HPLC: IC, 254 nm, 40 °C, hexane/ isopropanol = 70/ 
30, flow rate 0.5 mL/ min, tr(minor)= 40.0 min, tr(major) = 50.5 min); []D20 23.5 (c 1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.35–6.91 (m, 10H), 5.07 (s, 2H), 4.20 (s, 2H), 3.95 (s, 1H), 3.05 (dd, J 
= 13.7, 4.1 Hz, 1H), 2.912.12 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 157.3, 155.2, 135.3, 135.1, 
128.9, 128.6, 128.4, 128.2, 127.2, 68.0, 67.1, 57.7, 37.9. IR (film) max: 3278, 3029, 2938, 1773, 1725, 
1496, 1450, 1419, 1221, 1117, 1026, 742, 698 cm1. HRMS (ESI, m/z) calcd for C18H18N2O4Na 
[M+Na]+: 349.1159, found: 349.1156. 
 
(S)-Di-tert-butyl 1-(1-hydroxy-3-phenylpropan-2-yl)hydrazine-1,2-dicarboxylate (13k) 
 
From di-tert-butyl azodicarboxylate 11e (46.0 mg, 0.20 mmol) and 3-phenylpropanal 10j (29.6 μL, 
0.30 mmol) for 15 h according to the general procedure to give 13k (67.0 mg, yield: 91%) as a white 
solid. Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IC column, ee = 
96% (HPLC: IC, 254 nm, 40 °C, hexane/ isopropanol = 80/ 20, flow rate 0.5 mL/ min, tr(major) = 13.9 
min, tr(minor)= 16.9 min); []D20 33.7 (c 1.0, CHCl3), (lit12 []D25 30.8 (c 0.53, CHCl3) product 
obtained by L-proline catalyzed -amination with R-configuration), 
1H NMR (300 MHz, CDCl3) δ 7.506.76 (m, 5H), 6.215.78 (m, 1H), 4.944.31 (m, 1H), 3.703.23 
(m, 2H), 2.932.14 (m, 2H), 1.43 (s, 9H), 1.23 (m, 9H). 13C NMR (75 MHz, CDCl3) δ 158.7, 155.7, 
155.5, 154.7, 137.8, 128.8, 128.5, 126.5, 82.6, 82.3, 81.7, 81.3, 62.2, 61.9, 34.7, 28.1, 28.0, 27.8. IR 
(film) max: 3419, 3224, 2975, 2930, 1720, 1675, 1531, 1392, 1367, 1333, 1278, 1255, 1160, 1022, 791, 
752, 701 cm1. HRMS (ESI, m/z) calcd for C19H30N2O5Na [M+Na]+: 389.2047, found: 389.2045. 
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(S)-Diethyl 1-(1-hydroxy-3-phenylpropan-2-yl)hydrazine-1,2-dicarboxylate (13l) 
 
From diethyl azodicarboxylate 11f (2.2 M in toluene, 90.9 μL, 0.20 mmol) and 3-phenylpropanal 10j 
(29.6 μL, 0.30 mmol) for 15 h according to the general procedure to give 13l (54.6 mg, yield: 88%) as 
a white solid. Enantiomeric excess established by HPLC analysis using a Daicel Chiralpak IC column, 
ee = 95% (HPLC: IC, 254 nm, 40 °C, hexane/ isopropanol = 70/ 30, flow rate 0.5 mL/ min, tr(minor)= 
31.3 min, tr(major) = 76.1 min); []D20 26.1 (c 1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.536.78 (m, 5H), 6.596.09 (m, 1H), 4.924.40 (m, 1H), 4.294.09 
(m, 2H), 4.083.84 (m, 2H), 3.693.19 (m, 2H), 2.902.30 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H), 1.05 (t, J 
= 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 159.4, 156.8, 137.4, 128.7, 128.6, 126.6, 62.9, 62.7, 61.9, 
34.6, 14.2. IR (film) max: 3428, 3244, 2989, 2922, 2864, 1724, 1678, 1524, 1416, 1254, 1219, 1061, 
1025, 776, 753 cm1. HRMS (ESI, m/z) calcd for C15H22N2O5Na [M+Na]+: 333.1421, found: 333.1417. 
 
5.2.3 Single Crystal X-Ray Diffraction of Iridium Catalyst rac-Ir4 
An X-ray crystal structure of the racemic complex /-Ir4 was obtained as an iodide salt 
(identification code = cat112_0m_sq). Suitable crystals were obtained by slow diffusion from a 
solution of /-Ir4 in CH2Cl2/MeOH 5:1 saturated with NaI and layered with Et2O. The structure 
information is detailed in Appendices 6.7. 
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5.3 Metal-Centered Chirality Directs Friedel-Crafts Addition 
5.3.1 Synthesis of Iridium Catalysts -IrO and -IrO 
5-tert-Butyl-2-phenylbenzo[d]oxazole (16) 
 
The compound was synthesized following a published procedure with slight modifications.3 A solution 
of 2-amino-4-tert-butylphenol (1.650 g, 10.0 mmol) and benzaldehyde (1.0 mL, 10.0 mmol) in 
m-xylene (33.0 mL) was stirred at 120 °C for 0.5 h. 4-Methoxy-TEMPO (93.0 mg, 5 mol%) was 
added to the mixture which was stirred at 120 °C for additional 5 h under an oxygen atmosphere. The 
reaction mixture was cooled and concentrated under reduced pressure. The residue was purified by 
flash chromatography on silica gel (EtOAc/hexane = 1:20) to afford the desired product 2 (2.380 g, 9.5 
mmol, yield: 95%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.33-8.20 (m, 2H), 7.81 (d, J = 1.8 Hz, 1H), 7.59-7.47 (m, 4H), 7.42 
(dd, J = 8.6, 1.9 Hz, 1H), 1.40 (s, 9H). 
All spectroscopic data were in agreement with the literature.13 
 
Precursor Iridium Complex rac-17 
 
The new compound rac-17 was synthesized according to a route developed by Nonoyama for 
iridium(III) μ-chloro-bridged dimers with related cyclometalated ligands,9 which involves refluxing 
IrCl3•nH2O with 2.0-2.5 equivalents of cyclometalating ligand in a 3:1 mixture of 2-methoxyethanol 
and water. Accordingly, 5-tert-butyl-2-phenylbenzo[d]oxazole 16 (1.030g, 4.1 mmol) was added to 
iridium chloride hydrate (723.0 mg, 2.0 mmol) in a mixture of 2-ethoxyethanol/water (3:1, 92.0 mL). 
The reaction mixture was heated at 120 °C for 24 h under argon. The resulting precipitate was 
collected by centrifugation, washed with diethyl ether and dried to yield the product rac-17 (1.281g, 
0.88 mmol, yield: 86% with >95% purity as judged by 1H-NMR) as a yellow solid. 
1H NMR (300 MHz, CD2Cl2) δ 8.40-8.27 (m, 4H), 7.58 (dd, J = 7.6, 1.3 Hz, 4H), 7.36-7.16 (m, 8H), 
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6.88 (dd, J = 11.0, 3.9 Hz, 4H), 6.64 (td, J = 7.5, 1.3 Hz, 4H), 6.09 (d, J = 7.8 Hz, 4H), 1.25 (s, 36H). 
13C NMR (75 MHz, CD2Cl2) δ 177.0 (4C), 149.2 (4C), 148.2 (4C), 144.4 (4C), 139.8 (4C), 132.9 (4C), 
131.6 (4C), 130.5 (4C), 125.8 (4C), 123.7 (4C), 121.9 (4C), 115.1 (4C), 110.6 (4C), 35.3 (4C), 31.8 
(12C). 
IR (film): ν (cm1) 3053, 2961, 2870, 1590, 1556, 1517, 1478, 1444, 1382, 1268, 1194, 1123, 1077, 
1037, 974, 929, 890, 809, 772, 734, 702, 649, 584, 510, 452, 406. 
HRMS (ESI, m/z) calcd for C68H64Cl2Ir2N4O4Na [M+Na]+: 1479.3442, found: 1479.3444. 
 
Iridium Auxiliary Complexes -(S)-18 and -(S)-18 
 
A mixture of iridium(III) dimer complex rac-17 (364.0 mg, 0.25 mmol), the chiral auxiliary 
(S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline {(S)-6} (138.0 mg, 0.62 mmol), and triethylamine 
(348.0 L, 2.0 mmol) in ethanol (10.0 mL) was purged with argon for 5 min and then heated at reflux 
overnight. The reaction mixture was cooled to room temperature and concentrated to dryness. The 
residue was subjected to a flash silica gel chromatography (hexane/CH2Cl2 = 1:2) to separate the two 
diastereomers. The first eluting diastereomer (orange solid, 215.0 mg, 0.24 mmol, 47%) was assigned 
as Λ-(S)-18 and the second eluting diastereomer (orange solid, 177.0 mg, 0.19 mmol, 39%) as 
-(S)-18 according to CD spectroscopy.1 The assigned configurations were confirmed by a crystal 
structure of the catalyst -IrO, obtained from -(S)-18 (see below). 
-(S)-18: 
1H NMR (300 MHz, CD2Cl2) δ 8.01 (d, J = 1.7 Hz, 1H), 7.74 (dd, J = 7.6, 0.7 Hz, 1H), 7.71-7.61 (m, 
2H), 7.60-7.46 (m, 5H), 7.19 (ddd, J = 8.6, 6.8, 1.8 Hz, 1H), 6.96 (dtd, J = 8.9, 7.5, 1.2 Hz, 2H), 6.88 
(td, J = 7.5, 1.5 Hz, 1H), 6.84-6.76 (m, 2H), 6.76-6.71 (m, 1H), 6.42 (d, J = 7.3 Hz, 1H), 6.33 (ddd, J 
= 8.1, 6.8, 1.2 Hz, 1H), 4.84-4.70 (dd, J = 8.1, 2.5 Hz, 1H), 3.42 (dd, J = 11.6, 9.8 Hz, 1H), 3.04 (dd, J 
= 11.7, 1.5 Hz, 1H), 1.49 (s, 9H), 1.24 (s, 9H), 0.87-0.72 (m, 1H), 0.27 (d, J = 7.0 Hz, 3H), 0.19 (d, J = 
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7.0 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 178.5, 178.1, 168.0, 167.6, 150.9, 150.6, 150.2, 149.9, 148.9, 148.5, 
139.4, 138.9, 135.3, 133.7, 131.9, 131.8, 131.6, 131.3, 126.3, 126.0, 124.7, 123.4, 123.2, 122.1, 121.0, 
118.5, 115.2, 113.4, 113.2, 111.2, 110.7, 85.2, 35.8, 35.4, 32.1, 31.9, 31.8, 28.2, 19.2, 14.3. 
IR (film): ν (cm1) 2957, 2868, 2032, 1661, 1593, 1556, 1518, 1440, 1380, 1266, 1192, 1150, 1037, 
1009, 929, 810, 776, 736, 646, 555, 521, 452. 
HRMS (ESI, m/z) calcd for C46H46IrN3NaO3S [M+Na]+: 936.2787, found: 936.2790. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 452 (9), 360 (+29), 323 (+40), 303 (25), 292 (28), 263 (+12), 
249 (+12), 227 (33), 216 (32). 
-(S)-18: 
1H NMR (300 MHz, CD2Cl2) δ 7.98 (d, J = 1.8 Hz, 1H), 7.79-7.67 (m, 2H), 7.64 (d, J = 8.8 Hz, 1H), 
7.59-7.49 (m, 2H), 7.45 (dd, J = 6.9, 1.8 Hz, 2H), 7.38 (dd, J = 8.0, 1.6 Hz, 1H), 7.04 (ddd, J = 8.6, 6.9, 
1.7 Hz, 1H), 6.93 (td, J = 7.3, 0.9 Hz, 2H), 6.88-6.69 (m, 3H), 6.62 (d, J = 8.6 Hz, 1H), 6.46 (d, J = 7.6 
Hz, 1H), 6.31 (td, J = 7.5, 0.8 Hz, 1H), 3.64 (d, J = 9.9 Hz, 1H), 2.92 (dd, J = 11.2, 1.7 Hz, 1H), 2.70 
(t, J = 10.6 Hz, 1H), 2.34-2.03 (m, 1H), 1.29 (s, 9H), 1.20 (s, 9H), 1.08 (d, J = 6.8 Hz, 3H), 0.06 (d, J 
= 7.0 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 178.9, 178.9, 167.7, 167.5, 151.3, 150.7, 150.4, 149.6, 149.0, 148.4, 
139.8, 138.7, 136.0, 133.2, 132.6, 132.1, 131.6, 131.4, 131.2, 130.6, 126.4, 126.1, 124.2, 123.4, 123.2, 
121.8, 120.9, 119.9, 114.9, 114.1, 113.1, 110.9, 110.8, 82.2, 35.6, 35.3, 32.1, 32.0, 31.6, 30.1, 20.4, 
17.2. 
IR (film): ν (cm1) 3050, 2956, 2867, 2032, 1732, 1593, 1561, 1518, 1437, 1377, 1270, 1193, 1149, 
1124, 1073, 1033, 1010, 930, 809, 734, 648, 591, 555, 521, 451. 
HRMS (ESI, m/z) calcd for C46H46IrN3NaO3S [M+Na]+: 936.2787, found: 936.2788. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 451 (11), 404 (7), 327 (29), 305 (23), 300 (20), 283 (24), 
247 (9), 210 (31). 
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Synthesis of Enantiopure Iridium Catalysts 
 
A suspension of the iridium auxiliary complexes -(S)-18 (200.0 mg, 0.22 mmol) or -(S)-18 (220.0 
mg, 0.24 mmol) and NH4PF6 (538.0 mg, 3.30 mmol) in acetonitrile (22.0 mL) was heated at 50 C for 
4 h under argon in the dark. The reaction mixture was concentrated to dryness and subjected to a flash 
silica gel chromatography (100% CH2Cl2 to CH2Cl2/CH3CN = 10:1) to give the enantiopure catalysts 
-IrO (200.3 mg, 0.22 mmol, 99%) or -IrO (210.0 mg, 0.23 mmol, 95%) as yellow solids. The 
absolute configurations of the obtained - and -configured iridium(III) complexes were verified by 
CD spectroscopy and confirmed by an X-ray crystal structure of -IrO. The enantiomeric purity was 
verified by chiral HPLC analysis. 
1H NMR (300 MHz, CD2Cl2) δ 7.85 (d, J = 1.3 Hz, 2H), 7.82-7.64 (m, 6H), 7.02 (td, J = 7.5, 1.0 Hz, 
2H), 6.85 (td, J = 7.5, 1.5 Hz, 2H), 6.37 (d, J = 7.4 Hz, 2H), 2.44 (s, 6H), 1.46 (s, 18H). 
13C NMR (75 MHz, CD2Cl2) δ 177.4, 151.2, 148.8, 142.0, 138.4, 132.9, 132.6, 130.0, 126.3, 125.0, 
123.6, 120.9, 113.0, 112.0, 35.6, 31.8, 30.1, 3.9. 
IR (film): ν (cm1) 2959, 2870, 1594, 1521, 1479, 1453, 1388, 1275, 1194, 1162, 1128, 1084, 1041, 
933, 837, 778, 736, 651, 555, 452. 
-IrO:  
HRMS (ESI, m/z) calcd for C38H38IrN4O2 [MPF6]+: 775.2619, found: 775.2622. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 436 (11), 345 (43), 271 (37), 208 (88). 
-IrO:  
HRMS (ESI, m/z) calcd for C38H38IrN4O2 [MPF6]+: 775.2619, found: 775.2619. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 436 (10), 344 (35), 272 (34), 208 (82). 
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5.3.2 Synthesis of Substrates 
1) Synthesis of ,-Unsaturated 2-Acyl Imidazoles 
All ,-unsaturated 2-acylimidazoles were synthesized according to reported procedures with 
some modifications (methods A-D).14 
Method A 
 
General procedure for method A. To a solution of N-methylimidazole (5.2 mL, 66.0 mmol) in THF 
(100.0 mL) at 78 C was added dropwise n-BuLi (26.4 mL, 2.5 M in hexane, 66.0 mmol). The 
reaction was stirred at 78 C for 10 min, then stirred at room temperature for additional 30 min. The 
corresponding carboxylic acid (30.0 mmol) was added to the flask after the reaction was cooled back 
down to 78 C. The reaction was allowed to warm to room temperature slowly (over a period of 3-4 
h) and stirred overnight. The reaction was quenched with a saturated aqueous solution of Na2CO3 and 
extracted with EtOAc (4  100 mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica gel (EtOAc/hexane = 1:1). 
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)but-2-en-1-one (18a) 
 
Following the general method A, (E)-but-2-enoic acid (2.580 g, 30.0 mmol) was converted to 
,-unsaturated 2-acylimidazole 18a (1.575 g, 10.5 mmol, yield: 35%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.39 (dq, J = 15.7, 1.6 Hz, 1H), 7.19-7.03 (m, 2H), 7.02 (s, 1H), 4.01 (s, 
3H), 1.96 (dd, J = 6.9, 1.6 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 180.6, 143.8, 129.0, 127.8, 127.0, 36.2, 18.4. 
All spectroscopic data were in agreement with the literature.14 
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(E)-1-(1-Methyl-1H-imidazol-2-yl)pent-2-en-1-one (18b) 
 
Following the general method A, (E)-pent-2-enoic acid (3.004 g, 30.0 mmol) was converted to 
,-unsaturated 2-acylimidazole 18b (1.378 g, 8.4 mmol, yield: 28%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.38 (dt, J = 15.7, 1.6 Hz, 1H), 7.22-7.08 (m, 2H), 7.02 (s, 1H), 4.02 (s, 
3H), 2.44-2.18 (m, 2H), 1.11 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 180.8, 150.1, 143.7, 129.0, 127.0, 125.3, 36.2, 25.6, 12.3. 
All spectroscopic data were in agreement with the literature.14  
 
(E)-4-Methyl-1-(1-methyl-1H-imidazol-2-yl)pent-2-en-1-one (18d) 
 
Following the general method A, (E)-4-methylpent-2-enoic acid (2.280 g, 20.0 mmol) was converted 
to ,-unsaturated 2-acylimidazole 18d (1.440 g, 8.1 mmol, yield: 40%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.33 (dd, J = 15.7, 1.3 Hz, 1H), 7.14 (d, J = 0.8 Hz, 1H), 7.11-6.99 (m, 
2H), 4.01 (s, 3H), 2.69-2.41 (m, 1H), 1.09 (d, J = 6.8 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 181.0, 154.8, 143.7, 129.0, 127.0, 123.4, 36.2, 31.3, 21.3. 
All spectroscopic data were in agreement with the literature.14 
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)-3-phenylprop-2-en-1-one (18e) 
 
Following the general procedure, cinnamic acid (2.960 g, 20.0 mmol) was converted to 
,-unsaturated 2-acylimidazole 18e (2.417 g, 11.4 mmol, yield: 57%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.09 (d, J = 16.0 Hz, 1H), 7.83 (d, J = 16.0 Hz, 1H), 7.77-7.63 (m, 2H), 
7.53-7.32 (m, 3H), 7.23 (d, J = 0.9 Hz, 1H), 7.08 (s, 1H), 4.10 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 180.4, 143.9, 143.5, 134.9, 130.5, 129.1, 128.8, 128.8, 127.2, 122.8, 
36.4. 
All spectroscopic data were in agreement with the literature.14 
Chapter 6. Experimental Part 
181 
 
Method B 
 
(E)-1-(1-Isopropyl-1H-imidazol-2-yl)but-2-en-1-one (18g) 
 
Procedure for the preparation of the Weinreb amide 18g-1. To a solution of 
N,O-dimethylhydroxylamine hydrochloride (3.900 g, 40.0 mmol) in CH2Cl2 (80.0 mL) at 0 C were 
added trans-crotonyl chloride (4.2 mL, 44.0 mmol) and pyridine (7.1 mL, 88.0 mmol) successively. 
The reaction was stirred at 0 C for 30 min, then stirred at room temperature for additional 30 min. 
The reaction was diluted with EtOAc (150 mL). The organic layer was washed with 1 N HCl (3  30 
mL), aqueous saturated NaHCO3 (3  50 mL), and brine (50 mL). The combined organic layers were 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (EtOAc/hexane = 1:3) to give 18g-1 (4.021 g, 31.2 
mmol, 78%) as a colorless oil. 
Procedure for the preparation of 18g. To a solution of N-isopropylimidazole (2.4 mL, 21.4 mmol) in 
THF (44.0 mL) at 78 C was added n-BuLi (8.6 mL, 2.5 M in hexane, 21.4 mmol) dropwise. The 
reaction was stirred at 78 C for 10 min, then stirred at room temperature for 30 min. The Weinreb 
amide 18g-1 (2.300 g, 17.8 mmol) was added to the flask after the reaction was cooled back down to 
78 C. The reaction was allowed to warm to room temperature slowly (over a period of 3-4 h) and 
stirred overnight. The reaction was quenched with a saturated aqueous solution of Na2CO3 and 
extracted with EtOAc (4  50 mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica gel (EtOAc/hexane = 1:1) to produce 18g (2.376 g, 13.3 mmol, 75%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.42 (dq, J = 15.5, 1.4 Hz, 1H), 7.24 (s, 1H), 7.15 (s, 1H), 7.11-6.96 (m, 
1H), 5.61 (sept., J = 6.5 Hz, 1H), 1.94 (dd, J = 6.8, 1.2 Hz, 3H), 1.41 (d, J = 6.6 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 180.6, 143.4, 142.9, 129.5, 128.4, 121.1, 49.1, 23.5, 18.3. 
All spectroscopic data were in agreement with the literature.14 
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Method C 
 
(E)-Ethyl 4-(1-methyl-1H-imidazol-2-yl)-4-oxobut-2-enoate (18f) 
 
To a solution of N-methylimidazole (2.2 mL, 27.5 mmol) in THF (83.0 mL) at 78 C was added 
dropwise n-BuLi (10.0 mL, 2.5 M in hexane, 25.0 mmol). The reaction was stirred at 78 C for 10 
min, then stirred at room temperature for 30 min. (E)-Ethyl 4-oxobut-2-enoate 18f-1 (3.6 mL, 30.0 
mmol) was added at 78 C. After being stirred at 78 C for 2 h, the reaction was quenched with H2O 
and extracted with EtOAc (4  100 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The crude product was dissolved in CH2Cl2 
(150 mL). Then MnO2 (34.562 g, 350.0 mmol) was added to the mixture. After being stirred at room 
temperature for overnight, MnO2 was removed by filtration. The combined organic layers were 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:1) to produce 18f (619.0 mg, 3.0 mmol, yield: 12%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.29 (d, J = 15.9 Hz, 1H), 7.22 (s, 1H), 7.11 (s, 1H), 6.91 (d, J = 15.9 
Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 4.05 (s, 3H), 1.32 (t, J = 7.1 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 179.4, 165.4, 143.3, 137.0, 131.6, 130.1, 128.1, 61.1, 36.2, 14.1. 
All spectroscopic data were in agreement with the literature.14 
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Method D 
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)hept-2-en-1-one (18c) 
 
Preparation of 18c-2. To a solution of N-methylimidazole (1.6 mL, 20.0 mmol) in THF (50.0 mL) at 
78 C was added dropwise n-BuLi (8.0 mL, 2.5 M in hexane, 20.0 mmol). The reaction was stirred at 
78 C for 10 min, and then stirred at room temperature for additional 30 min. Next, tert-butyl 
2-chloroacetate 18c-1 (30.0 mmol) was added to the flask at 78 C. After being stirred at 78 C for 
2.5 h, the reaction was quenched with H2O and extracted with EtOAc (4  50 mL). The combined 
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. 
The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:1) to afford 18c-2 
(2.519 g, 15.9 mmol, 80%) as a white solid. 
Preparation of 18c-3. To a solution of 18c-2 (2.519 g, 15.9 mmol) in toluene (40.0 mL) at room 
temperature was added PPh3 (4.595 g, 17.5 mmol). After being stirred at 95 C for overnight, the 
reaction was diluted with 1 N HCl (130 mL) and Et2O (120 mL). The aqueous layer was separated and 
organic layer was extracted with 1 N HCl (2  30 mL). The combined aqueous layers were washed 
with Et2O (2  80 mL) and neutralized with aqueous saturated Na2CO3. Then, the aqueous layer was 
extracted with EtOAc (3  80 mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure to produce Wittig reagent 18c-3 (5.617 g, 14.6 mmol, 
92%) as a white solid foam which was used for the next reaction without further purification. 
Preparation of 18c. To a solution of Wittig reagent 18c-3 (3.840g, 10.0 mmol) in CH2Cl2 (50.0 mL) at 
room temperature was added pentanal (1.3 mL, 12.0 mmol). The reaction was stirred at room 
temperature overnight. After the solvent was removed in vacuo, the residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:1) to produce 18c (0.979 g, 5.1 mmol, 51%) as a 
mixture of E:Z isomers (E:Z = 13:1, determined by 1H NMR). Then, to a solution of purified 6c (284.0 
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mg, 1.48 mmol) in CH2Cl2 (5.0 mL) at room temperature was added DMAP (300.0 mg, 2.46 mmol). 
The reaction was sealed and stored at 20 C (freezer) for 3 days. The mixture was diluted with 
EtOAc (50 mL) and washed with aqueous saturated NH4Cl (2  50 mL) followed by brine (50 mL). 
The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure. The isomerization proceeded well to afford 18c (280.0 mg, 1.46 mmol, yield = 98% 
with >97% purity as judged by 1H NMR) with an improved E:Z = 90:1 as determined by 1H NMR. 
1H NMR (300 MHz, CDCl3) δ 7.38 (dt, J = 15.6, 1.4 Hz, 1H), 7.20-6.95 (m, 3H), 4.02 (s, 3H), 
2.50-2.02 (m, 2H), 1.58-1.42 (m, 2H), 1.42-1.28 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 180.7, 148.8, 143.7, 129.1, 126.9, 126.1, 36.2, 32.3, 30.2, 22.2, 13.8. 
All spectroscopic data were in agreement with the literature.14 
 
2) Synthesis of Substituted Indoles 
The N-benzylated indoles 20h-k were synthesized according to a reported procedure with some 
modifications.14 All other indoles were commercially available. 
 
General Procedure for the preparation of N-benzylated indoles. To a solution of 1H-indole or 
substituted 1H-indole (5.0 mmol) in DMF (10.0 mL) at room temperature was added NaH (220.0 mg, 
60% dispersion in mineral oil, 5.5 mmol) and BnBr (1.3 mL, 5.5 mmol) successively. After being 
stirred at room temperature overnight, the reaction was quenched with aqueous saturated NH4Cl (5 mL) 
and extracted with CH2Cl2 (4  10 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:10) to produce 20h-k. 
 
1-Benzyl-1H-indole (20h) 
 
Following the general procedure, 1H-indole (585.0 mg, 5.0 mmol) was converted to 
1-benzyl-1H-indole 20h (983.0 mg, 4.7 mmol, 95%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.01-7.90 (m, 1H), 7.57-7.37 (m, 6H), 7.37-7.27 (m, 3H), 6.84 (dd, J = 
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3.2, 0.8 Hz, 1H), 5.44 (s, 2H). 
13C NMR (75 MHz, CDCl3) δ 137.5, 136.2, 128.65, 128.59 128.1, 127.4, 126.6, 121.6, 120.9, 119.5, 
109.6, 101.6, 49.8. 
All spectroscopic data were in agreement with the literature.14  
 
1-Benzyl-5-methyl-1H-indole (20i) 
 
Following the general procedure, 5-methyl-1H-indole (656.0 mg, 5.0 mmol) was converted to 
1-benzyl-1H-indole 20i (729.0 mg, 3.3 mmol, 66%) as a pale yellow oil. 
1H NMR (300 MHz, CDCl3) δ 7.35 (d, J = 0.6 Hz, 1H), 7.26-7.11 (m, 3H), 7.07 (d, J = 8.4 Hz, 1H), 
7.03-6.96 (m, 3H), 6.90 (dd, J = 8.4, 1.3 Hz, 1H), 6.38 (d, J = 2.8 Hz, 1H), 5.19 (s, 2H), 2.36 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 137.7, 134.7, 129.0, 128.7, 128.3, 127.5, 126.7, 123.3, 120.6, 109.4, 
101.1, 50.1, 21.4. 
All spectroscopic data were in agreement with the literature.14  
 
1-Benzyl-5-methoxy-1H-indole (20j) 
 
Following the general procedure, 5-methoxy-1H-indole (736.0 mg, 5.0 mmol) was converted to 
1-benzyl-1H-indole 20j (1.114 g, 4.7 mmol, 94%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.19-7.08 (m, 3H), 7.05-6.90 (m, 5H), 6.71 (dd, J = 8.8, 2.5 Hz, 1H), 
6.35 (d, J = 3.1 Hz, 1H), 5.09 (s, 2H), 3.70 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 154.1, 137.6, 131.6, 129.1, 128.8, 128.6, 127.5, 126.6, 111.9, 110.4, 
102.6, 101.1, 55.7, 50.1. 
All spectroscopic data were in agreement with the literature.14 
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1-Benzyl-6-methoxy-1H-indole (20k) 
 
Following the general procedure, 6-methoxy-1H-indole (736.0 mg, 5.0 mmol) was converted to 
1-benzyl-1H-indole 20k (1.078 g, 4.55 mmol, yield: 91%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.5 Hz, 1H), 7.51-7.36 (m, 3H), 7.31-7.19 (m, 2H), 7.15 (d, 
J = 3.2 Hz, 1H), 6.98 (dd, J = 8.6, 2.3 Hz, 1H), 6.91 (d, J = 2.2 Hz, 1H), 6.66 (dd, J = 3.2, 0.8 Hz, 1H), 
5.34 (s, 2H), 3.93 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 156.2, 137.4, 137.0, 128.6, 127.4, 127.1, 126.7, 122.9, 121.4, 109.3, 
101.5, 93.4, 55.5, 49.8. 
All spectroscopic data were in agreement with the literature.14 
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5.3.3 Iridium-Catalyzed Reactions 
Catalytic Reactions of Table 1. To a solution of catalyst Λ-IrO (1 mol%) in the indicated solvent 
(entries 1-4: 0.60 mL, 0.5 M; entries 5-8: 0.30 mL, 1.0 M) was added acylimidazole 18a (45.0 mg, 
0.30 mmol) in a glass vial. After being stirred at room temperature for 20 min, 1H-indole (entries 1-4: 
53.0 mg, 0.45 mmol, 1.5 equiv; entries 5-8: 88.0 mg, 0.75 mmol, 2.5 equiv) was added at room 
temperature or 0 C (entries 1-7: room temperature; entry 8: 0 C). The reaction was stirred at the 
indicated temperature for 20 or 36 h under argon atmosphere or air as indicated. The conversion was 
determined by 1H NMR analysis of the crude product, and ee values were determined by chiral HPLC 
chromatography using a Daicel Chiralpak IC column. Shown below is an example for the calculation 
of the conversion (Figure 109). It also demonstrates that no significant byproducts are formed in this 
reaction. 
 
Figure 109 1H NMR spectra of 18a, (S)-19a (both as reference) and the crude product for the catalysis 
reaction of entry 1 in Table 1. Area integration ratio = 1.86: 1.00 (conversion = 1.00/(1.86  1.00)  
100% = 35%). 
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General Catalysis Procedure (Reactions of Tables 2 and 3). To a solution of catalyst Λ-IrO or 
-IrO (0.25-2 mol%) in distilled, anhydrous THF (0.30 mL = 1.0 M, 150.0 L = 2.0 M) was added the 
acylimidazole (0.30 mmol) in a glass vial. After being stirred at room temperature for 20 min, indole 
or indole derivative (0.75 mmol, 2.5 eq) was added at room temperature or 0 C. The reaction was 
stirred at the indicated temperature for the indicated time (conversion monitored by TLC) under argon 
atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (EtOAc/hexane = 2:3 to 2:1) to afford the products 
19a-m and 21a-f. 
 
(S)-3-(1H-Indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19a) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 1H-indole (88.0 mg, 0.75 mmol) according to the general 
procedure to give 19a as a white solid (77.7 mg, 0.291 mmol, yield: 97%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak IC column, ee = 96% (HPLC: IC, 254 nm, 
hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (minor) = 22.5 min, tr (major) = 26.1 min); 
[]D20 = 14.5 (c 2.7, CH2Cl2) (Lit.S6 []D25 = 9.5 (c 2.4, CH2Cl2) for 65% ee of product with 
R-configuration).  
1H NMR (300 MHz, CDCl3) δ 8.81 (br s, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 
7.22-7.18 (m, 1H), 7.17-7.05 (m, 2H), 6.99 (s, 1H), 6.98-6.95 (m, 1H), 3.93 (s, 3H), 3.91-3.79 (m, 1H), 
3.58 (dd, J = 16.0, 6.2 Hz, 1H), 3.50 (dd, J = 16.0, 8.4 Hz, 1H), 1.42 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.2, 143.2, 136.4, 128.6, 126.8, 126.5, 121.6, 121.2, 120.3, 119.1, 
118.9, 111.1, 46.8, 36.1, 27.0, 21.6. 
All spectroscopic data were in agreement with the literature.14  
 
(S)-1-(1-Methyl-1H-imidazol-2-yl)-3-(5-methyl-1H-indol-3-yl)butan-1-one (19b) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 5-methyl-1H-indole (98.3 mg, 0.75 mmol) according to 
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the general procedure to give 19b as a pale yellow solid (82.6 mg, 0.294 mmol, yield: 98%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 94% (HPLC: IC, 
254 nm, hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 40 C, tr (minor) = 34.6 min, tr (major) = 
36.5 min); []D20 = 25.1 (c 1.4, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.77 (br s, 1H), 7.44 (d, J = 0.6 Hz, 1H), 7.25-7.16 (m, 2H), 7.06-6.96 
(m, 2H), 6.94 (d, J = 2.3 Hz, 1H), 3.93 (s, 3H), 3.89-3.77 (m, 1H), 3.55 (s, 1H), 3.53 (s, 1H), 2.46 (s, 
3H), 1.42 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.3, 143.3, 134.7, 128.7, 127.9, 126.8, 126.7, 123.2, 120.6, 120.4, 
118.7, 110.7, 46.8, 36.0, 27.0, 21.6, 21.4. 
IR (film): ν (cm1) 3225, 3136, 3015, 2963, 2917, 2875, 1675, 1446, 1406, 1366, 1288, 1150, 1109, 
1079, 983, 921, 868, 792, 765, 695, 667, 630, 546, 427. 
HRMS (ESI, m/z) calcd for C17H20N3O [M+H]+: 282.1601, found: 282.1603.  
 
(S)-3-(5-Methoxy-1H-indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19c) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 5-methoxy-1H-indole (110.3 mg, 0.75 mmol) according 
to the general procedure to give 19c as a white solid (88.0 mg, 0.296 mmol, yield: 99%). Enantiomeric 
excess established by HPLC analysis using a Chiralpak IC column, ee = 94% (HPLC: IC, 254 nm, 
hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (minor) = 31.3 min, tr (major) = 37.0 min); 
[]D20 = 11.5 (c 1.4, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.85 (br s, 1H), 7.24-7.10 (m, 3H), 7.02-6.97 (m, 1H), 6.95 (d, J = 2.3 
Hz, 1H), 6.81 (dd, J = 8.7, 2.4 Hz, 1H), 3.93 (s, 3H), 3.86 (s, 3H), 3.84-3.73 (m, 1H), 3.58 (dd, J = 
15.7, 5.8 Hz, 1H), 3.44 (dd, J = 15.8, 8.6 Hz, 1H), 1.40 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.2, 153.6, 143.2, 131.5, 128.6, 126.9, 126.8, 121.0, 120.6, 111.9, 
111.8, 100.9, 55.8, 46.8, 36.0, 27.0, 21.3. 
IR (film): ν (cm1) 3405, 3224, 2957, 2829, 1668, 1624, 1582, 1479, 1451, 1404, 1280, 1212, 1166, 
1112, 1084, 1034, 988, 917, 828, 790, 729, 698, 428. 
HRMS (ESI, m/z) calcd for C17H19N3NaO2 [M+Na]+: 320.1369, found: 320.1371. 
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(S)-3-(5-Bromo-1H-indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19d) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 5-bromo-1H-indole (146.0 mg, 0.75 mmol) according to 
the general procedure to give 19d as a white solid (78.0 mg, 0.226 mmol, yield: 75%). Enantiomeric 
excess established by HPLC analysis using a Chiralpak IB column, ee = 92% (HPLC: IB, 254 nm, 
solvent A = 0.1% TFA, solvent B = MeCN, with a linear gradient of 30% to 50% B in 40 min, flow 
rate 0.5 mL/min, 20 C, tr (minor) = 32.1 min, tr (major) = 33.6 min); []D20 = 23.0 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.78 (br s, 1H), 7.75-7.64 (m, 1H), 7.25-7.10 (m, 3H), 7.03 (s, 1H), 
6.97 (d, J = 2.3 Hz, 1H), 3.93 (s, 3H), 3.85-3.66 (m, 1H), 3.46 (s, 1H), 3.44 (s, 1H), 1.38 (d, J = 6.9 Hz, 
3H). 
13C NMR (75 MHz, CDCl3) δ 191.9, 143.0, 135.0, 128.7, 128.3, 127.0, 124.6, 121.7, 121.5, 121.0, 
112.5, 112.3, 47.1, 36.2, 27.0, 21.5. 
IR (film): ν (cm1) 3410, 3151, 2958, 2924, 1667, 1454, 1403, 1330, 1279, 1220, 1153, 1102, 1045, 
985, 917, 878, 771, 728, 693, 612, 589, 545, 493, 419. 
HRMS (ESI, m/z) calcd for C16H16BrN3NaO [M+Na]+: 368.0369, found: 368.0375. 
 
(S)-3-(5-Chloro-1H-indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19e) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 5-chloro-1H-indole (114.0 mg, 0.75 mmol) for 48 h 
according to the general procedure to give 19e as a white solid (69.6 mg, 0.231 mmol, yield: 77%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak IB column, ee = 94% (HPLC: IB, 
254 nm, solvent A = 0.1% TFA, solvent B = MeCN, with a linear gradient of 30% to 45% B in 40 min, 
flow rate 0.5 mL/min, 20 C, tr (minor) = 32.0 min, tr (major) = 33.1 min); []D20 = 19.4 (c 0.7, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.86 (br s, 1H), 7.54 (d, J = 1.9 Hz, 1H), 7.25-7.13 (m, 2H), 7.07 (dd, J 
= 8.6, 2.0 Hz, 1H), 7.02 (s, 1H), 6.97 (d, J = 2.3 Hz, 1H), 3.93 (s, 3H), 3.84-3.67 (m, 1H), 3.46 (s, 1H), 
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3.44 (d, J = 1.8 Hz, 1H), 1.38 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 191.9, 143.1, 134.7, 128.8, 127.6, 127.0, 124.7, 122.0, 121.7, 121.1, 
118.6, 112.1, 47.0, 36.1, 27.0, 21.5. 
IR (film): ν (cm1) 3162, 3033, 2951, 2903, 1675, 1565, 1451, 1402, 1363, 1292, 1265, 1235, 1154, 
1105, 1056, 1009, 967, 922, 888, 861, 818. 771, 728, 693, 636, 566, 538, 415. 
HRMS (ESI, m/z) calcd for C16H16ClN3NaO [M+Na]+: 324.0874, found: 324.0879. 
 
(S)-3-(6-Methoxy-1H-indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19f) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 6-methoxy-1H-indole (110.3 mg, 0.75 mmol) according 
to the general procedure to give 19f as a white solid (81.0 mg, 0.272 mmol, yield: 91%). Enantiomeric 
excess established by HPLC analysis using a Chiralpak IC column, ee = 95% (HPLC: IC, 254 nm, 
hexane/isopropanol = 80:20, flow rate 0.5 mL/min, 40 C, tr (minor) = 27.1 min, tr (major) = 33.8 min); 
[]D20 = 0.47 (c 1.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.63 (br s, 1H), 7.65-7.42 (m, 1H), 7.16 (d, J = 0.9 Hz, 1H), 7.05-6.93 
(m, 1H), 6.85 (d, J = 1.8 Hz, 1H), 6.81-6.70 (m, 2H), 3.92 (s, 3H), 3.87-3.72 (m, 4H), 3.55 (dd, J = 
15.9, 6.1 Hz, 1H), 3.45 (dd, J = 15.9, 8.4 Hz, 1H), 1.39 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.2, 156.2, 143.2, 137.1, 128.7, 126.8, 121.2, 121.0, 119.6, 119.0, 
108.8, 94.7, 55.5, 46.8, 36.0, 27.1, 21.6. 
IR (film): ν (cm1) 3402, 3191, 3126, 2957, 2832, 1668, 1625, 1578, 1550, 1502, 1456, 1403, 1299, 
1262, 1228, 1197, 1156, 1095, 1019, 985, 917, 779, 697, 655, 596, 550, 513, 460. 
HRMS (ESI, m/z) calcd for C17H19N3NaO2 [M+Na]+: 320.1369, found: 320.1369. 
 
(S)-1-(1-Methyl-1H-imidazol-2-yl)-3-(1-methyl-1H-indol-3-yl)butan-1-one (19g) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 1-methyl-1H-indole (98.3 mg, 0.75 mmol) according to 
the general procedure to give 19g as a white solid (83.0 mg, 0.296 mmol, yield: 99%). Enantiomeric 
excess established by HPLC analysis using a Chiralpak IC column, ee = 96% (HPLC: IC, 254 nm, 
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hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (minor) = 21.3 min, tr (major) = 23.4 min); 
[]D20 = 4.5 (c 1.4, CH2Cl2). (Lit.S6 []D25 = 4.4 (c 1.0, CH2Cl2) for 93% ee of product with 
R-configuration). 
1H NMR (300 MHz, CDCl3) δ 7.73-7.63 (m, 1H), 7.26 (dd, J = 7.1, 0.8 Hz, 1H), 7.24-7.17 (m, 1H), 
7.14 (d, J = 0.9 Hz, 1H), 7.09 (ddd, J = 8.0, 6.8, 1.3 Hz, 1H), 6.97-6.95 (m, 1H), 6.94 (s, 1H), 3.90 (s, 
3H), 3.89-3.879 (m, 1H), 3.71 (s, 3H), 3.59 (dd, J = 15.8, 6.5 Hz, 1H), 3.46 (dd, J = 15.8, 8.0 Hz, 1H), 
1.44 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 192.2, 143.2, 137.0, 128.7, 126.9, 126.7, 125.0, 
121.3, 119.9, 119.3, 118.4, 109.0, 46.8, 36.0, 32.4, 27.1, 21.8. 
All spectroscopic data were in agreement with the literature.14  
 
(S)-3-(1-Benzyl-1H-indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19h) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 1-benzyl-1H-indole (155.3 mg, 0.75 mmol) according to 
the general procedure to give 19h as a pale yellow solid (88.0 mg, 0.246 mmol, yield: 82%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 95% (HPLC: IC, 
254 nm, hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (minor) = 20.0 min, tr (major) = 
23.3 min); []D20 = 3.8 (c 1.4, CH2Cl2). (Lit.S6 []D25 = 2.5 (c 4.4, CH2Cl2) for 98% ee of product 
with R-configuration). 
1H NMR (300 MHz, CDCl3) δ 7.59 (dd, J = 7.0, 1.2 Hz, 1H), 7.22-7.08 (m, 4H), 7.08-6.88 (m, 6H), 
6.84 (s, 1H), 5.13 (s, 2H), 3.78 (s, 3H), 3.77-3.68 (m, 1H), 3.48 (dd, J = 15.7, 6.3 Hz, 1H), 3.37 (dd, J 
= 15.7, 8.3 Hz, 1H), 1.34 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 192.2, 143.2, 137.7, 136.6, 
128.9, 128.7, 128.6, 127.4, 127.2, 126.7, 124.5, 121.6, 120.6, 119.4, 118.8, 109.5, 49.8, 46.8, 36.0, 
27.2, 21.7. 
All spectroscopic data were in agreement with the literature.14 
 
(S)-3-(1-Benzyl-5-methyl-1H-indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19i) 
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Starting from 18a (45.0 mg, 0.30 mmol) and 1-benzyl-5-methyl-1H-indole (166.0 mg, 0.75 mmol) 
according to the general procedure to give 19i as a white solid (102.0 mg, 0.275 mmol, yield: 92%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 94% (HPLC: IC, 
254 nm, hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 40 C, tr (minor) = 22.5 min, tr (major) = 
24.0 min); []D20 = 7.1 (c 1.7, CH2Cl2). (Lit.S6 []D25 = 0.13 (c 1.9, CH2Cl2) for 93% ee of product 
with R-configuration). 
1H NMR (300 MHz, CDCl3) δ 7.51 (s, 1H), 7.42-7.22 (m, 3H), 7.22-7.07 (m, 4H), 7.06-7.00 (m, 2H), 
6.99 (s, 1H), 5.25 (s, 2H), 3.93 (s, 3H), 3.92-3.83 (m, 1H), 3.61 (dd, J = 15.7, 6.4 Hz, 1H), 3.54 (dd, J 
= 15.7, 8.2 Hz, 1H), 2.50 (s, 3H), 1.50 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.3, 143.3, 137.9, 135.0, 128.7, 128.5, 127.8, 127.4, 127.3, 126.64, 
126.57, 124.6, 123.1, 120.0, 119.0, 109.2, 49.8, 46.8, 35.9, 27.2, 21.7, 21.4. 
All spectroscopic data were in agreement with the literature.14 
 
(S)-3-(1-Benzyl-5-methoxy-1H-indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19j) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 1-benzyl-5-methoxy-1H-indole (178.0 mg, 0.75 mmol) 
according to the general procedure to give 19j as a white solid (106.0 mg, 0.274 mmol, yield: 91%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 94% (HPLC: IC, 
254 nm, hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (minor) = 25.9 min, tr (major) = 
30.2 min); []D20 = 3.6 (c 1.8, CH2Cl2). (Lit.6 []D25 = 0.06 (c 1.4, CH2Cl2) for 97% ee of product 
with R-configuration).  
1H NMR (300 MHz, CDCl3) δ 7.35-7.27 (m, 3H), 7.25 (d, J = 2.3 Hz, 1H), 7.19-7.09 (m, 4H), 7.06 (s, 
1H), 7.00 (s, 1H), 6.86 (dd, J = 8.8, 2.4 Hz, 1H), 5.24 (s, 2H), 3.94 (s, 3H), 3.91 (s, 3H), 3.90-3.84 (m, 
1H), 3.66 (dd, J = 15.4, 6.1 Hz, 1H), 3.45 (dd, J = 15.4, 8.5 Hz, 1H), 1.49 (d, J = 6.9 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 192.3, 153.6, 143.3, 137.8, 131.9, 128.7, 128.5, 127.5, 127.3, 126.7, 
126.6, 125.0, 120.1, 111.7, 110.3, 101.3, 55.8, 50.0, 46.8, 35.9, 27.2, 21.4. 
All spectroscopic data were in agreement with the literature.14 
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(S)-3-(1-Benzyl-6-methoxy-1H-indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19k) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 1-benzyl-6-methoxy-1H-indole (178.0 mg, 0.75 mmol) 
according to the general procedure to give 19k as a pale yellow solid (104.0 mg, 0.269 mmol, yield: 
90%). Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 95% 
(HPLC: IC, 254 nm, hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (minor) = 30.4 min, 
tr (major) = 41.1 min); []D20 = 11.0 (c 1.7, CH2Cl2). (Lit.S6 []D25 = 0.11 (c 1.4, CH2Cl2) for 95% 
ee of product with R-configuration). 
1H NMR (300 MHz, CDCl3) δ 7.45 (d, J = 8.6 Hz, 1H), 7.26-7.09 (m, 3H), 7.01 (d, J = 0.9 Hz, 1H), 
6.96 (dd, J = 7.7, 1.7 Hz, 2H), 6.91-6.82 (m, 1H), 6.79 (d, J = 0.4 Hz, 1H), 6.66 (dd, J = 8.7, 2.2 Hz, 
1H), 6.58 (d, J = 2.2 Hz, 1H), 5.07 (s, 2H), 3.78 (s, 3H), 3.76-3.69 (m, 1H), 3.67 (s, 3H), 3.45 (dd, J = 
15.7, 6.2 Hz, 1H), 3.33 (dd, J = 15.7, 8.3 Hz, 1H), 1.31 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.2, 156.2, 143.2, 137.6, 137.4, 128.7, 128.6, 127.3, 126.7, 126.6, 
123.3, 121.7, 120.6, 120.0, 108.4, 93.4, 55.6, 49.7, 46.8, 36.0, 27.3, 21.6. 
All spectroscopic data were in agreement with the literature.14  
 
(S)-3-(1,2-Dimethyl-1H-indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (19l) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 1,2-dimethyl-1H-indole (109.0 mg, 0.75 mmol) for 36 h 
according to the general procedure to give 19l as a white solid (82.4 mg, 0.279 mmol, yield: 93%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 98% (HPLC: IC, 
254 nm, hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (major) = 25.9 min, tr (minor) = 
32.7 min); []D20 = 65.2 (c 1.2, CH2Cl2). (Lit.S6 []D25 = 63.4 (c 2.2, CH2Cl2) for 91% ee of 
product with R-configuration).  
1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 7.4 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.17-6.99 (m, 3H), 
6.95-6.82 (m, 1H), 4.00-3.75 (m, 4H), 3.68 (s, 1H), 3.65 (s, 1H), 3.60 (s, 3H), 2.44 (s, 3H), 1.51 (d, J = 
7.1 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 192.2, 143.1, 136.6, 132.1, 128.6, 126.5, 126.1, 120.0, 119.2, 118.3, 
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114.7, 108.5, 46.3, 35.8, 29.2, 27.2, 21.2, 10.5. 
All spectroscopic data were in agreement with the literature.14 
 
(S)-1-(1-Methyl-1H-imidazol-2-yl)-3-(1-methyl-2-phenyl-1H-indol-3-yl)butan-1-one (19m) 
 
Starting from 18a (45.0 mg, 0.30 mmol) and 1-methyl-2-phenyl-1H-indole (155.5 mg, 0.75 mmol) 
according to the general procedure to give 19m as a white solid (104.0 mg, 0.291 mmol, yield: 97%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 90% (HPLC: IC, 
254 nm, hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (major) = 20.7 min, tr (minor) = 
36.7 min); []D20 = 20.3 (c 1.8, CH2Cl2). (Lit.S6 []D25 = 0.24 (c 1.65, CH2Cl2) for 91% ee of 
product with R-configuration).  
1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 7.8 Hz, 1H), 7.42-7.24 (m, 5H), 7.19 (d, J = 8.0 Hz, 1H), 
7.15-7.06 (m, 1H), 7.01 (ddd, J = 8.0, 7.0, 1.2 Hz, 1H), 6.94 (d, J = 0.9 Hz, 1H), 6.77 (s, 1H), 3.70 (s, 
3H), 3.66-3.53 (m, 2H), 3.50-3.39 (m, 1H), 3.38 (s, 3H), 1.30 (d, J = 6.6 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.1, 143.1, 137.2, 137.1, 132.2, 130.8, 128.6, 128.1, 128.0, 126.4, 
126.1, 121.2, 120.2, 118.9, 116.8, 109.3, 46.4, 35.8, 30.5, 27.9, 21.5. 
All spectroscopic data were in agreement with the literature.14 
 
(R)-3-(1H-Indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)pentan-1-one (21a) 
 
Starting from 18b (49.0 mg, 0.30 mmol) and 1H-indole (88.0 mg, 0.75 mmol) according to the general 
procedure to give 21a as a white solid (75.0 mg, 0.267 mmol, yield: 89%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak IC column, ee = 96% (HPLC: IC, 254 nm, 
hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 40 C, tr (minor) = 38.4 min, tr (major) = 40.7 min); 
[]D20 = 15.8 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.34 (br s, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.26-7.14 (m, 1H), 7.11-6.94 
(m, 3H), 6.92 (d, J = 2.3 Hz, 1H), 6.88-6.85 (m, 1H), 3.76 (s, 3H), 3.65-3.51 (m, 1H), 3.51-3.41 (m, 
2H), 1.88-1.62 (m, 2H), 0.78 (t, J = 7.4 Hz, 3H); 
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13C NMR (75 MHz, CDCl3) δ 192.3, 143.2, 136.3, 128.6, 127.0, 126.7, 121.6, 121.2, 119.3, 119.1, 
118.9, 111.0, 45.1, 36.0, 33.9, 28.9, 11.9. 
IR (film): ν (cm1) 3409, 3214, 2961, 2925, 2871, 1669, 1456, 1404, 1339, 1287, 1256, 1154, 1100, 
1014, 976, 915, 773, 734, 697, 591, 555, 480, 426. 
HRMS (ESI, m/z) calcd for C17H19N3NaO [M+Na]+: 304.1420, found: 304.1421. 
 
(R)-3-(1H-Indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)heptan-1-one (21b) 
 
Starting from 18c (58.0 mg, 0.30 mmol) and 1H-indole (88.0 mg, 0.75 mmol) according to the general 
procedure to give 21b as a white solid (90.0 mg, 0.291 mmol, yield: 97%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak IC column, ee = 91% (HPLC: IC, 254 nm, 
hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (minor) = 21.5 min, tr (major) = 23.9 min); 
[]D20 = 5.7 (c 1.2, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.51 (br s, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.28-7.13 (m, 1H), 7.11-6.92 
(m, 3H), 6.88 (d, J = 2.3 Hz, 1H), 6.85 (d, J = 0.5 Hz, 1H), 3.75 (s, 3H), 3.70-3.54 (m, 1H), 3.47 (s, 
1H), 3.45 (d, J = 1.8 Hz, 1H), 1.68 (dt, J = 8.3, 7.4 Hz, 2H), 1.25-1.04 (m, 4H), 0.71 (t, J = 6.9 Hz, 
3H). 
13C NMR (75 MHz, CDCl3) δ 192.3, 143.3, 136.3, 128.6, 127.0, 126.7, 121.5, 121.1, 119.5, 119.3, 
118.8, 111.0, 45.6, 36.0, 35.9, 32.3, 29.6, 22.7, 14.0. 
IR (film): ν (cm1) 3410, 3215, 3052, 2954, 2925, 2860, 1670, 1458, 1405, 1340, 1285, 1153, 1101, 
1016, 977, 915, 771, 736, 698, 425. 
HRMS (ESI, m/z) calcd for C19H23N3NaO [M+Na]+: 332.1733, found: 332.1733. 
 
(S)-3-(1H-Indol-3-yl)-4-methyl-1-(1-methyl-1H-imidazol-2-yl)pentan-1-one (21c) 
 
Starting from 18d (54.0 mg, 0.30 mmol) and 1H-indole (88.0 mg, 0.75 mmol) according to the general 
procedure to give 21c as a pale yellow solid (69.0 mg, 0.234 mmol, yield: 78%). Enantiomeric excess 
Chapter 6. Experimental Part 
197 
 
established by HPLC analysis using a Chiralpak IC column, ee = 93% (HPLC: IC, 254 nm, 
hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (minor) = 17.6 min, tr (major) = 19.8 min); 
[]D20 = 20.3 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.14 (br s, 1H), 7.68-7.37 (m, 1H), 7.29-7.12 (m, 1H), 7.12-6.89 (m, 
4H), 6.83 (s, 1H), 3.67 (s, 3H), 3.64-3.49 (m, 2H), 3.43-3.31 (m, 1H), 2.13-1.93 (m, 1H), 0.86 (d, J = 
4.6 Hz, 3H), 0.84 (d, J = 4.6 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.5, 143.3, 136.1, 128.5, 127.7, 126.6, 121.8, 121.5, 119.5, 118.9, 
118.1, 110.9, 41.9, 38.4, 35.9, 32.9, 20.4, 20.2. 
IR (film): ν (cm1) 3410, 3216, 3053, 2957, 2871, 1670, 1457, 1404, 1339, 1287, 1256, 1225, 1154, 
1099, 1029, 988, 918, 769, 738, 692, 610, 476, 425. 
HRMS (ESI, m/z) calcd for C18H22N3O [M+H]+: 296.1757, found: 296.1760. 
 
(R)-3-(1H-Indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)-3-phenylpropan-1-one (21d) 
 
Starting from 18e (63.6 mg, 0.30 mmol) and 1H-indole (88.0 mg, 0.75 mmol) according to the general 
procedure to give 21d as a white solid (97.2 mg, 0.295 mmol, yield: 98%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak IC column, ee = 93% (HPLC: IC, 254 nm, 
hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (minor) = 25.4 min, tr (major) = 35.4 min); 
[]D20 = 92.5 (c 0.9, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 8.48 (br s, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.40-7.28 (m, 3H), 7.29-7.20 
(m, 2H), 7.20-7.07 (m, 4H), 7.04 (s, 1H), 7.02-6.93 (m, 1H), 5.02 (t, J = 7.6 Hz, 1H), 4.02 (dd, J = 
16.3, 7.6 Hz, 1H), 3.88 (s, 3H), 3.78 (dd, J = 16.3, 7.8 Hz, 1H); 
13C NMR (75 MHz, CD2Cl2) δ 191.3, 145.2, 143.7, 137.0, 129.1, 128.7, 128.3, 127.5, 127.2, 126.5, 
122.4, 121.9, 119.6, 119.6, 111.5, 45.7, 38.6, 36.4. 
IR (film): ν (cm1) 3218, 3113, 3052, 2903, 1670, 1620, 1548, 1485, 1451, 1409, 1332, 1294, 1262, 
1207, 1153, 1107, 1029, 973, 950, 919, 852, 730, 697, 636, 583, 561, 421. 
HRMS (ESI, m/z) calcd for C21H19N3NaO [M+Na]+: 352.1420, found: 352.1422. 
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(R)-Ethyl 2-(1H-indol-3-yl)-4-(1-methyl-1H-imidazol-2-yl)-4-oxobutanoate (21e) 
 
Starting from 18f (62.0 mg, 0.30 mmol) and 1H-indole (88.0 mg, 0.75 mmol) according to the general 
procedure to give 21e as a white solid (95.0 mg, 0.292 mmol, yield: 97%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak IC column, ee = 98% (HPLC: IC, 254 nm, 
hexane/isopropanol = 70:30, flow rate 0.5 mL/min, 40 C, tr (minor) = 25.8 min, tr (major) = 35.3 min); 
[]D20 = 70.7 (c 1.8, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 9.90 (br s, 1H), 7.85-7.73 (m, 1H), 7.37-7.26 (m, 1H), 7.21 (d, J = 0.9 
Hz, 1H), 7.19-7.07 (m, 3H), 7.04 (d, J = 0.4 Hz, 1H), 4.55 (dd, J = 11.0, 3.7 Hz, 1H), 4.28 (dd, J = 
18.2, 11.0 Hz, 1H), 4.14 (dtt, J = 17.9, 10.8, 7.1 Hz, 2H), 3.98 (s, 3H), 3.60 (dd, J = 18.2, 3.8 Hz, 1H), 
1.20 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.4, 173.9, 142.4, 136.2, 128.7, 127.0, 126.3, 122.2, 121.8, 119.3, 
119.1, 112.3, 111.3, 60.8, 42.0, 37.4, 36.0, 14.0. 
IR (film): ν (cm1) 3223, 2990, 2917, 1716, 1678, 1448, 1408, 1362, 1347, 1269, 1238, 1212, 1170, 
1096, 1056, 1019, 980, 919, 898, 864, 782, 750, 727, 682, 618, 565, 519, 485, 462, 421. 
HRMS (ESI, m/z) calcd for C18H19N3NaO3 [M+Na]+: 348.1319, found: 348.1319. 
 
(R)-3-(1H-Indol-3-yl)-1-(1-isopropyl-1H-imidazol-2-yl)butan-1-one (21f) 
 
Starting from 18g (54.0 mg, 0.30 mmol) and 1H-indole (88.0 mg, 0.75 mmol) according to the general 
procedure to give 21f as a white solid (88.0 mg, 0.298 mmol, yield: 99%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak IC column, ee = 97% (HPLC: IC, 254 nm, 
hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 40 C, tr (major) = 30.8 min, tr (minor) = 33.6 min); 
[]D20 = 5.4 (c 1.2, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.87 (br s, 1H), 7.57 (d, J = 7.6 Hz, 1H), 7.18 (d, J = 8.1 Hz, 1H), 7.12 
(dd, J = 7.9, 0.9 Hz, 2H), 7.00 (dtd, J = 14.6, 7.0, 1.2 Hz, 2H), 6.84 (d, J = 2.2 Hz, 1H), 5.40 (hept, J = 
6.7 Hz, 1H), 3.86-3.67 (m, 1H), 3.45 (dd, J = 7.3, 2.5 Hz, 2H), 1.30 (d, J = 4.8 Hz, 3H), 1.28 (d, J = 
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2.4 Hz, 3H), 1.26 (d, J = 4.6 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 192.4, 142.5, 136.4, 129.1, 126.5, 121.5, 121.2, 121.0, 120.3, 119.0, 
118.8, 111.1, 49.1, 47.4, 27.1, 23.43, 23.39, 21.5. 
IR (film): ν (cm1) 3175, 3106, 3070, 2974, 2950, 2923, 2868, 1660, 1456, 1387, 1341, 1257, 1223, 
1157, 1132, 1092, 1044, 1001, 927, 878, 816, 782, 745, 708, 679, 638, 578, 482, 428. 
HRMS (ESI, m/z) calcd for C18H21N3NaO [M+Na]+: 318.1577, found: 318.1580. 
 
5.3.4 Investigation of the Proposed Substrate-Coordinated Catalyst 
To a solution of -IrO (10.0 mg, 0.011 mmol) in CD2Cl2 (1.0 mL) at room temperature was added 
18a (8.2 mg, 0.054 mmol). The reaction was stirred at room temperature for 20 min and then analyzed 
by 1H NMR spectroscopy. The fast bidentate coordination of 18a to the catalyst could be found, and 
the released CH3CN was obvious (see Figure 110, 111). When used 1.0 equivalent 18a, the proposed 
intermediate -IrO-18a was obtained as a black solid (90% purity as judged by 1H NMR). The 1H 
NMR and 13C NMR spectra were also consistent with the hypothesis structure -IrO-18a. When tried 
to purify the intermediate -IrO-18a by flash silica gel column chromatography, it decomposed on the 
silica gel column. 
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Figure 110 1H-NMR spectra of substrate-coordinated catalyst. 
 
Figure 111 Partial 1H-NMR spectra of substrate-coordinated catalyst.  
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5.3.5 Investigation of the Stability of Iridium Catalyst -IrO 
1) Catalyst Stability Investigated by 1H NMR 
The iridium complex -IrO (12.0 mg) was dissolved in CD2Cl2 and kept in the NMR tube at room 
temperature under reduced light. 1H-NMR spectra were recorded after 2, 4, 6, and 8 days (see Figure 
112). 
 
Figure 112 1H NMR of Λ-IrO recorded in CD2Cl2 over 8 days. 
2) Catalyst Stability Investigated by Chiral HPLC 
Enantiopure iridium complexes -IrO (2.0 mg) and -IrO (2.0 mg) were dissolved in CH2Cl2 (1.0 
mL, HPLC grade). A solution containing 99.5% -IrO (995.0 L) and 0.5% -IrO (5.0 L) was 
prepared and the enantiomeric ratio was then monitored over time while kept in a brown glass vial at 
room temperature. The HPLC spectra were collected after 2-8 days. HPLC conditions: Daicel 
Chiralpak IB (250 × 4.6 mm) HPLC column, the column temperature was 20 °C and UV-absorption 
was measured at 254 nm. Solvent A = 0.1% TFA, solvent B = MeCN with a linear gradient of 20% to 
43% B in 60 min at a flow rate = 0.5 mL/min (Figures 113-117). 
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Figure 113 HPLC trace of the freshly prepared mixture Λ-IrO:-IrO. Area integration = 99.5:0.5 
(99.0% ee) 
 
 
Figure 114 HPLC trace after 2 days in CH2Cl2. Area integration = 99.5:0.5 (99.0% ee) 
 
 
Figure 115 HPLC trace after 4 days in CH2Cl2. Area integration = 99.4:0.6 (98.8% ee) 
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Figure 116 HPLC trace after 6 days in CH2Cl2. Area integration = 99.5:0.5 (99.0% ee) 
 
 
Figure 117 HPLC trace after 8 days in CH2Cl2. Area integration = 99.4:0.6 (98.8% ee) 
 
5.3.6 Single Crystal X-Ray Diffraction of Iridium Catalyst -IrO 
Crystals of -IrO were obtained by slow diffusion from a solution of -IrO in CH2Cl2 layered with 
Et2O. Data were collected on a STOE-IPDS2T diffractometer employing graphite-monochromated 
Mo-Kα radiation (λ = 0.71073 Å) at a temperature of 100 K. The structure was solved by direct 
methods (SIR92). Refinement was done by full-matrix least squares based on F2 data of one twin 
domain using SHELXS-97, SHELXL-2013. The absolute configuration was determined. The structure 
information is shown Appendices 6.7. 
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5.4 Visible-Light-Activated Asymmetric Alkylation of 2-Acyl Imidazoles 
5.4.1 Synthesis of Substrates 
 
Figure 118 Synthesis of the 2-acyl imidazoles. 
1) Synthesis of Weinreb Amides 
All Weinreb amides were synthesized according to reported procedures with some modifications 
(methods A-B).15 
Method A: 
 
To a mixture of the corresponding carboxylic acid (10.0 mmol), N,O-dimethylhydroxylamine 
hydrochloride (1.268 g, 13.0 mmol) and DMAP (0.122 g, 1.0 mmol) in CH2Cl2 (50.0 mL) at 0 C were 
added NEt3 (1.8 mL, 13.3 mmol) and EDC (2.492 g, 13.0 mmol) successively. The reaction mixture 
was stirred at 0 C for 1 h, then allowed to warm to room temperature and stirred overnight. The 
reaction was diluted with EtOAc (100 mL). The organic layer was washed with 1 N HCl (3  10 mL), 
aqueous saturated NaHCO3 (3  10 mL), and brine (20 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (EtOAc/hexane = 1:3). 
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Method B: 
 
To a solution of N,O-dimethylhydroxylamine hydrochloride (1.073 g, 11.0 mmol) in CH2Cl2 (20.0 mL) 
at 0 C were added the corresponding acyl chloride (10.0 mmol) and pyridine (2.0 mL, 25.0 mmol) 
successively. The reaction was stirred at 0 C for 30 min, then stirred at room temperature for 
additional 30 min. The reaction was diluted with EtOAc (100 mL). The organic layer was washed with 
1 N HCl (3  10 mL), aqueous saturated NaHCO3 (3  10 mL), and brine (20 mL). The combined 
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. 
The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:3). 
 
N-Methoxy-N-methyl-2-phenylacetamide (24’a) 
 
Following the general method B, 2-phenylacetyl chloride (1.546 g, 10.0 mmol) was converted to 
Weinreb amide 24’a (1.790 g, 9.5 mmol, yield: 95%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.46-7.15 (m, 5H), 3.79 (s, 2H), 3.62 (s, 3H), 3.21 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.3, 134.9, 129.2, 128.4, 126.7, 61.2, 39.3, 32.2. 
All spectroscopic data were in agreement with the literature.16 
 
N-Methoxy-N-methyl-2-(m-tolyl)acetamide (24’b) 
 
Following the general method A, 2-(m-tolyl)acetic acid (1.500 g, 10.0 mmol) was converted to 
Weinreb amide 24’b (1.776 g, 9.2 mmol, yield: 92%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.27-6.83 (m, 4H), 3.66 (s, 2H), 3.53 (s, 3H), 3.11 (s, 3H), 2.26 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.4, 138.0, 134.8, 129.9, 128.3, 127.5, 126.3, 61.2, 39.3, 32.2, 21.3. 
All spectroscopic data were in agreement with the literature.15 
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N-Methoxy-N-methyl-2-(o-tolyl)acetamide (24’c) 
 
Following the general method A, 2-(o-tolyl)acetic acid (1.500 g, 10.0 mmol) was converted to Weinreb 
amide 24’c (1.821 g, 9.4 mmol, yield: 94%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.16-6.96 (m, 4H), 3.70 (s, 2H), 3.52 (s, 3H), 3.13 (s, 3H), 2.23 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.5, 136.8, 133.6, 130.2, 129.8, 126.9, 126.0, 61.1, 37.1, 32.4, 19.6. 
All spectroscopic data were in agreement with the literature.15 
 
N-Methoxy-2-(4-methoxyphenyl)-N-methylacetamide (24’d) 
 
Following the general method B, 2-(4-methoxyphenyl)acetyl chloride (1.846 g, 10.0 mmol) was 
converted to Weinreb amide 24’d (1.861 g, 8.9 mmol, yield: 89%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.23 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 3.80 (s, 3H), 3.72 (s, 
2H), 3.63 (s, 3H), 3.20 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.7, 158.4, 130.2, 126.9, 113.9, 61.2, 55.2, 38.4, 32.2. 
All spectroscopic data were in agreement with the literature.17 
 
2-(4-Chlorophenyl)-N-methoxy-N-methylacetamide (24’e) 
 
Following the general method B, 2-(4-chlorophenyl)acetyl chloride (1.880 g, 10.0 mmol) was 
converted to Weinreb amide 24’e (2.051 g, 9.6 mmol, yield: 96%) as pale yellow solid. 
1H NMR (300 MHz, CDCl3) δ 7.31 (d, J = 8.6 Hz, 2H), 7.24 (d, J = 8.6 Hz, 2H), 3.76 (s, 2H), 3.65 (s, 
3H), 3.21 (s, 3H). 
All spectroscopic data were in agreement with the literature.18 
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N-Methoxy-N-methyl-2-(naphthalen-2-yl)acetamide (24’f) 
 
Following the general method B, 2-(naphthalen-2-yl)acetyl chloride (2.040 g, 10.0 mmol) was 
converted to Weinreb amide 24’f (2.130 g, 9.3 mmol, yield: 93%) as a yellow oil. 
1H NMR (300 MHz, CDCl3) δ 7.97-7.65 (m, 4H), 7.56-7.35 (m, 3H), 3.97 (s, 2H), 3.63 (s, 3H), 3.24 (s, 
3H). 
All spectroscopic data were in agreement with the literature.19 
 
N-Methoxy-N-methyl-2-(thiophen-3-yl)acetamide (24’g) 
 
Following the general method A, 2-(thiophen-3-yl)acetic acid (1.421 g, 10.0 mmol) was converted to 
Weinreb amide 24’g (1.702 g, 9.2 mmol, yield: 92%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.30 (dd, J = 4.9, 3.0 Hz, 1H), 7.19-7.12 (m, 1H), 7.08 (dd, J = 4.9, 1.2 
Hz, 1H), 3.82 (s, 2H), 3.65 (s, 3H), 3.22 (s, 3H). 
All spectroscopic data were in agreement with the literature.20 
 
N-Methoxy-N-methylpropionamide (24’h) 
 
Following the general method A, propionic acid (1.421 g, 10.0 mmol) was converted to Weinreb 
amide 24’h (1.030 g, 8.8 mmol, yield: 88%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 3.77-3.51 (m, 3H), 3.19 (s, 3H), 2.46 (q, J = 7.5 Hz, 2H), 1.15 (t, J = 
7.5 Hz, 2H). 
All spectroscopic data were in agreement with the literature.21 
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2) Synthesis of 2-Acyl Imidazoles 
 
General procedure for the preparation of the 2-acyl imidazoles. To a solution of 
N-methylimidazole or N-isopropylimidazole (1.1 eq) in THF (0.4 M referring to the Weinreb amide 
24’a-i) at 78 C was added n-BuLi (1.1 eq) dropwise. The reaction was stirred at 78 C for 30 min, 
then stirred at room temperature for 30 min. The corresponding Weinreb amide 24’ (1.0 eq in THF) 
was added dropwise to the flask after the reaction was cooled back down to 78 C. The reaction was 
allowed to warm to room temperature slowly (over a period of 3-4 h) and stirred overnight. The 
reaction was quenched with AcOH (6.0 eq) at room temperature and extracted with EtOAc. The 
organic layer was washed with aqueous saturated NaHCO3 and brine. The combined organic layers 
were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (EtOAc/hexane = 1:3) to produce 24a-j. 
 
1-(1-Methyl-1H-imidazol-2-yl)-2-phenylethanone (24a) 
 
Following the general procedure, Weinreb amide 24’a (3.580 g, 20.0 mmol) was converted to 2-acyl 
imidazole 24a (3.721 g, 18.6 mmol, yield: 93%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.32-7.13 (m, 5H), 7.11 (d, J = 0.8 Hz, 1H), 6.96 (s, 1H), 4.36 (s, 2H), 
3.88 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.1, 142.8, 134.6, 129.9, 129.2, 128.4, 127.3, 126.8, 45.4, 36.1. 
IR (film): ν (cm1) 3109, 3061, 3029, 2954, 1670, 1459, 1399, 1284, 1153, 1077, 992, 913, 774, 731, 
694, 468. 
HRMS (ESI, m/z) calcd for C12H12N2ONa [M+Na]+: 223.0842, found: 223.0843. 
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1-(1-Methyl-1H-imidazol-2-yl)-2-(m-tolyl)ethanone (24b) 
 
Following the general procedure, Weinreb amide 24’b (1.776 g, 9.2 mmol) was converted to 2-acyl 
imidazole 24b (1.702 g, 8.0 mmol, yield: 87%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.33-6.94 (m, 6H), 4.42 (s, 2H), 3.99 (s, 3H), 2.36 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.2, 142.8, 138.0, 134.4, 130.6, 129.2, 128.3, 127.6, 127.3, 126.9, 
45.3, 36.2, 21.3. 
IR (film): ν (cm1) 3108, 3019, 2919, 1672, 1605, 1464, 1399, 1285, 1153, 1085, 1027, 994, 913, 766, 
696. 
HRMS (ESI, m/z) calcd for C12H15N2O [M+H]+: 215.1179, found: 215.1176. 
 
1-(1-Methyl-1H-imidazol-2-yl)-2-(o-tolyl)ethanone (24c) 
 
Following the general procedure, Weinreb amide 24’c (1.821 g, 9.4 mmol) was converted to 2-acyl 
imidazole 24c (1.627 g, 7.6 mmol, yield: 81%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.23-7.04 (m, 5H), 6.97 (d, J = 0.4 Hz, 1H), 4.42 (s, 2H), 3.89 (s, 3H), 
2.24 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.0, 142.8, 137.2, 133.3, 130.7, 130.2, 129.1, 127.2, 127.1, 125.9, 
43.2, 36.1, 19.8. 
IR (film): ν (cm1) 3108, 3017, 2954, 1672, 1463, 1399, 1285, 1153, 993, 913, 775, 742, 686, 603. 
HRMS (ESI, m/z) calcd for C12H15N2O [M+H]+: 215.1179, found: 215.1178. 
 
2-(4-Methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)ethanone (24d) 
 
Following the general procedure, Weinreb amide 24’d (1.861 g, 8.9 mmol) was converted to 2-acyl 
imidazole 24d (1.476 g, 6.4 mmol, yield: 72%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.29 (d, J = 8.5 Hz, 2H), 7.20 (d, J = 0.7 Hz, 1H), 7.05 (s, 1H), 6.88 (d, 
Chapter 6. Experimental Part 
210 
 
J = 8.7 Hz, 2H), 4.38 (s, 2H), 3.97 (s, 3H), 3.79 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.4, 158.5, 142.7, 130.8, 129.2, 127.2, 126.6, 113.9, 55.2, 44.5, 36.1. 
IR (film): ν (cm1) 3112, 3010, 2954, 2833, 1666, 1607, 1504, 1395, 1241, 1156, 1109, 1081, 1026, 
911, 822, 782, 716, 664, 631, 602, 521, 418. 
HRMS (ESI, m/z) calcd for C13H15N2O2 [M+H]+: 231.1128, found: 231.1133. 
 
2-(4-Chlorophenyl)-1-(1-methyl-1H-imidazol-2-yl)ethanone (24e) 
 
Following the general procedure, Weinreb amide 24’e (1.819 g, 8.5 mmol) was converted to 2-acyl 
imidazole 24e (1.595 g, 6.8 mmol, yield: 80%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.21 (s, 4H), 7.11 (d, J = 0.9 Hz, 1H), 6.98 (s, 1H), 4.32 (s, 2H), 3.89 (s, 
3H). 
13C NMR (75 MHz, CDCl3) δ 189.5, 142.5, 133.0, 132.8, 131.2, 129.3, 128.5, 127.5, 44.6, 36.1. 
IR (film): ν (cm1) 3102, 2961, 2909, 1670, 1484, 1401, 1316, 1289, 1226, 1197, 1150, 1083, 990, 908, 
857, 828, 802, 766, 681, 532, 496, 419. 
HRMS (ESI, m/z) calcd for C12H12ClN2O [M+H]+: 235.0633, found: 235.0635. 
 
1-(1-Methyl-1H-imidazol-2-yl)-2-(naphthalen-2-yl)ethanone (24f) 
 
Following the general procedure, Weinreb amide 24’f (2.061 g, 9.0 mmol) was converted to 2-acyl 
imidazole 24f (1.959 g, 7.8 mmol, yield: 87%) as a pale yellow oil. 
1H NMR (300 MHz, CDCl3) δ 8.00-7.74 (m, 4H), 7.52 (dd, J = 8.4, 1.7 Hz, 1H), 7.50-7.41 (m, 2H), 
7.23 (d, J = 0.9 Hz, 1H), 7.03 (s, 1H), 4.62 (s, 2H), 3.96 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.0, 142.7, 133.4, 132.3, 132.1, 129.2, 128.5, 128.0, 127.9, 127.6, 
127.5, 127.4, 125.9, 125.5, 45.5, 36.1. 
IR (film): ν (cm1) 3122, 3053, 2932, 1665, 1504, 1465, 1396, 1263, 1148, 1076, 1028, 951, 910, 837, 
788, 680, 627, 627, 591, 475. 
HRMS (ESI, m/z) calcd for C16H15N2O [M+H]+: 251.1179, found: 251.1177. 
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1-(1-Methyl-1H-imidazol-2-yl)-2-(thiophen-3-yl)ethanone (24g) 
 
Following the general procedure, Weinreb amide 24’g (1.300 g, 7.0 mmol) was converted to 2-acyl 
imidazole 24g (1.150 g, 5.6 mmol, yield: 80%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.28 (dd, J = 4.7, 3.2 Hz, 1H), 7.25-7.15 (m, 2H), 7.10 (dd, J = 4.9, 1.2 
Hz, 1H), 7.05 (s, 1H), 4.47 (s, 2H), 3.98 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 189.4, 142.5, 134.1, 129.2, 129.0, 127.3, 125.3, 123.1, 39.8, 36.1. 
IR (film): ν (cm1) 3099, 2952, 1665, 1466, 1401, 1280, 1225, 1142, 1073, 1029, 943, 915, 858, 819, 
774, 689, 606, 516. 
HRMS (ESI, m/z) calcd for C10H11N2OS [M+H]+: 207.0587, found: 207.0585. 
 
1-(1-Methyl-1H-imidazol-2-yl)propan-1-one (24h) 
 
Following the general procedure, Weinreb amide 24’h (0.960 g, 8.2 mmol) was converted to 2-acyl 
imidazole 24h (0.872 g, 6.3 mmol, yield: 77%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.09 (d, J = 0.7 Hz, 1H), 7.00 (s, 1H), 3.97 (s, 3H), 3.11 (q, J = 7.4 Hz, 
2H), 1.16 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 193.7, 142.9, 128.8, 126.6, 36.0, 32.2, 8.0. 
IR (film): ν (cm1) 3108, 2976, 2939, 2879, 1672, 1460, 1404, 1289, 1227, 1154, 1090, 1011, 948, 911, 
768, 696, 683. 
HRMS (ESI, m/z) calcd for C7H10N2ONa [M+Na]+: 161.0685, found: 161.0685. 
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1-(1-Methyl-1H-imidazol-2-yl)butan-1-one (24i) 
 
Following the general procedure, Weinreb amide 24’i (1.049 g, 8.0 mmol) was converted to 2-acyl 
imidazole 24i (0.876 g, 5.8 mmol, yield: 72%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.14 (s, 1H), 7.03 (s, 1H), 4.01 (s, 3H), 3.28-3.01 (m, 2H), 1.87-1.65 (m, 
2H), 1.01 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 193.2, 143.0, 128.8, 126.7, 41.0, 36.2, 17.7, 13.8. 
IR (film): ν (cm1) 3108, 2962, 2874, 1671, 1463, 1405, 1285, 1225, 1154, 1113, 1081, 1044, 991, 914, 
891, 769, 693. 
HRMS (ESI, m/z) calcd for C8H12N2ONa [M+Na]+: 175.0842, found: 175.0842. 
 
1-(1-Isopropyl-1H-imidazol-2-yl)-2-phenylethanone (24j) 
 
Following the general procedure, Weinreb amide 24’a (1.790 g, 10.0 mmol) was converted to 2-acyl 
imidazole 24j (2.032 g, 8.9 mmol, yield: 89%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.39-7.23 (m, 7H), 5.77-5.33 (m, 1H), 4.49 (s, 2H), 1.43 (d, J = 6.7 Hz, 
6H). 
13C NMR (75 MHz, CDCl3) δ 190.2, 142.0, 134.7, 129.9, 129.6, 128.4, 126.7, 121.5, 49.3, 46.0, 23.5. 
IR (film): ν (cm1) 3061, 3029, 2977, 2934, 1671, 1494, 1456, 1390, 1255, 1215, 1139, 1080, 1010, 
984, 914, 772, 730, 696, 617, 544, 518, 477. 
HRMS (ESI, m/z) calcd for C14H17N2O [M+H]+: 229.1335, found: 229.1333. 
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5.4.2 Iridium-Catalyzed Photoredox Reactions 
 
General catalysis procedure. A dried 10 mL Schlenk tube was charged with the catalyst Λ-IrS (2 
mol%), Na2HPO4 (31.2 mg, 0.22 mmol, 1.1 eq) and the corresponding bromide (0.2 mmol, 1.0 eq). 
The tube was purged with argon and MeOH/THF (4:1, 0.5 mL) was added via syringe, followed by 
the corresponding 2-acyl imidazoles (0.6 mmol, 3.0 eq). The reaction mixture was degassed via 
freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and 
positioned approximately 5 cm from a 14 w white light energy saving lamp. The reaction was stirred 
at 40 C for the indicated time (monitored by TLC) under argon atmosphere. Afterwards, the mixture 
was diluted with CH2Cl2 (8 mL), the inorganic salt was removed by centrifugation. The combined 
organic layers were concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:5 to 1:3) to afford the products 26a-o. Racemic 
samples were obtained by carrying out the reactions with rac-IrS. The enantiomeric excess was 
determined by chiral HPLC analysis. 
 
(R)-2-(3-(1-Methyl-1H-imidazol-2-yl)-3-oxo-2-phenylpropyl)-5-nitrobenzonitrile (26a) 
 
Starting from 2-acyl imidazole 24a (120.0 mg, 0.60 mmol) and 2-(bromomethyl)-5-nitrobenzonitrile 
(48.0 mg, 0.20 mmol) according to the general procedure to give 26a as a white solid (72.0 mg, 0.20 
mmol, yield: 100%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H 
column, ee = 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.8 mL/min, 25 C, 
tr (minor) = 44.6 min, tr (major) = 49.8 min). []D25 = 145.9 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.34 (d, J = 2.4 Hz, 1H), 8.14 (dd, J = 8.6, 2.4 Hz, 1H), 7.43 (d, J = 8.6 
Hz, 1H), 7.37-7.29 (m, 2H), 7.26-7.11 (m, 3H), 7.01 (d, J = 0.8 Hz, 1H), 6.89 (s, 1H), 5.52 (t, J = 7.7 
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Hz, 1H), 3.86 (s, 3H), 3.72 (dd, J = 14.2, 8.3 Hz, 1H), 3.40 (dd, J = 14.2, 7.2 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.6, 150.7, 146.2, 142.1, 137.2, 131.4, 129.6, 128.9, 128.5, 127.7, 
127.6, 126.9, 115.8, 114.6, 53.0, 37.1, 36.0. 
IR (film): ν (cm1) 3058, 2959, 2867, 1663, 1591, 1522, 1478, 1445, 1398, 1354, 1272, 1078, 1037, 
735, 694. 
HRMS (ESI, m/z) calcd for C20H16N4O3Na [M+Na]+: 383.1115, found: 383.1110. 
 
(R)-3-(2,4-Dinitrophenyl)-1-(1-methyl-1H-imidazol-2-yl)-2-phenylpropan-1-one (26b) 
 
Starting from 2-acyl imidazole 24a (120.0 mg, 0.60 mmol) and 1-(bromomethyl)-2,4-dinitrobenzene 
(52.2 mg, 0.20 mmol) according to the general procedure to give 26b as a white solid (73.7 mg, 0.194 
mmol, yield: 97%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H 
column, ee = 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 85:15, flow rate 0.8 mL/min, 25 C, 
tr (major) = 27.4 min, tr (minor) = 29.0 min). []D25 = 138.6 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.66 (d, J = 2.4 Hz, 1H), 8.14 (dd, J = 8.5, 2.4 Hz, 1H), 7.41 (d, J = 8.6 
Hz, 1H), 7.36-7.26 (m, 2H), 7.26-7.10 (m, 3H), 6.99 (d, J = 0.8 Hz, 1H), 6.88 (s, 1H), 5.51 (dd, J = 8.0, 
6.9 Hz, 1H), 3.86 (s, 3H), 3.80 (dd, J = 13.8, 8.1 Hz, 1H), 3.44 (dd, J = 13.8, 6.7 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 190.0, 149.5, 146.4, 142.2, 141.8, 137.7, 134.0, 129.6, 128.9, 128.5, 
127.6, 126.5, 120.3, 53.1, 36.1, 35.7. 
IR (film): ν (cm1) 3111, 2957, 2863, 1663, 1602, 1525, 1399, 1344, 1287, 903, 776, 731, 699, 533. 
HRMS (ESI, m/z) calcd for C19H16N4O5Na [M+Na]+: 403.1013, found: 403.1025. 
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(R)-Methyl 2-(3-(1-methyl-1H-imidazol-2-yl)-3-oxo-2-phenylpropyl)-5-nitrobenzoate (26c) 
 
Starting from 2-acyl imidazole 24a (120.0 mg, 0.60 mmol) and methyl 
2-(bromomethyl)-5-nitrobenzoate (54.6 mg, 0.20 mmol) according to the general procedure to give 
26c as a white solid (76.6 mg, 0.195 mmol, yield: 98%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 99% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
90:10, flow rate 1.0 mL/min, 25 C, tr (major) = 17.0 min, tr (minor) = 20.5 min). []D25 = 119.0 (c 
1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.63 (d, J = 2.5 Hz, 1H), 8.00 (dd, J = 8.5, 2.5 Hz, 1H), 7.33-7.25 (m, 
2H), 7.24-7.06 (m, 4H), 6.95 (d, J = 0.8 Hz, 1H), 6.84 (s, 1H), 5.44 (t, J = 7.4 Hz, 1H), 3.90-3.78 (m, 
7H), 3.50 (dd, J = 13.1, 7.2 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 190.9, 165.7, 148.9, 146.1, 142.4, 138.3, 133.0, 131.0, 129.3, 128.59, 
128.58, 127.3, 127.2, 125.8, 125.7, 53.8, 52.6, 37.1, 36.0. 
IR (film): ν (cm1) 3112, 2949, 2853, 1720, 1660, 1607, 1514, 1444, 1399, 1341, 1249, 1125, 1067, 
905, 746, 697, 535. 
HRMS (ESI, m/z) calcd for C21H19N3O5Na [M+Na]+: 416.1217, found: 416.1215. 
 
(R)-3-(3-Fluoro-4-nitrophenyl)-1-(1-methyl-1H-imidazol-2-yl)-2-phenylpropan-1-one (26d) 
 
Starting from 2-acyl imidazole 24a (120.0 mg, 0.60 mmol) and methyl 
4-(bromomethyl)-2-fluoro-1-nitrobenzene (46.6 mg, 0.20 mmol) according to the general procedure to 
give 26d as a white solid (68.5 mg, 0.194 mmol, yield: 97%). Enantiomeric excess established by 
HPLC analysis using a Chiralpak OD-H column, ee = 95% (HPLC: OD-H, 254 nm, 
hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 18.5 min, tr (major) = 21.6 min). 
[]D25 = 118.4 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.80 (t, J = 8.2 Hz, 1H), 7.35-7.28 (m, 2H), 7.26-7.08 (m, 3H), 
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7.06-7.00 (m, 2H), 6.99 (s, 1H), 6.89 (s, 1H), 5.41 (t, J = 7.8 Hz, 1H), 3.83 (s, 3H), 3.48 (dd, J = 13.9, 
8.4 Hz, 1H), 3.10 (dd, J = 13.9, 7.3 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 190.3, 157.0, 153.5, 149.4, 149.3, 142.3, 137.7, 129.5, 128.8, 128.5, 
127.7, 127.4, 125.9, 125.8, 125.20, 125.15, 118.9, 118.7, 53.4, 38.4, 36.0. 
IR (film): ν (cm1) 3031, 2957, 1664, 1602, 1518, 1397, 1336, 1286, 1242, 1156, 1080, 946, 907, 835, 
778, 739, 692, 512. 
HRMS (ESI, m/z) calcd for C19H16FN3O3Na [M+Na]+: 376.1068, found: 376.1070. 
 
(R)-3-(2,4-Dinitrophenyl)-1-(1-methyl-1H-imidazol-2-yl)-2-(m-tolyl)propan-1-one (26e) 
 
Starting from 2-acyl imidazole 24b (128.4 mg, 0.60 mmol) and 1-(bromomethyl)-2,4-dinitrobenzene 
(52.2 mg, 0.20 mmol) according to the general procedure to give 26e as a white solid (78.0 mg, 0.198 
mmol, yield: 99%). Enantiomeric excess established by HPLC analysis using a Chiralpak IB column, 
ee = 99% (HPLC: IB, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 C, tr (major) = 
16.5 min, tr (minor) = 18.9 min). []D25 = 151.9 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.64 (d, J = 2.4 Hz, 1H), 8.13 (dd, J = 8.5, 2.4 Hz, 1H), 7.43 (d, J = 8.6 
Hz, 1H), 7.16-7.03 (m, 3H), 7.01-6.90 (m, 2H), 6.90-6.81 (m, 1H), 5.46 (dd, J = 8.3, 6.6 Hz, 1H), 3.84 
(s, 3H), 3.77 (dd, J = 13.8, 8.3 Hz, 1H), 3.42 (dd, J = 13.8, 6.5 Hz, 1H), 2.22 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.1, 149.5, 146.4, 142.2, 141.9, 138.6, 137.5, 134.0, 129.5, 129.0, 
128.7, 128.4, 127.6, 126.4, 125.6, 120.2, 53.0, 36.0, 35.6, 21.3. 
IR (film): ν (cm1) 3109, 2951, 1664, 1601, 1527, 1462, 1398, 1342, 1151, 1056, 977, 942, 906, 833, 
780, 739, 696, 511. 
HRMS (ESI, m/z) calcd for C20H18N4O5Na [M+Na]+: 417.1169, found: 417.1170. 
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(R)-3-(2,4-Dinitrophenyl)-1-(1-methyl-1H-imidazol-2-yl)-2-(o-tolyl)propan-1-one (26f) 
 
Starting from 2-acyl imidazole 24c (128.4 mg, 0.60 mmol) and 1-(bromomethyl)-2,4-dinitrobenzene 
(52.2 mg, 0.20 mmol) according to the general procedure to give 26f as a white solid (73.3 mg, 0.186 
mmol, yield: 93%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H 
column, ee = 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 C, 
tr (major) = 7.6 min, tr (minor) = 9.0 min). []D25 = 166.1 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.64 (d, J = 2.4 Hz, 1H), 8.11 (dd, J = 8.5, 2.4 Hz, 1H), 7.36-7.25 (m, 
2H), 7.16-6.96 (m, 3H), 6.94 (d, J = 0.8 Hz, 1H), 6.86 (s, 1H), 5.71 (t, J = 7.5 Hz, 1H), 3.85 (s, 3H), 
3.74 (dd, J = 13.6, 7.8 Hz, 1H), 3.36 (dd, J = 13.6, 7.2 Hz, 1H), 2.33 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.7, 149.6, 146.4, 142.5, 141.8, 137.5, 136.1, 134.2, 131.0, 129.5, 
127.52, 127.48, 127.0, 126.33, 126.28, 120.1, 48.7, 36.0, 35.9, 19.7. 
IR (film): ν (cm1) 3126, 2950, 2866, 1663, 1602, 1527, 1399, 1341, 943, 907, 735, 692, 547. 
HRMS (ESI, m/z) calcd for C20H18N4O5Na [M+Na]+: 417.1169, found: 417.1170. 
 
(R)-3-(2,4-Dinitrophenyl)-2-(4-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)propan-1-one 
(26g) 
 
Starting from 2-acyl imidazole 24d (138.0 mg, 0.60 mmol) and 1-(bromomethyl)-2,4-dinitrobenzene 
(52.2 mg, 0.20 mmol) according to the general procedure to give 26g as a white solid (79.5 mg, 0.194 
mmol, yield: 97%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H 
column, ee = 97% (HPLC: AD-H, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 C, 
tr (minor) = 16.6 min, tr (major) = 20.8 min). []D25 = 152.5 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.64 (d, J = 2.2 Hz, 1H), 8.13 (dd, J = 8.5, 2.2 Hz, 1H), 7.40 (d, J = 8.5 
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Hz, 1H), 7.21 (d, J = 8.6 Hz, 2H), 6.98 (s, 1H), 6.88 (s, 1H), 6.73 (d, J = 8.6 Hz, 2H), 5.44 (t, J = 7.4 
Hz, 1H), 3.85 (s, 3H), 3.76 (dd, J = 13.8, 7.9 Hz, 1H), 3.67 (s, 3H), 3.41 (dd, J = 13.8, 7.0 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 190.2, 159.0, 149.5, 146.4, 142.2, 141.9, 134.0, 129.6, 129.5, 127.5, 
126.4, 120.2, 114.3, 55.2, 52.2, 36.0, 35.6. 
IR (film): ν (cm1) 3107, 2956, 2837, 1669, 1604, 1530, 1400, 1344, 1248, 1178, 1031, 874, 834, 786, 
730, 544. 
HRMS (ESI, m/z) calcd for C20H18N4O6Na [M+Na]+: 433.1119, found: 433.1116. 
 
(R)-2-(4-Chlorophenyl)-3-(2,4-dinitrophenyl)-1-(1-methyl-1H-imidazol-2-yl)propan-1-one (26h) 
 
Starting from 2-acyl imidazole 24e (140.4 mg, 0.60 mmol) and 1-(bromomethyl)-2,4-dinitrobenzene 
(52.2 mg, 0.20 mmol) according to the general procedure to give 26h as a white solid (81.1 mg, 0.196 
mmol, yield: 98%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H 
column, ee = 96% (HPLC: AD-H, 254 nm, hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 C, 
tr (minor) = 17.6 min, tr (major) = 20.8 min). []D25 = 126.2 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.66 (d, J = 1.7 Hz, 1H), 8.16 (dd, J = 8.5, 1.5 Hz, 1H), 7.43 (d, J = 8.5 
Hz, 1H), 7.26 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 6.98 (s, 1H), 6.90 (s, 1H), 5.49 (t, J = 7.3 
Hz, 1H), 3.86 (s, 3H), 3.78 (dd, J = 13.7, 8.3 Hz, 1H), 3.40 (dd, J = 13.8, 6.4 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.6, 149.4, 146.5, 142.0, 141.5, 136.3, 134.0, 133.6, 129.9, 129.7, 
129.1, 127.8, 126.6, 120.3, 52.4, 36.1, 35.5. 
IR (film): ν (cm1) 3296, 3105, 2954, 1670, 1603, 1530, 1486, 1401, 1345, 1285, 908, 874, 833, 774. 
HRMS (ESI, m/z) calcd for C19H15ClN4O5Na [M+Na]+: 437.0623, found: 437.0621. 
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(R)-3-(2,4-Dinitrophenyl)-1-(1-methyl-1H-imidazol-2-yl)-2-(naphthalen-2-yl)propan-1-one (26i) 
 
Starting from 2-acyl imidazole 24f (150.0 mg, 0.60 mmol) and 1-(bromomethyl)-2,4-dinitrobenzene 
(52.2 mg, 0.20 mmol) according to the general procedure to give 26i as a white solid (84.3 mg, 0.196 
mmol, yield: 98%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H 
column, ee = 98% (HPLC: AD-H, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 C, 
tr (minor) = 16.6 min, tr (major) = 24.4 min). []D25 = 198.4 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.62 (d, J = 2.4 Hz, 1H), 8.05 (dd, J = 8.5, 2.4 Hz, 1H), 7.82-7.60 (m, 
4H), 7.53-7.26 (m, 4H), 6.95 (d, J = 0.8 Hz, 1H), 6.83 (s, 1H), 5.67 (dd, J = 7.9, 6.8 Hz, 1H), 3.88 (dd, 
J = 13.8, 8.1 Hz, 1H), 3.83 (s, 3H), 3.51 (dd, J = 13.8, 6.7 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.9, 149.4, 146.4, 142.2, 141.7, 135.1, 134.0, 133.4, 132.6, 129.5, 
128.7, 127.8, 127.59, 127.55, 126.5, 126.24, 126.22, 126.1, 120.2, 53.2, 36.0, 35.6. 
IR (film): ν (cm1) 3109, 3048, 2954, 1671, 1602, 1528, 1399, 1340, 908, 750, 688, 542, 475. 
HRMS (ESI, m/z) calcd for C23H18N4O5Na [M+Na]+: 453.1169, found: 453.1161. 
 
(R)-3-(2,4-Dinitrophenyl)-1-(1-methyl-1H-imidazol-2-yl)-2-(thiophen-3-yl)propan-1-one (26j) 
 
Starting from 2-acyl imidazole 24g (124.1 mg, 0.60 mmol) and 1-(bromomethyl)-2,4-dinitrobenzene 
(52.2 mg, 0.20 mmol) according to the general procedure to give 26j as a white solid (76.4 mg, 0.198 
mmol, yield: 99%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 C, 
tr (minor) = 17.8 min, tr (major) = 22.0 min). []D25 = 85.5 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.65 (d, J = 2.4 Hz, 1H), 8.15 (dd, J = 8.5, 2.4 Hz, 1H), 7.41 (d, J = 8.5 
Hz, 1H), 7.21-7.14 (m, 1H), 7.11 (dd, J = 2.9, 1.2 Hz, 1H), 7.03 (dd, J = 5.0, 1.3 Hz, 1H), 7.01 (d, J = 
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0.8 Hz, 1H), 6.92 (s, 1H), 5.67 (t, J = 7.4 Hz, 1H), 3.87 (s, 3H), 3.74 (dd, J = 13.8, 7.9 Hz, 1H), 3.48 
(dd, J = 13.8, 7.0 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.6, 149.4, 146.4, 142.0, 141.6, 137.6, 133.9, 129.5, 127.8, 127.2, 
126.5, 126.2, 123.3, 120.2, 48.3, 36.1, 35.5. 
IR (film): ν (cm1) 3108, 2956, 1665, 1604, 1526, 1398, 1345, 944, 905, 772, 731, 683. 
HRMS (ESI, m/z) calcd for C17H14N4O5SNa [M+Na]+: 409.0577, found: 409.0580. 
 
(S)-2-(2-Methyl-3-(1-methyl-1H-imidazol-2-yl)-3-oxopropyl)-5-nitrobenzonitrile (26k) 
 
Starting from 2-acyl imidazole 24h (82.8 mg, 0.60 mmol) and 2-(bromomethyl)-5-nitrobenzonitrile 
(48.0 mg, 0.20 mmol) according to the general procedure to give 26k as a pale yellow oil (51.8 mg, 
0.174 mmol, yield: 87%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H 
column, ee = 97% (HPLC: AD-H, 254 nm, hexane/isopropanol = 85:15, flow rate 0.8 mL/min, 25 C, 
tr (minor) = 19.2 min, tr (major) = 27.1 min). []D25 = +70.6 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.38 (d, J = 2.4 Hz, 1H), 8.23 (dd, J = 8.6, 2.4 Hz, 1H), 7.56 (d, J = 8.7 
Hz, 1H), 7.05 (d, J = 0.9 Hz, 1H), 6.97 (s, 1H), 4.43-4.17 (m, 1H), 3.91 (s, 3H), 3.39 (dd, J = 14.1, 8.0 
Hz, 1H), 3.04 (dd, J = 14.1, 6.4 Hz, 1H), 1.26 (d, J = 7.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 193.6, 151.2, 146.2, 141.9, 131.4, 129.3, 127.7, 127.5, 127.0, 115.9, 
114.6, 42.4, 37.0, 36.2, 17.8. 
IR (film): ν (cm1) 3081, 2962, 2928, 2869, 2231, 1670, 1525, 1460, 1405, 1348, 972, 910, 839, 791, 
734. 
HRMS (ESI, m/z) calcd for C15H14N4O3Na [M+Na]+: 321.0958, found: 321.0954. 
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(S)-2-(2,4-Dinitrobenzyl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (26l) 
 
Starting from 2-acyl imidazole 24i (91.2 mg, 0.60 mmol) and 1-(bromomethyl)-2,4-dinitrobenzene 
(52.2 mg, 0.20 mmol) according to the general procedure to give 26l as a pale yellow oil (55.8 mg, 
0.168 mmol, yield: 84%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H 
column, ee = 91% (HPLC: AD-H, 254 nm, hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 C, 
tr (minor) = 9.0 min, tr (major) = 11.5 min). []D25 = +35.0 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.65 (d, J = 2.4 Hz, 1H), 8.18 (dd, J = 8.5, 2.4 Hz, 1H), 7.57 (d, J = 8.6 
Hz, 1H), 6.98 (d, J = 0.8 Hz, 1H), 6.93 (s, 1H), 4.32-4.11 (m, 1H), 3.87 (s, 3H), 3.42-3.15 (m, 2H), 
1.99-1.75 (m, 1H), 1.74-1.53 (m, 1H), 0.90 (t, J = 7.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 194.0, 149.4, 146.3, 142.7, 142.5, 133.8, 129.2, 127.5, 126.5, 120.2, 
48.6, 36.2, 33.6, 26.2, 11.3. 
IR (film): ν (cm1) 3107, 2964, 2874, 1668, 1604, 1530, 1456, 1406, 1345, 1287, 1153, 1069, 1004, 
908, 836, 778, 735, 528. 
HRMS (ESI, m/z) calcd for C15H16N4O5Na [M+Na]+: 355.1013, found: 355.1015. 
 
(R)-1-(1-Isopropyl-1H-imidazol-2-yl)-4-(4-nitrophenyl)-2-phenylbutane-1,4-dione (26m) 
 
Starting from 2-acyl imidazole 24j (136.8 mg, 0.60 mmol) and 2-bromo-1-(4-nitrophenyl)ethanone 
(48.8 mg, 0.20 mmol) according to the general procedure to give 26m as a white solid (71.2 mg, 0.182 
mmol, yield: 91%). Enantiomeric excess established by HPLC analysis using a Chiralpak IB column, 
ee = 90% (HPLC: IB, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 C, tr (major) = 
14.9 min, tr (minor) = 18.0 min). []D25 = 154.6 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.38-8.13 (m, 2H), 8.12-7.92 (m, 2H), 7.47-7.35 (m, 2H), 7.29-7.19 (m, 
2H), 7.19-7.07 (m, 3H), 5.73 (dd, J = 10.8, 3.8 Hz, 1H), 5.53-5.15 (m, 1H), 4.08 (dd, J = 18.2, 10.8 Hz, 
1H), 3.32 (dd, J = 18.2, 3.8 Hz, 1H), 1.34 (d, J = 6.7 Hz, 3H), 1.24 (d, J = 6.7 Hz, 3H). 
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13C NMR (75 MHz, CDCl3) δ 196.4, 190.7, 150.3, 141.8, 140.9, 138.1, 130.0, 129.1, 128.8, 128.4, 
127.2, 123.7, 121.3, 49.1, 48.5, 43.4, 23.4. 
IR (film): ν (cm1) 3109, 2977, 2922, 1670, 1600, 1523, 1455, 1394, 1341, 1248, 1197, 996, 945, 909, 
853, 744, 695, 583, 520. 
HRMS (ESI, m/z) calcd for C22H22N3O4 [M+H]+: 392.1605, found: 392.1604. 
 
(R)-4-(4-Bromophenyl)-1-(1-isopropyl-1H-imidazol-2-yl)-2-phenylbutane-1,4-dione (26o) 
 
Starting from 2-acyl imidazole 24j (136.8 mg, 0.60 mmol) and 2-bromo-1-(4-bromophenyl)ethanone 
(55.6 mg, 0.20 mmol) according to the general procedure to give 26o as a pale yellow oil (73.0 mg, 
0.172 mmol, yield: 86%). Enantiomeric excess established by HPLC analysis using a Chiralpak IB 
column, ee = 91% (HPLC: IB, 254 nm, hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 C, tr 
(major) = 7.3 min, tr (minor) = 9.2 min). []D25 = 160.4 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.83-7.68 (m, 2H), 7.55-7.44 (m, 2H), 7.45-7.34 (m, 2H), 7.27-7.09 (m, 
5H), 5.70 (dd, J = 10.9, 3.7 Hz, 1H), 5.55-5.25 (m, 1H), 4.02 (dd, J = 18.0, 10.9 Hz, 1H), 3.26 (dd, J = 
18.0, 3.8 Hz, 1H), 1.34 (d, J = 6.7 Hz, 3H), 1.23 (d, J = 6.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 196.8, 191.0, 141.9, 138.5, 135.2, 131.8, 129.9, 129.6, 128.7, 128.5, 
128.2, 127.1, 121.1, 49.1, 48.5, 43.0, 23.4. 
IR (film): ν (cm1) 3155, 3068, 3028, 2980, 2921, 1666, 1578, 1488, 1457, 1394, 1205, 1151, 1123, 
1092, 1068, 987, 946, 909, 830, 795, 771, 745, 695, 580, 524. 
HRMS (ESI, m/z) calcd for C22H22BrN2O2 [M+H]+: 425.0859, found: 425.0855. 
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(R)-4-(4-Chlorophenyl)-1-(1-isopropyl-1H-imidazol-2-yl)-2-phenylbutane-1,4-dione (26p) 
 
Starting from 2-acyl imidazole 24j (136.8 mg, 0.60 mmol) and 2-bromo-1-(4-chlorophenyl)ethanone 
(37.6 mg, 0.20 mmol) according to the general procedure to give 26p as a pale red oil (69.2 mg, 0.182 
mmol, yield: 91%). Enantiomeric excess established by HPLC analysis using a Chiralpak IB column, 
ee = 91% (HPLC: IB, 254 nm, hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 C, tr (major) = 
7.2 min, tr (minor) = 9.4 min). []D25 = 147.5 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.89-7.77 (m, 2H), 7.51-7.37 (m, 2H), 7.36-7.28 (m, 2H), 7.27-7.07 (m, 
5H), 5.70 (dd, J = 10.9, 3.7 Hz, 1H), 5.38 (hept, J = 6.7 Hz, 1H), 4.03 (dd, J = 18.0, 10.9 Hz, 1H), 3.27 
(dd, J = 18.0, 3.8 Hz, 1H), 1.35 (d, J = 6.7 Hz, 3H), 1.24 (d, J = 6.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 196.6, 191.1, 141.9, 139.5, 138.5, 134.8, 129.9, 129.5, 128.8, 128.7, 
128.5, 127.1, 121.1, 49.1, 48.5, 43.0, 23.4. 
IR (film): ν (cm1) 3159, 3071, 3028, 2982, 2922, 1668, 1583, 1489, 1457, 1396, 1248, 1205, 1156, 
1089, 988, 946, 910, 834, 771, 747, 696, 666, 550, 521. 
HRMS (ESI, m/z) calcd for C22H22ClN2O2 [M+H]+: 381.1364, found: 381.1361. 
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5.4.3 Assignment of Absolute Configurations for Asymmetric Catalysis Products 
The absolute configuration of the product 26l (synthesized through catalysis with -IrS) was assigned 
by converting it to the corresponding reported non-racemic aldehyde 26l'' for which the absolute 
configuration has been established. 22  As shown below, the (R)-configuration was assigned by 
comparison with published optical rotation and chiral HPLC retention time data.22 Thus, it can be 
concluded for the results of Figure 41-43 in which the catalyst -IrS was employed, that 26l was 
provided as (S)-26l. All other products were assigned accordingly. 
 
Optical rotation of (R)-26l'': 
[]D25 = +67.8 (c 1.0, CHCl3, 89% ee) 
Lit.22: []D29 = +59.3 (c 1.0, CHCl3, 92% ee for R-configuration) 
Chiral HPLC with(R)-26l'': 
(Daicel Chiralpak IC column, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 C) 
tr (minor) = 16.3 min, tr (major) = 18.8 min 
Lit.22: tr (minor) = 16.7 min, tr (major) = 19.9 min 
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(R)-Methyl 2-(2,4-dinitrobenzyl)butanoate (26l) 
 
The compound was synthesized following a published procedure with some modifications.[12] To a 
solution of (R)-3l (160 mg, 0.48 mmol) in CH3CN (2.4 mL) was added methyl 
trifluoromethanesulfonate (158 L, 1.44 mmol) at room temperature. After being stirred at room 
temperature for 8 h, MeOH (2.4 mL) and DBU (1.0 mL) were added to the reaction mixture. After 
being stirred at room temperature for 30 min, the reaction was quenched with a saturated aqueous 
solution of Na2HCO3 and extracted with EtOAc (4  4 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (EtOAc/hexane = 1:10) to give 3l (91.2 mg, 0.32 mmol, yield: 
67%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 8.73 (d, J = 2.4 Hz, 1H), 8.28 (dd, J = 8.5, 2.4 Hz, 1H), 7.53 (d, J = 8.5 
Hz, 1H), 3.51 (s, 3H), 3.29-3.00 (m, 2H), 2.91-2.55 (m, 1H), 1.97- 1.42 (m, 2H), 0.91 (t, J = 7.4 Hz, 
3H). 
13C NMR (75 MHz, CDCl3) δ 174.8, 149.2, 146.7, 141.8, 134.0, 126.8, 120.5, 51.7, 47.7, 34.9, 26.2, 
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11.4. 
IR (film): ν (cm1) 3104, 2963, 2876, 1730, 1604, 1530, 1454, 1345, 1265, 1203, 1168, 1096, 1062, 
1012, 910, 832, 801, 737. 
HRMS (ESI, m/z) calcd for C12H14N2O6Na [M+Na]+: 305.0744, found: 305.0747. 
 
(R)-2-(2,4-Dinitrobenzyl)butanal (26l) 
 
To a solution of (R)-3l (91.2 mg, 0.32 mmol) in CH2Cl2 (3.2 mL) was added DIBAL-H (0.8 mL, 1.0 
M in toluene, 0.80 mmol) at 78 C. After being stirred at 78 C for 2 h, the reaction was quenched 
with a saturated aqueous solution of Na2HCO3 and extracted with EtOAc (4  5 mL). The combined 
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. 
The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:10) to give 3l 
(59.3 mg, 0.24 mmol, yield: 75%) as a pale yellow oil. []D25 = +67.8 (c 1.0, CHCl3) (Lit.[11] []D29 = 
59.3 (c 1.0, CHCl3) for 92% ee of product with R-configuration). 
1H NMR (300 MHz, CDCl3) δ 9.64 (d, J = 1.4 Hz, 1H), 8.78 (s, 1H), 8.35 (dd, J = 8.5, 2.3 Hz, 1H), 
7.68 (d, J = 8.5 Hz, 1H), 3.36 (dd, J = 13.7, 8.9 Hz, 1H), 3.09 (dd, J = 13.7, 4.8 Hz, 1H), 2.87-2.62 (m, 
1H), 1.94-1.60 (m, 2H), 1.02 (t, J = 7.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 202.5, 149.2, 146.6, 141.9, 134.6, 126.8, 120.4, 53.6, 31.2, 22.5, 10.9. 
All spectroscopic data were in agreement with the literature.22 
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5.4.4 Mechanistic Experiments 
1) Synthesis of the Proposed Intermediate Complexes I and II 
 
The racemic complex I was obtained by reacting substrate 24a (14.2 mg, 0.071 mmol) with racemic 
/-IrS (45 mg, 0.047 mmol) at room temperature overnight in CH2Cl2 (1.0 mL). After the slow 
addition of hexane (5.0 mL), crystals were collected after several days (37.7 mg, yield: 65%).  
1H NMR (300 MHz, CD2Cl2) δ 7.98 (d, J = 8.6 Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.85 (dd, J = 7.7, 0.9 
Hz, 1H), 7.78 (dd, J = 7.7, 1.1 Hz, 1H), 7.61 (dd, J = 8.6, 1.8 Hz, 1H), 7.57-7.49 (m, 3H), 7.11-7.02 
(m, 3H), 6.94 (d, J = 1.0 Hz, 1H), 6.88-6.75 (m, 4H), 6.55-6.48 (m, 3H), 6.38 (d, J = 7.5 Hz, 1H), 6.30 
(d, J = 1.6 Hz, 1H), 4.48 (dd, J = 31.5, 14.7 Hz, 3H), 4.05 (s, 2H), 1.34 (s, 9H), 0.85 (s, 9H). 
13C NMR (75 MHz, CD2Cl2) δ 195.1, 183.4, 179.4, 152.8, 152.6, 150.0, 149.0, 147.7, 147.4, 141.9, 
140.1, 137.9, 134.8, 134.0, 133.4, 131.9, 131.7, 131.6, 130.2, 129.7, 128.9, 128.8, 128.6, 128.5, 126.7, 
126.6, 125.1, 124.6, 123.8, 123.4, 123.3, 115.5, 115.3, 45.8, 37.7, 35.4, 35.0, 31.6, 31.2. 
IR (film): ν (cm1) 3146, 3053, 2959, 1576, 1522, 1464, 1439, 1409, 1296, 1249, 1039, 995, 836, 730, 
553. 
 
 
To a solution of catalyst /-IrS (100.0 mg, 0.105 mmol) in CH2Cl2 (3 mL) was added substrate 24a 
(31.8 mg, 0.159 mmol). The reaction mixture was concentrated after around 12 hours. The residue was 
purified by flash chromatography on silica gel (CH2Cl2/EtOAc = 50:1) to afford the enolate complex 
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II as a red solid (90.0 mg, 0.097 mmol, yield: 93%). 
1H NMR (300 MHz, CD2Cl2) δ 8.80 (d, J = 1.6 Hz, 1H), 7.82-7.73 (m, 5H), 7.71 (dd, J = 7.7, 0.9 Hz, 
1H), 7.43 (dt, J = 8.5, 1.8 Hz, 2H), 7.14 (d, J = 1.6 Hz, 1H), 7.10 (dd, J = 10.7, 4.8 Hz, 2H), 7.00-6.80 
(m, 3H), 6.76-6.63 (m, 3H), 6.59-6.50 (m, 1H), 6.48-6.36 (m, 2H), 5.46 (s, 1H), 3.79 (s, 3H), 1.13 (s, 
9H), 1.07 (s, 9H). 
13C NMR (75 MHz, CD2Cl2) δ 181.6, 179.7, 156.0, 155.4, 154.7, 152.4, 151.4, 151.32, 151.28, 149.9, 
142.4, 142.0, 140.3, 135.2, 134.5, 130.6, 130.4, 129.1, 128.8, 127.8, 127.6, 126.1, 126.0, 125.0, 124.6, 
123.5, 123.3, 123.2, 122.4, 121.7, 121.3, 120.9, 119.3, 117.1, 102.8, 37.0, 35.21, 35.17, 31.6, 31.4. 
IR (film): ν (cm1) 3048, 2953, 2866, 1480, 1462, 1421, 1375, 1282, 1241, 1165, 1089, 1026, 990, 931, 
728, 692, 457. 
 
2) Trapping Experiment with TEMPO 
With excess TEMPO as shown in Scheme 7: A dried 10 mL Schlenk tube was charged with the 
catalyst rac-IrS (2 mol%), Na2HPO4 (31.2 mg, 0.22 mmol), TEMPO (78.0 mg, 0.5 mmol) and the 
2-(bromomethyl)-5-nitrobenzonitrile (48.0 mg, 0.2 mmol). The tube was purged with argon and 
MeOH/THF (4:1, 0.5 mL) was added via syringe, followed by the 2-acyl imidazole 24a (34.0 L, 0.2 
mmol). The reaction mixture was degassed via freeze-pump-thaw for three cycles. After the mixture 
was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 14 w white 
light energy saving lamp. The reaction was stirred at 40 C for 22 h under argon atmosphere. 
Afterwards, the mixture was diluted with CH2Cl2 (8 mL), the inorganic salt was removed by 
centrifugation. The combined organic layers were concentrated under reduced pressure. The residue 
was purified by flash chromatography on silica gel (EtOAc/hexane = 1:20 to 1:5) to afford the 
products 27 (55.0 mg, 0.174 mmol, yield: 87%) as a white solid and 28 (65.1 mg, 0.183 mmol, yield: 
92%) as a white solid. 
 
With 5 mol% TEMPO as shown in Scheme 8: The experiment was executed as describe above but 
with only 0.05 equivalents of TEMPO. As a result, TEMPO was consumed within 15 min and 
products 27 and 28 were observed by 1H-NMR analysis of the crude reaction mixture. 
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5-Nitro-2-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)benzonitrile (27) 
 
1H NMR (300 MHz, CDCl3) δ 8.43 (d, J = 2.2 Hz, 1H), 8.38 (dd, J = 8.6, 2.3 Hz, 1H), 7.84 (d, J = 8.5 
Hz, 1H), 5.07 (s, 2H), 1.57-1.25 (m, 6H), 1.14 (s, 6H), 1.11 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ 149.0, 146.7, 128.9, 127.6, 127.4, 115.1, 111.6, 75.5, 60.3, 39.6, 32.8, 
20.3, 16.9. 
IR (film): ν (cm1) 2969, 2931, 1610, 1583, 1529, 1472, 1447, 1348, 1132, 1057, 959, 926, 906, 820, 
734. 
HRMS (ESI, m/z) calcd for C17H24N3O3 [M+H]+: 318.1812, found: 318.1805. 
 
1-(1-Methyl-1H-imidazol-2-yl)-2-phenyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)ethanone (28) 
 
1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 6.8 Hz, 2H), 7.37-7.10 (m, 4H), 7.00 (s, 1H), 6.67 (s, 1H), 
3.93 (s, 3H), 1.65-1.20 (m, 9H), 1.12 (s, 3H), 1.06 (s, 3H), 0.78 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 190.4, 141.9, 138.3, 129.3, 127.9, 127.8, 127.2, 127.1, 88.97, 59.6, 
59.4, 39.9, 35.7, 33.6, 33.1, 20.0, 17.0. 
IR (film): ν (cm1) 2925, 2861, 1686, 1455, 1405, 1373, 1257, 1052, 969, 919, 881, 833, 787, 751, 693, 
614, 514. 
HRMS (ESI, m/z) calcd for C21H30N3O2 [M+H]+: 356.2333, found: 356.2342. 
 
3) Trapping Experiment with 1,1-Diphenylethylene 
As shown in Scheme 9, A dried 10 mL Schlenk tube was charged with the catalyst rac-IrS (2 mol%), 
Na2HPO4 (31.2 mg, 0.22 mmol), 1,1-diphenylethylene (88.0 L, 0.5 mmol) and the 
2-(bromomethyl)-5-nitrobenzonitrile 25a (48.0 mg, 0.2 mmol). The tube was purged with argon and 
MeOH/THF (4:1, 0.5 mL) was added via syringe, followed by the 2-acyl imidazole 24a (102.0 L, 0.6 
mmol). The reaction mixture was degassed via freeze-pump-thaw for three cycles. After the mixture 
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was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 14 w white 
light energy saving lamp. The reaction was stirred at 40 C for 22 h under argon atmosphere. 
Afterwards, the mixture was diluted with CH2Cl2 (8 mL), the inorganic salt was removed by 
centrifugation. The combined organic layers were concentrated under reduced pressure. The residue 
was purified by flash chromatography on silica gel (EtOAc/hexane = 1:20) to afford the products 29 
(42.4 mg, 0.114 mmol, yield: 57%) as a white solid and 26a (4.2 mg, 0.012 mmol, yield: 6%) as a 
white solid. 
2-(3-Methoxy-3,3-diphenylpropyl)-5-nitrobenzonitrile (29) 
 
1H NMR (300 MHz, CDCl3) δ 8.37 (d, J = 2.4 Hz, 1H), 8.19 (dd, J = 8.6, 2.4 Hz, 1H), 7.34-7.09 (m, 
11H), 3.08 (s, 3H), 2.71 (ddd, J = 6.3, 5.6, 2.5 Hz, 2H), 2.61 (ddd, J = 9.5, 5.6, 2.5 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 154.0, 146.1, 144.4, 131.1, 128.2, 127.9, 127.2, 127.1, 126.8, 115.9, 
113.8, 82.1, 50.4, 36.3, 29.0. 
IR (film): ν (cm1) 3079, 2929, 2817, 2230, 2152, 1609, 1530, 1485, 1447, 1346, 1301, 1182, 1073, 
1031, 910, 850, 746, 698, 498. 
HRMS (ESI, m/z) calcd for C23H20N2O3Na [M+Na]+: 395.1366, found: 395.1372. 
 
4) Luminescence Quenching Experiments 
Emission intensities were recorded on a Spectra Max M5 microplate reader in a 10.0 mm quartz 
cuvette. Catalyst /-IrS solutions were excited at max = 425 nm and the emission was measured at 
560 nm (emission maximum). The enolate complex II solutions were excited at max = 440 nm and the 
emission measured at 550 nm (emission maximum). The concentration of iridium complex (IrS and 
enolate complex II) was 0.5 mM in MeOH/THF (4:1). The concentration of the quencher (benzyl 
bromide 25a) stock solution was 200 mM in MeOH/THF (4:1). For each quenching experiment, 5 L 
of this stock solution were titrated to a solution (1 mL) of iridium complex in a screw-top 10.0 mm 
quartz cuvette. The addition of 5 L stock solution refers to an increase of the quencher concentration 
of 1 mM. After degassing with an argon stream for 5 minutes, the emission intensity was collected. 
See Figure 53 for the obtained Stern-Volmer plots. 
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5.4.5 Cyclic Voltammetry 
Cyclic voltammetry was carried out on a BAS C3 Cell Stand and a BAS 100 series Electrochemical 
Analyzer using a platinum disk anode (2.0 mm diameter) and a platinum wire cathode (0.5 mm 
diameter) at r.t. in acetonitrile containing 0.1 M Bu4NBF4. Potentials were referred to a saturated 
Ag/AgCl reference electrode. Before each experiment the surface of the anode was polished followed 
by thorough rinsing with distilled water. The solution was purged with nitrogen before each 
measurement. See Figure 54 for the results. 
 
5.4.6 Single-Crystal X-Ray Diffraction Studies 
Single crystals of Λ-IrS suitable for X-ray diffraction were obtained by slow diffusion from a solution 
of Λ-IrS (30 mg) in CH2Cl2 (0.5 mL) layered with n-hexane (1.5 mL) at room temperature for several 
days in an NMR-tube. Single crystals suitable for X-ray diffraction of the substrate coordinated 
iridium catalyst (intermediate I, here denoted as zll3) were obtained by reacting substrate 24a (14.2 
mg, 0.071 mmol) with /-IrS (45 mg, 0.047 mmol) overnight at room temperature in CH2Cl2 (1.0 
mL). After the slow addition of n-hexane (5.0 mL), crystals were collected after several days (65% 
yield). Single crystals of the intermediate enolate complex II (zll4) were obtained as follows: To a 
solution of /-IrS catalyst (100.0 mg, 0.105 mmol) in CH2Cl2 (3 mL) was added substrate 24a (31.8 
mg, 0.159 mmol). The reaction mixture was concentrated after around 12 hours, purified by 
chromatography over silica gel using CH2Cl2-EtOAc (50:1), affording compound as red solid (90.0 mg, 
0.097 mmol). Single crystals suitable for X-ray diffraction were obtained by slow diffusion from a 
solution of the compound in CH2Cl2 layered with n-hexane at room temperature for several days. 
Crystal data and details of the structure determination are presented in the Appendices (Chapter 6.7). 
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5.5 Visible-Light-Activated Enantioselective Trichloromethylation 
5.5.1 Synthesis of Substrates 
1) Synthesis of 2-Acyl Imidazoles 
2-Acyl imidazoles 30a-h, 30j-l and the corresponding Weinreb amides were synthesized according to 
our recently published procedures (method A).23 2-Acyl imidazole 30i was synthesized according to a 
reported procedure with some modifications (method B).24 
 
General procedure for method A. To a solution of N-phenylimidazole (1.1 eq) in THF at 78 C was 
added n-BuLi (1.1 eq) dropwise. The reaction was stirred at 78 C for 30 min, and then stirred at 
room temperature for 30 min. The corresponding Weinreb amide (1.0 eq in THF) was added dropwise 
to the flask after the reaction was cooled back down to 78 C. The overall concentration of Weinreib 
amide was 0.4 M. The reaction was allowed to warm to room temperature slowly (over a period of 3-4 
h) and stirred overnight. The reaction was quenched with AcOH (6.0 eq) at room temperature and 
extracted with EtOAc. The organic layer was washed with aqueous saturated NaHCO3 and brine. The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:3) to 
produce 30a-h, 30j-l. 
The experimental data of 30f and 30l are shown below. The other 2-acyl imidazoles (30a-e, 30g-h, 
30j-k) have been reported previously.23 
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2-(2-Chlorophenyl)-1-(1-phenyl-1H-imidazol-2-yl)ethanone (30f) 
 
Following the general procedure, Weinreb amide 30’f (852 mg, 4.0 mmol) was converted to 2-acyl 
imidazole 30f (890 mg, 3.0 mmol, yield: 75%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.64-6.99 (m, 12H), 4.69 (s, 2H). 
13C NMR (75 MHz, CDCl3) δ 187.1, 142.7, 138.2, 134.8, 133.0, 132.2, 129.7, 129.4, 128.9, 128.7, 
128.4, 127.3, 126.7, 125.9, 43.8. 
IR (film): ν (cm1) 3136, 3069, 3014, 2914, 1727, 1677, 1590, 1484, 1442, 1393, 1306, 1141, 1032, 
957, 909, 744, 685, 538, 503, 442. 
HRMS (ESI, m/z) calcd for C17H14ClN2O [M+H]+: 297.0789, found: 297.0789. 
 
1-(1-Phenyl-1H-imidazol-2-yl)hexan-1-one (30l) 
 
Following the general procedure, Weinreb amide 30’l (636 mg, 4.0 mmol) was converted to 2-acyl 
imidazole 30l (808 mg, 3.4 mmol, yield: 84%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.57-7.40 (m, 3H), 7.37-7.23 (m, 3H), 7.19 (d, J = 0.9 Hz, 1H), 3.16 (t, 
J = 7.5 Hz, 2H), 1.88-1.47 (m, 2H), 1.58-1.11 (m, 4H), 0.91 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 191.7, 143.2, 138.5, 129.4, 128.9, 128.6, 126.9, 125.9, 39.2, 31.4, 23.7, 
22.4, 13.9. 
IR (film): ν (cm1) 3109, 3062, 2954, 2928, 2863, 1683, 1596, 1496, 1446, 1404, 1306, 1040, 957, 910, 
761, 691, 554, 515. 
HRMS (ESI, m/z) calcd for C15H19N2O [M+H]+: 243.1492, found: 243.1493. 
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Procedure for the preparation of 30i. To a solution of N-phenylimidazole (864 mg, 6.0 mmol) in 
THF (15 mL) at 78 C was added n-BuLi (2.4 mL, 2.5 M in hexane, 6.0 mmol) dropwise. The 
reaction was stirred at 78 C for 1 h, and then stirred at room temperature for 30 min. The tert-butyl 
chloroacetate (1.3 mL, 7.5 mmol) was added at one portion to the flask after the reaction was cooled 
back down to 78 C. The reaction was allowed to warm to room temperature slowly (over a period of 
3-4 h) and stirred overnight. The reaction was quenched with water at room temperature and extracted 
with EtOAc. The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:3) to produce 30’i (960 mg, 4.4 mmol, yield: 73%) as a white solid. 
To a mixture of 30’i (880 mg, 4.0 mmol) and K2CO3 (552 mg, 4.0 mmol) in DMF (8.0 mL) at 0 C 
were added p-cresol (648 mg, 6.0 mmol). The reaction mixture was stirred at room temperature for 
overnight. The reaction was quenched with water (8 mL) at room temperature and extracted with 
DCM (4  10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:3) to afford 1i (595 mg, 2.0 mmol, yield: 50%) as a white solid. 
 
1-(1-Phenyl-1H-imidazol-2-yl)-2-(p-tolyloxy)ethanone (30i) 
 
1H NMR (300 MHz, CDCl3) δ 7.53-7.39 (m, 3H), 7.39-7.30 (m, 3H), 7.28 (d, J = 1.0 Hz, 1H), 7.07 (d, 
J = 8.2 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 5.50 (s, 2H), 2.28 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 184.8, 156.0, 140.8, 137.6, 130.5, 130.0, 129.9, 129.0, 128.9, 127.3, 
125.9, 114.5, 70.1, 20.4. 
All spectroscopic data were in agreement with the literature.24 
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2) Synthesis of 2-Acyl Pyridines 
All 2-acyl pyridines (33a-i) were synthesized according to reported procedures with some 
modifications.25 
 
General procedure for the synthesis of 2-acyl pyridines. To a solution of the corresponding 
2-pyridinecarbonitrile 33’ (1.0 eq) in Et2O (0.5 M) at 15 C were added ethylmagnesium bromide or 
benzylmagnesium bromide (1.2 eq, 1.0 M in THF). The reaction mixture was stirred at 15 C for 30 
min, then allowed to warm to room temperature and stirred for a further 2.5 h. The mixture was added 
2 N HCl (2.4 eq) and stirred at room temperature for 15 min. The reaction was neutralized with 2 N 
NaOH to pH 8 and diluted with EtOAc. The organic layer was washed with aqueous saturated 
NaHCO3 and brine (20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, 
and concentrated under reduced pressure. The residue was purified by flash chromatography on silica 
gel (EtOAc/hexane = 1:10) to obtain the pure compounds 33a-i. 
 
2-Phenyl-1-(pyridin-2-yl)ethanone (33a) 
 
Following the general procedure, 2-pyridinecarbonitrile (1.5 mL, 16.0 mmol) was converted to 2-acyl 
pyridine 33a (2.648 g, 13.4 mmol, yield: 84%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.65 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 8.06-7.88 (m, 1H), 7.74 (td, J = 7.7, 
1.7 Hz, 1H), 7.39 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.32-7.07 (m, 5H), 4.48 (s, 2H). 
13C NMR (75 MHz, CDCl3) δ 199.1, 153.1, 148.9, 136.9, 134.8, 129.9, 128.4, 127.1, 126.6, 122.3, 
43.9. 
IR (film): ν (cm1) 3058, 3032, 2890, 1698, 1578, 1494, 1435, 1396, 1333, 1219, 991, 769, 737, 697, 
562. 
HRMS (ESI, m/z) calcd for C13H12NO [M+H]+: 198.0913, found: 198.0917. 
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1-(Pyridin-2-yl)propan-1-one (33b) 
 
Following the general procedure, 2-pyridinecarbonitrile (1.5 mL, 16.0 mmol) was converted to 2-acyl 
pyridine 4b (1.837 g, 13.6 mmol, yield: 85%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 8.60 (ddd, J = 4.7, 1.6, 0.8 Hz, 1H), 8.03-7.86 (m, 1H), 7.75 (td, J = 7.7, 
1.7 Hz, 1H), 7.38 (ddd, J = 7.5, 4.8, 1.2 Hz, 1H), 3.17 (q, J = 7.3 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 202.5, 153.5, 148.9, 136.8, 126.9, 121.7, 31.0, 7.9. 
IR (film): ν (cm1) 3057, 2977, 2938, 2881, 1696, 1580, 1459, 1353, 1222, 1093, 996, 954, 756, 667, 
617, 568. 
HRMS (ESI, m/z) calcd for C8H10NO [M+H]+: 136.0757, found: 136.0758. 
 
1-(4-Methylpyridin-2-yl)propan-1-one (33c) 
 
Following the general procedure, 4-methyl-2-pyridinecarbonitrile (733 mg, 6.2 mmol) was converted 
to 2-acyl pyridine 33c (711 mg, 4.8 mmol, yield: 77%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 8.53 (d, J = 4.9 Hz, 1H), 8.16-7.57 (m, 1H), 7.46-7.00 (m, 1H), 3.23 (q, 
J = 7.3 Hz, 2H), 2.43 (s, 3H), 1.22 (t, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 202.8, 153.4, 148.7, 148.1, 127.7, 122.5, 31.1, 21.0, 8.0. 
IR (film): ν (cm1) 3052, 2976, 2936, 2879, 1696, 1599, 1457, 1408, 1345, 1266, 1165, 1032, 996, 972, 
841, 801, 672, 577, 526, 481. 
HRMS (ESI, m/z) calcd for C9H11NONa [M+Na]+: 172.0733, found: 172.0733. 
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1-(4-Phenylpyridin-2-yl)propan-1-one (33d) 
 
Following the general procedure, 4-phenyl-2-pyridinecarbonitrile (900 mg, 5.0 mmol) was converted 
to 2-acyl pyridine 33d (847 mg, 4.0 mmol, yield: 80%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 8.70 (d, J = 5.1 Hz, 1H), 8.38-8.20 (m, 1H), 7.81-7.59 (m, 3H), 
7.58-7.39 (m, 3H), 3.28 (q, J = 7.3 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 202.6, 154.0, 149.4, 137.5, 129.4, 129.2, 127.0, 124.6, 119.6, 31.3, 8.0. 
IR (film): ν (cm1) 2975, 2933, 2898, 1696, 1589, 1543, 1501, 1454, 1402, 1342, 1282, 1196, 964, 760, 
683, 609, 449. 
HRMS (ESI, m/z) calcd for C14H13NONa [M+Na]+: 234.0889, found: 234.0890. 
 
1-(4-Chloropyridin-2-yl)propan-1-one (33e) 
 
Following the general procedure, 4-chloro-2-pyridinecarbonitrile (889 mg, 6.4 mmol) was converted 
to 2-acyl pyridine 33e (898 mg, 5.3 mmol, yield: 83%) as a pale yellow oil. 
1H NMR (300 MHz, CDCl3) δ 8.49 (dd, J = 5.2, 0.4 Hz, 1H), 7.95 (dd, J = 2.1, 0.5 Hz, 1H), 7.38 (dd, 
J = 5.2, 2.1 Hz, 1H), 3.14 (q, J = 7.3 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 201.3, 154.7, 149.8, 145.4, 127.0, 122.2, 31.2, 7.8. 
IR (film): ν (cm1) 3056, 2978, 2939, 2907, 2880, 1700, 1562, 1458, 1399, 1346, 1279, 1221, 1095, 
1022, 971, 899, 841, 793, 706, 487. 
HRMS (ESI, m/z) calcd for C8H8NOClNa [M+Na]+: 192.0187, found: 192.0188. 
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1-(4-Bromopyridin-2-yl)propan-1-one (33f) 
 
Following the general procedure, 4-bromo-2-pyridinecarbonitrile (819 mg, 4.5 mmol) was converted 
to 2-acyl pyridine 33f (776 mg, 3.4 mmol, yield: 76%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.59-8.38 (m, 1H), 8.32-8.02 (m, 1H), 7.71-7.53 (m, 1H), 3.42-2.92 (m, 
2H), 1.38-1.11 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 201.2, 154.3, 149.7, 134.0, 130.0, 125.2, 31.2, 7.8. 
IR (film): ν (cm1) 3051, 2976, 2937, 2907, 2879, 1699, 1554, 1455, 1392, 1344, 1215, 1082, 1020, 
967, 899, 837, 801, 777, 684, 576, 478. 
HRMS (ESI, m/z) calcd for C8H8NOBrNa [M+Na]+: 235.9681 and 237.9661, found: 235.9684 and 
237.9664. 
 
1-(5-Bromopyridin-2-yl)propan-1-one (33g) 
 
Following the general procedure, 5-bromo-2-pyridinecarbonitrile (819 mg, 4.5 mmol) was converted 
to 2-acyl pyridine 33g (796 mg, 3.5 mmol, yield: 78%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.69 (dd, J = 2.1, 0.9 Hz, 1H), 7.94 (dd, J = 8.4, 2.1 Hz, 1H), 7.90 (dd, 
J = 8.4, 0.9 Hz, 1H), 3.17 (q, J = 7.3 Hz, 2H), 1.18 (t, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 201.6, 151.7, 150.0, 139.5, 125.0, 122.9, 31.0, 7.8. 
IR (film): ν (cm1) 3113, 2912, 2867, 1693, 1556, 1454, 1369, 1342, 1253, 1208, 1122, 1079, 997, 949, 
862, 800, 728, 620, 559, 497. 
HRMS (ESI, m/z) calcd for C8H8NOBrNa [M+Na]+: 235.9681 and 237.9661, found: 235.9686 and 
237.9666. 
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1-(4-Propylpyridin-2-yl)propan-1-one (33h) 
 
Following the general procedure, 4-n-propyl-2-pyridinecarbonitrile (819 mg, 4.0 mmol) was converted 
to 2-acyl pyridine 33h (572 mg, 3.2 mmol, yield: 80%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 8.34 (d, J = 4.9 Hz, 1H), 7.67 (d, J = 1.0 Hz, 1H), 7.07 (dd, J = 4.9, 1.7 
Hz, 1H), 3.03 (q, J = 7.3 Hz, 2H), 2.64-2.19 (m, 2H), 1.80-1.25 (m, 2H), 1.01 (t, J = 7.3 Hz, 3H), 0.75 
(t, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 202.9, 153.4, 152.6, 148.7, 127.1, 121.8, 37.3, 31.2, 23.3, 13.6, 8.0. 
IR (film): ν (cm1) 3051, 2965, 2934, 2872, 1697, 1598, 1460, 1412, 1347, 1254, 1164, 1023, 993, 862, 
833, 801, 492. 
HRMS (ESI, m/z) calcd for C11H15NONa [M+Na]+: 200.1046, found: 200.1046. 
 
1-(Isoquinolin-3-yl)-2-phenylethanone (33i) 
 
Following the general procedure, isoquinoline-3-carbonitrile (363 mg, 2.4 mmol) was converted to 
2-acyl pyridine 33i (248 mg, 1.0 mmol, yield: 42%) as a white solid. 
1H NMR (300 MHz, CD2Cl2) δ 9.33 (s, 1H), 8.49 (s, 1H), 8.17-7.92 (m, 2H), 7.85- 7.67 (m, 2H), 
7.49-7.17 (m, 5H), 4.69 (s, 2H). 
13C NMR (75 MHz, CDCl3) δ 199.3, 151.8, 147.4, 135.6, 135.1, 130.9, 130.2, 130.0, 129.4, 128.6, 
128.4, 127.5, 126.6, 121.0, 44.7. 
IR (film): ν (cm1) 3083, 3027, 2924, 1683, 1618, 1584, 1489, 1448, 1381, 1264, 1222, 1115, 1030, 
945, 902, 834, 755, 719, 686, 557, 481. 
HRMS (ESI, m/z) calcd for C17H14NO [M+H]+: 248.1070, found: 248.1070. 
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5.5.2 Iridium-Catalyzed Photoredox Reactions 
 
General procedure A: -trichloromethylation of 2-acyl imidazoles. A dried 10 mL Schlenk tube 
was charged with the catalyst Λ-IrS (2 or 4 mol%), NaHCO3 (18.5 mg, 0.22 mmol, 1.1 eq) and the 
corresponding 2-acyl imidazole 30a-l (0.2 mmol, 1.0 eq). The tube was purged with argon and 
MeOH/THF (4:1, 0.5 mL) was added via syringe, followed by bromotrichloromethane (118.0 L, 1.2 
mmol, 6.0 eq). The reaction mixture was degassed via freeze-pump-thaw for three cycles. After the 
mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 20 W 
white light energy saving lamp. The reaction was stirred at room temperature for the indicated time 
(monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was diluted with CH2Cl2 (8 
mL), the inorganic salt was removed by centrifugation. The combined organic layers were 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:15 to 1:10) to afford the products 31a-l. Racemic samples were obtained by 
carrying out the reactions with rac-IrS. The enantiomeric excess was determined by chiral HPLC 
analysis. 
Exemplary reaction setup: 
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General procedure B: -trichloromethylation of 2-acylpyridines. A dried 10 mL Schlenk tube was 
charged with the catalyst Λ-IrS (4 mol%) and the corresponding 2-acyl pyridine 33a-i (0.2 mmol, 1.0 
eq). The tube was purged with nitrogen and MeOH/MeCN (1:1, 0.5 mL) was added via syringe, 
followed by 2,6-lutidine (25.0 L, 0.22 mmol, 1.1 eq) and bromotrichloromethane (118.0 L, 1.2 
mmol, 6.0 eq). The reaction mixture was degassed via freeze-pump-thaw for three cycles. After the 
mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 20 W 
white light energy saving lamp. The reaction was stirred at 40 C (silicone oil bath) for the indicated 
time (monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 
1:30 to 1:15) to afford the products 34a-i. Racemic samples were obtained by carrying out the 
reactions with rac-IrS. The enantiomeric excess was determined by chiral HPLC analysis. 
Exemplary reaction setup: 
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(R)-3,3,3-Trichloro-2-phenyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (31a) 
 
Starting from 2-acyl imidazole 30a (52.4 mg, 0.20 mmol) according to the general procedure A to give 
31a as a white solid (58.3 mg, 0.154 mmol, yield: 77%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 99.7% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 12.3 min, tr (major) = 13.0 min). []D22 = 206.4 (c 
0.7, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.76-7.63 (m, 2H), 7.58-7.46 (m, 3H), 7.45-7.36 (m, 3H), 7.31-7.19 (m, 
4H), 6.58 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 183.5, 142.8, 138.5, 132.5, 132.1, 130.5, 129.6, 129.5, 129.4, 128.9, 
128.8, 126.1, 98.9, 67.7. 
IR (film): ν (cm1) 1686, 1592, 1494, 1448, 1392, 1304, 1153, 1062, 1032, 958, 914, 871, 760, 740, 
691, 634, 547. 
HRMS (ESI, m/z) calcd for C18H13Cl3N2ONa [M+Na]+: 400.9997 and 402.9969, found: 401.0000 and 
402.9971. 
 
(R)-3,3,3-Trichloro-1-(1-phenyl-1H-imidazol-2-yl)-2-(m-tolyl)propan-1-one (31b) 
 
Starting from 2-acyl imidazole 30b (55.2 mg, 0.20 mmol) according to the general procedure A to give 
31b as a white solid (71.0 mg, 0.181 mmol, yield: 91%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 99.0% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 12.6 min, tr (major) = 11.2 min). []D22 = 229.4 (c 
0.7, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.66-7.46 (m, 5H), 7.40-7.06 (m, 6H), 6.54 (s, 1H), 2.38 (s, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 183.5, 142.8, 138.7, 138.5, 132.6, 132.3, 130.5, 130.4, 129.5, 129.3, 
129.1, 128.9, 128.6, 126.1, 98.9, 67.8, 21.6. 
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IR (film): ν (cm1) 3125, 3064, 2966, 2919, 2856, 1685, 1594, 1492, 1447, 1393, 1306, 1145, 1050, 
968, 877, 823, 761, 716, 638, 556, 517. 
HRMS (ESI, m/z) calcd for C19H16Cl3N2O [M+H]+: 393.0323 and 395.0295, found: 393.0326 and 
395.0295. 
 
(R)-3,3,3-Trichloro-1-(1-phenyl-1H-imidazol-2-yl)-2-(o-tolyl)propan-1-one (31c) 
 
Starting from 2-acyl imidazole 30c (55.2 mg, 0.20 mmol) according to the general procedure A to give 
31c as a white solid (64.3 mg, 0.164 mmol, yield: 82%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee > 99.9% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.7 min, tr (major) = 9.9 min). []D22 = 270.8 (c 0.7, 
CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.77 (d, J = 7.6 Hz, 1H), 7.60-7.39 (m, 3H), 7.29 (dd, J = 5.2, 1.1 Hz, 
2H), 7.27-7.12 (m, 5H), 6.89 (s, 1H), 2.84 (s, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 183.8, 143.0, 140.6, 138.5, 131.7, 131.2, 130.5, 130.4, 129.6, 129.5, 
129.3, 128.9, 126.1, 126.0, 99.6, 63.0, 20.9. 
IR (film): ν (cm1) 3118, 3061, 2978, 1691, 1596, 1494, 1449, 1393, 1307, 1057, 960, 916, 872, 725, 
693, 635, 543. 
HRMS (ESI, m/z) calcd for C19H16Cl3N2O [M+H]+: 393.0323 and 395.0295, found: 393.0326 and 
395.0296. 
 
(R)-3,3,3-Trichloro-2-(4-methoxyphenyl)-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (31d) 
 
Starting from 2-acyl imidazole 30d (58.4 mg, 0.20 mmol) according to the general procedure A to give 
31d as a white solid (73.1 mg, 0.179 mmol, yield: 90%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak IC column, ee = 99.4% (HPLC: IC, 254 nm, hexane/isopropanol = 95:5, 
Chapter 6. Experimental Part 
244 
 
flow rate 1.0 mL/min, 25 C, tr (minor) = 11.2 min, tr (major) = 8.1 min). []D22 = 236.4 (c 0.7, 
CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.60 (d, J = 8.9 Hz, 2H), 7.55-7.46 (m, 3H), 7.35-7.16 (m, 4H), 6.92 (d, 
J = 8.9 Hz, 2H), 6.51 (s, 1H), 3.80 (s, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 183.8, 160.9, 142.8, 138.6, 133.3, 130.5, 129.5, 129.4, 128.8, 126.2, 
124.4, 114.2, 99.4, 67.1, 55.7. 
IR (film): ν (cm1) 3135, 2967, 2927, 2842, 1687, 1602, 1505, 1451, 1392, 1308, 1254, 1179, 1072, 
1024, 952, 767, 723, 627, 535. 
HRMS (ESI, m/z) calcd for C19H15Cl3N2O2 [M+Na]+: 431.0091 and 433.0064, found: 431.0094 and 
433.0065. 
 
(R)-3,3,3-Trichloro-2-(4-chlorophenyl)-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (31e) 
 
Starting from 2-acyl imidazole 30e (59.2 mg, 0.20 mmol) according to the general procedure A to give 
31e as a white solid (56.2 mg, 0.136 mmol, yield: 68%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 99.4% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 11.5 min, tr (major) = 10.5 min). []D22 = 222.8 (c 
0.5, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.66 (d, J = 8.5 Hz, 2H), 7.57-7.46 (m, 3H), 7.38 (d, J = 8.6 Hz, 2H), 
7.32-7.20 (m, 4H), 6.58 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 183.2, 142.7, 138.5, 135.9, 133.4, 131.2, 130.7, 129.6, 129.5, 129.1, 
129.0, 126.2, 98.5, 66.9. 
IR (film): ν (cm1) 2965, 2927, 2880, 1691, 1594, 1492, 1448, 1394, 1307, 1092, 1062, 957, 764, 717, 
691, 645, 543, 438. 
HRMS (ESI, m/z) calcd for C18H12Cl4N2ONa [M+Na]+: 434.9596, 436.9568 and 438.9541, found: 
434.9597, 436.9567 and 438.9539. 
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(R)-3,3,3-Trichloro-2-(2-chlorophenyl)-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (31f) 
 
Starting from 2-acyl imidazole 30f (59.2 mg, 0.20 mmol) according to the general procedure A to give 
31f as a white solid (68.0 mg, 0.165 mmol, yield: 83%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 99.6% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 12.5 min, tr (major) = 13.6 min). []D22 = 269.6 (c 
0.7, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.92 (dd, J = 7.7, 1.9 Hz, 1H), 7.62-7.43 (m, 4H), 7.43-7.15 (m, 7H). 
13C NMR (75 MHz, CD2Cl2) δ 183.1, 142.9, 138.5, 137.5, 132.2, 130.9, 130.83, 130.78, 130.5, 129.6, 
129.4, 129.2, 126.9, 126.2, 98.8, 62.2. 
IR (film): ν (cm1) 3132, 3090, 3037, 2852, 1686, 1591, 1486, 1443, 1395, 1301, 1147, 1051, 961, 863, 
759, 716, 687, 630, 540. 
HRMS (ESI, m/z) calcd for C18H12Cl4N2ONa [M+Na]+: 434.9596, 436.9568 and 438.9541, found: 
434.9595, 436.9566 and 438.9537. 
 
(R)-3,3,3-Trichloro-2-(naphthalen-2-yl)-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (31g) 
 
Starting from 2-acyl imidazole 30g (62.4 mg, 0.20 mmol) according to the general procedure A to give 
31g as a white solid (61.2 mg, 0.143 mmol, yield: 71%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 99.2% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
98:2, flow rate 1.0 mL/min, 25 C, tr (minor) = 10.5 min, tr (major) = 13.6 min). []D22 = 279.2 (c 
0.5, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 8.19 (d, J = 1.1 Hz, 1H), 7.99-7.77 (m, 4H), 7.63-7.46 (m, 5H), 
7.33-7.22 (m, 3H), 7.21 (d, J = 0.9 Hz, 1H), 6.76 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 183.4, 142.8, 138.5, 133.8, 133.4, 131.8, 130.5, 129.9, 129.5, 129.4, 
129.2, 128.9, 128.7, 128.3, 128.0, 127.4, 126.8, 126.2, 99.0, 67.8. 
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IR (film): ν (cm1) 2969, 2927, 2884, 1686, 1596, 1498, 1449, 1392, 1306, 1152, 1056, 950, 817, 761, 
724, 690, 477. 
HRMS (ESI, m/z) calcd for C22H15Cl3N2ONa [M+Na]+: 451.0142 and 453.0116, found: 451.0143 and 
453.0114. 
 
(R)-3,3,3-Trichloro-1-(1-phenyl-1H-imidazol-2-yl)-2-(thiophen-3-yl)propan-1-one (31h) 
 
Starting from 2-acyl imidazole 30h (53.6 mg, 0.20 mmol) according to the general procedure A to give 
31h as a white solid (48.0 mg, 0.125 mmol, yield: 62%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee = 96% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.6 min, tr (major) = 11.2 min). []D22 = 158.8 (c 0.3, 
CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.62 (dd, J = 2.8, 1.4 Hz, 1H), 7.57-7.45 (m, 3H), 7.35 (qd, J = 5.0, 2.1 
Hz, 2H), 7.30-7.22 (m, 4H), 6.74 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 183.4, 142.8, 138.6, 132.7, 130.6, 130.2, 129.6, 129.4, 129.1, 128.4, 
126.2, 125.6, 98.7, 63.3. 
IR (film): ν (cm1) 3144, 3107, 3067, 2847, 1686, 1491, 1444, 1394, 1302, 1148, 1062, 966, 761, 713, 
671, 532. 
HRMS (ESI, m/z) calcd for C16H11Cl3N2OSNa [M+Na]+: 406.9550 and 408.9521, found: 406.9552 and 
408.9523. 
 
(R)-3,3,3-Trichloro-1-(1-phenyl-1H-imidazol-2-yl)-2-(p-tolyloxy)propan-1-one (31i) 
 
Starting from 2-acyl imidazole 30i (58.4 mg, 0.20 mmol) according to the general procedure A to give 
31i as a colorless oil (52.1 mg, 0.128 mmol, yield: 64%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 92% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
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97:3, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.4 min, tr (major) = 9.7 min). []D22 = 92.8 (c 1.0, 
CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.54-7.45 (m, 3H), 7.41 (d, J = 0.9 Hz, 1H), 7.35 (d, J = 0.9 Hz, 1H), 
7.32-7.25 (m, 2H), 7.10 (br s, 4H), 6.93 (s, 1H), 2.28 (s, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 181.6, 155.6, 143.3, 137.9, 133.0, 131.2, 130.55, 129.60, 129.5, 129.0, 
126.0, 116.7, 96.5, 83.4, 20.7. 
IR (film): ν (cm1) 3121, 3036, 2924, 2862, 1698, 1598, 1503, 1447, 1398, 1303, 1218, 1060, 946, 901, 
809, 766, 727, 689, 580, 521. 
HRMS (ESI, m/z) calcd for C19H15Cl3N2O2Na [M+Na]+: 431.0091 and 433.0064, found: 431.0092 and 
433.0062. 
 
(R)-3,3,3-Trichloro-2-methyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (31j) 
 
Starting from 2-acyl imidazole 30j (40.0 mg, 0.20 mmol) according to the general procedure A to give 
31j as a white solid (46.0 mg, 0.146 mmol, yield: 73%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak IC column, ee = 98.8% (HPLC: IC, 254 nm, hexane/isopropanol = 99:1, 
flow rate 1.0 mL/min, 25 C, tr (minor) = 9.4 min, tr (major) = 8.2 min). []D22 = 25.2 (c 0.5, 
CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.49-7.33 (m, 3H), 7.28-7.12 (m, 4H), 5.30 (q, J = 6.8 Hz, 1H), 1.50 (d, 
J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 186.6, 142.9, 138.6, 130.5, 129.5, 129.3, 128.9, 126.2, 100.5, 58.3, 
16.0. 
IR (film): ν (cm1) 3154, 3122, 3065, 2961, 2930, 1688, 1591, 1492, 1449, 1399, 1299, 1151, 1078, 
1012, 953,905, 831, 767, 687, 601, 532. 
HRMS (ESI, m/z) calcd for C13H11Cl3N2ONa [M+Na]+: 338.9829 and 340.9801, found: 338.9830 and 
340.9800. 
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(R)-1-(1-Phenyl-1H-imidazol-2-yl)-2-(trichloromethyl)butan-1-one (31k) 
 
Starting from 2-acyl imidazole 30k (42.8 mg, 0.20 mmol) according to the general procedure A to give 
31k as a white solid (63.3 mg, 0.192 mmol, yield: 96%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak IC column, ee = 99.4% (HPLC: IC, 254 nm, hexane/isopropanol = 99:1, 
flow rate 1.0 mL/min, 25 C, tr (minor) = 7.3 min, tr (major) = 6.3 min). []D22 = 1.6 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.50-7.35 (m, 3H), 7.27 (d, J = 0.9 Hz, 1H), 7.26-7.15 (m, 3H), 5.23 
(dd, J = 8.7, 5.2 Hz, 1H), 2.25-1.92 (m, 2H), 0.91 (t, J = 7.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 186.6, 144.0, 138.1, 130.3, 129.2, 128.9, 128.1, 125.6, 99.2, 63.9, 24.3, 
11.6. 
IR (film): ν (cm1) 3120, 3059, 2971, 2878, 1735, 1686, 1495, 1448, 1399, 1308, 1201, 1148, 1113, 
1073, 1031, 961, 762, 684. 
HRMS (ESI, m/z) calcd for C14H13Cl3N2ONa [M+Na]+: 352.9986 and 354.9957, found: 352.9986 and 
354.9958. 
 
(R)-1-(1-Phenyl-1H-imidazol-2-yl)-2-(trichloromethyl)hexan-1-one (31l) 
 
Starting from 2-acyl imidazole 30l (48.4 mg, 0.20 mmol) according to the general procedure A to give 
31l as a colorless oil (54.4 mg, 0.152 mmol, yield: 76%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 98.8% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 6.3 min, tr (major) = 6.8 min). []D22 = 28.0 (c 0.5, 
CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.58-7.44 (m, 3H), 7.40-7.20 (m, 4H), 5.36 (dd, J = 10.3, 3.4 Hz, 1H), 
2.22-1.96 (m, 2H), 1.51-1.17 (m, 4H), 0.87 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 186.9, 144.3, 138.7, 130.6, 129.5, 129.3, 128.9, 126.2, 100.0, 62.6, 
31.2, 29.5, 23.0, 13.9. 
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IR (film): ν (cm1) 3113, 3064, 2957, 2930, 2865, 1688, 1596, 1497, 1448, 1399, 1310, 1039, 905, 854, 
761, 685, 547. 
HRMS (ESI, m/z) calcd for C16H17Cl3N2ONa [M+Na]+: 381.0299 and 383.0271, found: 381.0298 and 
383.0269. 
 
(R)-3,3,3-Trichloro-2-phenyl-1-(pyridin-2-yl)propan-1-one (34a) 
 
Starting from 2-acyl pyridine 33a (39.4 mg, 0.20 mmol) according to the general procedure B to give 
34a as a white solid (52.0 mg, 0.166 mmol, yield: 83%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak IC column, ee = 99.6% (HPLC: IC, 254 nm, hexane/isopropanol = 99:1, 
flow rate 1.0 mL/min, 25 C, tr (minor) = 9.6 min, tr (major) = 7.6 min). []D22 = 85.0 (c 0.3, 
CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 8.64 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 8.10 (dt, J = 7.9, 1.1 Hz, 1H), 7.84 
(td, J = 7.7, 1.7 Hz, 1H), 7.78-7.66 (m, 2H), 7.46 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.40-7.33 (m, 3H), 
6.89 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 194.3, 152.6, 149.4, 137.7, 132.4, 129.5, 128.7, 128.2, 123.2, 99.3, 
65.8. 
IR (film): ν (cm1) 3057, 2949, 1704, 1580, 1436, 1324, 1248, 1213, 1067, 992, 893, 871, 809, 742, 
699, 616, 560. 
HRMS (ESI, m/z) calcd for C14H10Cl3N2ONa [M+Na]+: 335.9720 and 337.9692, found: 335.9722 and 
337.9692. 
 
(R)-3,3,3-Trichloro-2-methyl-1-(pyridin-2-yl)propan-1-one (34b) 
 
Starting from 2-acyl pyridine 33b (27.0 mg, 0.20 mmol) according to the general procedure B to give 
34b as a colorless oil (33.6 mg, 0.134 mmol, yield: 67%). Enantiomeric excess established by HPLC 
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analysis using a Chiralpak OD-H column, ee = 95% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.8 min, tr (major) = 6.7 min). []D22 = 40.3 (c 0.4, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.65 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 8.05 (dt, J = 7.9, 1.0 Hz, 1H), 7.82 
(td, J = 7.7, 1.7 Hz, 1H), 7.46 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 5.60 (q, J = 6.9 Hz, 1H), 1.55 (d, J = 6.9 
Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 197.1, 152.3, 149.0, 137.3, 127.7, 122.7, 100.0, 55.5, 15.7. 
IR (film): ν (cm1) 3288, 3170, 3130, 3061, 2957, 2924, 1701, 1578, 1443, 1333, 1213, 968, 923, 810, 
768, 741, 665, 582, 408. 
HRMS (ESI, m/z) calcd for C9H8Cl3NONa [M+Na]+: 273.9564 and 275.9535, found: 273.9565 and 
275.9535. 
 
(R)-3,3,3-Trichloro-2-methyl-1-(4-methylpyridin-2-yl)propan-1-one (34c) 
 
Starting from 2-acyl pyridine 33c (29.8 mg, 0.20 mmol) according to the general procedure B to give 
34c as a colorless oil (34.2 mg, 0.129 mmol, yield: 65%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 93% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 11.1 min, tr (major) = 7.5 min). []D22 = 43.1 (c 0.4, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.58-8.32 (m, 1H), 7.98-7.68 (m, 1H), 7.26 (ddd, J = 4.9, 1.7, 0.7 Hz, 
1H), 5.59 (q, J = 6.9 Hz, 1H), 2.38 (s, 3H), 1.54 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 197.4, 152.2, 148.8, 128.6, 123.5, 100.0, 55.5, 21.1, 15.7. 
IR (film): ν (cm1) 3112, 3055, 2989, 2952, 2878, 1702, 1598, 1497, 1451, 1400, 1317, 1158, 1019, 
981, 934, 842, 817, 771, 727, 671, 584, 514, 427. 
HRMS (ESI, m/z) calcd for C10H10Cl3NONa [M+Na]+: 287.9720 and 289.9691, found: 287.9722 and 
289.9693. 
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(R)-3,3,3-Trichloro-2-methyl-1-(4-phenylpyridin-2-yl)propan-1-one (34d) 
 
Starting from 2-acyl pyridine 33d (42.2 mg, 0.20 mmol) according to the general procedure B to give 
34d as a white solid (46.5 mg, 0.142 mmol, yield: 71%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 94% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 14.4 min, tr (major) = 10.0 min). []D22 = 48.7 (c 0.4, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.68 (dd, J = 5.1, 0.6 Hz, 1H), 8.27 (dd, J = 1.8, 0.7 Hz, 1H), 7.66 (dd, 
J = 5.1, 1.9 Hz, 1H), 7.61 (dt, J = 8.5, 2.3 Hz, 2H), 7.53-7.31 (m, 3H), 1.58 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 197.2, 152.9, 149.9, 149.5, 137.2, 129.6, 129.3, 127.1, 125.4, 120.5, 
100.0, 55.6, 15.7. 
IR (film): ν (cm1) 3062, 3034, 2962, 2927, 1699, 1591, 1455, 1401, 1324, 1262, 1188, 1087, 1027, 
984, 930, 825, 768, 707, 667, 578, 507, 428. 
HRMS (ESI, m/z) calcd for C15H12Cl3NONa [M+Na]+: 349.9877 and 351.9849, found: 349.9879 and 
351.9849. 
 
(R)-3,3,3-Trichloro-1-(4-chloropyridin-2-yl)-2-methylpropan-1-one (34e) 
 
Starting from 2-acyl pyridine 33e (33.8 mg, 0.20 mmol) according to the general procedure B to give 
34e as a colorless oil (46.0 mg, 0.161 mmol, yield: 81%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 95% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 9.9 min, tr (major) = 6.7 min). []D22 = 44.4 (c 0.5, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.55 (d, J = 5.2 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.46 (dd, J = 5.2, 2.0 
Hz, 1H), 5.52 (q, J = 6.8 Hz, 1H), 1.54 (d, J = 6.9 Hz, 3H). 
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13C NMR (75 MHz, CDCl3) δ 196.0, 153.5, 149.9, 145.9, 127.8, 123.1, 99.6, 55.7, 15.6. 
IR (film): ν (cm1) 3083, 3057, 2992, 2952, 2879, 1709, 1562, 1454, 1395, 1322, 1214, 1094, 993, 930, 
829, 777, 700, 666, 583, 517, 425. 
HRMS (ESI, m/z) calcd for C9H8Cl4NO [M+H]+: 285.9355, 287.9325 and 289.9297, found: 285.9356, 
287.9327 and 289.9297. 
 
(R)-1-(4-Bromopyridin-2-yl)-3,3,3-trichloro-2-methylpropan-1-one (34f) 
 
Starting from 2-acyl pyridine 33f (42.6 mg, 0.20 mmol) according to the general procedure B to give 
34f as a colorless oil (44.8 mg, 0.136 mmol, yield: 68%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 92% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 10.5 min, tr (major) = 6.8 min). []D22 = 36.9 (c 0.3, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 8.25 (dd, J = 1.9, 0.4 Hz, 1H), 7.69 (dd, J = 
5.2, 1.9 Hz, 1H), 5.58 (q, J = 6.9 Hz, 1H), 1.61 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 195.9, 153.2, 149.7, 134.4, 130.8, 126.2, 99.6, 55.7, 15.6. 
IR (film): ν (cm1) 3091, 3055, 2991, 2961, 2879, 1707, 1555, 1453, 1386, 1326, 1205, 1086, 989, 931, 
829, 778, 674, 581, 509, 425. 
HRMS (ESI, m/z) calcd for C9H8BrCl3NO [M+H]+: 329.8849, 331.8825, 333.8798 and 335.8771, 
found: 329.8852, 331.8827, 333.8800 and 335.8773. 
 
(R)-1-(5-Bromopyridin-2-yl)-3,3,3-trichloro-2-methylpropan-1-one (34g) 
 
Starting from 2-acyl pyridine 33g (42.6 mg, 0.20 mmol) according to the general procedure B to give 
34g as a colorless oil (60.1 mg, 0.182 mmol, yield: 91%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 96% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
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99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 10.5 min, tr (major) = 8.5 min). []D22 = 24.8 (c 0.6, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.70 (dd, J = 1.9, 0.9 Hz, 1H), 8.04-7.91 (m, 2H), 5.49 (q, J = 6.8 Hz, 
1H), 1.54 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 196.3, 150.5, 150.2, 140.1, 126.1, 123.9, 99.7, 55.4, 15.6. 
IR (film): ν (cm1) 3053, 2983, 2942, 2879, 1703, 1560, 1453, 1370, 1329, 1208, 1086, 1006, 967, 826, 
777, 676, 625, 583. 
HRMS (ESI, m/z) calcd for C9H8BrCl3NO [M+H]+: 329.8849, 331.8825, 333.8798 and 335.8771, 
found: 329.8853, 331.8828, 333.8803 and 335.8774. 
 
(R)-3,3,3-Trichloro-2-methyl-1-(4-propylpyridin-2-yl)propan-1-one (34h) 
 
Starting from 2-acyl pyridine 33h (35.4 mg, 0.20 mmol) according to the general procedure B to give 
34h as a colorless oil (39.3 mg, 0.134 mmol, yield: 67%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 94% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.8 min, tr (major) = 6.0 min). []D22 = 44.3 (c 0.4, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.58 (d, J = 4.9 Hz, 1H), 7.93 (s, 1H), 7.33 (dd, J = 4.9, 1.6 Hz, 1H), 
5.66 (q, J = 6.9 Hz, 1H), 2.87-2.50 (m, 2H), 1.70 (dq, J = 14.8, 7.5 Hz, 2H), 1.61 (d, J = 6.9 Hz, 3H), 
0.96 (t, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 197.4, 153.2, 152.3, 148.8, 127.9, 122.8, 100.1, 55.6, 37.3, 23.3, 15.7, 
13.6. 
IR (film): ν (cm1) 2961, 2934, 2871, 1706, 1597, 1414, 1324, 1159, 1003, 934, 825, 779, 731, 669, 
580, 428. 
HRMS (ESI, m/z) calcd for C12H14Cl3NONa [M+Na]+: 316.0033, 318.0005 and 319.9977, found: 
316.0034, 318.0005 and 319.9977. 
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(R)-3,3,3-Trichloro-1-(isoquinolin-3-yl)-2-phenylpropan-1-one (34i) 
 
Starting from 2-acyl pyridine 33i (49.4 mg, 0.20 mmol) according to the general procedure B to give 
34i as a white solid (52.3 mg, 0.144 mmol, yield: 72%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 90% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
98:2, flow rate 1.0 mL/min, 25 C, tr (minor) = 11.1 min, tr (major) = 7.5 min). []D22 = 102.0 (c 0.4, 
CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 9.22 (s, 1H), 8.56 (s, 1H), 8.10-7.90 (m, 2H), 7.86-7.64 (m, 4H), 
7.47-7.25 (m, 3H), 7.01 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 194.5, 152.3, 146.8, 136.0, 132.6, 132.5, 131.7, 130.9, 130.5, 129.5, 
129.1, 128.7, 128.0, 122.3, 99.5, 66.5. 
IR (film): ν (cm1) 3058, 2947, 2855, 1963, 1694, 1490, 1444, 1384, 1309, 1245, 1161, 1124, 1060, 
939, 908, 864, 737, 697, 622, 562, 485. 
HRMS (ESI, m/z) calcd for C18H12Cl3NONa [M+Na]+: 385.9877, 387.9849 and 389.9823, found: 
385.9878, 387.9849 and 389.9820. 
5.5.3 Mechanistic Experiments 
1) Control Experiments for Table 9 
As shown in Scheme 11-12 and Figure 65-66, the experiment data of compound 32 and 36 are shown 
below. 
2-Bromo-2-phenyl-1-(1-phenyl-1H-imidazol-2-yl)ethanone (32) 
 
White solid. 
1H NMR (300 MHz, CD2Cl2) δ 7.55-7.45 (m, 2H), 7.44-7.34 (m, 3H), 7.31-7.13 (m, 7H), 6.90 (s, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 182.3, 141.1, 138.4, 136.3, 130.6, 130.0, 129.5, 129.4, 129.1, 129.0, 
126.2, 50.2. 
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IR (film): ν (cm1) 1686, 1591, 1492, 1446, 1394, 1304, 1148, 1064, 1028, 955, 914, 867, 741, 690, 
633, 547. 
HRMS (ESI, m/z) calcd for C17H14BrN2O [M+H]+: 341.0284 and 343.0265, found: 341.0297 and 
343.0277. 
 
3,3-Dichloro-2-phenyl-1-(1-phenyl-1H-imidazol-2-yl)prop-2-en-1-one (36) 
 
White solid. 
1H NMR (300 MHz, CD2Cl2) δ 7.47-7.36 (m, 5H), 7.34-7.24 (m, 4H), 7.24-7.15 (m, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 181.6, 142.1, 140.5, 138.2, 134.4, 131.6, 130.0, 129.6, 129.4, 129.3, 
129.2, 129.0, 128.4, 126.1, 122.7. 
IR (film): ν (cm1) 1669, 1597, 1494, 1446, 1389, 1301, 1252, 1203, 1150, 1073, 1029, 996, 937, 913, 
839, 802, 756, 692, 643, 576, 536. 
HRMS (ESI, m/z) calcd for C18H13Cl2N2O [M+H]+: 343.0399 and 345.0373, found: 343.0414 and 
345.0388. 
 
2) Synthesis of the Proposed Intermediate Complex I and II 
Intermediate I 
 
The racemic complex I was obtained by reacting substrate 30a (31.4 mg, 0.12 mmol) with racemic 
/-IrS (95.2 mg, 0.10 mmol) at room temperature overnight in CH2Cl2 (2.0 mL). Afterwards, the 
mixture was concentrated under vacuum. The residue black solid was washed by Et2O (4  1 mL), the 
yellow solid was obtained (110.0 mg, yield: 97%).  
1H NMR (300 MHz, CD2Cl2) δ 7.98 (dd, J = 8.6, 1.4 Hz, 2H), 7.83 (ddd, J = 11.8, 7.7, 1.0 Hz, 2H), 
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7.75 (tt, J = 7.5, 1.1 Hz, 1H), 7.70-7.58 (m, 4H), 7.54 (dd, J = 8.6, 1.8 Hz, 1H), 7.50 (d, J = 1.5 Hz, 
1H), 7.16 (d, J = 1.2 Hz, 1H), 7.08 (dddd, J = 9.3, 8.2, 4.7, 3.6 Hz, 4H), 6.94 (t, J = 7.4 Hz, 1H), 6.84 
(dtd, J = 8.8, 7.5, 1.4 Hz, 2H), 6.72-6.56 (m, 3H), 6.50 (d, J = 7.4 Hz, 1H), 6.41 (d, J = 7.3 Hz, 1H), 
5.92 (d, J = 7.5 Hz, 2H), 4.02 (d, J = 14.0 Hz, 1H), 3.76 (d, J = 14.0 Hz, 1H), 1.38 (s, 9H), 0.99 (s, 
9H). 
13C NMR (75 MHz, CD2Cl2) δ 196.4, 183.2, 179.9, 152.9, 152.6, 149.8, 149.1, 147.3, 146.8, 141.9, 
140.0, 137.4, 134.8, 134.1, 133.2, 132.7, 131.93, 131.88, 131.86, 129.9, 129.22, 129.18, 128.9, 128.5, 
128.4, 126.9, 126.6, 125.2, 124.8, 124.1, 123.8, 123.6, 123.5, 115.4, 114.9, 45.8, 35.5, 35.2, 31.8, 31.5. 
IR (film): ν (cm1) 3214, 3060, 2962, 2868, 1578, 1503, 1444, 1404, 1360, 1289, 1245, 1161, 1113, 
1025, 994, 838, 760, 731, 694, 554, 455. 
 
Intermediate II 
 
To a mixture of catalyst /-IrS (95.2 mg, 0.10 mmol) and NaHCO3 (16.8 mg, 0.20 mmol) in CH2Cl2 
(5 mL) was added substrate 30a (52.4 mg, 0.20 mmol). The reaction mixture was concentrated after 
around 12 hours. The residue was purified by flash chromatography on activated basic aluminum 
oxide (EtOAc / hexane= 1:10) to afford the enolate complex II as a red solid (89.8 mg, 0.091 mmol, 
yield: 91% ). 
1H NMR (300 MHz, CD2Cl2) δ 8.84 (d, J = 1.7 Hz, 1H), 7.86-7.68 (m, 4H), 7.59-7.38 (m, 6H), 7.29 (d, 
J = 7.3 Hz, 2H), 7.16 (d, J = 6.9 Hz, 2H), 7.05-6.88 (m, 4H), 6.86 (d, J = 1.4 Hz, 1H), 6.71 (td, J = 8.5, 
1.2 Hz, 3H), 6.64-6.53 (m, 2H), 6.45 (d, J = 7.5 Hz, 1H), 4.59 (s, 1H), 1.21 (s, 9H), 1.07 (s, 9H). 
13C NMR (75 MHz, CD2Cl2) δ 181.4, 179.8, 155.8, 154.6, 154.3, 152.4, 151.4, 151.3, 149.6, 142.4, 
142.1, 139.9, 138.3, 135.2, 134.5, 130.6, 130.4, 129.7, 129.1, 128.9, 127.5, 127.4, 127.3, 126.1, 126.0, 
125.3, 124.8, 123.7, 123.3, 123.1, 122.4, 121.7, 121.4, 120.9, 119.0, 117.1, 104.6, 35.3, 35.2, 31.8, 
31.4. 
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IR (film): ν (cm1) 3112, 3049, 2956, 2903, 2864, 1584, 1492, 1462, 1421, 1378, 1285, 1243, 1196, 
1156, 1096, 1018, 991, 926, 909, 868, 810, 781, 760, 733, 692, 666, 502, 466. 
 
3) Luminescence Quenching Experiments (Figure 68) 
Emission intensities were recorded on a Spectra Max M5 microplate reader in a 10.0 mm quartz 
cuvette. The methyl imidazole derivatives were used due to higher stability of the enolate complex. 
Catalyst /-IrS solutions were excited at max = 420 nm and the emission was measured at 550 nm 
(emission maximum). The enolate complex I (N = Me) solutions were excited at max = 420 nm and 
the emission measured at 550 nm (emission maximum). The enolate complex II (N = Me) solutions 
were excited at max = 440 nm and the emission measured at 550 nm (emission maximum). The 
concentration of iridium complex (IrS and intermediate complex I and II) was 0.2 mM in MeOH/THF 
(4:1). The concentration of the quencher (BrCCl3) stock solution was 200 mM in MeOH/THF (4:1). 
For each quenching experiment, 5 L of this stock solution were titrated to a solution (1 mL) of 
iridium complex in a screw-top 10.0 mm quartz cuvette. The addition of 5 L stock solution refers to 
an increase of the quencher concentration of 1 mM. After degassing with an argon stream for 5 
minutes, the emission intensity was collected. See Figure 65 for the obtained Stern-Volmer plots. 
 
4) Trapping Experiments 
As shown in Scheme 15-16, the experiment data of compound 40 and 41 are shown below. 
3,3-Dichloro-1-phenylprop-2-en-1-one (40) 
 
Colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.94-7.78 (m, 2H), 7.58-7.49 (m, 1H), 7.48-7.35 (m, 2H), 7.19 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ 186.6, 137.0, 135.4, 133.7, 128.8, 128.5, 124.1. 
IR (film): ν (cm1) 1668, 1595, 1563, 1447, 1318, 1293, 1265, 1216, 1181, 1011, 935, 843, 794, 769, 
690, 624, 491. 
HRMS (ESI, m/z) calcd for C9H6Cl2ONa [M+Na]+: 222.9688 and 224.9659, found: 222.9688 and 
224.9659. 
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1-(1-Phenyl-1H-imidazol-2-yl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-(m-tolyl)ethanone 
(41) 
 
1H NMR (300 MHz, CD2Cl2) δ 7.47-7.35 (m, 3H), 7.34-7.24 (m, 3H), 7.23-7.13 (m, 2H), 7.11-6.97 (m, 
3H), 6.58 (s, 1H), 2.32 (s, 3H), 1.45 (s, 6H), 1.17 (s, 3H), 1.05 (s, 6H), 0.78 (s, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 189.3, 142.9, 138.6, 138.37, 138.35, 130.2, 129.3, 129.0, 128.9, 128.7, 
128.4, 127.6, 125.9, 125.8, 90.0, 60.2, 60.0, 40.6, 34.1, 33.6, 21.6, 20.3, 17.6. 
IR (film): ν (cm1) 3139, 2969, 2926, 1688, 1496, 1493, 1448, 1398, 1303, 1252, 1140, 1062, 1012, 
959, 916, 862, 762, 693, 632, 546, 442. 
HRMS (APCI, m/z) calcd for C27H33N3O2Na [MNa]+: 454.2465, found:454.2468. 
 
5) Quantum Yield Measurement 
The quantum yield was measured by standard ferrioxalate actinometry. A 6 W blue LED lamp (420 nm) 
was used as the light source. The measured method was designed according to published procedures 
with slight modifications.26 
The solutions were prepared and stored in the dark:  
Potassium ferrioxalate solution (0.15 M): 736.9 mg of potassium ferrioxalate hydrate was dissolved 
in 10 mL of 0.05 M H2SO4. 
Buffered solution of phenanthroline: 50 mg of 1,10-phenanthroline and 11.25 g of sodium acetate 
were dissolved in 50 mL of 0.5 M H2SO4. 
 
a) Measurement of light intensity at 420 nm 
1 mL of the ferrioxalate solution was added to a quartz cuvette (l = 10 mm). The actinometry solution 
was irradiated with 6 W blue LED lamp (420 nm  10 nm) for 90.0 seconds. After irradiation, 175 L 
of the phenanthroline solution was added to the cuvette. The solution was kept in dark for 30 min to 
make sure the complete coordination. The absorbance of the actinometry solution was monitored at 
510 nm. The absorbance of a non-irradiated (in dark) sample was also measured at 510 nm.  
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The moles of Fe2 formed were determined using Beer’s Law: 
moles Fe2 = 
)510(10
)510(
2
3
31
nmlV
nmAVV


 
Where V1 (1 mL) is the irradiated volume, V2 (1 mL) is the aliquot of the irradiated solution taken for 
the determination of the ferrous ions. V3 (1.175 mL) is the final volume after complexation with 
phenanthroline (all in mL), l is the path length (1 cm), and A(510nm) is the optical difference in 
absorbance between the irradiated and non-irradiated solutions, (510 nm) is the molar absorptivity of 
Fe(phen)32 (11100 L mol-1 cm-1). 
The photon flux can be calculated as:  
photon flux (einstein s-1) = 
ft
Femoles

2
 
Where Φ is the quantum yield for the ferrioxalate actinometer (1.05 for a 0.15 solution at 412 nm; 1.04 
for a 0.15 solution at 422 nm; 1.03 for a 0.15 solution at 433 nm),27 t is the irradiated time (90.0 s), 
and f is the fraction of light absorbed at  = 420 nm (f = 110-A, A is the absorbance of above 
ferrioxalate solution at 420 nm is > 3, indicating f is > 0.999). 
The calculations were done as follows: 
A(510nm) was calculated (average of three cycles) to be 0.860. 
moles Fe2 = 
113 111001110
860.0175.11
 

cmmolLcmmL
mLmL
= 9.10310-8 mol 
photon flux =
0.19004.1
10103.9 8

 
s
mol
= 9.72 10-10 einstein/s 
b) Measurement of quantum yield: 
Model reaction: 
 
A screw-top cuvette (10.0 mm) was charged with the catalyst rac-IrS (2 mol%), 2-acyl imidazole 30a 
(0.2 mmol, 1.0 eq), NaHCO3 (0.22 mmol, 1.1 eq), 0.5 mL MeOH/THF (4:1, 0.4 M), 
bromotrichloromethane (1.2 mmol, 6.0 eq) and a small magnetic stir bar. The cuvette was degassed 
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with an argon stream for 10 min. After the mixture was thoroughly degassed, the vial was sealed and 
positioned approximately 8 cm from a 6 W blue lamp. The reaction mixture was stirred and irradiated 
for 10800 s (3 h). After irradiation, the reaction mixture was passed through a short silica gel column. 
The yield of product formed was measured by 1H-NMR with trimethyl(phenyl)silane as internal 
standard. 
Experiment 1: Rac-IrS (3.8 mg, 0.004 mmol), 2-acyl imidazole 30a (52.4 mg, 0.2 mmol), NaHCO3 
(18.5 mg, 0.22 mmol), MeOH/THF (4:1, 0.4 M, 0.5 mL), bromotrichloromethane (118.0 L, 1.2 
mmol). After irradiation for 10800 s, the product 31a was formed in 26.8% yield. The quantum yield 
calculation as following: 
Φ = 
absorbedlightofeinsteins
formedproductofmoles
= 
sseinstein
mol
108001072.9
268.0102.0
110
3




 = 5.1 
Experiment 2: Rac-IrS (3.8 mg, 0.004 mmol), 2-acyl imidazole 30a (52.5 mg, 0.2 mmol), NaHCO3 
(18.4 mg, 0.22 mmol), MeOH/THF (4:1, 0.4 M, 0.5 mL), bromotrichloromethane (118.0 L, 1.2 
mmol). After irradiation for 10800 s, the product 31a was formed in 28.5% yield. The quantum yield 
calculation as following: 
Φ = 
absorbedlightofeinsteins
formedproductofmoles
= 
sseinstein
mol
108001072.9
285.0102.0
110
3




 = 5.4 
 
Figure 119 The output wavelength of the used 6 w blue LED (420 nm  10 nm). 
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5.5.4 Efforts towards Removal of Imidazole Moieties 
 
To a solution of rac-2a (151.2 mg, 0.4 mmol) in CH3CN (2.0 mL) was added 4 Å MS (200 mg, 50 
mg/0.1 mmol of 2a) under nitrogen atmosphere. The suspension was stirred vigorously under a 
positive pressure of nitrogen for 2 h at room temperature, and then methyl trifluoromethansulfonate 
(88 L, 0.8 mmol) was added at room temperature. After being stirred at room temperature for 6 h, 
MeOH (0.32 mL, 8.0 mmol) and DBU (90 L, 0.6 mmol) were added to the reaction mixture at 0 C. 
After being stirred at 0 C for 60 min, the solvent was evaporated and the residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:50) to give S5 (50.2 mg, 0.15 mmol, yield: 37%) as 
a white solid and S8 (40.0 mg, 0.17 mmol, yield: 43%) as a colorless oil. 
Methyl 3,3-dichloro-2-phenylacrylate (37) 
 
1H NMR (300 MHz, CD2Cl2) δ 7.57-7.23 (m, 5H), 3.79 (s, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 165.8, 134.5, 134.3, 129.4, 129.0, 129.0, 127.5, 53.2. 
IR (film): ν (cm1) 3059, 3027, 2952, 2844, 1729, 1599, 1490, 1435, 1272, 1211, 1073, 1034, 954, 881, 
839, 706, 589. 
HRMS (ESI, m/z) calcd for C10H8Cl2O2Na [M+Na]+: 252.9794 and 254.9765, found: 252.9799 and 
254.9766. 
 
 
To a solution of rac-31l (107.0 mg, 0.3 mmol) in CH3CN (1.5 mL) was added 4 Å MS (150 mg, 50 
mg/0.1 mmol of 31l) under nitrogen atmosphere. The suspension was stirred vigorously under a 
positive pressure of nitrogen for 2 h at room temperature, and then methyl trifluoromethanesulfonate 
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(98 L, 0.9 mmol) was added at room temperature. After being stirred at room temperature for 16 h, 
BnOH (0.31 mL, 3.0 mmol) and DBU (90 L, 0.6 mmol) were added to the reaction mixture at 0 C. 
After being stirred at 0 C for 60 min, the solvent was evaporated and the residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:50) to give 38 (62.1 mg, 0.22 mmol, yield: 72%) as a 
colorless oil. 
Benzyl 2-(dichloromethylene)hexanoate (38) 
 
1H NMR (300 MHz, CD2Cl2) δ 7.52-7.20 (m, 5H), 5.24 (s, 2H), 2.66-2.35 (m, 2H), 1.51-1.20 (m, 4H), 
0.89 (t, J = 7.2 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 165.9, 135.9, 134.3, 129.0, 128.9, 128.8, 128.6, 67.8, 32.8, 29.8, 22.6, 
13.9. 
IR (film): ν (cm1) 3066, 3033, 2958, 2929, 2866, 1725, 1588, 1496, 1455, 1374, 1267, 1203, 1135, 
946, 907, 741, 695. 
HRMS (ESI, m/z) calcd for C14H16Cl2O2Na [M+Na]+: 309.0420 and 311.0391, found: 309.0422 and 
311.0395. 
5.5.5 Single-Crystal X-Ray Diffraction Studies 
Single crystals of (R)-31a (3hnb) suitable for X-ray diffraction were obtained by slow diffusion from a 
solution of (R)-31a (30 mg) in CH2Cl2 (0.5 mL) layered with n-hexane (2.5 mL) at room temperature 
for several days in a glass tube. The absolute configurations of compound (R)-31a (3hnb) has been 
determined. Crystal data and details of the structure determination are presented in the Appendices 
(Chapter 6.7). 
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5.6 Visible-Light-Activated Enantioselective Perfluoroalkylation 
5.6.1 Synthesis of Catalysts 
The Catalysts -IrS(tBu) and -IrS(tBu) were synthesized according to the following route. 
1) Synthesis of Ligand 
4-(tert-Butyl)-N-(3-(tert-butyl)phenyl)benzothioamide (50)  
Compound 50 was synthesized following a published procedure with slight modifications. 28 
Na2S·9H2O (1.5 g, 6.25 mmol) was added to a mixture of sulfur (1.0 g, 31.2 mmol) and 
3-(tert-butyl)aniline (5.6 g, 37.5 mmol) in DMF (25 mL). The suspension was stirred at 115 °C for 0.5 
h under nitrogen. Afterwards, the mixture was cooled to room temperature, 4-(tert-butyl)benzaldehyde 
(4.1 g, 25 mmol) was added and the mixture was stirred at 115 °C for 24 h under nitrogen. After 
cooling to room temperature, the resulting solution was quenched with saturated NH4Cl aqueous 
solution and extracted with ethyl acetate. The organic fraction was thoroughly washed with water and 
dried with Na2SO4. After concentration, the residue was purified by silica gel column 
(n-hexane/EtOAc = 40:1) to yield thioamide 50 as a yellow solid (4.72 g, 58%). 
1H NMR (300 MHz, CDCl3) δ 9.06 (brs, 1H), 7.83-7.76 (m, 3H), 7.72-7.62 (m, 1H), 7.51-7.27 (m, 
4H), 1.35 (s, 18H). 
13C NMR (75 MHz, CDCl3) δ 197.8, 154.7, 152.3, 140.6, 138.9, 128.5, 126.5, 125.5, 123.7, 120.6, 
120.5, 34.83, 34.78, 31.2, 31.1. 
IR (film): ν (cm1) 3173, 2957, 2867, 1595, 1512, 1472, 1419, 1336, 1274, 1240, 1199, 1112, 999, 907, 
843, 747, 701. 
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5-(tert-Butyl)-2-(4-(tert-butyl)phenyl)benzo[d]thiazole (51)  
Compound 51 was synthesized following a published procedure with slight modifications.29 A 
mixture of 50 (2.1 g, 6.46 mmol), PdCl2 (115 mg, 0.65 mmol), CsF (491 mg, 3.2 mmol), DMSO (13 
mL) was stirred under O2 atmosphere at 120 C for 4 hours. Then the reaction was heated to 140 C 
for 15 h. Afterwards, the mixture was cooled to room temperature, the resulting solution was quenched 
with saturated NH4Cl aqueous solution and extracted with ethyl acetate. The organic fraction was 
thoroughly washed with water and dried with Na2SO4. After concentration, the residue was purified by 
silica gel column (n-hexane/EtOAc = 50:1) to yield ligand 51 as a white solid (1.065 g, 51%).  
1H NMR (300 MHz, CDCl3) δ 8.11 (d, J = 1.5 Hz, 1H), 8.03 (dt, J1 = 8.4 Hz, J2 = 2.1 Hz, 2H), 7.81 (d, 
J = 8.4 Hz, 1H), 7.51 (dt, J1 = 8.7 Hz, J2 = 2.1 Hz, 2H), 7.46 (dd, J1 = 8.7 Hz, J2 = 2.1 Hz, 1H), 1.42 (s, 
9H), 1.38 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 168.2, 154.6, 154.4, 150.0, 131.9, 131.1, 127.3, 125.9, 123.2, 120.9, 
119.6, 35.0, 34.9, 31.5, 31.2. 
IR (film): ν (cm1) 3069, 2958, 2865, 1598, 1541, 1473, 1402, 1361, 1310, 1258, 1204, 1107, 1020, 
966, 925, 877, 832, 812, 734, 702, 659, 609, 541, 459, 409. 
 
2) Synthesis of racemic catalyst 
Iridium Dimer Complex (52) 
Benzothiazole ligand (51) (790 mg, 2.44 mmol) was added to iridium chloride hydrate (420 mg, 1.19 
mmol) in a mixture of 2-ethoxyethanol/water (3:1, 52.9 mL). The reaction mixture was heated at 
130 °C for 24 h under nitrogen atmosphere. The resulting precipitate was collected by centrifugation 
and dried to yield the iridium dimer (52) as a red solid (624 mg, 60% yield).  
1H NMR (300 MHz, CD2Cl2) δ 9.15 (d, J = 1.8 Hz, 4H), 7.48 (d, J = 8.4 Hz, 4H), 7.42 (d, J = 8.1 Hz, 
4H), 7.27 (dd, J1 = 8.7 Hz, J2 = 1.8 Hz, 4H), 6.82 (dd, J1 = 8.1 Hz, J2 = 2.1 Hz, 4H), 5.79 (d, J = 1.5 
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Hz, 4H), 1.19 (s, 36H), 0.71 (s, 36H). 
13C NMR (75 MHz, CD2Cl2) δ 179.6, 152.9, 152.6, 150.4, 144.9, 139.3, 129.3, 128.0, 125.1, 123.3, 
121.3, 120.1, 119.4, 35.5, 34.5, 32.0, 30.9. 
IR (film): ν (cm1) 3108, 3054, 2958, 2904, 2867, 1582, 1551, 1437, 1366, 1289, 1260, 1199, 1147, 
1109, 991, 928, 884, 804, 731, 670, 594, 459. 
 
Rac-IrS(tBu) complex  
A mixture of iridium dimer (52) (583 mg, 0.335 mmol) and AgPF6 (253 mg, 1.0 mmol) in CH3CN 
(22.4 mL) was purged with nitrogen for 5 min and then heated at 60 C overnight. The reaction 
mixture was cooled to room temperature and concentrated to dryness. The residue was subjected to a 
flash silica gel chromatography (DCM/MeCN = 500:1 to 50:1) to obtain the racemic catalyst 
rac-IrS(tBu) as a yellow solid (711 mg, 100% yield). 
1H NMR (300 MHz, CD2Cl2) δ 8.40 (d, J = 1.5 Hz, 2H), 8.00 (d, J = 9.0 Hz, 2H), 7.71 (dd, J1 = 8.7 Hz, 
J2 = 1.8 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 7.01 (dd, J1 = 8.1 Hz, J2 = 1.8 Hz, 2H), 6.14 (d, J = 1.5 Hz, 
2H), 2.39 (s, 6H), 1.45 (s, 18H), 0.88 (s, 18H). 
13C NMR (75 MHz, CD2Cl2) δ 181.3, 155.3, 152.9, 150.5, 142.4, 138.6, 129.8, 128.7, 125.8, 125.1, 
123.1, 121.5, 121.0, 116.9, 35.6, 34.9, 31.7, 31.0, 4.1. 
IR (film): ν (cm1) 2957, 2869, 1584, 1463, 1435, 1366, 1295, 1267, 1203, 1151, 1111, 995, 935, 839, 
730, 673, 641, 598, 556, 458. 
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3) Synthesis of chiral catalyst 
 
Auxiliary complexes -(S)-IrS(tBu) and -(S)-IrS(tBu) 
A mixture of rac-IrS(tBu) (400.0 mg, 0.376 mmol), the chiral auxiliary (S)-6 (166.4 mg, 0.752 mmol) 
and triethylamine (95.1 mg, 0.940 mmol) in DCM (37.6 mL) was purged with argon for 5 min and 
then stirred for 4 hours. The reaction mixture was concentrated to dryness. The residue was subjected 
to a flash silica gel chromatography (EtOAc/n-hexane = 1:10) to separate the two diastereomers. The 
first eluting diastereomer was assigned as -(S)-IrS(tBu) (an orange solid, 161 mg, 41%) and the 
second eluting diastereomer as -(S)-IrS(tBu) (an orange solid, 173 mg, 44%). The absolute 
configurations of -(S)-IrS(tBu) and -(S)-IrS(tBu) were assigned by comparison with CD spectra of 
the published analogous complexes 30  and further confirmed by an X-ray crystal structure of 
-IrS(tBu) which was obtained by the follow-up transformation. 
 
-(S)-IrS(tBu): 
1H NMR (300 MHz, CD2Cl2) δ 9.01 (d, J = 1.5 Hz, 1H), 7.88-7.82 (m, 2H), 7.74 (d, J = 8.4 Hz， 1H), 
7.66 (d, J = 8.1 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.51 (d, J = 2.1 Hz, 1H), 7.49 (d, J = 2.1 Hz, 1H), 
7.22 (dd, J1 = 7.8 Hz, J2 = 1.8 Hz, 1H), 7.00-6.90 (m, 4H), 6.59 (dd, J1 = 8.4 Hz, J2 = 1.2 Hz, 1H), 
6.15-6.07 (m, 1H), 6.06 (d, J = 1.8 Hz, 1H), 4.44 (dt, J1 = 10.2 Hz, J2 = 2.4 Hz, 1H), 3.37 (dd, J1 = 
11.4 Hz, J2 = 9.9 Hz, 1H), 3.00 (dt, J1 = 11.7 Hz, J2 = 2.1 Hz, 1H), 1.50 (s, 9H), 1.20 (s, 9H), 1.01 (s, 
9H), 0.97 (s, 9H), 0.90-0.80 (m, 1H), 0.34 (d, J = 6.9 Hz, 3H), 0.15 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 181.0, 180.1, 169.8, 169.4, 154.0, 152.8, 152.3, 151.9, 151.5, 151.0, 
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150.1, 140.4, 140.1, 133.2, 133.1, 132.6, 129.0, 128.4, 128.3, 126.0, 125.7, 124.3, 123.7, 123.3, 122.3, 
121.5, 120.0, 119.8, 119.5, 118.6, 116.1, 113.2, 83.8, 35.4, 35.3, 34.8, 34.7, 32.1, 31.5, 31.3, 31.1, 30.1, 
28.3, 19.8, 14.9. 
IR (film): ν (cm1) 3059, 2955, 2965, 1729, 1583, 1555, 1523, 1435, 1356, 1288, 1259, 1195, 1145, 
1110, 997, 931, 878, 846, 806, 746, 672, 639, 598, 567, 462. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 461 (–19), 343 (+66), 319 (–22), 268 (+10), 253 (–4), 242 (+13), 
229 (–45), 216 (+131). 
 
-(S)-IrS(tBu): 
1H NMR (300 MHz, CD2Cl2) δ 8.86 (d, J = 1.5 Hz, 1H), 7.92 (d, J = 1.5 Hz, 1H), 7.86 (d, J = 8.4 Hz, 
1H), 7.79 (d, J = 8.4 Hz, 1H), 7.62-7.48 (m, 3H), 7.47 (dd, J1 = 8.4 Hz, J2 = 1.8 Hz 1H), 7.04-6.90 (m, 
3H), 6.60-6.53 (m, 2H), 6.31-6.22 (m, 2H), 3.67-3.59 (m, 1H), 2.93 (dd, J1 = 11.4 Hz, J2 = 4.8 Hz, 1H), 
2.59 (dd, J1 = 11.4 Hz, J2 = 9.6 Hz, 1H), 1.95-1.83 (m, 1H), 1.28 (s, 9H), 1.17 (s, 9H), 1.05 (s, 9H), 
1.01 (s, 9H), 0.94-0.88(m, 1H), 0.86 (d, J = 6.9 Hz, 3H), 0.12 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 181.3, 180.5, 169.3, 168.2, 153.59, 153.55, 152.7, 152.4, 151.9, 151.7, 
151.0, 150.3, 140.3, 139.6, 133.3, 132.4, 132.2, 129.3, 128.4, 128.3, 126.1, 125.5, 124.2, 123.9, 123.7, 
122.1, 121.7, 121.2, 119.3, 118.9, 118.4, 117.6, 112.9, 83.3, 35.5, 35.3, 34.7, 34.6, 31.8, 31.4, 31.2, 
31.1, 30.1, 21.0, 17.8. 
IR (film): ν (cm1) 3058, 2955, 2966, 1582, 1556, 1523, 1436, 1356, 1288, 1258, 1196, 1147, 1108, 
994, 934, 882, 845, 806, 746, 671, 637, 596, 555, 463. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 488 (+12), 348 (–48), 325 (+38), 271(–4), 256 (+7), 245 (+2), 228 
(+66), 216 (–96). 
 
Chiral catalysts -IrS(tBu) and -IrS(tBu) 
A suspension of the auxiliary complex -(S)-IrS(tBu) (150 mg, 0.142 mmol) or -(S)-IrS(tBu) (150 
mg, 0.142 mmol) in MeCN (5.7 ml, 25 mM) was added trifluoroacetic acid (97.2 mg, 0.852 mmol) 
under argon in the dark. The reaction mixture was concentrated to dryness and dissolved in MeCN. 
NH4PF6 (462.9 mg, 2.84 mmol) was added to the solution. After stirring for 15 min, the reaction 
mixture was concentrated to dryness and subjected to a flash silica gel chromatography 
(CH2Cl2/CH3CN = 100:1 to 30:1) to give the enantiopure catalyst -IrS(tBu) (143.7 mg, 95%) or 
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-IrS(tBu) (146.3 mg, 97%) as a yellow solid. The absolute configurations were verified by CD 
spectroscopy and confirmed by a crystal structure of -IrS(tBu). 
CD (MeOH) for -IrS(tBu): λ, nm (Δε, M-1cm-1) 465 (–12), 363 (+56), 347 (+39), 338 (+47), 293 
(–53), 259 (+6), 242 (–35), 236 (–25), 229 (–45), 216 (+216). 
CD (MeOH) for -IrS(tBu): λ, nm (Δε, M-1cm-1) 465 (+10), 363 (–44), 348 (–31), 339 (–34), 294 
(+44), 259 (–4), 242 (+29), 237 (+20), 229 (+36), 215 (–171). 
 
5.6.2 Synthesis of Substrates 
The2-Acyl imidazoles 30a, 46a-g and the corresponding Weinreb amides were synthesized according 
to our recently published procedures (method A).31 2-Acyl imidazole 46h was synthesized according 
to a reported procedure with some modifications (method B).32 
Method A: 
 
General procedure for method A. To a solution of N-phenylimidazole (1.1 eq.) in THF at 78 C 
was added n-BuLi (1.1 eq.) dropwise. The reaction was stirred at 78 C for 30 min, then stirred at 
room temperature for 30 min. The corresponding Weinreb amide (1.0 eq. in THF) was added dropwise 
to the flask after the reaction was cooled back down to 78 C. The overall concentration of Weinreib 
amide was 0.4 M. The reaction was allowed to warm to room temperature slowly (over a period of 3-4 
h) and stirred overnight. The reaction was quenched with AcOH (6.0 eq.) at room temperature and 
extracted with EtOAc. The organic layer was washed with aqueous saturated NaHCO3 and brine. The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:3) to 
produce 46a-g. 
The experimental data of 46a-d, 46e-g are shown below. The other 2-acyl imidazoles (30a32, 46e33) 
have been reported previously. 
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2-Phenyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (46a)  
 
75% yield. A white solid. 
1H NMR (300 MHz, CDCl3) δ 7.30-7.09 (m, 9H), 7.03-6.96 (m, 2H), 6.89-6.80 (m, 2H), 4.41 (q, J = 
15.0 Hz, 1H), 4.31 (q, J = 15.0 Hz, 1H), 1.81 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 188.3, 143.2, 137.7, 134.4, 134.3, 130.6, 129.9, 129.8, 128.9, 128.3, 
126.71, 126.67, 126.5, 126.2, 45.3, 16.9. 
IR (film): ν (cm1) 3105, 3030, 2914, 1685, 1592, 1494, 1452, 1390, 1340, 1307, 1208, 1147, 1079, 
1023, 991, 958, 912, 887, 840, 789, 761, 721, 696, 590, 542, 512, 480, 454. 
 
2-(4-Methoxyphenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (46b) 
 
72% yield. A white solid.  
1H NMR (300 MHz, CDCl3) δ 7.40-7.21 (m, 6H), 7.14-7.07 (m, 2H), 6.89-6.80 (m, 2H), 4.45 (d, J = 
15.0 Hz, 1H), 4.35 (d, J = 15.6 Hz, 1H), 3.79 (s, 3H), 1.92 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 188.7, 158.6, 143.3, 137.9, 134.5, 130.9, 130.7, 129.8, 129.0, 126.7, 
126.5, 126.4, 126.3, 113.9, 55.2, 44.5, 17.0. 
IR (film): ν (cm1) 3158, 2916, 1668, 1607, 1583, 1509, 1488, 1460, 1447, 1421, 1394, 1302, 1261, 
1239, 1179, 1146, 1114, 1087, 1057, 1037, 975, 941, 916, 830, 818, 787, 768, 714, 671, 615, 567, 549, 
530, 518, 458, 445, 419. 
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2-(4-Chlorophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (46c) 
 
72% yield. A white solid. 
1H NMR (300 MHz, CDCl3) δ 7.37 (d, J = 1.0 Hz, 1H), 7.35-7.31 (m, 1H), 7.30-7.20 (m, 6H), 7.11 (d, 
J = 1.0 Hz, 1H), 7.08 (dd, J1 = 7.7 Hz, J2 = 1.4 Hz, 1H), 4.45 (d, J = 15.3 Hz, 1H), 4.36 (d, J = 15.4 Hz, 
1H), 1.90 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 187.8, 143.0, 137.7, 134.4, 132.79, 132.75, 131.2, 130.7, 130.0, 129.1, 
128.5, 126.9, 126.6, 126.2, 44.7, 17.0. 
IR (film): ν (cm1) 3111, 3029, 2913, 1684, 1591, 1494, 1451, 1392, 1306, 1207, 1145, 1079, 1023, 
958, 912, 841, 788, 764, 718, 591, 543, 454. 
 
2-(2-Chlorophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (46d) 
 
62% yield. A white solid. 
1H NMR (300 MHz, CDCl3) δ 7.39 (d, J = 1.0 Hz, 1H), 7.37-7.20 (m, 5H), 7.20-7.14 (m, 3H), 7.13 (d, 
J = 1.0 Hz, 1H), 4.77 (d, J = 17.6 Hz, 1H), 4.57 (d, J = 17.7 Hz, 1H), 1.99 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 187.0, 143.0, 137.7, 134.7, 134.5, 132.9, 132.1, 130.7, 129.9, 129.3, 
129.0, 128.4, 126.6, 126.5, 126.2, 43.6, 17.1. 
IR (film): ν (cm1) 3089, 1683, 1501, 1488, 1472, 1460, 1444, 1400, 1344, 1309, 1150, 1094, 1050, 
1032, 963, 948, 915, 811, 802, 787, 766, 751, 717, 692, 678, 598, 573, 554, 535, 504, 459, 448, 436. 
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1-(1-(o-Tolyl)-1H-imidazol-2-yl)butan-1-one (46f) 
 
93% yield. A white solid. 
1H NMR (300 MHz, CDCl3) δ 7.34-7.15 (m, 4H), 7.07-6.96 (m, 2H), 3.12-2.94 (m, 2H), 1.90 (s, 3H), 
1.68-1.52 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 191.4, 143.5, 138.0, 134.4, 130.7, 129.6, 129.0, 126.5, 126.24, 126.17, 
40.9, 17.4, 17.1, 13.7. 
IR (film): ν (cm1) 3102, 2961, 2877, 1685, 1496, 1457, 1407, 1400, 1301, 1211, 1149, 1025, 967, 886, 
766, 699. 
 
1-(1-(o-Tolyl)-1H-imidazol-2-yl)hexan-1-one (46g) 
 
91% yield. A colorless liquid. 
1H NMR (300 MHz, CDCl3) δ 7.43-7.24 (m, 4H), 7.16-7.05 (m, 2H), 3.22-3.04 (m, 2H), 1.99 (s, 3H), 
1.70-1.61 (m, 2H), 1.38-1.28 (m, 4H), 0.92-0.84 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ 191.6, 143.5, 138.1, 134.5, 130.7, 129.6, 129.0, 126.5, 126.3, 126.2, 
38.9, 31.4, 23.6, 22.4, 17.1, 13.8. 
IR (film): ν (cm1) 3108, 2927, 2862, 1681, 1496, 1452, 1404, 1303, 1141, 1037, 956, 910, 762, 714. 
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Method B: 
 
Procedure for the preparation of 46h. To a solution of 1-(o-tolyl)-1H-imidazole (948 mg, 6.0 mmol) 
in THF (15 mL) at 78 C was added n-BuLi (2.4 mL, 2.5 M in hexane, 6.0 mmol) dropwise. The 
reaction was stirred at 78 C for 1 h, then stirred at room temperature for 30 min. The tert-butyl 
chloroacetate (1.3 mL, 7.5 mmol) was added at one portion to the flask after the reaction was cooled 
back down to 78 C. The reaction was allowed to warm to room temperature slowly (over a period of 
3-4 h) and stirred overnight. The reaction was quenched with water at room temperature and extracted 
with EtOAc. The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:3) to produce 46’h (1.0 g, yield: 72%) as a white solid. 
To a mixture of 46’h (936 mg, 4.0 mmol) and K2CO3 (552 mg, 4.0 mmol) in DMF (8.0 mL) at 0 C 
were added p-cresol (648 mg, 6.0 mmol). The reaction mixture was stirred at room temperature for 
overnight. The reaction was quenched with water (8 mL) at room temperature and extracted with 
DCM (4  10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:3) to afford 46h (713 mg, yield: 58%) as a white solid. 
1-(1-(o-Tolyl)-1H-imidazol-2-yl)-2-(p-tolyloxy)ethanone (46h) 
 
1H NMR (300 MHz, CDCl3) δ 7.28-7.10 (m, 4H), 7.06-6.98 (m, 2H), 6.94 (d, J = 8.4 Hz, 2H), 6.72 (d, 
J = 8.7 Hz, 2H), 5.42 (d, J = 17.7 Hz, 1H), 5.31 (d, J s= 17.7 Hz, 1H), 2.15 (s, 3H), 1.88 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 184.5, 155.9, 141.2, 137.1, 134.4, 130.7, 130.4, 130.1, 129.8, 129.2, 
126.7, 126.5, 126.3, 114.4, 69.8, 20.3, 17.0. 
IR (film): ν (cm1) 3134, 2922, 1697, 1506, 1459, 1424, 1404, 1337, 1295, 1262, 1214, 1178, 1144, 
1081, 1013, 946, 911, 822, 803, 787, 771, 720, 704, 678, 561, 536, 508, 459, 448. 
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5.6.3 Iridium-Catalyzed Photoredox Reactions 
 
General procedure: A dried 10 mL Schlenk tube was charged with the catalyst Λ-IrS(tBu) or 
Δ-IrS(tBu) (2 or 4 mol%), NaHCO3 (25.2 mg, 0.3 mmol, 1.5 equiv) and the corresponding 2-acyl 
imidazole 46 (0.2 mmol, 1.0 equiv). The tube was purged with nitrogen and MeOH/THF (4:1, 0.5 mL) 
was added via syringe, followed by CnFmI. The reaction mixture was degassed via freeze-pump-thaw 
for three cycles. After the mixture was thoroughly degassed, the vial was sealed and positioned 
approximately 5 cm from a 21 W white light energy saving lamp. The reaction was stirred at room 
temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the 
mixture was diluted with CH2Cl2 (8 mL). The combined organic layers were concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (hexane/EtOAc = 
30:1 to 10:1) to afford the products 49a-h and 47a-f. Racemic samples were obtained by carrying out 
the reactions with rac-IrS(tBu). The enantiomeric excess was determined by chiral HPLC analysis. 
 
(S)-3,3,4,4,5,5,6,6,6-Nonafluoro-2-phenyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)hexan-1-one (48a) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46a (55.3 mg, 0.20 mmol) and 
C4F9I (415.1 mg, 1.20 mmol) catalyzed by Δ-Ir(tBu) (4.3 mg, 0.004 mol) gave 48a as a yellow liquid 
(78.3 mg, yield: 79%) after 46 hours. Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1 
mL/min, 25 C, tr (major) = 5.7 min, tr (minor) = 5.0 min). []D22 = –134.6 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.59-7.54 (m, 2H), 7.46-6.94 (m, 9H), 6.44-6.27 (m, 1H), 2.00 (s, 3H), 
1.62 (s, 3H, other rotamer). 
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13C NMR (75 MHz, CD2Cl2) δ 181.6, 142.3, 137.9 (d, J = 3.3 Hz), 135.1 (d, J = 27.5 Hz), 131.2 (d, J 
= 5.9 Hz), 131.1, 131.0 (d, J = 3.5 Hz), 129.7 (d, J = 3.9 Hz), 129.3 (d, J = 12.5 Hz), 129.2, 128.7 (d, J 
= 9.6 Hz), 127.1 (d, J = 9.7 Hz), 126.6 (d, J = 21.6 Hz), 52.4-51.6 (m), 16.9 (d, J = 15.4 Hz). 
19F NMR (282 MHz, CD2Cl2) δ –81.92 - –82.44 (m, 3F), –110.84 - –115.21 (m, 2F), –121.21- –122.07 
(m, 2F), –125.66 - –128.36 (m, 2F). 
IR (film): ν (cm1) 3115, 3067, 3036, 2978, 1694, 1497, 1456, 1401, 1350, 1214, 1129, 1026, 971, 866, 
813, 763, 739, 707, 645, 578, 550, 525, 455. 
HRMS (FD, m/z) calcd for C22H15F9N2O [M]+: 494.1041, found: 494.1028. 
 
(S)-3,3,4,4,5,5,6,6,7,7,8,8,8-Tridecafluoro-2-phenyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)octan-1-one 
(49a) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46a (55.3 mg, 0.20 mmol) and 
C6F13I (535.2 mg, 1.20 mmol) catalyzed by Δ-Ir(tBu)  (4.3 mg, 0.004 mol) gave 49a as a yellow 
liquid (103.5 mg, yield: 87%) after 46 hours. Enantiomeric excess established by HPLC analysis using 
a Chiralpak AD-H column, ee = 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1 
mL/min, 25 C, tr (major) = 4.2 min, tr (minor) = 4.8 min). []D22 = –100.9 (c 0.3, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.59-7.51 (m, 2H), 7.46-6.93 (m, 9H), 6.42-6.24 (m, 1H), 1.99 (s, 3H), 
1.67 (s, 3H, other rotamer). 
13C NMR (75 MHz, CD2Cl2) δ 181.6, 142.9 (d, J = 3.6 Hz), 137.9 (d, J = 2.6 Hz), 135.1 (d, J = 27.0 
Hz), 131.2 (d, J = 7.6 Hz), 131.1, 131.0 (d, J = 4.3 Hz), 129.7 (d, J = 3.5 Hz), 129.3 (d, J = 11.7 Hz), 
129.2, 128.7 (d, J = 9.2 Hz), 127.1 (d, J = 9.5 Hz), 126.7 (d, J = 21.8 Hz), 52.6-51.8 (m), 16.9 (d, J = 
9.1 Hz). 
19F NMR (282 MHz, CD2Cl2) δ –81.97 - –82.11 (m, 3F), –110.62 - –114.90 (m, 2F), –120.62 - 
–120.94 (m, 2F), –122.43 - –123.11 (m, 2F), –123.57 - –124.12 (m, 2F), –126.98 - –127.43 (m, 2F). 
IR (film): ν (cm1) 3068, 3037, 2973, 1695, 1497, 1457, 1401, 1234, 1196, 1142, 1027, 975, 910, 862, 
810, 766, 736, 703, 633, 527, 454. 
HRMS (FD, m/z) calcd for C24H15F13N2O [M]+: 594.0977, found: 594.0992. 
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(R)-3,3,4,4,5,5,6,6,7,7,8,8,8-Tridecafluoro-2-(4-methoxyphenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)oc
tan-1-one (49b) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46b (61.3 mg, 0.20 mmol) and 
C6F13I (535.2 mg, 1.20 mmol) catalyzed by -Ir(tBu) (4.3 mg, 0.004 mol) gave 49b as a yellow liquid 
(111.8 mg, yield: 90%) after 48 hours. Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1 
mL/min, 25 C, tr (major) = 4.4 min, tr (minor) = 5.4 min). []D22 = 123.5 (c 1.1, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.52-6.85 (m, 10H), 6.37-6.18 (m, 1H), 3.78 (s, 3H), 1.99 (s, 3H), 1.64 
(s, 3H, other rotamer). 
13C NMR (75 MHz, CD2Cl2) δ 181.9 (d, J = 4.2 Hz), 160.8, 143.1-142.9 (m), 138.1, 135.2 (d, J = 28.6 
Hz), 132.4, 131.2 (d, J = 6.1 Hz), 130.9 (d, J = 2.1 Hz), 129.7 (d, J = 3.5 Hz), 128.6 (d, J = 7.8 Hz), 
127.1 (d, J = 9.5 Hz), 126.7 (d, J = 21.6 Hz), 121.4 (d, J = 3.4 Hz), 114.7, 55.6, 51.8-51.1 (m), 16.9 (d, 
J = 9.3 Hz). 
19F NMR (282 MHz, CD2Cl2) δ –80.95 - –82.05 (m, 3F), –109.85 - –115.05 (m, 2F), 119.05 - 
–120.90 (m, 2F), –120.95 - –122.55 (m, 2F), –122.60 - –124.70 (m, 2F), –125.15 - –127.80 (m, 2F). 
IR (film): ν (cm1) 2926, 2850, 1695, 1610, 1509, 1458, 1402, 1355, 1303, 1235, 1190, 1142, 1031, 
976, 944, 911, 863, 841, 768, 734, 654, 627, 529, 452. 
HRMS (FD, m/z) calcd for C24H17F13N2O2 [M]+: 624.1082, found: 624.1107. 
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(R)-2-(4-Chlorophenyl)-3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-(1-(o-tolyl)-1H-imidazol-2-yl)octa
n-1-one (49c) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46c (62.2 mg, 0.20 mmol) and 
C6F13I (535.2 mg, 1.20 mmol) catalyzed by -Ir(tBu) (4.3 mg, 0.004 mol) gave 49c as a yellow liquid 
(78.6 mg, yield: 63%) after 72 hours. Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 96% (HPLC: AD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1 
mL/min, 25 C, tr (major) = 4.2 min, tr (minor) = 4.9 min). []D22 = 96.9 (c 0.9, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.57-7.50 (m, 2H), 7.48-6.95 (m, 8H), 6.44-6.26 (m, 1H), 1.99 (s, 3H), 
1.65 (s, 3H, other rotamer). 
13C NMR (75 MHz, CD2Cl2, mixture of rotamers) δ 181.3, 142.7, 137.8 (d, J = 2.9 Hz), 135.6 (d, J = 
1.7 Hz), 135.1, 135.0 (d, J = 29.0 Hz), 132.5, 132.2, 131,3, 131.2, 131.1, 129.9, 129.8, 129.7, 129.5, 
129.4, 129.0, 128.9, 128.6, 128.3, 127.2, 127.1, 127.0, 126.8, 126.5, 51.7-51.0 (m), 16.9 (d, J = 4.8 
Hz). 
19F NMR (282 MHz, CD2Cl2) δ –81.03 - –81.32 (m, 3F), –109.92 - –114.91 (m, 2F), –119.69 - 
–120.19 (m, 2F), –121.45 - –122.62 (m, 2F), –122.81 - –123.43 (m, 2F), –126.11- –126.65 (m, 2F). 
IR (film): ν (cm1) 3116, 2964, 2928, 2860, 1694, 1610, 1494, 1456, 1400, 1309, 1233, 1196, 1142, 
1055, 1021, 976, 859, 769, 714, 657, 552, 452. 
HRMS (FD, m/z) calcd for C24H14ClF13N2O [M]+: 628.0587, found: 628.0573. 
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(R)-2-(2-Chlorophenyl)-3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-(1-(o-tolyl)-1H-imidazol-2-yl)octa
n-1-one (49d) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46d (62.2 mg, 0.20 mmol) and 
C6F13I (535.2 mg, 1.20 mmol) catalyzed by -Ir(tBu) (4.3 mg, 0.004 mol) gave 49d as a yellow liquid 
(93.1 mg, yield: 74%) after 72 hours. Enantiomeric excess established by HPLC analysis using a 
Chiralpak OD-H column, ee = 98% (HPLC: OD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1 
mL/min, 25 C, tr (major) = 6.9 min, tr (minor) = 6.3 min). []D22 = 152.6 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.74-7.67 (m, 1H), 7.52-6.94 (m, 10H), 2.00 (s, 3H), 1.69 (s, 3H, other 
rotamer). 
13C NMR (75 MHz, CD2Cl2) δ 181.4-181.1 (m), 143.1 (d, J = 2.8 Hz), 137.9 (d, J = 2.6 Hz), 136.5 (d, 
J = 4.1 Hz), 135.1 (d, J = 35.6 Hz), 131.7 (d, J = 10.8 Hz), 131.3 (d, J = 2.6 Hz), 131.2 (d, J = 5.2 Hz), 
130.7 (d, J = 3.9 Hz), 130.5 (d, J = 7.4 Hz), 129.7 (d, J = 2.0 Hz), 129.0 (d, J = 7.5 Hz), 127.6 (d, J = 
2.2 Hz), 127.4 (d, J = 4.7 Hz), 127.1 (d, J = 11.9 Hz), 126.7 (d, J = 23.7 Hz), 47.8-46.8 (m), 16.9. 
9F NMR (282 MHz, CD2Cl2) δ –80.95 - –81.40 (m, 3F), –109.16 - –114.44 (m, 2F), –119.23 - –121.05 
(m, 2F), –121.58 - –122.31 (m, 2F), –122.82 - –123.38 (m, 2F), –126.17 - –126.74 (m, 2F). 
IR (film): ν (cm1) 3070, 2978, 2930, 1694, 1496, 1459, 1401, 1353, 1311, 1233, 1196, 1141, 1029, 
974, 865, 812, 754, 709, 653, 547. 
HRMS (FD, m/z) calcd for C24H14ClF13N2O [M]+: 628.0587, found: 628.0614. 
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(R)-3,3,4,4,5,5,6,6,7,7,8,8,8-Tridecafluoro-2-methyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)octan-1-one(4
9e) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46e (42.9 mg, 0.20 mmol) and 
C6F13I (535.2 mg, 1.20 mmol) catalyzed by Λ-Ir(tBu)  (8.6 mg, 0.008 mol) gave 49e as a yellow 
liquid (86.0 mg, yield: 82%) after 24 hours. Enantiomeric excess established by HPLC analysis using 
a Chiralpak OJ-H column, ee = 97% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1.0 
mL/min, 25 C, tr (major) = 4.4 min, tr (minor) = 7.0 min). []D22 = 1.5 (c 1.1, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.46-7.26 (m, 4H), 7.22-7.08 (m, 2H), 5.23-5.05 (m, 1H), 1.99 (s, 3H), 
1.94 (s, 3H, other rotamer), 1.41 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 185.2, 143.1, 138.1 (d, J = 5.1 Hz), 135.2 (d, J = 22.7 Hz), 131.2 (d, J 
= 5.0 Hz), 130.9 (d, J = 4.4 Hz), 129.7, 128.6 (d, J = 6.1 Hz), 127.1 (d, J = 13.3 Hz), 126.8 (d, J = 8.0 
Hz), 42.2-41.5 (m), 17.1 (d, J = 30.3 Hz) 11.3 (d, J = 5.1 Hz). 
19F NMR (282 MHz, CD2Cl2) δ 81.15 (t, J = 9.7 Hz, 3F), 113.35 - 116.35 (m, 2F), 120.38 - 
121.25 (m, 2F), 121.65 - 122.30 (m, 2F), 122.75 - 123.35 (m, 2F), 126.05 - 126.50 (m, 2F). 
IR (film): ν (cm1) 2925, 2859, 1693, 1497, 1457, 1404, 1351, 1309, 1234, 1197, 1143, 1018, 948, 905, 
766, 704, 626, 529, 465. 
HRMS (FD, m/z) calcd for C19H13F13N2O [M]+: 532.0820, found: 532.0832. 
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(R)-2-Ethyl-3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-(1-(o-tolyl)-1H-imidazol-2-yl)octan-1-one 
(49f) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46f 5.7 mg, 0.20 mmol) and 
C6F13I (535.2 mg, 1.20 mmol) Λ-Ir(tBu)  (8.6 mg, 0.008 mol) gave 49f as a yellow liquid (64.3 mg, 
yield: 59%) after 62 hours. Enantiomeric excess established by HPLC analysis using a Chiralpak 
OD-H column, ee = 99% (HPLC: OD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1.0 mL/min, 
25 C, tr (major) = 4.5 min, tr (minor) = 4.9 min). []D22 = 22.1 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.46-7.24 (m, 4H), 7.22-7.18 (m, 1H), 7.17-7.06 (m, 1H), 5.15-4.96 (m, 
1H), 2.04-1.90 (m, 2H), 1.99 (s, 3H), 1.94 (s, 3H, other rotamer), 0.92 (q, J = 8.0 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 185.2, 144.3, 138.2 (d, J = 3.4 Hz), 135.2 (d, J = 21.6 Hz), 131.2 (d, J 
= 9.0 Hz), 131.0 (d, J = 3.5 Hz), 129.7, 128.6, 127.0 (d, J = 11.6 Hz), 126.8 (d, J = 8.0 Hz), 48.5-47.8 
(m), 20.2-20.0 (m), 17.1 (d, J = 34.5 Hz) 11.6 (d, J = 5.4 Hz). 
19F NMR (282 MHz, CD2Cl2) δ –81.89 (t, J = 9.7 Hz, 3F), –113.45 - –115.64 (m, 2F), –120.38 - 
–121.25 (m, 2F), –121.65 - –122.30 (m, 2F), –122.75 - –123.35 (m, 2F), –126.75 - –126.45 (m, 2F). 
IR (film): ν (cm1) 2928, 2861, 1691, 1498, 1457, 1405, 1317, 1233, 1196, 1142, 1024, 964, 905, 850, 
764, 714, 647, 531, 459. 
HRMS (FD, m/z) calcd for C20H15F13N2O [M]+: 546.0977, found: 546.1001. 
 
(R)-2-Butyl-3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-(1-(o-tolyl)-1H-imidazol-2-yl)octan-1-one 
(49g) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46g 51.3 mg, 0.20 mmol) and 
C6F13I (535.2 mg, 1.20 mmol) Λ-Ir(tBu) (8.6 mg, 0.008 mol) gave 49g as a yellow liquid (70.2 mg, 
yield: 61%) after 72 hours. Enantiomeric excess established by HPLC analysis using a Chiralpak 
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OD-H column, ee = 98% (HPLC: OD-H, 254 nm, hexane/isopropanol = 99.5:0.5, flow rate 0.5 
mL/min, 25 C, tr (major) = 13.5 min, tr (minor) = 14.5 min). []D22 = 34.5 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.46-7.25 (m, 4H), 7.22-7.07 (m, 2H), 5.22-5.03 (m, 1H), 2.03-1.82 (m, 
2H), 1.99 (s, 3H), 1.94 (s, 3H, other rotamer), 1.45-1.15 (m, 4H), 0.85 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 185.3, 144.2, 138.1 (d, J = 3.8 Hz), 135.2 (d, J = 24.5 Hz), 131.2 (d, J 
= 8.4 Hz), 131.0 (d, J = 2.8 Hz), 129.7, 128.6 (d, J = 1.6 Hz), 127.0 (d, J = 12.4 Hz), 126.8 (d, J = 8.6 
Hz), 47.1-46.4 (m), 29.4 (d, J = 9.4 Hz), 26.4-26.2 (m), 22.9 (d, J = 1.2 Hz), 17.1 (d, J = 34.2 Hz) 
13.8. 
19F NMR (282 MHz, CD2Cl2) δ –81.30 (t, J = 9.9 Hz, 3F), –110.60 - –115.40 (m, 2F), –119.38 - 
–121.25 (m, 2F), –121.65 - –122.40 (m, 2F), –122.75 - –123.35 (m, 2F), –126.20 - –126.65 (m, 2F). 
IR (film): ν (cm1) 2961, 2930, 2869, 1691, 1498, 1457, 1405, 1234, 1197, 1142, 1053, 904, 766, 716, 
644, 531. 
HRMS (FD, m/z) calcd for C22H19F13N2O [M]+: 574.1290, found: 574.1263. 
 
 
(R)-3,3,4,4,5,5,6,6,7,7,8,8,8-Tridecafluoro-1-(1-(o-tolyl)-1H-imidazol-2-yl)-2-(p-tolyloxy)octan-1-o
ne (49h) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46h 61.3 mg, 0.20 mmol) and 
C6F13I (535.2 mg, 1.20 mmol) catalyzed by -Ir(tBu) (4.3 mg, 0.004 mol) gave 49h as a yellow liquid 
(78.1 mg, yield: 62%) after 62 hours. Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 98% (HPLC: AD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1 
mL/min, 25 C, tr (major) = 6.0 min, tr (minor) = 5.0 min). []D22 = 30.6 (c 1.0, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.49-7.26 (m, 5H), 7.22-7.03 (m, 3H), 6.97-6.84 (m, 3H), 2.27 (s, 3H), 
1.949 (s, 3H), 1.87 (s, 3H, other rotamer). 
13C NMR (75 MHz, CD2Cl2) δ 180.3, 154.6, 143.2, 137.3, 135.3, 134.9, 132.9, 132.1, 131.8, 131.4, 
131.3, 131.2, 130.6, 130.0, 129.9, 129.0, 128.2, 127.2, 127.03, 126.98, 126.9, 126.7, 118.0, 115.7, 73.5, 
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37.6, 32.4, 30.5, 30.2, 29.9, 27.6, 23.2, 20.6, 17.2, 16.8, 14.3. 
19F NMR (282 MHz, CD2Cl2) δ –81.65 - –82.65 (m, 3F), –115.20 - –118.05 (m, 2F), –121.50 - 
–124.90 (m, 6F), –125.90 - –128.45 (m, 2F). 
IR (film): ν (cm1) 3118, 3035, 2928, 2865, 1702, 1610, 1506, 1456, 1403, 1315, 1197, 1144, 902, 812, 
766, 714, 525. 
HRMS (FD, m/z) calcd for C25H17F13N2O2 [M]+: 624.1082, found: 624.1103. 
 
(R)-3,3,3-Trifluoro-2-phenyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)propan-1-one (47a) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46a (53.3 mg, 0.20 mmol) and 
trifluoroiodomethane (391.8 mg, 2.00 mmol) catalyzed by -Ir(tBu) (4.3 mg, 0.004 mol) gave 47a as 
a yellow liquid (29.8 mg, yield: 43%) after 44 hours. Enantiomeric excess established by HPLC 
analysis using a Chiralpak IC column, ee = 93% (HPLC: IC, 254 nm, hexane/isopropanol = 99:1, flow 
rate 1 mL/min, 25 C, tr (major) = 6.1 min, tr (minor) = 5.7 min). []D22 = 303.0 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.54-7.47 (m, 2H), 7.46-6.97 (m, 9H), 6.17-6.04 (m, 1H), 2.03 (s, 3H), 
1.70 (s, 3H, other rotamer). 
13C NMR (75 MHz, CD2Cl2) δ 182.1, 137.9, 135.2, 134.9, 131.3, 131.2, 131.0, 130.5, 130.3, 129.7, 
129.4, 129.3, 128.9, 128.5, 127.1, 127.0, 126.9, 126.8, 126.5, 123.0, 56.2-55.2 (m), 17.1 (d, J = 20.8 
Hz). 
19F NMR (282 MHz, CD2Cl2) δ –67.33 (d, J = 7.9 Hz, 3F).  
IR (film): ν (cm1) 3114, 3065, 3035, 2963, 2928, 1692, 1497, 1455, 1402, 1328, 1257, 1153, 1120, 
1027, 976, 861, 822, 764, 739, 698, 674, 588, 522, 455. 
HRMS (FD, m/z) calcd for C19H15F3N2O [M]+: 344.1137, found: 344.1120. 
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(R)-3,3,4,4,5,5,5-Heptafluoro-2-methyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)pentan-1-one (47b) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46e 42.9 mg, 0.20 mmol) and 
1,1,1,2,2,3,3-heptafluoro-3-iodopropane (355.1 mg, 1.20 mmol) catalyzed by -Ir(tBu) (4.3 mg, 
0.004 mol) gave 47b as a yellow liquid (40.7 mg, yield: 53%) after 45 hours. Enantiomeric excess 
established by HPLC analysis using a Chiralpak OJ-H column, ee = 95% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 99:1, flow rate 1 mL/min, 25 C, tr (major) = 14.6 min, tr (minor) = 20.6 min). 
[]D22 = 11.5 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.45-7.25 (m, 4H), 7.22-7.08 (m, 2H), 5.20-5.02 (m, 1H), 1.98 (s, 3H), 
1.93 (s, 3H, other rotamer), 1.40 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 185.1, 142.9, 138.0 (d, J = 5.3 Hz), 135.1 (d, J = 23.2 Hz), 131.1 (d, J 
= 4.2 Hz), 130.8 (d, J = 5.1 Hz), 129.6, 128.6 (d, J = 5.7 Hz), 127.0 (d, J = 13.3 Hz), 126.7 (d, J = 8.6 
Hz), 41.9-41.1 (m), 17.0 (d, J = 27.1 Hz), 11.2 (d, J = 5.0 Hz). 
19F NMR (282 MHz, CD2Cl2) δ –80.47 - –81.47 (td, J2 = 11.0 Hz, J2 = 1.7 Hz, 3F), –114.45 - –117.36 
(m, 2F), –125.09 - –125.36 (m, 2F). 
IR (film): ν (cm1) 3114, 2924, 2855, 1693, 1497, 1457, 1404, 1346, 1306, 1222, 1180, 1116, 1070, 
1008, 949, 914, 762, 711, 672, 631, 535, 453. 
HRMS (FD, m/z) calcd for C16H13F7N2O [M]+: 382.0916, found: 382.0904. 
 
(R)-3,3,4,4,5,5,6,6,6-Nonafluoro-2-methyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)hexan-1-one (47c) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46e 42.9 mg, 0.20 mmol) and 
1,1,1,2,2,3,3,4,4-nonafluoro-4-iodobutane (345.9 mg, 1.20 mmol) catalyzed by -Ir(tBu) (4.3 mg, 
0.004 mol) gave 47c as a yellow liquid (42.2 mg, yield: 49%) after 24 hours. Enantiomeric excess 
established by HPLC analysis using a Chiralpak OJ-H column, ee = 95% (HPLC: OJ-H, 254 nm, 
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hexane/isopropanol = 99:1, flow rate 1 mL/min, 25 C, tr (major) = 14.6 min, tr (minor) = 20.6 min). 
[]D22 = 4.5 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.45-7.26 (m, 4H), 7.18-7.08 (m, 2H), 5.22-5.04 (m, 1H), 1.98 (s, 3H), 
1.93 (s, 3H, other rotamer), 1.40 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 185.1, 143.0, 138.1 (d, J = 4.7 Hz), 135.1 (d, J = 23.9 Hz), 131.2 (d, J 
= 5.0 Hz), 130.9 (d, J = 4.6 Hz), 129.7, 128.6 (d, J = 5.2 Hz), 127.0 (d, J = 13.9 Hz), 126.7 (d, J = 7.6 
Hz), 42.1-41.2 (m), 17.0 (d, J = 29.1 Hz), 11.2 (d, J = 5.3 Hz). 
19F NMR (282 MHz, CD2Cl2) δ –80.47 - –81.47 (m, 3F), –113.64 - –116.76 (m, 2F), –121.07 - 
–122.98 (m, 2F), –125.06 - –127.62 (m, 2F). 
R (film): ν (cm1) 3116, 2956,2928, 1693, 1497, 1458, 1405, 1346, 1307, 1212, 1131, 1016, 946, 907, 
874, 840, 762, 712, 527, 458. 
HRMS (FD, m/z) calcd for C17H13F9N2O [M]+: 432.0884 found: 432.0883. 
 
(R)-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluoro-2-methyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)
decan-1-one (47d) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46e 42.9 mg, 0.20 mmol) and 
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro-8-iodooctane (655.0 mg, 1.20 mmol) catalyzed by 
-Ir(tBu) (4.3 mg, 0.004 mol) gave 47d as a yellow liquid (80.0 mg, yield: 63%) after 24 hours. 
Enantiomeric excess established by HPLC analysis using a Chiralpak OJ-H column, ee = 95% (HPLC: 
OJ-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1 mL/min, 25 C, tr (major) = 4.2 min, tr (minor) 
= 6.1 min). []D22 = +2.5 (c 0.9, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.45-7.25 (m, 4H), 7.22-7.08 (m, 2H), 5.22-5.04 (m, 1H), 1.98 (s, 3H), 
1.93 (s, 3H, other rotamer), 1.41 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 185.1, 143.0, 138.1 (d, J = 5.7 Hz), 135.1 (d, J = 22.8 Hz), 131.2 (d, J 
= 4.3 Hz), 130.9 (d, J = 5.0 Hz), 129.7, 128.6 (d, J = 5.9 Hz), 127.0 (d, J = 13.4 Hz), 126.7 (d, J = 7.8 
Hz), 42.2-41.4 (m), 17.0 (d, J = 31.4 Hz), 11.3 (d, J = 5.7 Hz). 
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19F NMR (282 MHz, CD2Cl2) δ –88.14 - –88.33 (m, 3F), –113.41 - –116.53 (m, 2F), –119.37 - 
–121.79 (m, 2F), –121.66 - –123.68 (m, 6F), –122.75 - –123.19 (m, 2F), –126.15 - –126.58 (m, 2F). 
IR (film): ν (cm1) 3115, 2924, 2854, 1694, 1498, 1458, 1405, 1202, 1144, 1011, 950, 908, 766, 708, 
652, 529, 459. 
HRMS (FD, m/z) calcd for C21H13F17N2O [M]+: 632.0756, found: 632.0785. 
 
(S)-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,12-Henicosafluoro-2-methyl-1-(1-(o-tolyl)-1H-imid
azol-2-yl)dodecan-1-one (47e) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46e (42.9 mg, 0.20 mmol) and 
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10-henicosafluoro-10-iododecane (775.2 mg, 1.20 mmol) 
catalyzed by Δ-Ir(tBu)  (8.6 mg, 0.008 mol) in MeOH/THF (0.8mL/0.2mL) gave 47e as a yellow 
solid (75.1 mg, yield: 51%) after 44 hours. Enantiomeric excess established by HPLC analysis using a 
Chiralpak OJ-H column, ee = 95% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1 
mL/min, 25 C, tr (major) = 5.4 min, tr (minor) = 3.8 min). []D22 = +4.6 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.45-7.26 (m, 4H), 7.22-7.07 (m, 2H), 5.22-5.05 (m, 1H), 1.98 (s, 3H), 
1.93 (s, 3H, other rotamer), 1.41 (t, J = 7.2 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 185.2, 143.0, 138.1 (d, J = 4.7 Hz), 135.1 (d, J = 23.5 Hz), 131.2 (d, J 
= 5.1 Hz), 130.9 (d, J = 4.9 Hz), 129.7, 128.6 (d, J = 6.1 Hz), 127.0 (d, J = 13.1 Hz), 126.8 (d, J = 7.4 
Hz), 42.2-41.4 (m), 17.0 (d, J = 32.3 Hz), 11.3 (d, J = 7.9 Hz). 
19F NMR (282 MHz, CD2Cl2) δ –81.14 - –81.38 (m, 3F), –113.04 - –116.95 (m, 2F), –119.47 - 
–121.12 (m, 2F), –121.66 - –122.38 (m, 10F), –122.71 - –123.18 (m, 2F), –126.18 - –126.60 (m, 2F). 
IR (film): ν (cm1) 3145, 2923, 2854, 1688, 1461, 1404, 1203, 1144, 1066, 950, 911, 761, 527, 524. 
HRMS (FD, m/z) calcd for C23H13F21N2O [M]+: 732.0693, found: 732.0720. 
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(R)-3,3-Difluoro-2-methyl-3-(perfluorophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)propan-1-one 
(47f) 
 
According to the general procedure, the reaction of 2-acyl imidazole 46e 42.9 mg, 0.20 mmol) and 
1-(difluoroiodomethyl)-2,3,4,5,6-pentafluorobenzene (413.0 mg, 1.20 mmol) catalyzed by -Ir(tBu) 
(4.3 mg, 0.004 mol) gave 47f as a yellow liquid (80.0 mg, yield: 93%) after 15 hours. Enantiomeric 
excess established by HPLC analysis using a Chiralpak OD-H column, ee > 99.5% (HPLC: OD-H, 
254 nm, hexane/isopropanol = 99:1, flow rate 1 mL/min, 25 C, tr (major) = 8.6 min, tr (minor) = 9.5 
min). []D22 = +70.6 (c 0.9, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.44-7.22 (m, 4H), 7.16-7.02 (m, 2H), 5.16-4.98 (m, 1H), 1.95 (s, 3H), 
1.89 (s, 3H, other rotamer), 1.39 (t, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 186.6, 143.1, 138.0 (d, J = 5.9 Hz), 131.1 (d, J = 8.4 Hz), 130.7 138.0 
(d, J = 3.9 Hz), 129.6, 128.3 (d, J = 12.4 Hz), 127.0 (d, J = 10.7 Hz), 126.6 (d, J = 7.1 Hz), 49.0-47.9 
(m), 17.0 (d, J = 37.3 Hz), 11.0 (dt, J1 = 20.1, J2 = 4.6 Hz). 
19F NMR (282 MHz, CD2Cl2) δ –87.75 - –93.05 (m, 1F), –95.75 - –98.85 (m, 1F), –119.05 - –120.90 
(m, 2F), –137.40 - –141.55 (m, 2F), –150.60 - –152.70 (m, 1F), –160.45 - –163.80 (m, 2F). 
IR (film): ν (cm1) 3117, 2926, 2891, 1688, 1654, 1498, 1457, 1402, 1336, 1190, 1084, 988, 943, 908, 
832, 764, 710, 546, 458. 
HRMS (FD, m/z) calcd for C20H13F7N2O [M]+: 430.0916, found: 430.0920. 
 
5.6.4 Single-Crystal X-Ray Diffraction Studies 
Single crystals of Δ-IrS(tBu) suitable for X-ray diffraction were obtained by slow diffusion from a 
solution of Δ-IrS(tBu) (20 mg) in toluene (2.0 mL) layered with n-hexane (0.5 mL) at room 
temperature for several days in a glass tube. The absolute configurations of compound Δ-IrS(tBu) has 
been determined. Crystal data and details of the structure determination are presented in the 
Appendices (Chapter 6.7). 
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5.7 Visible-Light-Activated Enantioselective Addition of Alkyl Radicals to 
Alkenes with a Chiral Rhodium Complex 
5.7.1 Synthesis of Substrates 
1) Synthesis of ,-Unsaturated Alkenes 
,-Unsaturated 2-acyl pyrazoles (58a-e) were synthesized according to published procedures without 
any further change,34 while ,-unsaturated 2-acyl imidazoles (18a, 18g, 53c-k, 53d’ and 53e’) were 
synthesized according to reported procedures with some modifications (shown as following).35 
General procedure for the synthesis of ,-unsaturated 2-acyl imidazoles. 
 
To a solution of Wittig reagent35 (2.4 mmol) in toluene (12.0 mL) at room temperature was added the 
corresponding aldehyde (2 to 10 equiv). The reaction was stirred at 85 C overnight. After the solvent 
was removed in vacuo, the residue was purified by flash chromatography on silica gel (EtOAc/hexane 
= 1/5 to 1/3) to produce the unsaturated alkenes as a mixture of E:Z isomers. Then, to a solution of 
purified alkene in CH2Cl2 (0.2 M) at room temperature was added DMAP (0.1 equiv). The reaction 
was sealed and stored at 4 C (fridge) for 24 hours. After isomerization, the solution was passed 
through a short silica column. The isomerization proceeded well to afford 18a, 18g, 53c-k, 53d’-e’ 
with an improved E/Z value (E/Z > 50/1, as judged by 1H NMR). 
The experimental data of 53d-g, 53j-k and 53e’ are shown below. The other 2-acyl imidazoles (18a, 
18g, 53c,35 53h-i,36 53d’35) have been reported previously. 
 
(E)-1-(1-Phenyl-1H-imidazol-2-yl)pent-2-en-1-one (53d) 
 
Following the general procedure, propionaldehyde (1.7 mL, 24.0 mmol, 10 equiv) was converted to 
,-Unsaturated 2-acyl imidazole 53d (462.1 mg, 2.04 mmol, yield: 85%) as a white solid. 
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1H NMR (300 MHz, CDCl3) δ 7.53 – 7.46 (m, 3H), 7.42 (dt, J = 15.6, 1.6 Hz, 1H), 7.36 – 7.28 (m, 
3H), 7.22 (d, J = 0.9 Hz, 1H), 7.14 (dt, J = 15.6, 6.4 Hz, 1H), 2.44 – 2.25 (m, 2H), 1.15 (t, J = 7.4 Hz, 
3H). 
13C NMR (75 MHz, CDCl3) δ 179.5, 150.7, 143.8, 138.6, 129.6, 128.9, 128.6, 127.0, 125.9, 125.3, 
25.8, 12.3. 
IR (film): ν (cm1) 1665, 1613, 1492, 1446, 1399, 1299, 1060, 971, 806, 761, 691. 
HRMS (ESI, m/z) calcd for C14H15N2O [MH]: 227.1179, found: 227.1181. 
 
(E)-1-(1-Phenyl-1H-imidazol-2-yl)hex-2-en-1-one (53e) 
 
Following the general procedure, butyraldehyde (1.1 mL, 12.0 mmol, 5 equiv) was converted to 
,-unsaturated 2-acyl imidazole 53e (440.0 mg, 1.83 mmol, yield: 76%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.53 – 7.38 (m, 4H), 7.37 – 7.26 (m, 3H), 7.22 (s, 1H), 7.09 (dt, J = 
15.6, 7.0 Hz, 1H), 2.31 (qd, J = 7.2, 1.4 Hz, 2H), 1.64 – 1.48 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 179.4, 149.2, 143.8, 138.6, 129.6, 128.9, 128.6, 127.0, 126.3, 125.9, 
34.7, 21.4, 13.7. 
IR (film): ν (cm1) 3113, 2958, 2926, 2870, 1666, 1617, 1495, 1446, 1398, 1303, 1148, 1063, 972, 826, 
798, 763, 692. 
HRMS (ESI, m/z) calcd for C15H17N2O [MH]: 241.1335, found: 241.1338. 
 
(E)-1-(1-Isopropyl-1H-imidazol-2-yl)hex-2-en-1-one (53e’) 
 
Following the general procedure, butyraldehyde (1.1 mL, 12.0 mmol, 5 equiv) was converted to 
,-Unsaturated 2-acyl imidazole 53e’ (381.2 mg, 1.85 mmol, yield: 77%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.46 (dd, J = 15.6, 1.0 Hz, 1H), 7.28 (s, 1H), 7.21 (s, 1H), 7.17 – 7.04 
(m, 1H), 5.67 (hept, J = 6.8 Hz, 1H), 2.31 (q, J = 7.2 Hz, 2H), 1.65 – 1.50 (m, 2H), 1.47 (dd, J = 6.7, 
1.0 Hz, 6H), 0.97 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 180.9, 148.3, 143.1, 129.6, 127.1, 121.1, 49.2, 34.7, 23.6, 21.5, 13.7. 
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IR (film): ν (cm1) 2962, 2931, 2873, 1665, 1616, 1391, 1253, 1013, 977, 809, 764, 649. 
HRMS (ESI, m/z) calcd for C12H19N2O [MH]: 207.1492, found: 207.1494. 
 
(E)-4-Methyl-1-(1-phenyl-1H-imidazol-2-yl)pent-2-en-1-one (53f) 
 
Following the general procedure, isobutyraldehyde (2.2 mL, 24.0 mmol, 10 equiv) was converted to 
,-Unsaturated 2-acyl imidazole 53f (505.0 mg, 2.10 mmol, yield: 88%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.53 – 7.43 (m, 3H), 7.43 – 7.27 (m, 4H), 7.22 (d, J = 1.0 Hz, 1H), 7.06 
(dd, J = 15.7, 6.7 Hz, 1H), 2.70 – 2.47 (m, 1H), 1.13 (d, J = 6.8 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 179.7, 155.4, 143.9, 138.6, 129.6, 128.9, 128.6, 127.0, 125.9, 123.3, 
31.4, 21.3. 
IR (film): ν (cm1) 3141, 3061, 2961, 2926, 2876, 1665, 1612, 1491, 1439, 1397, 1299, 1141, 1043, 
1003, 963, 918, 863, 777, 688, 651, 607, 532. 
HRMS (ESI, m/z) calcd for C15H17N2O [MH]: 241.1335, found: 241.1338. 
 
(E)-4-(Benzyloxy)-1-(1-phenyl-1H-imidazol-2-yl)but-2-en-1-one (53g) 
 
Following the general procedure, 2-(benzyloxy)acetaldehyde (674.0 µL, 4.8 mmol, 2 equiv) was 
converted to ,-Unsaturated 2-acyl imidazole 53g (560.4 mg, 1.76 mmol, yield: 73%) as a white 
solid. 
1H NMR (300 MHz, CDCl3) δ 7.68 (dt, J = 15.8, 1.9 Hz, 1H), 7.58 – 7.45 (m, 3H), 7.44 – 7.29 (m, 
8H), 7.24 (d, J = 0.8 Hz, 1H), 7.10 (dt, J = 15.8, 4.6 Hz, 1H), 4.62 (s, 2H), 4.29 (dd, J = 4.6, 1.9 Hz, 
2H). 
13C NMR (75 MHz, CDCl3) δ 179.1, 143.9, 143.7, 138.5, 137.9, 129.9, 129.0, 128.7, 128.4, 127.7, 
127.2, 126.2, 125.9, 72.7, 69.2. 
IR (film): ν (cm1) 3121, 3032, 2838, 2783, 1665, 1620, 1495, 1442, 1399, 1353, 1304, 1263, 1209, 
1125, 1030, 974, 912, 832, 791, 759, 739, 692, 638, 605, 561, 513, 469. 
HRMS (ESI, m/z) calcd for C20H19N2O2 [MH]: 319.1441, found: 319.1446. 
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(E)-3-(4-Fluorophenyl)-1-(1-phenyl-1H-imidazol-2-yl)prop-2-en-1-one (53j) 
 
Following the general procedure, 4-fluorobenzaldehyde (515.0 µL, 4.8 mmol, 2 equiv) was converted 
to ,-Unsaturated 2-acyl imidazole 53j (632.0 mg, 2.16 mmol, yield: 90%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.00 (d, J = 16.0 Hz, 1H), 7.78 – 7.58 (m, 3H), 7.54 – 7.41 (m, 3H), 
7.40 – 7.28 (m, 3H), 7.23 (d, J = 1.0 Hz, 1H), 7.08 (t, J = 8.6 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 179.0, 165.7, 162.4, 144.0, 142.5, 138.5, 131.21, 131.16, 130.7, 130.6, 
129.8, 129.0, 128.8, 127.3, 125.9, 122.5, 122.4, 116.1, 115.9. 
IR (film): ν (cm1) 3110, 3048, 1658, 1584, 1496, 1410, 1300, 1215, 1156, 1039, 975, 822, 756, 690, 
503, 451. 
HRMS (ESI, m/z) calcd for C18H14FN2O [MH]: 293.1085, found: 293.1085. 
 
(E)-3-(2-Bromophenyl)-1-(1-phenyl-1H-imidazol-2-yl)prop-2-en-1-one (53k) 
 
Following the general procedure, 2-bromobenzaldehyde (883.0 mg, 4.8 mmol, 2 equiv) was converted 
to ,-Unsaturated 2-acyl imidazole 53k (826.3 mg, 2.35 mmol, yield: 98%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.15 (d, J = 15.9 Hz, 1H), 8.04 (d, J = 15.9 Hz, 1H), 7.86 (dd, J = 7.8, 
1.6 Hz, 1H), 7.60 (dd, J = 8.0, 1.2 Hz, 1H), 7.54 – 7.44 (m, 3H), 7.42 – 7.28 (m, 4H), 7.29 – 7.16 (m, 
2H). 
13C NMR (75 MHz, CDCl3) δ 178.6, 143.9, 141.9, 138.5, 134.9, 133.5, 131.3, 129.9, 129.0, 128.8, 
128.1, 127.6, 127.5, 126.2, 126.0, 125.1. 
IR (film): ν (cm1) 1662, 1592, 1495, 1444, 1403, 1342, 1307, 1048, 1032, 975, 776, 743, 687, 580, 
516. 
HRMS (ESI, m/z) calcd for C18H14BrN2O [MH]: 353.0284 and 355.0265, found: 353.0289 and 
355.0268. 
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2) Synthesis of Potassium Organotrifluoroborates 
Potassium benzyltrifluoroborates (54a-f), potassium tert-butyltrifluoroborate (54p), potassium 
alkoxymethyltrifluoroborates (54h-l) were synthesized according to reported procedures with some 
modifications.37 The other trifluoroborates were purchased commercially. 
 
General procedure for the synthesis of potassium benzyltrifluoroborates (54a-f) and potassium 
tert-butyltrifluoroborate (54p).37a 
 
To a solution of fresh prepared Grignard reagent ArCH2MgX (25.0 mmol, 1.0 eq) or tert-BuLi (25.0 
mmol, 1.0 eq) in Et2O (50.0 mL, 0.5 M) at 78 C were added trimethyl borate (4.2 mL, 37.5 mmol, 
1.5 eq). The reaction mixture was stirred at 78 C for 30 min, then allowed to warm to room 
temperature and stirred for a further 1 h. After the reaction was cooled to 0 C, KHF2 (11.7 g, 150.0 
mmol) was added at one portion followed by the addition of H2O (20.0 mL) over 20 min. After stirring 
at room temperature for 1 h, the solution was evaporated and the resulting solid was dried under high 
vacuum at 40 C for 1 h. The solid was extracted in hot acetone (4  100 mL), filtered and the solvent 
was concentrated under reduced pressure. The crude solid was recrystallized in acetone/Et2O to afford 
benzylic trifluoroborates (54a-f) and tert-butyltrifluoroborate (54p).as a white solid (26-77% yield). 
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General procedure for the synthesis of -alkoxymethyl trifluoroborates (54h-l). 
 
To a suspension of NaH (1.620 g, 15.0 mmol, 3 eq) in anhydrous THF (25.0 mL, 0.2 M) at 0 C was 
added the corresponding alcohol (15.0 mmol, 3 eq). The reaction mixture was stirred at 0 C for 15 
min and then allowed to warm to room temperature for 30 min. Bromomethyltrifluoroborate (1.000 g, 
5.0 mmol, 1.0 eq.) was added to the mixture in one portion at 0 C. After stirring at room temperature 
overnight, the reaction was quenched with 4.5 M aqueous KHF2 (16.7 mL, 75.0 mmol). The reaction 
mixture was stirred at room temperature for 30 min and then concentrated and dried under high 
vacuum at 40 C for 1 h. The crude residue was suspended in hot acetone (3  50 mL) and filtered. 
The filtrate was concentrated to a minimal volume (5 to 10 mL) and Et2O (about 150 mL) was added 
to precipitate. The precipitate was collected by filtration and recrystallized in acetone/Et2O to produce 
-alkoxymethyltrifluoroborates 54h-l (39-99% yield) as a white solid. 
The experimental data of 54h is shown below. The other trifluoroborates (54a-f, 54i-l, 54p) have been 
reported previously.37 
 
Potassium ((benzo[d][1,3]dioxol-5-ylmethoxy)methyl)trifluoroborate (54h) 
 
Following the general procedure, bromomethyltrifluoroborate (1.004 g, 5.0 mmol) was converted to 
-alkoxymethyltrifluoroborates 54h (962.0 mg, 3.54 mmol, yield: 71%) as a white solid. 
1H NMR (300 MHz, DMSO) δ 6.82 (dd, J = 4.5, 3.3 Hz, 2H), 6.73 (d, J = 7.9 Hz, 1H), 5.97 (s, 2H), 
4.18 (s, 2H), 2.58 – 2.51 (m, 2H). 
13C NMR (75 MHz, DMSO) δ 147.0, 145.9, 134.3, 120.5, 107.9, 107.6, 100.6, 74.5. 
IR (film): ν (cm1) 2900, 2858, 1494, 1443, 1348, 1237, 1122, 1030, 920, 867, 804, 732, 651, 587. 
HRMS (ESI, m/z) calcd for C9H9BF3O3 [M]: 233.0593, found: 233.0610. 
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5.7.2 Rhodium-Catalyzed Photoredox Reactions 
 
General procedure for conjugate additions of alkyl radicals to alkenes. A dried 10 mL Schlenk 
tube was charged with the catalyst Λ-RhS (4 mol%), photosensitizer [Acr-Mes]ClO4 (2 mol%, applied 
for ,-unsaturated 2-acyl imidazoles) or Ir[dF(CF3)ppy]2(bpy)PF6 (2 mol%, applied for 
,-unsaturated 2-acyl pyrazoles), and the corresponding ,-unsaturated alkene (0.2 mmol, 1.0 eq). 
The tube was purged with nitrogen and acetone/H2O (4:1 or 1:1, 1.0 mL) was added via syringe, 
followed by potassium trifluoroborate (0.3 mmol, 1.5 eq). The reaction mixture was degassed via 
freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and 
positioned approximately 10 cm from a 24 W blue LEDs lamp. The reaction was stirred at room 
temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the 
reaction was quenched with aqueous saturated NaHCO3 at room temperature and extracted with 
CH2Cl2 (5  5 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:15 to 1:5) to afford the radical addition products. Racemic samples were obtained 
by carrying out the reactions with rac-RhS. The enantiomeric excess was determined by chiral HPLC 
analysis. 
Exemplary reaction setup: 
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(R)-3-Methyl-1-(1-methyl-1H-imidazol-2-yl)-4-phenylbutan-1-one (55a) 
 
According to the condition in table 12 (entry 5), ,-unsaturated acyl imidazole 18a (30.0 mg, 0.2 
mmol) reacted with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (1:1, 
1.0 mL) to give 55a as a colorless oil (32.5 mg, 0.134 mmol, yield: 67%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 88% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.8 min, tr (major) = 11.7 min). 
[]D22 = 24.4 (c 0.20, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.24 – 7.06 (m, 5H), 7.05 (d, J = 0.8 Hz, 1H), 6.92 (s, 1H), 3.88 (s, 3H), 
3.01 (d, J = 6.5 Hz, 2H), 2.71 – 2.53 (m, 1H), 2.53 – 2.25 (m, 2H), 0.89 (d, J = 6.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.7, 143.4, 140.7, 129.3, 128.7, 128.1, 126.8, 125.8, 45.6, 43.3, 36.2, 
31.6, 19.9. 
HRMS (ESI, m/z) calcd for C15H19N2O [MH]: 243.1492, found: 243.1494. 
 
(R)-1-(1-Isopropyl-1H-imidazol-2-yl)-3-methyl-4-phenylbutan-1-one (55b) 
 
According to the condition in table 12 (entry 6), ,-unsaturated acyl imidazole 18g (35.6 mg, 0.2 
mmol) reacted with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (1:1, 
1.0 mL) to give 55b as a colorless oil (35.7 mg, 0.132 mmol, yield: 66%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 93% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.0 min, tr (major) = 13.0 min). 
[]D22 = 26.7 (c 0.21, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.28 – 6.94 (m, 7H), 5.44 (hept, J = 6.8 Hz, 1H), 3.03 (d, J = 6.5 Hz, 
2H), 2.72 – 2.55 (m, 1H), 2.54 – 2.35 (m, 2H), 1.36 (d, J = 5.0 Hz, 3H), 1.34 (d, J = 5.0 Hz, 3H), 0.88 
(d, J = 6.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.8, 142.6, 140.7, 129.3, 129.2, 128.1, 125.8, 120.9, 49.2, 46.2, 43.3, 
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31.7, 23.6, 23.6, 19.8. 
IR (film): ν (cm1) 3061, 3026, 2964, 2925, 1670, 1455, 1396, 1254, 1203, 1151, 1087, 996, 912, 771, 
737, 699, 498. 
HRMS (ESI, m/z) calcd for C17H23N2O [MH]: 271.1805, found: 271.1806. 
 
(R)-3-Methyl-4-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55c) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53c (42.4 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 mL) to give 
55c as a white solid (44.4 mg, 0.146 mmol, yield: 73%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee = 96% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 10.0 min, tr (major) = 11.1 min). []D22 = 11.1 (c 
0.37, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.44 – 7.32 (m, 3H), 7.23 – 7.12 (m, 5H), 7.12 – 7.03 (m, 4H), 3.13 – 
2.92 (m, 2H), 2.68 – 2.52 (m, 1H), 2.51 – 2.28 (m, 2H), 0.85 (d, J = 6.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 191.0, 143.3, 140.6, 138.5, 129.30, 129.25, 128.9, 128.7, 128.1, 126.9, 
125.9, 125.8, 45.6, 43.3, 31.3, 19.8. 
IR (film): ν (cm1) 3110, 3056, 3025, 2963, 2916, 2856, 1682, 1596, 1496, 1449, 1406, 1305, 1025, 
970, 909, 777, 749, 694, 502. 
HRMS (ESI, m/z) calcd for C20H21N2O [MH]: 305.1648, found: 305.1649. 
 
(R)-3-Benzyl-1-(1-phenyl-1H-imidazol-2-yl)pentan-1-one (55d) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53d (45.2 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 mL) to give 
55d as a colorless oil (30.5 mg, 0.096 mmol, yield: 48%). Enantiomeric excess established by HPLC 
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analysis using a Chiralpak AD-H column, ee = 90% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 14.6 min, tr (major) = 16.3 min). []D22 = 24.4 (c 
0.20, CH2Cl2). []D22 = 30.3 (c 0.20, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.44 – 7.31 (m, 3H), 7.23 – 7.12 (m, 5H), 7.11 – 7.03 (m, 4H), 3.12 (dd, 
J = 17.0, 6.9 Hz, 1H), 2.96 (dd, J = 16.9, 6.4 Hz, 1H), 2.60 (dd, J = 13.5, 7.1 Hz, 1H), 2.48 (dd, J = 
13.5, 7.4 Hz, 1H), 2.34 – 2.18 (m, 1H), 1.38 – 1.20 (m, 2H), 0.83 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 191.2, 143.4, 140.8, 138.5, 129.3, 128.9, 128.7, 128.1, 126.9, 125.9, 
125.8, 42.7, 40.2, 37.3, 26.5, 11.1. 
IR (film): ν (cm1) 2960, 2925, 2868, 1683, 1597, 1496, 1448, 1404, 1307, 1035, 963, 912, 765, 735, 
696. 
HRMS (ESI, m/z) calcd for C21H23N2O [MH]: 319.1805, found: 319.1807. 
 
(R)-3-Benzyl-1-(1-methyl-1H-imidazol-2-yl)pentan-1-one (55d’) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53d’ (32.8 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 mL) to give 
55d’ as a colorless oil (38.0 mg, 0.148 mmol, yield: 74%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee = 95% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.7 min, tr (major) = 11.3 min). []D22 = 33.7 (c 
0.66, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.22 – 7.05 (m, 5H), 7.04 (d, J = 0.7 Hz, 1H), 6.90 (s, 1H), 3.83 (s, 3H), 
3.07 (dd, J = 16.6, 6.7 Hz, 1H), 2.96 (dd, J = 16.6, 6.8 Hz, 1H), 2.62 (dd, J = 13.5, 7.0 Hz, 1H), 2.50 
(dd, J = 13.5, 7.4 Hz, 1H), 2.41 – 2.25(m, 1H), 1.45 – 1.20 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.9, 143.4, 140.8, 129.3, 128.7, 128.0, 126.7, 125.7, 42.6, 40.3, 37.7, 
36.1, 26.6, 11.1. 
IR (film): ν (cm1) 3025, 2959, 2924,2871, 1669, 1404, 1285, 1152, 1018, 911, 768, 734, 696. 
HRMS (ESI, m/z) calcd for C16H21N2O [MH]: 257.1648, found: 257.1651. 
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(R)-3-Benzyl-1-(1-phenyl-1H-imidazol-2-yl)hexan-1-one (55e) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53e (48.0 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 mL) to give 
55e as a colorless oil (26.9 mg, 0.081 mmol, yield: 40%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee = 83% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 10.2 min, tr (major) = 11.0 min). []D22 = 12.4 (c 
0.24, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.42 – 7.31 (m, 3H), 7.21 – 7.10 (m, 5H), 7.10 – 7.00 (m, 4H), 3.10 (dd, 
J = 16.9, 6.7 Hz, 1H), 2.96 (dd, J = 16.9, 6.4 Hz, 1H), 2.59 (dd, J = 13.5, 6.9 Hz, 1H), 2.48 (dd, J = 
13.5, 7.4 Hz, 1H), 2.41 – 2.24 (m, 1H), 1.37 – 1.10 (m, 4H), 0.76 (t, J = 6.6 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 191.2, 143.4, 140.8, 138.5, 129.3, 128.9, 128.6, 128.1, 126.9, 125.9, 
125.7, 43.1, 40.7, 36.3, 35.7, 19.9, 14.2. 
IR (film): ν (cm1) 2955, 2923, 2864, 1681, 1595, 1494, 1446, 1402, 1038, 962, 911, 761, 695. 
HRMS (ESI, m/z) calcd for C22H25N2O [MH]: 333.1961, found: 333.1965. 
 
(R)-3-Benzyl-1-(1-isopropyl-1H-imidazol-2-yl)hexan-1-one (55e’) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53e’ (41.2 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 mL) to give 
55e’ as a colorless oil (37.1 mg, 0.125 mmol, yield: 62%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 92% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
98:2, flow rate 1.0 mL/min, 25 C, tr (major) = 6.6 min, tr (minor) = 7.3 min). []D22 = 26.5 (c 0.24, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.33 – 7.01 (m, 7H), 5.47 (hept, J = 6.7 Hz, 1H), 3.18 (dd, J = 16.7, 6.6 
Hz, 1H), 3.06 (dd, J = 16.7, 6.6 Hz, 1H), 2.69 (dd, J = 13.4, 7.0 Hz, 1H), 2.59 (dd, J = 13.4, 7.2 Hz, 
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1H), 2.48 (dq, J = 12.2, 6.1 Hz, 1H), 1.54 – 1.21 (m, 10H), 0.87 (t, J = 6.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 193.0, 142.8, 140.9, 129.3, 129.2, 128.1, 125.7, 120.8, 49.1, 43.7, 40.9, 
36.4, 36.0, 23.6, 23.5, 19.9, 14.2. 
IR (film): ν (cm1) 3060, 3027, 2956, 2873, 1682, 1597, 1495, 1446, 1402, 1306, 1034, 961, 911, 760, 
693. 
HRMS (ESI, m/z) calcd for C19H27N2O [MH]: 299.2118, found: 299.2119. 
 
(R)-3-Benzyl-4-methyl-1-(1-phenyl-1H-imidazol-2-yl)pentan-1-one (55f) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53f (48.0 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 mL) to give 
55f as a colorless oil (51.8 mg, 0.156 mmol, yield: 78%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee = 95% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
98:2, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.5 min, tr (major) = 9.9 min). []D22 = 20.2 (c 0.52, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.51 – 7.36 (m, 3H), 7.31 – 7.06 (m, 9H), 3.18 (dd, J = 17.1, 5.9 Hz, 
1H), 3.05 (dd, J = 17.1, 6.8 Hz, 1H), 2.70 (dd, J = 13.3, 6.4 Hz, 1H), 2.56 – 2.44 (m, 1H), 2.45 – 2.32 
(m, 1H), 1.83 – 1.64 (m, 1H), 0.96 (d, J = 6.9 Hz, 3H), 0.92 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 191.2, 143.4, 141.1, 138.5, 129.3, 128.8, 128.6, 128.1, 126.9, 125.9, 
125.7, 41.4, 39.6, 37.7, 29.6, 19.6, 18.5. 
HRMS (ESI, m/z) calcd for C22H25N2O [MH]: 333.1961, found: 333.1964. 
 
(R)-3-Benzyl-4-(benzyloxy)-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55g) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53g (63.6 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (4:1, 2.0 mL) to give 
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55g as a colorless oil (46.9 mg, 0.114 mmol, yield: 57%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OD-H column, ee = 92% (HPLC: OD-H, 254 nm, hexane/isopropanol = 
90:10, flow rate 1.0 mL/min, 25 C, tr (major) = 10.6 min, tr (minor) = 12.0 min). []D22 = 27.8 (c 
0.16, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.47 – 7.36 (m, 3H), 7.34 – 7.21 (m, 8H), 7.21 – 7.15 (m, 3H), 7.15 – 
7.05 (m, 3H), 4.41 (s, 2H), 3.56 – 3.26 (m, 3H), 3.04 (dd, J = 16.6, 5.0 Hz, 1H), 2.93 – 2.54 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.6, 143.3, 140.0, 138.6, 138.5, 129.3, 128.8, 128.5, 128.20, 128.17, 
127.6, 127.3, 126.8, 125.9, 125.8, 72.9, 72.7, 41.0, 37.8, 36.9. 
IR (film): ν (cm1) 3060, 3028, 2918, 2856, 1682, 1596, 1495, 1447, 1404, 1306, 1097, 1026, 971, 910, 
738, 695. 
HRMS (ESI, m/z) calcd for C27H26N2ONa [MNa]: 433.1886, found: 433.1894. 
 
(R)-3,4-Diphenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55h) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) to give 
55h as a colorless oil (66.0 mg, 0.180 mmol, yield: 90%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OJ-H column, ee = 95% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
50:50, flow rate 1.0 mL/min, 25 C, tr (minor) = 13.7 min, tr (major) = 22.6 min). []D22 = 11.4 (c 
0.68, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.46 – 7.34 (m, 3H), 7.32 – 7.15 (m, 9H), 7.15 – 7.07 (m, 3H), 7.07 – 
6.97 (m, 2H), 3.79 – 3.60 (m, 2H), 3.51 – 3.36 (m, 1H), 2.99 (d, J = 7.1 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 190.0, 143.9, 143.3, 139.8, 138.2, 129.4, 129.3, 128.8, 128.5, 128.2, 
128.0, 127.8, 126.8, 126.2, 125.9, 125.6, 44.4, 43.5, 43.0. 
IR (film): ν (cm1) 3059, 3027, 2921, 2852, 1683, 1597, 1495, 1446, 1403, 1306, 1065, 1031, 964, 911, 
759, 694, 518. 
HRMS (ESI, m/z) calcd for C25H23N2O [MH]: 367.1805, found: 367.1810. 
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(R)-3-(4-Methoxyphenyl)-4-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55i) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53i (60.8 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) to give 
55i as a colorless oil (70.7 mg, 0.179 mmol, yield: 89%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee = 93% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 17.4 min, tr (major) = 19.0 min). []D22 = 15.5 (c 
0.62, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.42 – 7.33 (m, 3H), 7.28 – 6.94 (m, 11H), 6.77 (d, J = 8.7 Hz, 2H), 
3.76 (s, 3H), 3.70 – 3.51 (m, 2H), 3.45 – 3.26 (m, 1H), 2.92 (d, J = 7.1 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 190.1, 158.0, 143.3, 139.9, 138.2, 136.1, 129.4, 129.3, 128.82, 128.76, 
128.5, 128.1, 126.8, 125.9, 125.7, 113.6, 55.2, 44.7, 43.7, 42.3. 
IR (film): ν (cm1) 3059, 3028, 2923, 2839, 1682, 1603, 1503, 1403, 1302, 1244, 1032, 963, 827, 757, 
694, 544, 514. 
HRMS (ESI, m/z) calcd for C26H25N2O2 [MH]: 397.1911, found: 397.1916. 
 
(R)-3-(4-Fluorophenyl)-4-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55j) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53j (58.4 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) to give 
55j as a white solid (63.7 mg, 0.179 mmol, yield: 83%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OJ-H column, ee = 96% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
70:30, flow rate 1.0 mL/min, 25 C, tr (minor) = 15.2 min, tr (major) = 26.6 min). []D22 = 6.3 (c 
0.76, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.46 – 7.36 (m, 3H), 7.27 (d, J = 0.8 Hz, 1H), 7.25 – 7.11 (m, 6H), 7.11 
– 7.01 (m, 4H), 6.92 (t, J = 8.7 Hz, 2H), 3.78 – 3.58 (m, 2H), 3.56 – 3.31 (m, 1H), 3.07 – 2.81 (m, 
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2H). 
13C NMR (75 MHz, CDCl3) δ 189.7, 163.0, 159.7, 143.2, 139.51, 139.49, 138.2, 129.4, 129.3, 129.21, 
129.15, 128.8, 128.6, 128.1, 126.9, 126.0, 125.6, 115.0, 114.8, 44.5, 43.5, 42.3. 
IR (film): ν (cm1) 3109, 3060, 3030, 2923, 2854, 1682, 1599, 1501, 1446, 1404, 1305, 1222, 1154, 
964, 912, 830, 758, 694, 540. 
HRMS (ESI, m/z) calcd for C25H22FN2O [MH]: 385.1711, found: 385.1717. 
 
(R)-3-(2-Bromophenyl)-4-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55k) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53k (70.4 mg, 0.2 mmol) reacted 
with potassium benzyltrifluorobroate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) to give 
55k as a white solid (63.9 mg, 0.144 mmol, yield: 72%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak OJ-H column, ee = 94% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
70:30, flow rate 1.0 mL/min, 25 C, tr (minor) = 10.7 min, tr (major) = 16.0 min). []D22 = 7.8 (c 
0.56, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.50 (dd, J = 8.0, 1.2 Hz, 1H), 7.42 – 7.30 (m, 4H), 7.28 – 7.13 (m, 7H), 
7.12 (d, J = 0.9 Hz, 1H), 7.08 – 6.97 (m, 3H), 4.32 – 4.13 (m, 1H), 3.64 (dd, J = 16.8, 8.1 Hz, 1H), 
3.46 (dd, J = 16.8, 6.8 Hz, 1H), 3.05 (dd, J = 13.6, 6.3 Hz, 1H), 2.82 (dd, J = 13.6, 8.4 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.3, 143.2, 142.8, 139.2, 138.2, 133.0, 129.4, 128.9, 128.5, 128.2, 
128.1, 127.7, 127.4, 126.9, 126.1, 125.7, 125.0, 43.0, 42.1, 41.2. 
IR (film): ν (cm1) 3055, 3025, 2909, 2850, 1683, 1593, 1492, 1444, 1410, 1300, 1020, 961, 911, 857, 
753, 694. 
HRMS (ESI, m/z) calcd for C25H21BrN2ONa [MNa]: 467.0729 and 469.0712, found: 467.0734 and 
469.0714. 
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(R)-4-(4-Methoxyphenyl)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55l) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium trifluoro(4-methoxybenzyl)borate 54b (68.4 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 
mL) to give 55l as a white solid (77.0 mg, 0.194 mmol, yield: 97%). Enantiomeric excess established 
by HPLC analysis using a Chiralpak OJ-H column, ee = 99% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 50:50, flow rate 1.0 mL/min, 25 C, tr (minor) = 17.4 min, tr (major) = 44.8 min). 
[]D22 = 4.3 (c 0.92, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.46 – 7.33 (m, 3H), 7.31 – 7.14 (m, 6H), 7.11 (d, J = 0.8 Hz, 2H), 7.01 
(d, J = 8.3 Hz, 4H), 6.76 (d, J = 8.6 Hz, 2H), 3.77 (s, 3H), 3.72 – 3.56 (m, 2H), 3.54 – 3.35 (m, 1H), 
2.92 (d, J = 7.1 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 190.0, 157.8, 144.1, 143.2, 138.2, 131.8, 130.2, 129.3, 128.8, 128.5, 
128.2, 127.8, 126.7, 126.2, 125.6, 113.5, 55.1, 44.3, 43.2, 42.7. 
IR (film): ν (cm1) 3060, 3028, 2916, 2839, 1682, 1603, 1504, 1446, 1403, 1303, 1243, 1176, 1032, 
826, 759, 693, 522. 
HRMS (ESI, m/z) calcd for C26H24N2O2Na [MNa]: 419.1730, found: 419.1735. 
 
(R)-3-Phenyl-1-(1-phenyl-1H-imidazol-2-yl)-4-(p-tolyl)butan-1-one (55m) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium trifluoro(4-methylbenzyl)borate 54c (63.6 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 
mL) to give 55m as a white solid (63.0 mg, 0.166 mmol, yield: 83%). Enantiomeric excess established 
by HPLC analysis using a Chiralpak OJ-H column, ee = 96% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 50:50, flow rate 1.0 mL/min, 25 C, tr (minor) = 11.6 min, tr (major) = 22.5 min). 
[]D22 = 2.3 (c 0.75, CH2Cl2). 
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1H NMR (300 MHz, CDCl3) δ 7.47 – 7.34 (m, 3H), 7.33 – 7.15 (m, 6H), 7.12 (d, J = 1.0 Hz, 1H), 7.09 
– 6.95 (m, 6H), 3.79 – 3.59 (m, 2H), 3.52 – 3.34 (m, 1H), 3.10 – 2.86 (m, 2H), 2.32 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.0, 144.1, 143.3, 138.2, 136.7, 135.3, 129.3, 129.1, 128.8, 128.7, 
128.4, 128.2, 127.8, 126.7, 126.2, 125.6, 44.4, 43.09, 43.05, 20.9. 
IR (film): ν (cm1) 3127, 3025, 2918, 1675, 1592, 1494, 1440, 1401, 1308, 1062, 1034, 972, 918, 863, 
787, 759, 696, 531. 
HRMS (ESI, m/z) calcd for C26H25N2O [MH]: 381.1961, found: 381.1966. 
 
(R)-3-Phenyl-1-(1-phenyl-1H-imidazol-2-yl)-4-(o-tolyl)butan-1-one (55n) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium trifluoro(2-methylbenzyl)borate 54d (63.6 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 
mL) to give 55n as a colorless oil (63.2 mg, 0.166 mmol, yield: 83%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 94% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.5 min, tr (major) = 9.7 min). 
[]D22 = 13.4 (c 0.38, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.44 – 7.31 (m, 3H), 7.31 – 7.15 (m, 6H), 7.13 – 6.93 (m, 7H), 3.76 (dd, 
J = 15.8, 8.7 Hz, 1H), 3.70 – 3.56 (m, 1H), 3.41 (dd, J = 15.8, 5.5 Hz, 1H), 2.95 (d, J = 7.4 Hz, 2H), 
2.25 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.0, 144.2, 143.3, 138.2, 138.0, 136.4, 130.20, 130.15, 129.4, 128.8, 
128.5, 128.2, 127.8, 126.8, 126.3, 126.1, 125.6, 125.5, 44.2, 41.8, 41.1, 19.4. 
IR (film): ν (cm1) 3060, 3024, 2924, 2863, 1683, 1494, 1447, 1306, 964, 911, 757, 694, 521. 
HRMS (ESI, m/z) calcd for C26H25N2O [MH]: 381.1961, found: 381.1966. 
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(R)-4-(Naphthalen-2-yl)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55o) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium trifluoro(naphthalen-2-ylmethyl)borate 54e (74.4 mg, 0.30 mmol) in acetone/H2O (4:1, 
1.0 mL) to give 55o as pale yellow solid (65.1 mg, 0.156 mmol, yield: 78%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 92% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 13.2 min, tr (major) = 14.8 min). 
[]D22 = 30.0 (c 0.81, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.84 – 7.64 (m, 3H), 7.55 (s, 1H), 7.51 – 7.30 (m, 5H), 7.30 – 7.12 (m, 
7H), 7.07 (s, 1H), 6.96 – 6.82 (m, 2H), 3.79 (p, J = 7.4 Hz, 1H), 3.67 (dd, J = 16.5, 7.9 Hz, 1H), 3.53 
(dd, J = 16.5, 6.5 Hz, 1H), 3.13 (d, J = 7.5 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 189.7, 144.2, 143.2, 138.2, 137.4, 133.4, 132.1, 129.3, 128.8, 128.5, 
128.3, 127.9, 127.8, 127.7, 127.6, 127.51, 127.47, 126.8, 126.3, 125.7, 125.6, 125.2, 44.4, 43.8, 42.9. 
IR (film): ν (cm1) 3053, 2921, 2853, 1682, 1596, 1496, 1445, 1402, 1335, 1305, 1064, 1024, 961, 907, 
857, 817, 753, 693, 649, 518, 475. 
HRMS (ESI, m/z) calcd for C29H24N2ONa [MNa]: 439.1781, found: 439.1788. 
 
(R)-4-(4-Chlorophenyl)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55p) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium (4-chlorobenzyl)trifluoroborate 54f (69.6 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) 
to give 55p as a white solid (70.5 mg, 0.176 mmol, yield: 88%). Enantiomeric excess established by 
HPLC analysis using a Chiralpak OD-H column, ee = 91% (HPLC: OD-H, 254 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 13.5 min, tr (major) = 16.9 min). 
[]D22 = 62.6 (c 0.78, CH2Cl2). 
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1H NMR (300 MHz, CDCl3) δ 7.46 – 7.33 (m, 3H), 7.30 – 7.19 (m, 3H), 7.19 – 7.09 (m, 6H), 7.07 – 
6.99 (m, 2H), 6.96 (d, J = 8.3 Hz, 2H), 3.69 – 3.53 (m, 2H), 3.53 – 3.36 (m, 1H), 3.02 – 2.79 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 189.7, 143.6, 143.2, 138.3, 138.2, 131.8, 130.6, 129.4, 128.9, 128.6, 
128.3, 128.1, 127.8, 126.9, 126.4, 125.7, 44.5, 42.9, 42.8. 
IR (film): ν (cm1) 3059, 3029, 2922, 2855, 1682, 1596, 1492, 1446, 1403, 1306, 1090, 1014, 964, 911, 
760, 730, 694, 517. 
HRMS (ESI, m/z) calcd for C25H21ClN2ONa [MNa]: 423.1235, 424.1268 and 425.1205, found: 
423.1240, 424.1272 and 425.1209. 
 
(R)-4-(tert-Butoxy)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55q) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium (tert-butoxymethyl)trifluoroborate 54g (58.2 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 
mL) to give 55q as a white solid (66.2 mg, 0.183 mmol, yield: 91%). Enantiomeric excess established 
by HPLC analysis using a Chiralpak OJ-H column, ee = 98% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 50:50, flow rate 1.0 mL/min, 25 C, tr (minor) = 5.6 min, tr (major) = 8.3 min). 
[]D22 = 58.4 (c 0.83, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.46 – 7.35 (m, 3H), 7.35 – 7.17 (m, 6H), 7.17 – 7.07 (m, 3H), 3.79 (dd, 
J = 15.8, 6.0 Hz, 1H), 3.67 – 3.37 (m, 4H), 1.12 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 190.2, 143.4, 142.4, 138.4, 129.2, 128.8, 128.4, 128.2, 128.1, 126.6, 
126.4, 125.7, 72.7, 66.4, 42.3, 42.1, 27.4. 
IR (film): ν (cm1) 2969, 2902, 2862, 1688, 1603, 1495, 1603, 1495, 1449, 1405, 1188, 1087, 974, 764, 
696, 561, 524. 
HRMS (ESI, m/z) calcd for C23H27N2O2 [MH]: 363.2067, found: 363.2067. 
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(R)-4-(Benzo[d][1,3]dioxol-5-ylmethoxy)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one 
(55r) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium ((benzo[d][1,3]dioxol-5-ylmethoxy)methyl)trifluoroborate 54h (81.6 mg, 0.30 mmol) 
in acetone/H2O (4:1, 1.0 mL) to give 55r as a colorless oil (70.7 mg, 0.161 mmol, yield: 80%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 95% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 C, tr (minor) = 14.0 min, tr 
(major) = 17.2 min). []D22 = 34.5 (c 0.86, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.47 – 7.35 (m, 3H), 7.35 – 7.18 (m, 6H), 7.15 (d, J = 0.8 Hz, 1H), 7.12 
– 6.97 (m, 2H), 6.79 – 6.58 (m, 3H), 5.92 (dd, J = 6.0, 1.3 Hz, 2H), 4.36 (s, 2H), 3.88 – 3.70 (m, 2H), 
3.70 – 3.55 (m, 2H), 3.44 (dd, J = 15.1, 5.8 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.7, 147.6, 146.9, 143.2, 141.8, 138.3, 132.2, 129.3, 128.8, 128.4, 
128.3, 128.0, 126.8, 126.6, 125.6, 121.2, 108.4, 107.8, 100.8, 74.6, 72.8, 42.3, 41.7. 
IR (film): ν (cm1) 3061, 3029, 2859, 1683, 1598, 1493, 1443, 1404, 1242, 1091, 1034, 969, 923, 809, 
762, 696, 523. 
HRMS (ESI, m/z) calcd for C27H24N2O4Na [MNa]: 463.1628, found: 463.1635. 
 
(R)-4-Methoxy-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55s) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium trifluoro(methoxymethyl)borate 54i (45.6 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 
mL) to give 55s as a white solid (41.7 mg, 0.130 mmol, yield: 65%). Enantiomeric excess established 
by HPLC analysis using a Chiralpak AD-H column, ee = 96% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 17.5 min, tr (major) = 19.0 min). 
[]D22 = 64.5 (c 0.47, CH2Cl2). 
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1H NMR (300 MHz, CDCl3) δ 7.49 – 7.36 (m, 3H), 7.35 – 7.19 (m, 6H), 7.19 – 7.08 (m, 3H), 3.76 – 
3.43 (m, 5H), 3.29 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 189.8, 143.3, 141.8, 138.3, 129.4, 128.9, 128.5, 128.4, 127.9, 126.7, 
126.6, 125.7, 77.1, 58.7, 42.4, 41.5. 
IR (film): ν (cm1) 3059, 3029, 2922, 2876, 2823, 1688, 1495, 1446, 1403, 1306, 1112, 909, 760, 695, 
526. 
HRMS (ESI, m/z) calcd for C20H21N2O2 [MH]: 321.1598, found: 321.1598. 
 
(R)-4-(Benzyloxy)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55t) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium ((benzyloxy)methyl)trifluoroborate 54j (68.4 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 
mL) to give 55t as a colorless oil (53.3 mg, 0.135 mmol, yield: 67%). Enantiomeric excess established 
by HPLC analysis using a Chiralpak OD-H column, ee = 95% (HPLC: OD-H, 254 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 22.1 min, tr (major) = 24.8 min). 
[]D22 = 38.0 (c 0.28, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.42 – 7.32 (m, 3H), 7.32 – 7.24 (m, 8H), 7.24 – 7.16 (m, 3H), 7.12 (d, 
J = 0.8 Hz, 1H), 7.07 – 6.93 (m, 2H), 4.45 (s, 2H), 3.86 – 3.56 (m, 4H), 3.55 – 3.34 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.8, 143.3, 141.9, 138.3, 129.3, 128.8, 128.5, 128.4, 128.2, 128.0, 
127.6, 127.4, 126.8, 126.6, 125.7, 74.9, 73.0, 42.3, 41.7. 
IR (film): ν (cm1) 3060, 3029, 2919, 2855, 1683, 1599, 1495, 1447, 1403, 1306, 1093, 1030, 969, 909, 
756, 693, 524. 
HRMS (ESI, m/z) calcd for C26H25N2O2 [MH]: 397.1911, found: 397.1917. 
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(R)-4-((4-Methoxybenzyl)oxy)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (55u) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium trifluoro(((4-methoxybenzyl)oxy)methyl)borate 54k (77.4 mg, 0.30 mmol) in 
acetone/H2O (4:1, 1.0 mL) to give 55u as a colorless oil (51.8 mg, 0.122 mmol, yield: 61%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 95% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 19.4 min, tr 
(major) = 21.2 min). []D22 = 34.2 (c 0.32, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.45 – 7.32 (m, 3H), 7.32 – 7.17 (m, 6H), 7.17 – 7.07 (m, 3H), 7.07 – 
6.94 (m, 2H), 6.82 (d, J = 8.7 Hz, 2H), 4.39 (s, 2H), 3.85 – 3.68 (m, 5H), 3.68 – 3.53 (m, 2H), 3.51 – 
3.34 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.8, 159.1, 143.3, 141.9, 138.3, 130.5, 129.3, 129.2, 128.8, 128.4, 
128.3, 128.0, 126.7, 126.6, 125.7, 74.5, 72.6, 55.2, 42.3, 41.7. 
IR (film): ν (cm1) 2906, 2849, 1683, 1605, 1503, 1447, 1403, 1303, 1243, 1174, 1085, 1031, 969, 910, 
819, 761, 697, 522. 
HRMS (ESI, m/z) calcd for C27H26N2O3Na [MNa]: 449.1836, found: 449.1843. 
 
(R)-3-Phenyl-1-(1-phenyl-1H-imidazol-2-yl)-4-(2-(trimethylsilyl)ethoxy)butan-1-one (55v) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium trifluoro((2-(trimethylsilyl)ethoxy)methyl)borate 54l (71.4 mg, 0.30 mmol) in 
acetone/H2O (4:1, 1.0 mL) to give 55v as a colorless oil (53.0 mg, 0.130 mmol, yield: 65%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 94% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.3 min, tr 
(major) = 9.1 min). []D22 = 49.2 (c 0.40, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.47 – 7.33 (m, 3H), 7.32 – 7.15 (m, 6H), 7.15 – 7.04 (m, 3H), 3.85 – 
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3.21 (m, 7H), 0.98 – 0.59 (m, 2H), -0.03 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 190.0, 143.4, 142.1, 138.4, 129.3, 128.8, 128.5, 128.3, 128.0, 126.7, 
126.5, 125.7, 74.7, 68.1, 42.4, 41.8, 18.0, –1.4. 
IR (film): ν (cm1) 2950, 2855, 1685, 1495, 1447, 1405, 1247, 1094, 834, 758, 693, 525. 
HRMS (ESI, m/z) calcd for C24H30N2O2SiNa [MNa]: 429.1969, found: 429.1976. 
 
(S)-3-Cyclohexyl-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (55w) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium cyclohexyltrifluoroborate 54m (57.0 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) to 
give 55w as a colorless oil (58.1 mg, 0.162 mmol, yield: 81%). Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column, ee = 97% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 98:2, flow rate 1.0 mL/min, 25 C, tr (minor) = 16.5 min, tr (major) = 19.6 min). 
[]D22 = 64.6 (c 0.70, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.31 – 7.19 (m, 3H), 7.18 – 7.10 (m, 3H), 7.10 – 7.01 (m, 3H), 6.99 (d, 
J = 1.0 Hz, 1H), 6.85 – 6.72 (m, 2H), 3.58 – 3.34 (m, 2H), 3.07 (dd, J = 15.0, 7.8 Hz, 1H), 1.87 – 1.32 
(m, 6H), 1.24 – 0.66 (m, 5H). 
13C NMR (75 MHz, CDCl3) δ 190.8, 143.5, 143.4, 138.2, 129.3, 128.8, 128.7, 128.4, 127.9, 126.5, 
125.9, 125.5, 47.2, 43.5, 42.7, 31.0, 30.8, 26.5, 26.47, 26.36. 
IR (film): ν (cm1) 2922, 2850, 1683, 1595, 1494, 1445, 1403, 1305, 1047, 960, 911, 759, 734, 695, 
527. 
HRMS (ESI, m/z) calcd for C24H27N2O [MH]: 359.2118, found: 359.2122. 
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(S)-3-Cyclopentyl-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (55x) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium cyclopentyltrifluoroborate 54n (52.8 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) to 
give 55x as a colorless oil (52.4 mg, 0.152 mmol, yield: 76%). Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column, ee = 98% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 10.4 min, tr (major) = 12.8 min). 
[]D22 = 72.0 (c 0.44, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.44 – 7.30 (m, 3H), 7.29 – 7.11 (m, 6H), 7.08 (d, J = 1.0 Hz, 1H), 6.91 
(dd, J = 8.0, 1.7 Hz, 2H), 3.66 (dd, J = 16.0, 10.0 Hz, 1H), 3.46 (dd, J = 16.0, 5.0 Hz, 1H), 3.15 (td, J 
= 9.9, 5.0 Hz, 1H), 2.24 – 2.01 (m, 1H), 1.91 (dtd, J = 10.7, 7.3, 3.5 Hz, 1H), 1.77 – 1.19 (m, 6H), 1.17 
– 0.97 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ 190.5, 144.5, 143.4, 138.2, 129.3, 128.8, 128.4, 128.2, 128.0, 126.5, 
125.9, 125.5, 47.1, 46.9, 44.9, 31.32, 31.26, 25.2, 24.9. 
IR (film): ν (cm1) 3027, 2948, 2864, 1683, 1597, 1495, 1446, 1403, 1305, 1146, 1051, 964, 912, 759, 
695, 530. 
HRMS (ESI, m/z) calcd for C23H25N2O [MH]: 345.1961, found: 345.1967. 
 
(S)-4-Methyl-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)pentan-1-one (55y) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium trifluoro(isopropyl)borate 54o (45.0 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) to 
give 55y as a colorless oil (53.8 mg, 0.169 mmol, yield: 85%). Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column, ee = 98% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 9.4 min, tr (major) = 11.9 min). 
[]D22 = 76.2 (c 0.64, CH2Cl2). 
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1H NMR (300 MHz, CDCl3) δ 7.43 – 7.30 (m, 3H), 7.31 – 7.22 (m, 3H), 7.22 – 7.14 (m, 3H), 7.10 (d, 
J = 0.9 Hz, 1H), 6.91 (dd, J = 8.0, 1.6 Hz, 2H), 3.64 (dd, J = 16.1, 9.6 Hz, 1H), 3.49 (dd, J = 16.1, 5.6 
Hz, 1H), 3.16 (ddd, J = 9.6, 7.5, 5.7 Hz, 1H), 2.03 – 1.81 (m, 1H), 1.00 (d, J = 6.7 Hz, 3H), 0.81 (d, J 
= 6.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.7, 143.4, 143.3, 138.2, 129.3, 128.8, 128.7, 128.4, 127.9, 126.6, 
126.0, 125.5, 48.1, 42.7, 33.7, 20.7, 20.3. 
IR (film): ν (cm1) 2958, 2871, 1683, 1595, 1494, 1446, 1403, 1307, 1249, 1050, 967, 912, 859, 760, 
697, 538. 
HRMS (ESI, m/z) calcd for C21H23N2O [MH]: 319.1805, found: 319.1809. 
 
(S)-4,4-Dimethyl-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)pentan-1-one (55z) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h (54.8 mg, 0.2 mmol) reacted 
with potassium tert-butyltrifluoroborate 54p (49.2 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) to 
give 55z as a colorless oil (45.5 mg, 0.137 mmol, yield: 69%). Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column, ee = 77% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.4 min, tr (major) = 10.3 min). 
[]D22 = 49.4 (c 0.55, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.40 – 7.12 (m, 9H), 7.07 (d, J = 0.9 Hz, 1H), 6.77 (dd, J = 8.1, 1.4 Hz, 
2H), 3.84 (dd, J = 15.8, 11.0 Hz, 1H), 3.38 (dd, J = 15.9, 4.5 Hz, 1H), 3.24 (dd, J = 10.9, 4.5 Hz, 1H), 
0.95 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 191.1, 143.6, 141.9, 138.1, 129.9, 129.2, 128.8, 128.3, 127.5, 126.4, 
126.0, 125.4, 51.6, 40.0, 33.8, 28.0. 
IR (film): ν (cm1) 3060, 3029, 2958, 2904, 2870, 1684, 1596, 1495, 1447, 1403, 1304, 1063, 1032, 
965, 913, 759, 696, 530. 
HRMS (ESI, m/z) calcd for C22H25N2O [MH]: 333.1961, found: 333.1965. 
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(S)-1-(1-Isopropyl-1H-imidazol-2-yl)-4,4-dimethyl-3-phenylpentan-1-one (55z’) 
 
According to the general procedure, ,-unsaturated acyl imidazole 53h’ (48.0 mg, 0.2 mmol) reacted 
with potassium tert-butyltrifluoroborate 54p (49.2 mg, 0.30 mmol) in acetone/H2O (4:1, 1.0 mL) to 
give 55z’ as a colorless oil (55.4 mg, 0.186 mmol, yield: 93%). Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column, ee = 98% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 7.8 min, tr (minor) = 9.1 min). 
[]D22 = 5.7 (c 0.68, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.18 – 6.97 (m, 7H), 5.19 (hept, J = 6.7 Hz, 1H), 3.79 (dd, J = 16.6, 
10.9 Hz, 1H), 3.32 (dd, J = 16.6, 4.2 Hz, 1H), 3.15 (dd, J = 10.9, 4.2 Hz, 1H), 1.20 (d, J = 6.7 Hz, 3H), 
1.11 (d, J = 6.7 Hz, 3H), 0.86 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 192.6, 142.8, 142.2, 129.6, 129.1, 127.3, 125.9, 120.6, 51.3, 48.8, 40.4, 
33.8, 28.1, 23.4, 23.2. 
IR (film): ν (cm1) 2960, 2905, 2870, 1673, 1455, 1396, 1254, 1224, 1140, 1081, 1018, 981, 915, 763, 
707. 
HRMS (ESI, m/z) calcd for C19H27N2O [MH]: 299.2118, found: 299.2120. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-methyl-4-phenylbutan-1-one (59a) 
 
According to the general procedure, ,-unsaturated acyl pyrazole 58a (32.8 mg, 0.2 mmol) reacted 
with potassium benzyltrifluoroborate 54a (59.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 mL) to give 
59a as a colorless oil (31.8 mg, 0.124 mmol, yield: 62%). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee = 96% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
99.5:0.5, flow rate 1.0 mL/min, 25 C, tr (minor) = 6.8 min, tr (major) = 7.3 min). []D22 = 53.8 (c 
0.28, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.33 – 7.23 (m, 2H), 7.23 – 7.13 (m, 3H), 5.94 (s, 1H), 3.11 (dd, J = 
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16.6, 5.9 Hz, 1H), 3.01 (dd, J = 16.6, 7.3 Hz, 1H), 2.83 – 2.65 (m, 1H), 2.62 – 2.40 (m, 5H), 2.24 (s, 
3H), 1.00 (d, J = 6.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.4, 151.6, 144.0, 140.5, 129.2, 128.2, 125.9, 111.0, 43.1, 41.7, 31.7, 
19.8, 14.6, 13.8. 
IR (film): ν (cm1) 3061, 3027, 2960, 2925, 1724, 1582, 1378, 1335, 993, 963, 745, 700. 
HRMS (ESI, m/z) calcd for C16H21N2O [MH]: 257.1648, found: 257.1651. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-methyl-4-(o-tolyl)butan-1-one (59b) 
 
According to the general procedure, ,-unsaturated acyl pyrazole 58a (32.8 mg, 0.2 mmol) reacted 
with potassium trifluoro(2-methylbenzyl)borate 54d (63.6 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 
mL) to give 59b as a colorless oil (33.0 mg, 0.122 mmol, yield: 61%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak OJ-H column, ee = 95% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 6.4 min, tr (major) = 6.8 min). 
[]D22 = 44.1 (c 0.28, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.23 – 6.96 (m, 4H), 5.94 (s, 1H), 3.15 (dd, J = 16.2, 5.6 Hz, 1H), 3.03 
(dd, J = 16.3, 7.2 Hz, 1H), 2.83 – 2.65 (m, 1H), 2.64 – 2.39 (m, 5H), 2.34 (s, 3H), 2.24 (s, 3H), 1.01 (d, 
J = 6.2 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.4, 151.6, 143.9, 138.8, 136.4, 130.2, 130.1, 126.1, 125.6, 110.9, 
42.2, 40.5, 30.5, 19.9, 19.4, 14.5, 13.8. 
IR (film): ν (cm1) 2958, 2926, 2867, 1722, 1580, 1375, 1331, 960, 741. 
HRMS (ESI, m/z) calcd for C17H22N2ONa [MNa]: 293.1624, found: 293.1628. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-methyl-4-(naphthalen-2-yl)butan-1-one (59c) 
 
According to the general procedure, ,-unsaturated acyl pyrazole 58a (32.8 mg, 0.2 mmol) reacted 
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with potassium trifluoro(naphthalen-2-ylmethyl)borate 54e (74.4 mg, 0.30 mmol) in acetone/H2O (1:1, 
1.0 mL) to give 59c as a colorless oil (41.8 mg, 0.137 mmol, yield: 68%). Enantiomeric excess 
established by HPLC analysis using a Chiralpak OJ-H column, ee = 96% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.4 min, tr (major) = 12.9 min). 
[]D22 = 42.0 (c 0.39, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.89 – 7.69 (m, 3H), 7.63 (s, 1H), 7.55 – 7.30 (m, 3H), 5.91 (s, 1H), 
3.17 (dd, J = 16.6, 6.0 Hz, 1H), 3.05 (dd, J = 16.5, 7.3 Hz, 1H), 2.91 (dd, J = 13.0, 6.4 Hz, 1H), 2.78 – 
2.53 (m, 2H), 2.48 (s, 3H), 2.24 (s, 3H), 1.04 (d, J = 6.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.3, 151.6, 143.9, 138.1, 133.5, 132.1, 127.9, 127.7, 127.54, 127.47, 
127.46, 125.8, 125.1, 111.0, 43.3, 41.7, 31.6, 19.9, 14.5, 13.8. 
IR (film): ν (cm1) 3052, 2960, 2924, 2872, 1721, 1582, 1375, 1330, 960, 893, 859, 809, 745, 474. 
HRMS (ESI, m/z) calcd for C20H22N2ONa [MNa]: 329.1624, found: 329.1629. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(4-methylbenzyl)pentan-1-one (59d) 
 
According to the general procedure, ,-unsaturated acyl pyrazole 58b (35.6 mg, 0.2 mmol) reacted 
with potassium trifluoro(4-methylbenzyl)borate 54c (63.6 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 
mL) to give 59d as a white solid (30.8 mg, 0.109 mmol, yield: 54%). Enantiomeric excess established 
by HPLC analysis using a Chiralpak OJ-H column, ee = 96% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 4.4 min, tr (major) = 5.8 min). 
[]D22 = 45.2 (c 0.35, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.11 – 7.02 (m, 4H), 5.92 (s, 1H), 3.09 (dd, J = 16.9, 6.8 Hz, 1H), 3.01 
(dd, J = 16.9, 6.8 Hz, 1H), 2.66 (dd, J = 13.6, 7.2 Hz, 1H), 2.58 (dd, J = 13.7, 7.3 Hz, 1H), 2.49 (s, 3H), 
2.40 – 2.25 (m, 5H), 2.23 (s, 3H), 1.51 – 1.32 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.8, 151.5, 143.9, 137.5, 135.2, 129.2, 128.8, 110.9, 39.7, 38.7, 38.0, 
26.4, 21.0, 14.5, 13.8, 11.1. 
IR (film): ν (cm1) 2962, 2925, 2866, 1724, 1581, 1513, 1450, 1410, 1378, 1340, 962, 805, 745. 
HRMS (ESI, m/z) calcd for C18H24N2ONa [MNa]: 307.1781, found:307.1786. 
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(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(4-methoxybenzyl)hexan-1-one (59e) 
 
According to the general procedure, ,-unsaturated acyl pyrazole 58c (38.4 mg, 0.2 mmol) reacted 
with potassium trifluoro(4-methoxybenzyl)borate 54b (68.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 
mL) to give 59e as a colorless oil (47.2 mg, 0.150 mmol, yield: 75%). Enantiomeric excess established 
by HPLC analysis using a Chiralpak OJ-H column, ee = 97% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 99.5:0.5, flow rate 1.0 mL/min, 25 C, tr (major) = 14.1 min, tr (minor) = 17.4 
min). []D22 = 57.0 (c 0.56, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.10 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 5.92 (s, 1H), 3.77 (s, 
3H), 3.08 (dd, J = 15.0, 4.7 Hz, 1H), 3.00 (dd, J = 14.9, 4.8 Hz, 1H), 2.65 (dd, J = 13.6, 7.0 Hz, 1H), 
2.55 (dd, J = 13.6, 7.3 Hz, 1H), 2.48 (s, 3H), 2.46 – 2.30 (m, 1H), 2.23 (s, 3H), 1.50 – 1.23 (m, 4H), 
0.88 (t, J = 6.6 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.7, 157.8, 151.4, 143.9, 132.6, 130.1, 113.6, 110.9, 55.2, 39.7, 39.1, 
36.3, 36.2, 19.9, 14.5, 14.2, 13.7. 
IR (film): ν (cm1) 2956, 2925, 2866, 1722, 1611, 1581, 1510, 1457, 1410, 1377, 1335, 1242, 1174, 
1034, 960, 805, 741, 521. 
HRMS (ESI, m/z) calcd for C19H26N2O2Na [MNa]: 337.1886, found: 337.1891. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(4-methoxybenzyl)octan-1-one (59f) 
 
According to the general procedure, ,-unsaturated acyl pyrazole 58d (44.0 mg, 0.2 mmol) reacted 
with potassium trifluoro(4-methoxybenzyl)borate 54b (68.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 
mL) to give 59f as a colorless oil (41.9 mg, 0.122 mmol, yield: 61%). Enantiomeric excess established 
by HPLC analysis using a Chiralpak OJ-H column, ee = 90% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 99.5:0.5, flow rate 1.0 mL/min, 25 C, tr (major) = 10.5 min, tr (minor) = 13.1 
min). []D22 = 31.8 (c 0.45, CH2Cl2). 
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1H NMR (300 MHz, CDCl3) δ 7.10 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 5.92 (s, 1H), 3.77 (s, 
3H), 3.07 (dd, J = 14.5, 4.4 Hz, 1H), 3.00 (dd, J = 14.5, 4.4 Hz, 1H), 2.65 (dd, J = 13.6, 7.0 Hz, 1H), 
2.55 (dd, J = 13.7, 7.3 Hz, 1H), 2.48 (s, 3H), 2.44 – 2.28 (m, 1H), 2.23 (s, 3H), 1.47 – 1.14 (m, 8H), 
0.86 (t, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.7, 157.8, 151.4, 143.9, 132.6, 130.2, 113.6, 110.9, 55.2, 39.7, 39.1, 
36.6, 33.8, 32.0, 26.4, 22.6, 14.5, 14.0, 13.8. 
IR (film): ν (cm1) 2925, 2856, 1723, 1510, 1377, 1336, 1242, 1175, 1035, 961, 804, 747, 521. 
HRMS (ESI, m/z) calcd for C21H30N2ONa [MNa]: 365.2199, found: 365.2205. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-(4-methoxyphenyl)-3-phenylbutan-1-one (59g) 
 
According to the general procedure, ,-unsaturated acyl pyrazole 58e (45.2 mg, 0.2 mmol) reacted 
with potassium trifluoro(4-methoxybenzyl)borate 54b (68.4 mg, 0.30 mmol) in acetone/H2O (1:1, 1.0 
mL) to give 59g as a white solid (51.0 mg, 0.147 mmol, yield: 73%). Enantiomeric excess established 
by HPLC analysis using a Chiralpak AD-H column, ee = 83% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 98:2, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.7 min, tr (major) = 8.6 min). 
[]D22 = 45.6 (c 0.31, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.34 – 7.14 (m, 5H), 7.02 (d, J = 8.6 Hz, 2H), 6.76 (d, J = 8.6 Hz, 2H), 
5.91 (s, 1H), 3.77 (s, 3H), 3.71 – 3.52 (m, 2H), 3.51 – 3.37 (m, 1H), 2.95 (d, J = 7.1 Hz, 2H), 2.43 (s, 
3H), 2.25 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.5, 157.9, 151.6, 144.0, 143.9, 131.8, 130.1, 128.2, 127.7, 126.3, 
113.5, 110.9, 55.1, 43.4, 42.3, 40.6, 14.4, 13.7. 
IR (film): ν (cm1) 3060, 2990, 2921, 2834, 1707, 1510, 1377, 1309, 1241, 1170, 963, 809, 757, 700, 
594, 523. 
HRMS (ESI, m/z) calcd for C22H24N2O2Na [MNa]: 371.1730, found: 371.1735. 
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5.7.3 Synthetic Transformations 
 
To a solution of 5e (46.0 mg, 0.146 mmol) in THF/H2O (4/1, 1.5 mL, 0.1 M) at 0 C was added 
NaBH4 (56.0 mg, 1.5 mmol). The reaction mixture was stirred at room temperature for overnight. The 
reaction was quenched with aqueous 2 N HCl (1.0 mL) at room temperature and extracted with DCM 
(4  10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:5) to afford 5e’ (32.5 mg, 0.146 mmol, yield: 100%) as a colorless oil. 
 
(R)-3-(4-Methoxybenzyl)hexan-1-ol (59e’) 
 
Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 97% (HPLC: 
OD-H, 254 nm, hexane/isopropanol = 96:4, flow rate 1.0 mL/min, 25 C, tr (major) = 11.7 min, tr 
(minor) = 13.0 min). []D22 = 6.9 (c 0.40, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.07 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 3.79 (s, 3H), 3.65 (pd, 
J = 10.5, 6.9 Hz, 2H), 2.57 (dd, J = 13.7, 6.7 Hz, 1H), 2.46 (dd, J = 13.7, 7.3 Hz, 1H), 1.84 – 1.67 (m, 
1H), 1.53 (dd, J = 13.5, 6.8 Hz, 2H), 1.46 – 1.21 (m, 5H), 0.89 (t, J = 7.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 157.8, 133.2, 130.0, 113.6, 61.1, 55.2, 39.8, 36.54, 36.45, 35.9, 19.7, 
14.3. 
IR (film): ν (cm1) 3336, 2922, 2867, 1611, 1510, 1456, 1242, 1176, 1034, 822, 520. 
HRMS (ESI, m/z) calcd for C14H22O2Na [MNa]: 245.1512, found: 245.1515. 
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To a solution of (S)-3w (90.0 mg, 0.25 mmol) in CH3CN (2.5 mL) was added 4 Å MS (250 mg, 100 
mg/0.1 mmol of 3w) under nitrogen atmosphere. The suspension was stirred vigorously under a 
positive pressure of nitrogen for 2 h at room temperature, and then methyl trifluoromethansulfonate 
(41 L, 0.38 mmol) was added at room temperature. After being stirred at room temperature for 2 h, 
EtOH (1.25 mL) and DBU (0.50 mL) were subsequently added to the reaction mixture at 0 C. After 
being stirred at 0 C for 60 min, the solvent was evaporated and the residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:50) to give 3w’ (58.6 mg, 0.225 mmol, yield: 90%) 
as a colorless oil. 
 
(S)-Ethyl 3-cyclohexyl-3-phenylpropanoate (55w’) 
 
Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 97% (HPLC: 
OD-H, 254 nm, hexane/isopropanol = 98:2, flow rate 0.5 mL/min, 25 C, tr (major) = 9.6 min, tr 
(minor) = 14.2 min). []D22 = 21.4 (c 0.64, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.25 – 7.14 (m, 2H), 7.14 – 7.00 (m, 3H), 3.88 (q, J = 7.1 Hz, 2H), 2.89 
– 2.77 (m, 1H), 2.72 (dd, J = 14.8, 5.6 Hz, 1H), 2.47 (dd, J = 14.8, 9.8 Hz, 1H), 1.80 – 1.62 (m, 2H), 
1.62 – 1.47 (m, 2H), 1.48 – 1.31 (m, 2H), 1.24 – 0.92 (m, 6H), 0.92 – 0.65 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 172.9, 143.2, 128.3, 128.0, 126.2, 60.0, 48.2, 42.9, 38.5, 31.0, 30.8, 26.5, 
26.4, 14.00. 
IR (film): ν (cm1) 2979, 2924, 2852, 1732, 1448, 1371, 1251, 1153, 1033, 758, 700. 
HRMS (ESI, m/z) calcd for C17H24O2Na [MNa]: 283.1669, found: 283.1669. 
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5.7.4 Mechanistic Experiments 
1) Trapping Experiment with TEMPO 
As shown in Scheme 20-21, the experiment data of compound 61 are shown below. 
 
1-((4-Methoxybenzyl)oxy)-2,2,6,6-tetramethylpiperidine (61) 
 
1H NMR (300 MHz, CDCl3) δ 7.21 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 4.66 (s, 2H), 3.72 (s, 
3H), 1.64 – 1.22 (m, 6H), 1.18 (s, 6H), 1.05 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ 159.0, 130.5, 129.1, 113.7, 78.4, 59.9, 55.2, 39.7, 33.2, 20.3, 17.1. 
All spectroscopic data were in agreement with the literature.38  
 
2) Control Experiments 
See Figure 87-90 
 
3) Competition Experiment (Figure 86) 
A dried 10 mL Schlenk tube was charged with the catalyst rac-RhS or rac-RhO (0 or 4 mol%), 
sensitizer [Acr-Mes]ClO4 (2 mol%), ,-unsaturated 2-acyl imidazole 53c (21.2 mg, 0.1 mmol, 1.0 
eq), 3-buten-2-one 53c’ (8.1 µL, 0.1 mmol, 1.0 eq), BnBF3K (0.15 mmol, 1.5 eq), 0.5 mL acetone/H2O 
(1:1, 0.1 M). The reaction mixture was degassed via freeze-pump-thaw for three cycles. After the 
mixture was thoroughly degassed, the vial was sealed and positioned approximately 10 cm from a 24 
W blue LEDs lamp. After being irradiated for 2.5 h, the reaction mixture was passed through a short 
silica gel column. The yield of product formed was measured by 1H-NMR analysis with 
1,1,2,2-tetrachloroethane (0.1 mmol/mL in CDCl3) as internal standard. 
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Figure 120 1H NMR (300 MHz, in CDCl3) spectra of 55c, 55c’ (as references) and the crude product 
from the photolysis. Yield was inferred by integration ratio (signals ‘ ’ and ‘ ’). 
Chapter 6. Experimental Part 
320 
 
4) Luminescence Quenching Experiments 
As shown in Figure 92-94, the luminescence quenching experiments with the photoredox catalyst were 
investigated both in the presence and absence of RhS and olefin. Emission intensities were recorded 
on a Spectra Max M5 microplate reader in a 10.0 mm quartz cuvette. The solutions of 
Ir[dF(CF3)ppy]2(bpy)PF6 were excited at max = 375 nm and the emission was measured at 475 nm 
(emission maximum). The sensitizer Ir[dF(CF3)ppy]2(bpy)PF6 was used for the quenching experiments 
due to stronger luminescence intensities. The concentration of the photoredox catalyst solution 
(iridium sensitizer or iridium sensitizer in presence of RhS and Michael acceptor 53c) was 0.5 mM in 
acetone/H2O (4:1). The concentration of the quencher (potassium trifluoroborates 54c, 54h, 54m, 
Michael acceptor 53c) stock solution was 200 mM in acetone/H2O (4:1). For each quenching 
experiment, 5 L of this stock solution were titrated to a solution (1 mL) of iridium complex in a 
screw-top 10.0 mm quartz cuvette. The addition of 5 L stock solution refers to an increase of the 
quencher concentration of 1 mM. After degassing with an argon stream for 5 minutes, the emission 
intensity was collected. 
 
5) Quantum Yield Measurement 
The quantum yield was measured by standard ferrioxalate actinometry. A 150 W xenon lamp (50% of 
light intensity, 420  5 nm bandpass filter) was used as the light source. The measured method was 
designed according to a published procedure with slight modifications.39 All the light sensitive 
operations were processed in the darkroom under red light. 
The solutions were prepared and stored in the dark:  
Potassium ferrioxalate solution (0.15 M): 736.9 mg of potassium ferrioxalate hydrate was dissolved 
in 10 mL of 0.05 M H2SO4. 
Buffered solution of phenanthroline: 50 mg of 1,10-phenanthroline and 11.25 g of sodium acetate 
were dissolved in 50 mL of 0.5 M H2SO4. 
 
5.1) Measurement of light intensity at 420 nm 
1000 L of the ferrioxalate solution was added to a quartz cuvette (l = 10 mm). The actinometry 
solution was irradiated with 150 W Xennon Lamp (50% of light intensity, 420 nm  5 nm) for 
specified time intervals (30, 60, 90, 120 seconds). After irradiation, 175 L of the phenanthroline 
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solution was added to the cuvette. The solution was kept in dark for 30 min to make sure the complete 
coordination. The absorbance of the actinometry solution was monitored at 510 nm. The absorbance of 
a non-irradiated (in dark) sample was also measured at 510 nm. 
The moles of Fe2 formed were determined using Beer’s Law: 
moles Fe2
)510(10
)510(
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nmlV
nmAVV
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
  
Where V1 (1 mL) is the irradiated volume, V2 (1 mL) is the aliquot of the irradiated solution taken for 
the determination of the ferrous ions. V3 (1.175 mL) is the final volume after complexation with 
phenanthroline (all in mL), l is the path length (1 cm), and A(510nm) is the optical difference in 
absorbance between the irradiated and non-irradiated solutions, (510 nm) is the molar absorptivity of 
Fe(phen)32 (11100 L mol-1 cm-1). 
One calculation example of moles Fe2 (when t = 30 s) was shown below: 
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= 2.879  108 mol 
The moles of Fe2 formed for each sample (30, 60, 90, 120 s) are listed as follows: 
irradiation time 30 s 60 s 90 s 120 s 
A 0.272 0.566 0.854 1.111 
Fe2 (108 mol) 2.879 5.991 9.040 11.760 
The moles of Fe2 formed are plotted as a function of time (t). The slope is shown as: 
d(moles Fe2)/dt = 9.891  1010 
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Adj. R-Square 0.9998
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The photon flux can be calculated as:  
photon flux (einstein s-1)
ft
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Where Φ is the quantum yield for the ferrioxalate actinometer (1.05 for a 0.15 solution at 412 nm; 1.04 
for a 0.15 solution at 422 nm; 1.03 for a 0.15 solution at 433 nm),40 t is the irradiated time, and f is the 
fraction of light absorbed at  = 420 nm (f = 110-A).The measurement of the fraction of the light at 
420 nm for the ferrioxalate solution was shown in Figure 120 The absorbance of the ferrioxalate 
solution at 420 nm is >3 indicating f (f = 110-A) is >0.999. 
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Figure 121 Absorbance of the ferrioxalate actinometer solution (0.15 M). 
 
5.2) Measurement of quantum yield: 
Model reaction: 
 
The Newport instrument for quantum yield determination was set up at a fixed position in a dark room 
(red light). A screw-top cuvette (10.0 mm) was charged with the Lewis acid catalyst rac-RhS (4 
mol%), sensitizer [Acr-Mes]ClO4 (2 mol%), ,-unsaturated 2-acyl imidazole 53h (0.1 mmol, 1.0 eq), 
trifluoroborate 54c (0.15 mmol, 1.5 eq), 1.0 mL acetone/H2O (4:1, 0.1 M) and a small magnetic stir 
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bar. The cuvette was degassed with an argon stream for 10 min. After the mixture was thoroughly 
degassed, the vial was sealed and fixed at the same position as the measurement of photon flux. The 
reaction mixture was stirred and irradiated for specified time intervals (2, 3, 4 h). After irradiation, the 
reaction mixture was passed through a short silica gel column. The moles of product formed was 
measured by GC analysis (FID detector, column: HP-5) using tetradecane as internal standard. 
Determination of response factor for GC analysis: 
The internal standard remained constant for every measurement. The number of moles of products is 
related to the ratios of integrated areas (product/internal standard). The relation formula was yielded as 
y = 1.228E-6  x (y is the moles of product 55m, x is the ratio of integrated areas). 
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Equation y = a + b*x
Adj. R-Square 0.99627
Value Standard Error
B Intercept 0 --
B Slope 1.22805E-6 3.35983E-8
 
The relation between the produced molecules and incident photons: 
After irradiation for specified time (2, 3, 4 h), the moles of formed product 55m was calculated below 
(y = 1.228E-6  x): 
irradiation time (S) 7200 10800 14400 
ratio of integrated areas 
(55m / tetradecane) 
1.687 2.539 3.568 
product (10-6 mol) 2.072 3.118 4.382 
The number of molecules generated is related to the number of photons absorbed. The number of 
photons absorbed is correlated to the number of incident photons. The relation between the number of 
formed molecules and the number of incident photons was shown below (y = 0.31x). 
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The measurements were repeated a second time to provide the moles of product as below (y = 
1.228E-6  x): 
irradiation time (S) 7200 10800 14400 
ratio of integrated areas 
(55m / tetradecane) 
1.715 2.634 3.748 
product (10-6 mol) 2.106 3.234 4.602 
The relation between the number of formed molecules and the number of incident photons was shown 
below (y = 0.32x). 
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Overall quantum yield: 

)101(
 
)420( nmAphotonsincidentofmoles
productofmoles
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  
The slope yields the value of d (moles of product)/ d (moles of incident photons). Absorbance at 420 
nm is >3 (Figure 121) demonstrating that the fraction of light absorbed is >0.999 (f = 110-A). The 
absorbance of reaction mixture in acetone/H2O (4:1) was measured at a dilute concentration (10% of 
the reaction conditions above). 
Due to the fraction of light absorbed is >0.999, the slopes provide the overall quantum yield () of the 
photoreaction as 0.31 and 0.32 respectively for these two independent measurements. It is important to 
note that these values present overall quantum yields and do not take into account that there are more 
than one photoactive species in this system (see Figure 91).  
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Figure 122 Absorbance of the reaction solution (RhS = 0.4 mM, [Acr-Mes]ClO4 = 0.2 mM in 
acetone/H2O (4:1)). 
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6) Synthesis of Intermediate Complex I 
 
The racemic complex RhS-Py was obtained by reacting Michael acceptor 6e (9.0 mg, 0.04 mmol) 
with racemic /-RhS (34.5 mg, 0.04 mmol) at room temperature for 5 min in CH2Cl2 (2.0 mL). 
Afterwards, the solution was evaporated and the resulting solid was dissolved in CH2Cl2 (2.0 mL) 
follow by concentrated under vacuum. The labile ligands (CH3CN) were completely removed via 
dissolved-evaporated for five cycles. The residue yellow solid was washed by Et2O (4  1 mL), the 
pure yellow solid was obtained (41.4 mg, yield: 100%). 
1H NMR (300 MHz, CD2Cl2) δ 8.44 (d, J = 15.3 Hz, 1H), 8.00 (dd, J = 8.3, 7.3 Hz, 2H), 7.89 – 7.78 
(m, 2H), 7.75 (d, J = 1.4 Hz, 1H), 7.70 (d, J = 7.1 Hz, 2H), 7.67 – 7.58 (m, 3H), 7.54 (t, J = 7.3 Hz, 
2H), 7.29 (d, J = 15.3 Hz, 1H), 7.24 – 7.11 (m, 2H), 7.06 (d, J = 1.4 Hz, 1H), 6.97 (qd, J = 7.7, 1.3 Hz, 
2H), 6.52 (s, 1H), 6.47 (d, J = 7.9 Hz, 1H), 6.36 (d, J = 7.8 Hz, 1H), 2.82 (s, 3H), 1.84 (s, 3H), 1.26 (s, 
9H), 1.22 (s, 9H). 
13C NMR (75 MHz, CD2Cl2) δ 178.1, 175.9, 169.4, 162.3, 161.9, 161.1, 160.7, 160.3, 156.5, 152.9, 
152.8, 150.1, 150.0, 145.9, 141.0, 140.2, 134.4, 134.2, 134.1, 133.2, 131.7, 131.6, 130.1, 130.0, 129.4, 
129.3, 127.1, 126.7, 125.4, 124.9, 124.7, 123.3, 117.9, 115.5, 115.0, 112.5, 35.5, 35.3, 31.7, 31.5, 16.2, 
13.6. 
IR (film): ν (cm1) 3057, 2959, 2868, 1632, 1564, 1442, 1410, 1354, 1321, 1291, 1249, 1080, 1031, 
987, 833, 758, 726, 671, 579, 552, 489, 455. 
HRMS (APCI, m/z) calcd for C48H46N4ORhS2 [M]: 861.2163 and 862.2194, found: 861.2168 and 
862.2202. 
Chapter 6. Experimental Part 
327 
 
 
The racemic complex RhS-Im was obtained by reacting Michael acceptor 53h (21.9 mg, 0.08 mmol) 
with racemic /-RhS (69.0 mg, 0.08 mmol) at room temperature for 5 min in CH2Cl2 (2.0 mL). 
Afterwards, the solution was evaporated and the resulting solid was dissolved in CH2Cl2 (2.0 mL) 
follow by concentrated under vacuum. The labile ligands (CH3CN) were completely removed via 
dissolved-evaporated for five cycles. The residue orange solid was washed by Et2O (4  1 mL), the 
pure orange solid was obtained (84.0 mg, yield: 99%). 
1H NMR (300 MHz, CD2Cl2) δ 8.15 (d, J = 15.4 Hz, 1H), 7.94 (t, J = 8.8 Hz, 2H), 7.84 (td, J = 7.5, 
1.0 Hz, 2H), 7.77 (d, J = 7.5 Hz, 1H), 7.72 – 7.62 (m, 4H), 7.58 (ddd, J = 17.4, 8.6, 1.6 Hz, 2H), 7.47 
(t, J = 7.4 Hz, 1H), 7.40 – 7.11 (m, 7H), 7.08 (d, J = 7.5 Hz, 2H), 6.96 (t, J = 7.6 Hz, 3H), 6.49 (dd, J = 
14.6, 7.8 Hz, 2H), 6.33 (d, J = 15.4 Hz, 1H), 1.19 (s, 9H), 1.18 (s, 9H). 
13C NMR (75 MHz, CD2Cl2) δ 182.5, 178.33, 178.28, 175.44, 175.40, 164.0, 163.6, 160.3, 159.9, 
153.1, 152.6, 152.4, 150.0, 149.3, 146.0, 141.4, 139.9, 135.8, 135.2, 134.4, 133.9, 133.3, 132.3, 131.5, 
131.3, 131.1, 129.9, 129.8, 129.5, 129.4, 126.9, 126.8, 126.6, 125.2, 124.8, 124.7, 124.5, 123.4, 123.2, 
118.9, 115.8, 115.7, 35.39, 35.37, 31.6. 
IR (film): ν (cm1) 2956, 2920, 2863, 1615, 1580, 1529, 1486, 1443, 1404, 1294, 1158, 1114, 1079, 
1026, 990, 928, 831, 769, 728, 691, 554, 458, 407. 
HRMS (APCI, m/z) calcd for C52H46N4ORhS2 [M]: 909.2163 and 910.2194, found: 909.2169 and 
910.2203. 
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5.7.5 Single-Crystal X-Ray Diffraction Studies 
Single crystals of (R)-55k (H53) suitable for X-ray diffraction were obtained by slow diffusion from a 
solution of (R)-55k (20 mg) in CH2Cl2 (0.3 mL) layered with Et2O (2.5 mL) at 20 C for several days 
in a glass tube. The absolute configuration of compound (R)-55k (H53) has been determined.  
Single crystals of intermediate I (RhS-Py) suitable for X-ray diffraction were obtained by slow 
diffusion from a solution of RhS-Py (20 mg) in CH2Cl2 (0.5 mL) layered with Et2O (1.5 mL) at room 
temperature for several days in a glass tube. 
Crystal data and details of the structure determination are presented in the Appendices (Chapter 6.7). 
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Chapter 6. Appendices 
6.1 List of Abbreviations 
1H NMR proton nuclear magnetic resonance spectroscopy 
13C NMR carbon nuclear magnetic resonance spectroscopy 
9F NMR fluorine nuclear magnetic resonance spectroscopy 
δ chemical shift 
J coupling constant 
br broad 
s singlet 
d doublet 
t triplet 
q quartet 
m multiplet 
ppm parts per million 
AcOH acetic acid 
ada adamantane 
aq aqueous 
Ar argon 
BArF24 tetrakis[(3,5-di-trifluoromethyl)phenyl]borate 
bpy 2,2 -´bipyridine 
CD circular dichroism 
CH2Cl2/ DCM dichloromethane 
CD2Cl2 dideuteromethylenechloride 
CHCl3 chloroform 
CDCl3 deuterochloroform 
CH3CN/ MeCN acetonitrile 
conc concentrated 
DBU 1,8-diazabicycloundec-7-ene 
DIPEA N,N-diisopropylethylamine 
DMAc dimethylacetamide 
DMAP 4-dimethylaminopyridine 
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DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNB dinitrobenzene 
DTBP 2,6-Di-tert-butylpyridine 
dr diastereomeric ratio 
EDA electron donor-acceptor 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
ee enantiomeric excesses 
e.g. exempli gratia (lat.: for example) 
en ethylenediamine 
er enantiomeric ratio 
et al. et alii (lat.: and others) 
ESI electrospray ionization 
EtOH ethanol 
Et2O diethyl ether 
Et2NH diethyl amine 
Et3N triethyl amine 
EtOAc ethyl acetate 
EWG electron withdrawing group 
HAT hydrogen atom transfer 
h hour(s) 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz Hertz 
IR spectra infrared spectra 
Ir iridium 
L liter(s) 
M mol/liter 
m meta- 
min minute(s) 
mL milliliter(s) 
MLCT metal-to-ligand charge transfer 
mmol millimole 
MS mass spectroscopy 
N2 nitrogen 
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NBS N-bromosuccinimide 
Nu nucleophile 
PCET proton-coupled electron transfer 
Ph phenyl 
PPh3 triphenylphosphine 
ppm parts per million 
ppy 2-phenylpyridine 
PS photosensitizer 
rac racemate 
RCM ring closing metathesis 
Rh rhodium 
rt room temperature 
sec secondary 
SET single-electron transfer 
TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxy 
4-MeO-TEMPO 4-methoxy-2,2,6,6-tetramethyl-1-piperidinyloxy 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
UV ultraviolet 
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6.6  List of Spectra of Iridium/Rhodium Complexes 
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Figure 123 1H-NMR and 13C-NMR spectrum of -(S)-7a. 
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Figure 124 1H-NMR and 13C-NMR spectrum of -(S)-7c. 
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Figure 125 1H-NMR and 13C-NMR spectrum of -(S)-7d. 
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Figure 126 1H-NMR and 13C-NMR spectrum of -(S)-7d. 
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Figure 127 1H-NMR and 13C-NMR spectrum of -Ir1. 
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Figure 128 1H-NMR and 13C-NMR spectrum of -Ir2. 
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Figure 129 1H-NMR and 13C-NMR spectrum of -Ir3. 
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Figure 130 1H-NMR and 13C-NMR spectrum of -Ir4. 
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Figure 131 1H-NMR and 13C-NMR spectrum of -Ir5. 
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Figure 132 1H-NMR and 13C-NMR spectrum of rac-17 
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Figure 133 1H-NMR and 13C-NMR spectrum of -(S)-18. 
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Figure 134 1H-NMR and 13C-NMR spectrum of -(S)-18. 
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Figure 135 1H-NMR and 13C-NMR spectrum of -IrO. 
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Figure 136 1H-NMR and 13C-NMR spectrum of racemic intermediate complex I. 
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Figure 137 1H-NMR and 13C-NMR spectrum of racemic intermediate enolate complex II. 
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Figure 138 1H-NMR and 13C-NMR spectrum of racemic intermediate complex I-(NPh). 
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Figure 139 1H-NMR and 13C-NMR spectrum of racemic intermediate complex II-(NPh). 
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Figure 140 1H-NMR and 13C-NMR spectrum of dimer-IrS(tBu). 
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Figure 141 1H-NMR and 13C-NMR spectrum of -(S)-IrS(tBu). 
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Figure 142 1H-NMR and 13C-NMR spectrum of -(S)-IrS(tBu). 
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Figure 143 1H-NMR and 13C-NMR spectrum of -IrS(tBu). 
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Figure 144 1H-NMR and 13C-NMR spectrum of intermediate I (RhS-Py). 
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Figure 145 1H-NMR and 13C-NMR spectrum of intermediate I (RhS-Im). 
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6.6.2 CD Spectra of Enantiopure Iridium Complexes 
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Figure 146 CD spectrum of complex Λ-(S)-9a recorded in CH3OH (0.2 mM). 
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Figure 147 CD spectrum of complex Λ-(S)-9b recorded in CH3OH (0.2 mM). 
Chapter 6. Appendices 
376 
 
200 300 400 500 600
-30
-20
-10
0
10
20
30


(M
-1
 c
m
-1
)
(nm)
 
Figure 148 CD spectrum of complex Λ-(S)-9c recorded in CH3OH (0.2 mM). 
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Figure 149 CD spectra of complexes Λ-(S)-9d and -(S)-9d recorded in CH3OH (0.2 mM). 
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Figure 150 CD spectrum of complex Λ-(S)-9e recorded in CH3OH (0.2 mM). 
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Figure 151 CD spectrum of catalyst Λ-Ir1 recorded in CH3OH (0.2 mM). 
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Figure 152 CD spectrum of catalyst Λ-Ir2 recorded in CH3OH (0.2 mM). 
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Figure 153 CD spectrum of catalyst Λ-Ir3 recorded in CH3OH (0.2 mM). 
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Figure 154 CD spectra of catalyst Λ-Ir4 and -Ir4 recorded in CH3OH (0.2 mM). 
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Figure 155 CD spectrum of catalyst Λ-Ir5 recorded in CH3OH (0.2 mM). 
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Figure 156 CD spectrum of auxiliary complex Λ-(S)-18 recorded in CH3OH (0.2 mM). 
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Figure 157 CD spectrum of auxiliary complex -(S)-18 recorded in CH3OH (0.2 mM). 
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Figure 158 CD spectra of complexes Λ-IrO and -IrO recorded in CH3OH (0.2 mM). 
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Figure 159 CD spectra of complexes Λ-(S)-IrS(tBu) and -(S)-IrS(tBu) recorded in CH3OH (0.2 
mM). 
 
Figure 160 CD spectra of complexes Λ-IrS(tBu) and -IrS(tBu) recorded in CH3OH (0.2 mM). 
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6.6.3 HPLC Spectra of Enantiopure Iridium Complexes 
The analysis was performed with a Daicel Chiralpak IA (250 × 4.6 mm) HPLC column on an Agilent 
1200 Series HPLC System. The column temperature was 30 °C and UV-absorption was measured at 
254 nm. mobile phase: solvent A = 0.1% TFA, solvent B = MeCN, flow rate = 0.5 mL/min, column 
temperature = 40 C, UV absorption = 254 nm. 
 
 
 
Figure 161 HPLC traces of the reference rac-Ir4, -Ir4, and -Ir4 (all as their PF6 salt). Integration 
of peak areas > 99% ee (Daicel Chiralpak IA, with a linear gradient of 30% to 60% B in 25 min, flow 
rate = 0.5 mL/min). 
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The analysis was performed with a Daicel Chiralpak IB (250 × 4.6 mm) HPLC column on an Agilent 
1200 Series HPLC System. The column temperature was 20 °C and UV-absorption was measured at 
254 nm. Solvent A = 0.1% TFA, solvent B = MeCN. 
 
 
 
Figure 162 HPLC traces for the complex rac-IrO, -IrO, -IrO. Integration of peak areas > 100:1 e.r. 
(Daicel Chiralpak IB with a linear gradient of 20% to 43% B in 60 min, flow rate = 0. 5 mL/min).  
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6.7  List of Crystal Structure Data 
 
Figure 163 Crystal structure of the racemic catalyst /-Ir4. ORTEP drawing of complex 1 with 30% 
probability thermal ellipsoids. Iodide counterions, water molecules and CH2Cl2 are omitted for clarity. 
 
Table 13. Crystal data and structure refinement for rac-Ir4. 
 
Crystal data  
Identification code  cat112_0m_sq 
Habitus, colour  plate,  yellow 
Crystal size 0.609 x 0.209 x 0.044 mm3 
Crystal system  Triclinic 
Space group  P -1 Z = 1 
Unit cell dimensions a = 14.9997(6) Å  
 b = 20.6925(7) Å  
 c = 26.1024(10) Å  
Volume 7451.9(5) Å3 
Cell determination  9717 peaks with Theta 2.5 to 27.2°. 
Empirical formula  C275 H308 Cl6 I10 Ir4 N20 O25 
Moiety formula  4[C68 H73 Ir N5 O5]+, 2(I-), I3-, I5-, 3(C H2 Cl2), 
5(H2 O) 
Formula weight  6543.90 
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Density (calculated) 1.458 Mg/m3 
Absorption coefficient 2.930 mm-1 
F(000) 3238 
 
Data collection:  
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71069 Å 
Temperature  100(2) K 
Theta range for data collection 2.005 to 25.371°. 
Index ranges -18<=h<=18, -24<=k<=24, -31<=l<=31 
Data collection software  BRUKER APEX2 2014.1-1 
Cell refinement software  SAINT V8.32B (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.32B (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
Reflections collected 173852 
Independent reflections 27246 [R(int) = 0.0892] 
Completeness to theta = 25.240° 99.9 %  
Observed reflections  20449[I > 2sigma(I)]  
Reflections used for refinement  27246 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.72 and 0.55 
Largest diff. peak and hole 4.544 and -2.517 e.Å-3 
Solution  direct/ difmap 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  mixed, mixed 
Programs used  SHELXS-97 (Sheldrick, 2008)  
SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 27246 / 1352 / 1746 
Goodness-of-fit on F2 1.055 
R index (all data) wR2 = 0.1826 
R index conventional  [I>2sigma(I)]         R1 = 0.0682 
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Figure 164 Crystal structure of -IrO. The PF6 counteranion is omitted for clarity. ORTEP drawing 
with 50% probability thermal ellipsoids. 
Table 14. Crystal data and structure refinement for -IrO. 
Crystal data:  
Identification code  -IrO 
Habitus, colour  block, yellow 
Crystal size 0.32 x 0.27 x 0.15 mm3 
Crystal system  Monoclinic 
Space group  P 21 Z = 4 
Unit cell dimensions a = 13.3232(7) Å  
 b = 24.2827(11) Å  
 c = 15.9879(8) Å  
Volume 4877.4(4) Å3 
Cell determination  9761 peaks with Theta 2.3 to 27.3°. 
Empirical formula  C38 H38 F6 Ir N4 O2 P 
Formula weight  919.89 
Density (calculated) 1.253 Mg/m3 
Absorption coefficient 2.823 mm-1 
F(000) 1824 
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Data collection:  
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.333 to 25.500°. 
Index ranges -16<=h<=16, -29<=k<=27, -19<=l<=19 
Data collection software  BRUKER APEX II 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Solution and refinement: 
Reflections collected 124260 
Independent reflections 17607 [R(int) = 0.0589] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  16949[II > 2(I)]  
Reflections used for refinement  17607 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.68 and 0.54 
Flack parameter (absolute struct.)   0.002(3) 
Largest diff. peak and hole 0.902 and -0.916 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constrained refinement 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 17607 / 1 / 953 
Goodness-of-fit on F2 1.067 
R index (all data) wR2 = 0.0728 
R index conventional  [I>2sigma(I)]         R1 = 0.0305 
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Figure 165 Crystal structure of intermediate complex I. The PF6 counteranion is omitted for clarity. 
ORTEP drawing with 50% probability thermal ellipsoids. 
Table 15. Crystal data and structure refinement for intermediate complex I (zll3_0m). 
 
Crystal data  
Identification code  zll3_0m 
Habitus, colour  block, red 
Crystal size 0.30 x 0.27 x 0.12 mm3 
Crystal system  Monoclinic 
Space group  P 21/c Z = 4 
Unit cell dimensions a = 15.4718(5) Å = 90°. 
 b = 16.7746(6) Å = 98.7851(12)°. 
 c = 19.3571(7) Å  = 90°. 
Volume 4964.9(3) Å3 
Cell determination  9819 peaks with Theta 2.3 to 25.3°. 
Empirical formula  C48 H48 Cl4 F6 Ir N4 O P S2 
Moiety formula  C46 H44 Ir N4 O S2, F6 P, 2(C H2 Cl2) 
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Formula weight  1239.99 
Density (calculated) 1.659 Mg/m3 
Absorption coefficient 3.085 mm-1 
F(000) 2472 
 
Data collection:  
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  115(2) K 
Theta range for data collection 2.194 to 25.326°. 
Index ranges -18<=h<=17, -20<=k<=20, -23<=l<=23 
Data collection software  BRUKER APEX2 2014.1-1 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
Reflections collected 43808 
Independent reflections 9050 [R(int) = 0.0350] 
Completeness to theta = 25.242° 99.8 %  
Observed reflections  8088[I> 2σ(I)]  
Reflections used for refinement  9050 
Absorption correction Numerical 
Max. and min. transmission 0.71 and 0.46 
Largest diff. peak and hole 0.791 and -0.442 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014) 
 SHELXL-2014 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 9050 / 147 / 666 
Goodness-of-fit on F2 1.048 
R index (all data) wR2 = 0.0464 
R index conventional  [I>2sigma(I)] R1 = 0.0200 
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Figure 166 Crystal structure of enolate complex II. The PF6 counteranion is omitted for clarity. 
ORTEP drawing with 50% probability thermal ellipsoids. 
Table 16. Crystal data and structure refinement for enolate complex II (zll4_0m). 
 
Crystal data  
 
Identification code  zll4_0m 
Habitus, colour  block,  red 
Crystal size 0.42 x 0.18 x 0.07 mm3 
Crystal system  Monoclinic 
Space group  P 21/c Z = 4 
Unit cell dimensions a = 18.2905(7) Å  
 b = 13.3765(5) Å  
 c = 16.8996(7) Å  
Volume 4071.9(3) Å3 
Cell determination  9963 peaks with Theta 2.4 to 25.3°. 
Empirical formula  C46 H43 Ir N4 O S2 
Moiety formula  C46 H43 Ir N4 O S2 
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Formula weight  924.16 
Density (calculated) 1.508 Mg/m3 
Absorption coefficient 3.422 mm-1 
F(000) 1856 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  115(2) K 
Theta range for data collection 2.148 to 25.325°. 
Index ranges -20<=h<=21, -16<=k<=16, -20<=l<=20 
Data collection software  BRUKER APEX2 2014.1-1 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 51042 
Independent reflections 7409 [R(int) = 0.0384] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  6331[I>2σ(I)]  
Reflections used for refinement  7409 
Absorption correction Numerical 
Max. and min. transmission 0.80 and 0.37 
Largest diff. peak and hole 1.230 and -0.632 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014) 
 SHELXL-2014 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 7409 / 111 / 571 
Goodness-of-fit on F2 1.079 
R index (all data) wR2 = 0.0503 
R index conventional  [I>2sigma(I)] R1 = 0.0221 
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Figure 167 Crystal structure of (R)-31a. ORTEP drawing with 50% probability thermal ellipsoids. 
 
Table 17. Crystal data and structure refinement for test_0m. 
 
Crystal data  
 
Identification code  test_0m (3hnb) 
Habitus, colour plate, colourless 
Crystal size 0.35  0.23  0.05 mm3 
Crystal system  Orthorhombic 
Space group  P212121 Z = 4 
Unit cell dimensions a = 8.5247(3) Å  
 b = 9.7490(4) Å  
 c = 20.5673(7) Å  
Volume 1709.29(11) Å3 
Cell determination  9868 peaks with Theta 2.3 to 29.6°. 
Empirical formula  C18 H13 Cl3 N2 O 
Moiety formula  C18 H13 Cl3 N2 O 
Formula weight  379.65 
Density (calculated) 1.475 Mg/m3 
Absorption coefficient 0.543 mm-1 
F(000) 776 
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Data collection:  
 
Diffractometer type Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  110(2) K 
Theta range for data collection 2.312 to 29.602°. 
Index ranges -11<=h<=11, -10<=k<=13, -28<=l<=28 
Data collection software  BRUKER APEX2 2014.9-0 
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 16634 
Independent reflections 4796 [R(int) = 0.0228] 
Completeness to theta = 25.242° 99.8 %  
Observed reflections  4638[I>2sigma(I) ]  
Reflections used for refinement  4796 
Absorption correction Numerical 
Max. and min. transmission 0.97 and 0.79 
Flack parameter (absolute struct.)   0.039(11) 
Largest diff. peak and hole 0.281 and -0.206 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Located, isotropic refinement 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 4796 / 0 / 269 
Goodness-of-fit on F2 1.068 
R index (all data) wR2 = 0.0583 
R index conventional  [I>2sigma(I)] R1 = 0.0233 
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Figure 168 Crystal structure of Δ-IrS(tBu). ORTEP drawing with 30% probability thermal ellipsoids. 
 
Table 18. Crystal data and structure refinement for test_0m. 
 
Crystal data  
 
Identification code  hxqA74_0m 
Habitus, colour  prism, yellow 
Crystal size 0.18 x 0.13 x 0.08 mm3 
Crystal system  Tetragonal 
Space group  P43212 Z = 8 
Unit cell dimensions a = 15.7940(7) Å  
 b = 15.7940(7) Å  
 c = 47.212(2) Å  
Volume 11777.2(12) Å3 
Cell determination  9731 peaks with Theta 2.5 to 24.8°. 
Empirical formula  C59.30 H69.20 F6 Ir N4 P S2 
Moiety formula  C46 H54 Ir N4 S2, F6 P, 1.9(C7 H8) 
Formula weight  1239.27 
Density (calculated) 1.398 Mg/m3 
Absorption coefficient 2.424 mm-1 
F(000) 5048 
 
Data collection:  
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Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.154 to 25.271°. 
Index ranges -18<=h<=18, -18<=k<=16, -42<=l<=56 
Data collection software  BRUKER APEX2 2014.9-0  
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 46629 
Independent reflections 10657 [R(int) = 0.0237] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  9518[I>2sigma(I) ]  
Reflections used for refinement  10657 
Absorption correction Numerical 
Max. and min. transmission 0.83 and 0.62 
Flack parameter (absolute struct.)   -0.012(2) 
Largest diff. peak and hole 0.800 and -1.568 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 10657 / 1907 / 948 
Goodness-of-fit on F2 1.037 
R index (all data) wR2 = 0.1240 
R index conventional [I>2sigma(I)] R1 = 0.0465 
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Figure 169 Crystal structure of (R)-55k. ORTEP drawing with 50% probability thermal ellipsoids. 
 
Table 19. Crystal data and structure refinement for H53_0m. 
 
Crystal data 
 
Identification code  H53_0m 
Habitus, colour block, colourless 
Crystal size 0.45 x 0.16 x 0.10 mm3 
Crystal system  Monoclinic 
Space group  P21 Z = 2 
Unit cell dimensions a = 10.7672(5) Å  
 b = 7.0157(3) Å  
 c = 14.4654(6) Å  
Volume 1021.83(8) Å3 
Cell determination  9845 peaks with Theta 2.9 to 25.3°. 
Empirical formula  C25 H21 Br N2 O 
Moiety formula  C25 H21 Br N2 O 
Formula weight  445.35 
Density (calculated) 1.447 Mg/m3 
Absorption coefficient 2.030 mm-1 
F(000) 456 
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Data collection: 
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.919 to 25.295°. 
Index ranges -12<=h<=12, -8<=k<=8, -17<=l<=17 
Data collection software  APEX3 (Bruker AXS Inc., 2015) 
Cell refinement software  SAINT V8.35A (Bruker AXS Inc., 2015)  
Data reduction software  SAINT V8.35A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 24779 
Independent reflections 3729 [R(int) = 0.0583] 
Completeness to theta = 25.242° 99.8 %  
Observed reflections  3551[I > 2(I)]  
Reflections used for refinement  3729 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.82 and 0.61 
Flack parameter (absolute struct.)   -0.005(3)  
Largest diff. peak and hole 0.292 and -0.346 e.Å-3 
Solution  direct/ difmap 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014) 
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact) 
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011) 
Data / restraints / parameters 3729 / 1 / 262 
Goodness-of-fit on F2 1.076 
R index (all data) wR2 = 0.0517 
R index conventional  [I>2sigma(I)] R1 = 0.0207 
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Figure 170 Crystal structure of intermediate I (RhS-Py). ORTEP drawing with 50% probability 
thermal ellipsoids. 
 
Table 20. Crystal data and structure refinement for G160_0m. 
 
Crystal data  
 
Identification code  G160_0m 
Habitus, colour prism, green 
Crystal size 0.39 x 0.22 x 0.17 mm3 
Crystal system  Orthorhombic 
Space group  P212121 Z = 4 
Unit cell dimensions a = 15.1642(9) Å  
 b = 18.1335(10) Å  
 c = 19.1046(11) Å  
Volume 5253.4(5) Å3 
Cell determination  9448 peaks with Theta 2.4 to 27.4°. 
Empirical formula  C49.75 H49.50 Cl3.50 F6 N4 O P Rh S2 
Moiety formula  C48 H46 N4 O Rh S2, F6 P, 1.75(C H2 Cl2) 
Formula weight  1155.51 
Density (calculated) 1.461 Mg/m3 
Absorption coefficient 0.675 mm-1 
F(000) 2358 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  120(2) K 
Theta range for data collection 2.410 to 27.548°. 
Index ranges -19<=h<=18, -21<=k<=23, -24<=l<=24 
Data collection software  APEX3 (Bruker AXS Inc., 2015)  
Cell refinement software  SAINT V8.35A (Bruker AXS Inc., 2015)  
Data reduction software  SAINT V8.35A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 87903 
Independent reflections 12110 [R(int) = 0.0410] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  11172[I > 2(I)]  
Reflections used for refinement  12110 
Absorption correction Numerical Mu From Formula 
Max. and min. transmission 0.89 and 0.78 
Flack parameter (absolute struct.)   0.46(3) 
Largest diff. peak and hole 0.888 and -0.786 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact)  
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)  
Data / restraints / parameters 12110 / 504 / 796 
Goodness-of-fit on F2 1.050 
R index (all data) wR2 = 0.0954 
R index conventional  [I>2sigma(I)] R1 = 0.0354 
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Fachbereiche und des Medizinischen Fachbereichs für seine mathematisch- 
naturwissenschaftlichen Fächer der Philipps-Universität Marburg vom 15.07.2009 
 
Ich erkläre, dass eine Promotion noch an keiner anderen Hochschule als der Philipps- 
Universität Marburg, Fachbereich Chemie, versucht wurde und versichere, dass ich meine 
vorgelegte Dissertation 
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selbst und ohne fremde Hilfe verfasst, nicht andere als die in ihr angegebenen Quellen oder 
Hilfsmittl benutz, alle vollständig oder sinngemäß übernommenen Zitate als solche 
gekennzeichnet sowie die Dissertation in der vorliegenden oder ähnlichen Form noch bei 
keiner anderen in- oder ausländischen Hochschule anlässlich eines Promotionsgesuchs oder 
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